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Abstract 
Central nervous system primitive neuroectodermal tumours (CNS-PNETs) are highly 
aggressive tumours with similar histopathological features to other intracranial PNETs 
(medulloblastomas). These two tumours have accordingly been treated using unified 
approaches, but CNS-PNETs have a dismal prognosis. Few studies have investigated the 
genetic features of CNS-PNETs. The molecular basis of CNS-PNET was therefore 
investigated in a cohort containing CNS-PNETs from children (n=33) and adults (n=5), to 
aid improvements in disease classification and treatment. 
The common medulloblastoma molecular defects were investigated in CNS-PNETs, and 
showed RASSF1A promoter hypermethylation is a frequent event (18/22, 82%), and MYC 
family gene amplification occurs in a subgroup (MYCN:  3/25 (12%), MYCC: 0/25 (0%)). In 
contrast and in distinction to medulloblastoma, chromosome 17p loss is not a common 
feature (2/23, 9%), whilst p53 pathway signalling appears to play a major role (20/22, 
91%), and associated with TP53 mutations (4/22, 18%). Aberrant Wnt signalling was 
identified in 2 cases (2/22, 9%) and coupled with CTNNB1 mutation in a single case. IDH1 
mutations (2/25, 8%) however, appear to occur in adult but not childhood CNS-PNETs or 
medulloblastoma. Subsequent genome-wide investigations of the CNS-PNET DNA 
methylome aimed at a wider characterisation of the molecular features of CNS-PNETs 
and its relationships to other childhood tumours identified CNS-PNETs as a 
heterogenous disease group without defined sub-clusters, which were predominantly 
distinct from medulloblastomas, but exhibited overlap with high-grade gliomas. A panel 
of 76 tumour-specific methylation events were identified as disease markers. The 
combination of either RASSF1A hypermethylation or HLA-DPB1 hypomethylation 
discerned normal brain from CNS-PNET in 94% of cases (64/68). In addition, 
hypermethylation of TAL1, MAP3K1 and IGFBP1 is associated with non-infant disease.   
In conclusion, this study has shown CNS-PNETs are a heterogenous group of tumours 
that are molecularly distinct from medulloblastomas, and has implicated developmental 
pathways and genetic events in their tumorigenesis. The associations between 
molecular events identified and clinical features warrant further investigation to aid 
classification and treatment advancements.
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1.1 Introduction to cancer 
1.1.1 Cancer 
The development and repair of normal tissue occurs through the highly regulated 
processes of cell growth (proliferation), differentiation and cell death (apoptosis). In 
health, response to different stimuli results in the transcription of genes to either 
promote or inhibit these processes. Tumour development ensues when abnormalities 
in gene expression result in aberrant regulation of cell cycle progression and cell death 
permitting increased cellular proliferation (Strachan and Read 2004). Tumours can be 
either benign or malignant. Benign tumours are contained within their local 
environment and do not invade adjacent tissues. Malignant tumours in contrast are 
more aggressive and may invade and cause damage to adjacent tissues. Malignant 
tumours may also spread to distant sites, and their ability to metastasise is facilitated 
by the lymphatic system and the bloodstream (Franks and Teich 1997). 
 
1.1.2 The clonal origin of cancer 
Cancer is a monoclonal disease and develops from a mutation in a single cell which 
provides it with a growth advantage over the surrounding cells. The mutated cell 
proliferates and creates a larger population of cells with the same genotype which 
increases the probability of further mutations, a process known as clonal evolution. 
Mutations may also render cells more susceptible to further mutational events by 
disrupting regulatory mechanisms including genes involved in DNA repair. Successive 
mutations confer additional growth advantages to the cancer cells which are clonally 
expanded until a tumour is formed from the different cancer clones. On average it has 
been proposed that six or seven successive mutations are required to convert a normal 
cell into an invasive carcinoma (Strachan and Read 2004) 
The monoclonal origin of cancer has been confirmed in some tumours with 
chromosome X inactivation studies (Jones, Carr et al. 2005; Wang, Wang et al. 2009). 
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In these studies it has been demonstrated that tumour cells at different sites within an 
individual patient have the same inactive X chromosome, suggesting that they have 
arisen from the same cell. It has in contrast also been shown that in some cancers, 
cells may contain variable numbers of inactive X chromosomes suggesting a polyclonal 
origin in these tumours (Parsons 2008). 
 
1.1.3 Cancer: A multistep process 
As a cancer develops from successive aberrant genetic events a stepped divergence 
from a normal healthy tissue can occur. Initially morphological examination may show 
an excessive proliferation of normal cells (hyperplasia). As the process develops the 
proliferative cells can become immature (dysplasia), and become severely dysplastic 
but non-invasive (carcinoma in situ) before progressing to an invasive carcinoma 
(Strachan and Read 2004). This multistep process in the development of a cancer 
requires the acquisition of six key functional capabilities, illustrated in Figure 1.1. 
Cancers must develop (i) limitless replicative potential, (ii) self-sufficiency from growth 
signals, (iii) an insensitivity to growth inhibitory signals, (iv) an ability to evade 
apoptosis, (v) a sustained angiogenesis, and (vi) an ability to invade tissue and 
metastasise (Hanahan and Weinberg 2000). 
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Figure 1.1. Acquired capabilities of cancer cells. Six essential capabilities of all cancers 
to facilitate tumour development. Figure taken from Hanahan and Weinberg (2000).  
 
1.1.4 Cancer epidemiology 
Cancer can affect any tissue within the body and in total more than 200 different types 
have been described in humans. One in three people will develop a cancer during their 
lifetime, and approximately one in every four people will die from this disease 
(www.info.cancerresearchuk.org). Cancer is responsible for 7.4 million worldwide 
deaths annually (13% of total), and this is expected to rise to 12 million by 2030 (WHO 
2009). In the UK breast, lung, colorectal and prostate cancer are the four most 
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commonly diagnosed cancers, and together account for more than half of all cancers 
diagnosed each year (www.info.cancerresearchuk.org/cancerstats )(Figure 1.2).  
The age at which people develop cancer varies significantly (Figure 1.3). As has been 
discussed (section 1.1.2), multiple genetic abnormalities are thought to be required to 
occur to promote the development of a cancer, and this may take a period of many 
years.  This is reflected in the incidence of cancer development in which an exponential 
relationship is observed between age of diagnosis and incidence with cancer 
predominantly arising in people over the age of 60 years (Figure 1.3). Cancers in adults 
(over the age of 16 years) represent over 99% of all cancers (ONS 2010). 
The current overall 5 year survival is 50% however there is significant variation in 
survival ranging from over 96% in testicular cancers to 3% in pancreatic cancers (Figure 
1.4). The four most common cancers, (lung, breast, colorectal and prostate) are also 
responsible for almost half of all cancer-related mortality and are also a significant 
cause of morbidity (www.info.cancerresearchuk.org). 
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Figure 1.2. Incidence of the most common cancers diagnosed in the UK. The most 
commonly diagnosed cancers in the UK in 2007. CNS: Central Nervous System. Figure 
adapted from http://info.cancerresearchuk.org/cancerstats. 
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Figure 1.3. Incidence of cancer in people of different ages in England in 2007. Figures exclude non-melanomatous skin cancers. Cancers in 
those aged under 45 amounted to just over 5.4 per cent of the total for males and 9.2 per cent for females. Of the total of 245,327 
malignancies, 1,147 (0.5 per cent) occurred in children aged under 15. Figure from(ONS 2010).
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Figure 1.4. Survival from different types of cancer in men and women. Five year age standardised relative survival for the 21 most common 
cancers in adult men and women (15-99) diagnosed with cancer during 2001-2006 and followed up to 2007 in England. *Unadjusted survival 
rates given for women with brain tumours as age standardised rate could not be calculated due to the comparatively low incidence and poor 
survival for this group (ONS 2010). 
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1.1.5 Paediatric cancer epidemiology 
Each year approximately 1200 new cases of cancer are diagnosed in children under the 
age of 15 in the UK, which represents 0.5-1% of all newly diagnosed cancers 
(www.info.cancerresearchuk.org). Overall, 1 in 500 children will develop a tumour 
before the age of 15. The risk of developing a leukaemia in childhood is 1 in 1600, 1 in 
2200 for developing a CNS (brain and spinal cord) tumour, and 1 in 1100 for 
developing another form of cancer (www.info.cancerresearchuk.org). The risk of 
developing a cancer is 20% greater overall fora boy than that for a girl before the age 
of 15. Leukaemias are the most common form of cancer in children, and account for a 
third of all childhood cancers, whilst brain tumours account for 20-25% (Stiller 2004), 
and together they are responsible for more than half of all childhood cancers (Figure 
1.5).  
Survival rates, as with adult cancers, vary depending on the individual cancer type 
ranging from 96% with retinoblastoma or germ cell tumours to less than 5% with some 
forms of glioma (Figure 1.7). Overall the five year survival rate for children with cancer 
is 75%.  In total however each year around 300 children with cancer will die from this 
disease, which account for 20% of all deaths in childhood (ONS 2010). Together, brain/ 
spinal cord tumours and leukaemias are responsible for almost two-thirds of childhood 
deaths from cancer (Figure 1.7). 
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Figure 1.5. Incidence of childhood cancer in the UK. Age-standardised rates of 
childhood cancer (aged 0-14 years) in the UK. Data taken from (Stiller 2004). 
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Figure 1.6. Survival rates at 5 years for children diagnosed with cancer in 1992-1996 
in Great Britain. Figure adapted from http://info.cancerresearchuk.org/cancerstats. 
 
 
 
Figure 1.7. UK annual average number of deaths in children diagnosed with cancer 
under the age of 15 in 1997 - 2001. Figure adapted from 
http://info.cancerresearchuk.org/cancerstats. 
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1.2 Cancer:  A genetic disease 
1.2.1 Introduction 
As has been discussed in section 1.1.3, multiple genetic anomalies are required to 
accumulate for a tumour to develop the characteristics required for tumorigenesis. 
These genetic anomalies may arise from environmental factors including exposure to 
ultraviolet light or ionizing radiation.  The most common exposure, which results in 
almost a third (29%) of all cancer related deaths in the UK, is tobacco smoke 
(www.cancerresearch.org). Inherited genetic abnormalities, in which an individual 
inherits an abnormality in one allele of a gene rendering the individual susceptible to 
developing a cancer, are also implicated in a proportion of cancers.  Individuals who 
inherit a BRCA1 or BRCA2 mutation, for example have an 85% chance of developing a 
breast cancer (Ford, Easton et al. 1998). Genes, such as BRCA1 and BRAC2 that may be 
implicated in the development of cancers are classified as being either oncogenes or 
tumour suppressor genes. 
 
1.2.2 Oncogenes 
An oncogene is a gene that when mutated or over-expressed is capable of dominantly 
promoting cancer by supporting the cellular processes required for tumour 
development (Figure 1.1).  First discovered in the 1970’s in viral induced cancers 
(leukaemias and lymphomas), over 100 oncogenes have now been described in human 
cancers and may be classified into five groups based on their function: (i) growth 
factors, (ii) growth factor receptors; (iii) signal transduction components; (iv) 
transcription factors; and (v) cell cycle/ apoptosis regulators (Strachan and Read 2004). 
Oncogenes, derived from mutated normal cellular genes are known as proto-
oncogenes. The conversion to oncogenes may occur by a number of mechanisms 
including gene amplification, point mutation, translocation which incorporates a gene 
within a transcriptionally active region of chromatin, transcriptional activation by 
proteins upstream of the oncogene, or through a translocation which creates a novel 
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chimeric gene. These alterations (exemplified in Table 1.1) result in either an increased 
normal product or a new product with tumourigenic properties.  
The targeting of oncogenic proteins by small molecules currently is an important area 
of both research in cancer therapeutics and clinical practice. Imatinib mesylate 
(Gleevec™, Novartis) for example was designed to target the chimeric BCR-ABL protein 
produced in chronic myeloid leukaemia (CML) and is now successfully used in the 
management of patients with this disease (Goldman and Melo 2001; Agrawal, Garg et 
al. 2010). It has also been shown to have activity both in other cancer types, and by 
operating on additional targets including PDGFR and KIT and has developed a broader 
clinical utility (Heinrich, Blanke et al. 2002; Casali, Messina et al. 2004)  
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Oncogene Location Function Mechanisms of activation Cancer association 
PDGFB 22q13.1 Growth factor Translocates to transcriptionally active region Dermatofibrosarcoma 
      Point mutation   
EGFR 7p12 Growth factor receptor Amplification Glioma 
      Point mutation Non-small cell lung cancer 
HRAS 11p15.5 Signal transduction pathway component Mutation Colorectal carcinoma 
      Amplification Rhabdomyosarcoma 
MYCC 8q24.1 DNA binding transcription factor Translocates to transcriptionally active region Burkitt lymphoma 
      Amplification Breast and Prostate cancer 
      Point mutation B-CLL,  
      Transcriptional activation Colorectal carcinoma 
BCL2 18q21.3 Anti-apoptosis Translocates to transcriptionally active region NHL, CLL 
      Transcriptional activation Melanoma 
BCR-ABL t(9;22)(q34;q11) Tyrosine kinase Translocation creating a novel chimeric gene Breast prostate, lung cancer 
Table 1.1. Function and activating mechanisms of common oncogenes. Examples of different oncogene functions and mechanisms of 
activation in different tumour types. CLL, chronic lymphocytic leukaemia; B-CLL, B-cell lineage CLL; NHL, Non-Hodgkin Lymphoma. Data collated 
from (Strachan and Read 2004; Croce 2008) and Wellcome Trust Sanger Institute Cancer Genome Project web site, 
http://www.sanger.ac.uk/genetics/CGP.
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1.2.3 Gene amplification 
The amplification of genes, as has been discussed in section 1.2.2, may result in the 
development of tumours by increasing mRNA and protein expression. Amplification of 
isolated genes may occur, but an amplicon may also comprise several genes an extend 
to several megabases (Storlazzi, Fioretos et al. 2004). Amplification, shown in Figure 
1.8, may arise by a number of mechanisms. Repeated duplication of chromosomal 
regions may give rise to homogeneously staining regions (HSR) which may contain 
thousands of additional copies of a given gene. Extrachromosomal additional copies of 
a gene may also occur, and form “double minutes” (DMs). The definition of an 
amplified gene varies in different tumour types. In breast cancer for example, a two-
fold increase in EGFR is considered amplified,  whereas in neuroblastoma at least a 
four-fold increase in MYCN is necessary before this gene is considered to be amplified 
(Press, Finn et al. 2008; Theissen, Boensch et al. 2009). In addition to enabling tumour 
formation, cancer cells may also use gene amplification to develop chemotherapy 
resistance. It has been shown for example, that amplification of the dihydrofolate 
reductase gene (DHFR) can confer resistance to methotrexate (MTX) (Trask and Hamlin 
1989), which would normally act to inhibit this enzyme, and is associated with an 
adverse clinical outcome (Goker, Waltham et al. 1995). 
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Figure 1.8. Schematic overview of gene amplification. Fluoresence insitu hybridisation 
(FISH) in a tumour cell using centromeric (green), and MYCN (red) probes. (a) Increased 
copy number of MYCN in a disomic cell, (b) MYCN amplification as part of a 
homogeneously staining region (HSR), (c) MYCN amplification with extra-chromosomal 
copies or double minutes (DM). Figure adapted from (Martin, Mazzucchelli et al. 2009). 
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1.2.4 Tumour suppressor genes 
Tumour suppressor genes (TSGs) code for proteins which function as regulators of 
cellular processes by inhibiting cell proliferation, stabilising the genome by ensuring 
accurate DNA replication and repair, and promote apoptosis should the DNA become 
damaged and not repairable. Cancer may develop if the regulatory function of the 
TSGs is lost. Both TSG alleles are thus typically required to become inactivated for 
tumour development to occur, as was first hypothesised in a landmark study by Alfred 
Knudson in 1971. In a study of familial and sporadic retinoblastomas, and noticing that 
tumours developed earlier in the familial form, Knudson hypothesised that for 
retinoblastomas to develop, 2 mutational events are required (“the Knudson two-hit 
hypothesis”) (Knudson 1971). In familial tumours it was postulated that one “hit” was 
inherited requiring only one mutational event or “hit” to occur, whilst for sporadic 
tumours to develop two mutational events or “hits” would be required to occur. This 
theorem was subsequently validated with the discovery of the retinoblastoma gene 
(RB1) and the observation that both alleles are inactivated in retinoblastomas (Friend, 
Bernards et al. 1986). Retinoblastomas in the familial form require only one “hit”, 
occur at an earlier age and are bilateral, whilst additional time is required to accrue the 
two “hits” in a later onset (>2 years old) and unilateral tumour in the sporadic form.  
Following the discovery of RB1 as a TSG a number of additional genes have been found 
to be associated with familial cancers (Table 1.10) and in total over 100 TSGs have 
been identified (Yang and Fu 2003). The most common TSG implicated in the 
development of cancer is TP53, which has been found to be mutated or deleted in over 
50% of all human cancers (Hollstein, Sidransky et al. 1991). 
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Gene Location Disease Functions 
APC 5q21 
Familial adenomatous 
polyposis coli (FAP) Nuclear signalling 
MSH2, 
ML1 
2p16, 
3p21.3 
Hereditary nonpolyposis 
colonic cancer (HNPCC) DNA mismatch repair 
BRCA1 17q21 Breast and ovarian cancer 
Transcription regulator, 
DNA binding, DNA repair, 
homologous 
recombination, 
ubiquitination of proteins BRCA2 13q12-q13 Early onset breast cancer 
TP53 17p13 Li-Fraumeni syndrome 
Cell cycle regulation, 
apoptosis 
PTCH 9q22-q31 Gorlin syndrome Transmembrane receptor 
ATM 11q22-q23 Ataxia telangiectasia DNA repair 
RB1 13q14 Retinoblastoma Cell cycle regulation 
NF1 17q12-q22 Neurofibromatosis type 1 RAS inactivation catalysis 
NF2 22q12.2 Neurofibromatosis type 2 
Cytoskeleton-membrane 
linkage 
CDKN2A 9p21 Familial melanoma p53 stabilizer 
VHL 3p25-p26 von Hippel-Lindau disease Transcription regulator 
Table 1.2. Common tumour suppressor genes and associated familial cancer 
syndromes. Gorlin syndrome also known as basal cell naevus syndrome. Table adapted 
from (Strachan and Read 2004). 
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1.2.4.1 Inactivation of tumour suppressor genes 
Loss of function of a TSG may occur by a variety of mechanisms (Figure 1.9). 
Chromosome loss, deletions, recombination, gene conversion and point mutations 
may all result in TSG loss of function (Reviewed in (Strachan and Read 2004)). 
Epigenetic modifications (reviewed in section 1.2.6) have also been shown to be 
involved in silencing TSG function by preventing the transcription of TSGs. Many of 
these mechanisms result in a loss of heterozygosity (LOH) of the TSG locus and 
therefore methods capable of detecting such LOH have been used to identify many loci 
harbouring candidate TSGs (Strachan and Read 2004).  
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Figure 1.9. Mechanisms of inactivation of the normal allele of a tumour suppressor gene. In sporadic cancer (top left), both alleles must be 
inactivated (purple band) for tumour suppressor gene (TSG) loss of function. In hereditary or familial cancer (top right), an inactivated allele is 
inherited (green band) and the remaining wild type allele needs to be inactivated before tumour development may occur. The possible 
mechanisms that may give rise to inactivation of the normal allele (“second hit”) are outlined in the bottom panel. Figure adapted from 
(Alberts, Johnson et al. 2002).
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1.2.5  Cytogenetic abnormalities 
Alterations in chromosomal structure and number, as illustrated in Figure 1.9, may 
result in tumorigenesis. These cytogenetic abnormalities, first detected in cancer cells 
in 1960, including the size and number of chromosomes are visualised by karyotyping, 
which requires analysis of the chromosomes of cells during cell cycle metaphase 
(Nowell and Hungerford 1960). 
More recently, alterations in chromosomal structure may also be determined by 
comparative genomic hybridisation (CGH). This technique, first devised in 1992 and 
used to interrogate bladder tumours (Kallioniemi, Kallioniemi et al. 1992), requires an 
investigative sample of DNA to be processed simultaneously with a sample of normal 
control DNA.  The two differentially labelled samples are then permitted to 
competitive hybridise with a normal metaphase spread on a slide, and the ratios of the 
two different signals along each chromosome is then recorded to determine whether 
there is a gain or loss at any given locus in the investigative sample. Unlike 
conventionally karyotyping which is limited both by the quality of the material being 
used and also the resolution at which defects can be determined (discussed in 
(Teyssier 1989)), CGH permits the use simply of fragments of DNA and yields an 
enhanced resolution, identifying smaller regions of chromosomal loss or gain which 
has aided in the identification of oncogenes and TSGs.  
 
1.2.6 Epigenetic modification 
In addition to genetic alterations, epigenetic modifications may also play a role in 
tumour development. Epigenetics is the study of heritable changes in gene expression 
that occur without a change in the DNA sequence. Epigenetic modification may occur 
by a number of mechanisms including DNA methylation, chromatin remodelling, 
histone modification and with micro ribonucleic acids (miRNAs). 
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1.2.6.1 Histone modification 
Histones are basic proteins that form an octamer (H3/H4 tetramer and two H2A/H2B 
dimmers) with 147bp of DNA to form a chromatin nucleosome. Histone tails protrude 
outside of the nucleosome where they may be subjected to post-translational 
modification including acetylation, methylation, phosphorylation, ubiquitylation, 
sumoylation, glycosylation, ADP-ribosylation, biotinylation or carbonylation (Strahl and 
Allis 2000). The various histone tail domain modifications act in a sequential and 
combinatorial fashion to regulate chromatin structure, a concept known as the histone 
code, and exert their epigenetic control by either preventing or promoting the binding 
of proteins to the genome to activate or repress genetic transcription (Mizzen and Allis 
2000).  
Disruption of histone modifications including loss and gain of histone lysine acetylation 
and methylation has been reported to occur in cancerous cells (Fraga, Ballestar et al. 
2005). The loss of lysine acetylation has been shown to be an early event in cancer 
development through gene silencing and also reducing a cell’s DNA repair capability 
(Mutskov and Felsenfeld 2004; Masumoto, Hawke et al. 2005). Mutations in EP300, a 
histone acetyltransferase for example, have been associated with breast, colonic and 
pancreatic cancers (Gayther, Batley et al. 2000), and has subsequently stimulated 
interest in the therapeutic targeting of histone modification control and in particular 
inhibitors of histone deacetylases (HDACs)(Workman 2001). 
 
1.2.6.2 Chromatin remodelling 
DNA within the nucleus is highly folded, constrained and compressed by histones and 
other proteins to form chromatin. The repositioning of nucleosomes along the DNA 
can create nucleosome-free regions which permit gene transcription (Davis and 
Brackmann 2003). Alterations in chromatin structure may consequently be associated 
with cell cycle progression, DNA repair, DNA replication and chromosomal stability 
(Wolffe and Guschin 2000). 
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Chromosomal regions that become transcriptionally repressed appear highly 
condensed in interphase nuclei  including the inactive X chromosome or “Barr body” in 
females (Brown 1966). Disorders of chromatin remodelling are implicated in a number 
of conditions including Rett, Rubinstein-Taybi and Coffin-Lowry syndromes (Ausio, 
Levin et al. 2003). Mutations in genes necessary for chromatin remodelling may also 
result in cancer development as occurs with mutations of INI1 and the development of 
paediatric atypical teratoid rhabdoid tumours (ATRT) (Versteege, Sevenet et al. 1998). 
 
1.2.6.3 DNA methylation 
DNA methylation occurs with the addition of a methyl group to a cytosine residue 5’ to 
a guanosine in a CpG dinucleotide. The CpG dinucleotide is under-represented in the 
genome apart from areas of approximately 0.5-4.0 Kb in length, with a high CpG 
content, located at the promoter region of almost half of all genes and known as “CpG 
islands”. These islands are defined as being at least 500bp in length, with a combined 
guanosine and cytosine content greater than 50%, and an observed over expected 
frequency of the dinucleotide CG greater than 0.6 (Wang and Leung 2004). 
Methylation of CpG dinucleotides is undertaken by DNA methyltransferases (DNMTs) 
which facilitates the replication of methylation patterns between parent and daughter 
cells. In normal somatic cells most promoter-associated CpG islands are unmethylated 
and associated with an open, transcriptionally active chromatin structure, whereas 
CpG dinucleotides elsewhere in the genome are generally methylated and therefore 
transcriptionally repressed (Figure 1.10) (Bestor 2000; Lindsey, Anderton et al. 2005). 
Epigenetic modification by DNA methylation is a dynamic process that facilitates 
variation in expression at different stages of development and in different tissue types 
and is therefore important in a range of processes including early development, tissue-
specific gene expression, host defence, genomic stability and gene imprinting 
(reviewed in (Gopalakrishnan, Van Emburgh et al. 2008). 
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Aberrations in methylation may also occur and are implicated in a number of diseases 
(Robertson 2005). In addition to sex differences as a result from inheriting different X 
and Y chromosome combinations, sex specific differences in methylation patterns on 
other chromosomes may give rise to differential expression, in a process known as 
imprinting (Robertson 2005). The developmental disorders Prader-Willi (PWS) and 
Angelman syndrome (AS), for example may result from a loss of paternally or 
maternally expressed alleles respectively at the imprinting centre located at 15q11-q13 
(Nicholls and Knepper 2001). Cancers have also been shown to occur as a result of 
genetic imprinting. The maternal allelic loss of expression on chromosome 11p15.5 of 
H19 by imprinting for example,  permits activation of the normally silent maternal IGF2 
gene which is associated with Wilms’ tumour development (Steenman, Rainier et al. 
1994). 
 Alterations in DNA methylation patterns are a hallmark of most human cancers (Baylin 
and Herman 2000). In cancer development, genome-wide hypomethylation of tumour 
cells compared to normal tissue has been shown predominate (Feinberg and 
Vogelstein 1983). This genome wide hypomethylation occurs as an early event in 
tumorigenesis and has been shown in some tumour types to correlate with both 
metastatic potential and disease severity (Widschwendter, Gattringer et al. 2004). 
Individual genes however may also become methylated in cancer. Methylation of RB1 
was the first gene to be associated with cancer (Ohtani-Fujita, Fujita et al. 1993), but 
DNA methylation has subsequently been shown to effect the expression of a plethora 
of genes involved in critical regulatory processes including those responsible for cell-
cycle regulation, tumour invasion, apoptosis, transcription, DNA repair, cell signalling 
and chromatin remodelling (summarised in Table 1.3) (Robertson 2005).  
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Figure 1.10. Epigenetic inactivation by promoter hypermethylation. (A) 
Transcriptionally active chromatin (euchromatin) is associated with widely spaced 
nucleosomes (light blue circles), unmethylated CpG residues (white circles), acetylation 
(green triangles) of histone H3 lysine residues (pink arrows) and an open chromatin 
structure. The open chromatin is easily accessible to transcription factors and enzymes 
involved in gene transcription including histone acetyl transferases (HATs). (B) The 
methylation of CpG residues (red circles), compacted nucleosomes (dark blue circles) 
and deacetylated histones (dark pink arrows) result in a compacted chromatin 
structure (heterochromatin) and repression of transcription. The establishment and 
maintenance of heterochromatin is performed by methyl-CpG binding proteins (MBPs), 
histone deacetylases (HDACs) and DNA methyltransferases (DNMTs). Figure taken 
from (Lindsey, Anderton et al. 2005). 
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Gene Function Gene Cancer type 
Cell cycle regulation RB1 Retinoblastoma 
  CDKN2A Colon, lung and others 
Tumour cell invasion CDH1 Breast, gastric, thyroid, leukaemia, liver 
  CDH13 Lung, ovarian, pancreatic 
  TIMP3 Brain, kidney 
  VHL Renal cell 
DNA repair/ detoxification MLH1 Colon, endometrial, gastric 
  MGMT Brain, colon, lung, breast 
  BRCA1 Breast, ovarian 
  GSTP1 Prostate, liver, colon, breast, kidney 
Chromatin remodelling SMARCA3 Colon, gastric 
Cell signalling RASSF1A Lung, liver, brain 
  SOCS3 Liver, colon, multiple myeloma 
Transcription ESR1 Colon, breast, lung, leukaemia 
Apoptosis DAPK1 Lymphoma 
Table 1.3. Epigenetic silencing of genes by aberrant DNA methylation in cancer. RB1, 
retinoblastoma 1; CDKN2A, cyclin-dependent kinase inhibitor 2A; CDH1, cadherin 1 (E-
cadherin); CDH13, cadherin 13 (H-cadherin); TIMP3, tissue inhibitor of 
metalloproteinase; VHL, von Hippel-Lindau; MLH1, mutL homolog; MGMT, 
methylguanine-DNA methyltransferase; BRCA1,breast cancer 1 ; GSTP1, glutathione S-
transferase pi 1; SMARCA3, SWI/SNF related matrix associated actin dependent 
regulator of chromatin 3; RASSF1A, Ras association domain family member 1; SOCS3, 
suppressor of cytokine signaling 3; ESR1, oestrogen receptor 1; DAPK1, death-
associated protein kinase 1 . Table adapted from (Robertson 2005). 
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1.2.6.4 MicroRNA 
Discovered in 1993, miRNAs are single stranded RNA molecules comprised of 21-23 
nucleotides which are not translated into a protein, but by complementing a number 
of messenger RNA (mRNA) molecules are able to down regulate gene expression (Lee, 
Feinbaum et al. 1993). In total more than 1000 miRNAs have been identified 
(http://microrna.sanger.ac.uk), and may be associated with cancer development by 
acting as oncogenes or tumour suppressor genes (Table 1.4). In chronic lymphocytic 
leukaemia (CLL) for example, down-regulation of anti-apoptotic BCL2 by miR-15a and 
miR-16-1 can promote tumour development, whilst up-regulation of antiapoptotic 
miR-21 is implicated in glioblastoma development (Calin, Dumitru et al. 2002; Chan, 
Krichevsky et al. 2005; Ciafrè, Galardi et al. 2005).  
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Function MicroRNA 
Confirmed 
targets Mechanism of action Cancer Association 
Tumour 
Suppressor 
miRNA 
miR-15a, 
miR-16-1 
BCL2, WT1 Induce apoptosis, 
reduce tumorigenicity 
CLL 
let-7 RAS, MYCC, 
HMGA2 
Induce apoptosis Lung & breast cancer 
  miR-29 
(a,b,c) 
TCL1, MCL1, 
DNMT3 
Induce apoptosis, 
reduce tumorigenicity 
CLL, AML,  
cholangiocarcinoma, 
lung & breast cancer 
  miR-34  
(a,b,c) 
CDK4, CDK6, 
cyclinE2, E2F3 
Induce apoptosis Pancreatic, breast & 
colon cancer 
Oncogenic 
miRNA 
miR-155 c-maf Induce 
lymphoproliferation 
CLL, DLBCL, AML, Burkitt 
lymphoma, lung & 
breast cancer 
  miR-17-92 
cluster 
E2F1, PTEN Cooperate with c-myc 
to induce tumour 
development 
Breast, lung, colon, 
stomach & pancreatic 
cancer. Lymphomas. 
  miR-21 PTEN, PDCD4, 
TPM1 
Blocks apoptosis, 
promotes 
tumorigenicity 
Breast, colon, 
pancreatic, lung, 
prostate, liver & 
stomach cancers. AML, 
CML, Glioblastoma 
  miR-372, 
miR-373 
LATS2 Promote 
tumorigenesis in 
cooperation with RAS 
Testicular tumours 
Table 1.4. MiRNAs with tumour suppressor or oncogenic function in cancer. CLL, 
chronic lymphocytic leukaemia; AML, acute myeloid leukaemia; DLBCL, diffuse large B 
cell lymphoma. Table adapted from (Garzon, Calin et al. 2009) 
 
 
 
 
 
31 
 
1.3 Paediatric brain tumours 
1.3.1 Introduction 
Brain tumours are the most common solid tumours of childhood and in total account 
for 20% of all childhood malignant tumours. In the UK each year approximately 350-
400 children are diagnosed with a brain tumour (CCLG 2010). Brain tumours are 
diagnosed in 3 per 100,000 children under the age of 15 each year and annually in 2 
per 100,000 15-19 year olds (Capra, Hargrave et al. 2003; Peris-Bonet, Martinez-Garcia 
et al. 2006). The incidence of brain tumours increased in the 1970s to 1990s, as shown 
in Figure 1.11, and in children increased by 1.7% per annum between 1988 and 1997 
(Peris-Bonet, Martinez-Garcia et al. 2006). This trend was recapitulated in a number of 
international studies during this period (Kaatsch, Steliarova-Foucher et al. 2006; Stiller 
2007). More recently however it has been reported that this trend has reached a 
plateau (Linabery and Ross 2008; Peris-Bonet, Salmeron et al. 2010) and that the 
previously observed increases may have in fact been an artefact of changes in 
diagnostic and neurosurgical practice (Smith, Freidlin et al. 1998; Smith, Seibel et al. 
2010). 
 
 
Figure 1.11. Age standardised European incidence rates of CNS tumours 1975 -2007. 
Figure taken from http://info.cancerresearchuk.org/cancerstats. 
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1.3.2 WHO classification 
The World Health Organisation (WHO) first published a classification of human CNS 
tumours after a decade in development in 1979 (Zulch 1979).  The aim of the WHO 
classification system was to establish a classification and grading system of human 
tumours that would be accepted worldwide and would facilitate the study of these 
tumours, but a consensus in classification has been difficult to establish (reviewed in 
(Scheithauer 2009) ).  The original classification was based on tumour site, grade and 
histology but developments in immunohistochemical techniques, clinical trial 
observations and molecular findings have resulted in 3 updated editions being 
produced in 1993, 2000 and 2007 respectively (Kleihues, Burger et al. 1993; Kleihues 
and Cavenee 2000; Louis, Ohgaki et al. 2007). The current fourth edition of the WHO 
classification of CNS tumours (summarised in Table 1.5.) includes eight new entities 
and additional histological variants.  
The tumours are graded I to IV based on their aggressiveness (Louis, Ohgaki et al. 
2007). Grade I tumours have a low proliferative potential and may be cured with 
surgical resection alone. Grade II tumours whilst also of low proliferative potential are 
infiltrative in nature and more likely to recur after surgical resection. Some of these 
grade II tumours also possess the ability to transform into higher grade tumours (eg 
diffuse astrocytomas, oligodendrogliomas, and oligoastrocytomas). Tumours which 
exhibit nuclear atypia and an increased mitotic index are classified as grade III. Patients 
with these tumours are usually treated with adjuvant therapy including radiotherapy 
and chemotherapy. The most aggressive tumours which are invasive and highly 
mitotically active are designated grade IV. Without successful multimodal therapy 
these tumours typically rapidly evolve and are fatal. The incidence of the different 
WHO brain tumour subtypes are shown in Figure 1.12. 
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Figure 1.12. The incidence of CNS tumours of childhood. UK Children’s Cancer 
registration data 1999-2008 (CCLG 2010). 
 
Ependymoma
Choroid plexus tumour
Low-grade astrocytoma
High-grade astrocytoma
Other glioma
Neuronal and neuronal-glial tumours
Medulloblastoma
CNS-PNET/ ATRT
Pituitary tumour
Craniopharyngioma
Pineal parenchymal tumour
Meningioma
Other CNS tumour
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Table 1.5. WHO Central Nervous System tumour classification. Tumours graded from 
benign to malignant (I to IV). Reproduced from (Louis, Ohgaki et al. 2007). 
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1.3.3 CNS Embryonal tumours  
CNS embryonal tumours comprise a group of 5 highly aggressive, WHO grade IV 
tumours including medulloblastomas, atypical teratoid rhabdoid tumours (ATRT), 
medulloepitheliomas, ependymoblastomas and CNS-PNETs. The clinical features of 
these tumours are summarised in Table 1.6. The most common embryonal tumour is 
the medulloblastoma which arises in the cerebellum particularly in children (mean age 
7 years) and accounts for a fifth of all brain tumours in childhood. The remaining 4 
forms of embryonal tumours are comparatively uncommon and in total account for 
less than 5% of childhood brain tumours. 
Recently, a new diagnostic category of “embryonal tumour with multilayered rosettes 
(ETMR) has been suggested to replace the ependymoblastoma sub-group (Paulus and 
Kleihues 2010), but this does not form part of the current WHO classification. 
Originally described by Eberhart et al in 2000, microscopically these tumours share 
classic features including ependymoblastic rosettes and neuronal differentiation and 
therefore have also been referred to as “embryonal tumours with abundant neuropil 
and true rosettes, (ETANTR)” (Eberhart, Brat et al. 2000; La Spina, Pizzolitto et al. 2006; 
Dunham, Sugo et al. 2007). Interestingly these tumours appear to only occur in young 
children and are associated with a poor outcome and with a focal amplification at 
19q13.42 (Li, Lee et al. 2009; Pfister, Remke et al. 2009; Korshunov, Remke et al. 2010). 
It has been suggested that this amplification could be used as a genetic marker in 
clinical practice to augment the histopathological diagnosis, and promisingly describes 
for the first time a distinct biological entity within the CNS-PNET group (Korshunov, 
Remke et al. 2010). 
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  Medulloblastoma CNS-PNET* ATRT Medulloepithelioma Ependymoblastoma 
Incidence 95% 1-2% 1-2% <1% <1% 
Age 70% <16 years 80% < 10 years 94% < 5 years < 5 years < 5 years 
  Mean: 7 years Mean: 5.5 years Mean: 17 months     
Location Cerebellum 
Cerebrum, 
Suprasellar Posterior fossa (52%) Periventricular Supratentorial, 
      Supratentorial (40%) Cerebral hemisphere Intraparenchymal 
      Pineal, Spinal      
Histopathology Undifferentiated cells 
Undifferentiated 
cells Rhabdoid cells 
Resembles embryonic 
neural tube 
Multilayered 
  ± neuronal/ glial 
differentiation 
± neuronal/ glial 
differentiation 
PNET, glial, epithelial 
and mesenchymal 
components 
ependymoblastic 
rosettes 
      
  5 sub-types         
Immunohistochemistry Synaptophysin + Synaptophysin + EMA and Vimentin + Nestin and vimentin + Vimentin + 
  Vimentin + GFAP / NF ± SMA, CK, GFAP, NF ± INI1 + GFAP, S100 negative 
  GFAP / NF ± INI1 + INI1 negative   EMA, NF negative 
  INI1 +       INI1 + 
Outcome 50-70% (5yr OS) 34% (5 year OS) Mean: 1 year (<20%) 6 months - 1 year 6 months - 1 year 
Table 1.6. Comparative profile of the clinical characteristics of CNS embryonal tumours. Five embryonal tumour/ PNET variants identified. 
CNS-PNET, central nervous system primitive neuroectodermal tumour; ATRT, atypical teratoid rhabdoid tumour; GFAP, glial fibrillary acidic 
protein; NF, neurofilament; EMA, epithelial membrane antigen; SMA, smooth muscle actin; CK, cytokeratin; wnt, wingless.  Figure is adapted 
from (Sarkar, Deb et al. 2005), *updated using the current 2007 WHO classification (Louis, Ohgaki et al. 2007) with the term CNS-PNET 
replacing supratentorial PNET (SPNET) and the classification of pineoblastomas as a separate entity and not an CNS embryonal tumour.
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1.3.4 The “PNET” concept and controversy 
Embryonal primitive neuroectodermal tumours of the CNS have historically been 
classified using a plethora of terms based upon their histopathological characteristics. 
This has resulted in considerable controversy which persists today and affects 
contemporary management of these tumours.  
Until 1837, these tumours were simply referred to as  sarcomas after which time they 
were given a variety of names including spongioblastoma, neuroblastoma malignum, 
neurogliocytome embryonaire and medulloblastoma (Tola 1951). In 1925 Bailey and 
Cushing, as reviewed in Rorke et al 1997,  named the undifferentiated ectodermal cells 
from which the tumours were considered to have arisen “medulloblasts”, and the 
resultant tumour a “medulloblastoma cerebelli” (Rorke, Trojanowski et al. 1997). It 
was however noticed at this time that whilst most of the tumours arose in the 
posterior fossa around the fourth ventricle that they occasionally occurred in the 
cerebral hemispheres, and therefore the term “medulloblastoma cerebri” was later 
applied to these tumours. 
Following a review of CNS tumours, in 1973 Hart and Earle established for the first 
time the term “primitive neuroectodermal tumour” (PNET), but applied this diagnostic 
category to cerebral neuroepithelial tumours only and specifically excluded pineal and 
cerebellar tumours (Hart and Earle 1973). The PNET diagnostic category was later 
adapted and expanded to include all poorly differentiated embryonal neuroepithelial 
tumours wherever they arose in the CNS, and the concept of the “PNET family” of 
tumours was established (Becker and Hinton 1983; Rorke 1983). The hypothesis that 
these histopathologically similar tumours may arise from a common precursor, and 
therefore would benefit from similar treatment approached, in turn facilitated the 
development of unifying “PNET” treatment strategies.  
Pineoblastomas were later removed from the PNET family in the 2nd WHO CNS tumour 
classification (Kleihues, Burger et al. 1993) and co-classified with other pineal tumours, 
although they continued to be often included in studies with other non-cerebellar 
PNETs, and referred to as supratentorial PNETs (SPNETs). A discordance in outcome (as 
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will be discussed in 1.4.5.6) along with emerging molecular studies which suggest 
alternative origins for medulloblastomas and SPNETs has resulted more recently in 
further controversy of the “PNET” concept (Marino, Vooijs et al. 2000; Pomeroy, 
Tamayo et al. 2002; Pfister, Remke et al. 2007). In the current 4th edition of the WHO 
classification of CNS tumours therefore a new term “CNS PNET” was derived to apply 
to PNETs of the CNS that do not arise in the cerebellum (medulloblastoma) or in the 
pineal gland (pineoblastoma)(Louis, Ohgaki et al. 2007). This diagnostic category 
replaced the term “supratentorial PNET” or “SPNET” used in previous classifications 
and importantly included non-cerebellar and non-pineal PNETs located not only in the 
supratentorial compartment but also those that occur, albeit rarely, in the brain stem 
and spinal cord. Medulloblastomas in this classification are not considered PNETs at all, 
but represent a separate and distinct diagnostic entity. 
The investigation and management of CNS-PNETs for over 30 years has been directed 
and moulded by advancements made predominantly in medulloblastoma as a result of 
the PNET concept. The suggestion that this hypothesis should be rejected and CNS-
PNETs investigated and treated as a distinct entity provides a pivotal challenge: if not 
part of the medulloblastoma family of tumours, then what are these tumours and how 
should they best be treated? 
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1.4 CNS-PNET 
1.4.1 Epidemiology 
CNS-PNETs are the second most common CNS embryonal tumour and account for 2-3% 
of all paediatric brain tumours (Bruno, Rorke et al. 1981; Gaffney, Sloane et al. 1985; 
Dai, Backstrom et al. 2003).  It is a disease of early childhood with a mean age of 
incidence of 5.5 years, and two-thirds of all CNS-PNETs occurring before the age of 5 
(Jakacki, Zeltzer et al. 1995; Louis, Ohgaki et al. 2007). CNS-PNETs rarely arise in 
adulthood. A review in 2008 found only 57 reported cases worldwide of supratentorial 
PNETs in adults (Ohba, Yoshida et al. 2008). 
 
1.4.2 Presentation features 
Most frequently CNS-PNETs affect the frontal, temporal or parietal lobes of the 
cerebral cortex, however these tumours may also arise rarely in the suprasellar region. 
The presentation signs and symptoms that a patient presents with depends both on 
the site of the tumour and the age of the patient. Typically the child will present with 
non-specific symptoms as a result of the mass effect of their tumour and subsequent 
raised intracranial pressure (RICP) (Ashwal, Hinshaw et al. 1984). Such non-specific 
symptoms include headache, dizziness, nausea, vomiting, blurred vision, somnolence, 
seizures, weakness and occasionally hemiparesis (Behdad and Perry 2010). These 
tumours are particularly common in very young children who may therefore not be 
able to verbalise their symptoms. Vomiting, seizures and irritability were the most 
common presenting features of thirteen children under the age of 3 years who were 
diagnosed with a SPNET between 1986 and 1990 as part of a larger POG 8633 trial (Dai, 
Backstrom et al. 2003). Focal motor deficits were noted in 46% and in a quarter of 
patients an increased head circumference was noted. This latter sign is specific to the 
infants as it requires the skull bone plates to have non-ossified malleable cartilaginous 
connections which permit expansion of the cranium. Presentation features are 
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therefore characteristically non-specific and similar to those reported in other 
supratentorial tumours (Wilne, Collier et al. 2007). 
 
1.4.3 Diagnostic investigations 
1.4.3.1 Neuroimaging 
MRI of the neuroaxis including the spinal cord is performed pre-operatively to avoid 
post-operative artefacts including subdural collections and contrast leakage into the 
subarachnoid and dural spaces from being misinterpreted as evidence of disease 
dissemination (Wiener, Boyko et al. 1990; Shaw, Weinberger et al. 1996). MRI scanning, 
as shown in Figure 1.13, reveal these tumours to be typically large, over 40% greater 
than 6cm in diameter at diagnosis (Albright, Wisoff et al. 1995) with heterogenous 
signals on both T1 and T2 weighted images due to the variable presence of calcification, 
cystic change and blood within the CNS-PNET tumour mass. Compared with glial 
tumours CNS-PNETs are typically hyperintense on diffusion weighted images (DWI), 
and fluid-attenuated inversion recovery (FLAIR) sequences may be used to 
differentiate necrotic areas (hyperintense) from cystic regions (hypointense). Whilst 
obstruction of CSF pathways resulting in hydrocephalus is a common finding, the 
presence of peritumoural oedema is typically absent (Dai, Backstrom et al. 2003). In 
accordance with other intracranial tumours, CNS-PNETs have been shown to exhibit 
high choline and low N-acetyl aspartate (NAA) on MR spectroscopy (MRS)(Chawla, 
Emmanuel et al. 2007).  
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Figure 1.13. Saggital section magnetic resonance images (MRI) of a supratentorial 
CNS-PNET. (a) T2-weighted image showing a large heterogenous cerebral mass, (b) 
areas of hypodensity on T1-weighted imaging suggestive of necrosis within the tumor. 
Figure adapted from (Behdad and Perry 2010). 
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1.4.3.2 Neurohistopathology 
CNS-PNETs, as described in the current WHO 2007 classification of CNS tumours (Louis, 
Ohgaki et al. 2007) appear as undifferentiated or poorly differentiated highly 
aggressive tumours composed of mitotically active cells, resulting in the proliferation 
index Ki67 antibody staining characteristically intensively, with high nuclear to 
cytoplasmic ratios. The nuclei are typically large and round although in some tumours 
the nuclei may be oval or elongated in shape. Homer-Wright rosettes (Figure 1.14) may 
also be present. The tumour cells may exhibit differentiation along neuronal, astrocytic, 
muscular or melanocytic lines. Neuronal markers such as synaptophysin and 
neurofilament are therefore characteristically positive, and markers such as glial 
fibrillary acidic protein (GFAP) may also be positive depending on the degree of 
astrocytic differentiation (Figure 1.15). 
The diagnosis of a CNS-PNET frequently poses a diagnostic challenge for the 
neuropathologist. Depending on the degree of differentiation these tumours may 
resemble other brain tumours. In the SIOP PNET3 study, for example, 12% of CNS-
PNET diagnoses were not confirmed at central pathological review and the diagnoses 
in these 6 patients changed to include anaplastic astrocytoma, atypical teratoid 
rhabdoid tumour (ATRT), anaplastic oligodendroglioma and anaplastic ependymoma 
(Pizer, Weston et al. 2006). Haberler et al have also reported a subset of previously 
diagnosed CNS-PNETs that were subsequently shown to have loss of INI1 nuclear 
expression (Haberler, Laggner et al. 2006). Whilst these tumours lacked the classical 
rhabdoid features of ATRT their aggressive phenotype and adverse outcome suggested 
that they should be reclassified as ATRT. Immunohistochemical testing for INI1, 
retained in CNS-PNETs and absent in ATRTs, now forms part of the mandatory 
diagnostic work up of these and all “PNET” tumours. 
In the recently proposed ETANTR subgroup of CNS-PNETs (see section 1.3.3) primitive 
ependymoblastoma-like and Homer-Wright rosettes constructed of primitive 
hyperchromatic neurocytic cells and embedded within abundant neuropil are 
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prominent (Figure 1.16). CD99 staining also shows a characteristic dot-like pattern 
within the apical aspect of the rosette primitive cells (Dunham, Sugo et al. 2007). 
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Figure 1.14. Classical CNS-PNET histopathological appearances. On haematoxylin and 
eosin staining (a) Hypercellularity with patchy necrosis is seen at low magnification 
(100x), (b) at higher magnification characteristic oval to carrot-shaped hyperchromatic 
nuclei with minimal cytoplasm is seen (400x). (c). Tumour-associated neuropil may be 
seen in a delicate fibrillary matrix (100x), (d) formation of Homer Wright neuroblastic 
rosettes (200x). Figure adapted from (Behdad and Perry 2010), no scale given in 
original paper, magnifications quoted are approximations. 
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Figure 1.15. Immunohistochemical histopathological features of CNS-PNETs. (a) CNS-
PNET with synaptophysin showing widespread presynaptic membranes (200x); (b) 
CNS-PNET with Neu-N. Neuronal marker showing patch uptake in areas of neuronal 
differentiation within the tumour (200x); (c) Glial-fibrillary acidic protein (GFAP) 
positivity in some tumour cells with glial features (200x); (d) retention of INI1 staining 
in the CNS-PNET, confirming that the tumour is not an atypical teratoid rhabdoid 
tumour (ATRT) in which this staining would be absent (200x). Figure adapted from 
(Behdad and Perry 2010), no scale given in original paper, magnifications quoted are 
approximations. 
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Figure 1.16. Histopathological features of ETANTR. Embryonal tumours with abundant 
neuropil and true rosettes (ETANTR) (a) show numerous ependymoblastic-like rosettes 
constructed of neurocytic cells and embedded within abundant neuropil (haematoxylin 
and eosin (H&E) staining, 200x).  Inset shows an ependymoblastic-like rosette at higher 
magnification (400x). (b) NeuN staining of neurocytic cells (200x). (c) Synaptophysin 
stain highlighting the tumour cells (200x). (d) With CD99 staining a dot-like positivity 
can be observed within the apical aspect of the primitive tumour rosette (400x). Figure 
adapted from (Dunham, Sugo et al. 2007). 
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1.4.4 Disease risk stratification 
There are no molecular or histopathological characteristics that are currently used to 
stratify CNS-PNET management. Treatment is based on the age of the patient, and is 
different in younger (age less than 3 years) and older (age greater than 3 years) 
patients, based on the need to avoid radiotherapy in young children (discussed in 
further detail in section 1.4.5.3). Staging is assigned using the modified Chang staging 
system originally designed for staging medulloblastomas which is based on a 
combination of MRI neuroaxis findings and morphological examination of 
cerebrospinal fluid (CSF) obtained through a lumbar puncture taken 10-14 days after 
surgery (Zeltzer, Boyett et al. 1999). In the same way that neuroaxis imaging is 
performed pre-operatively (section 1.4.3.1) to avoid misinterpretation of post-
operative artefacts, delayed CSF sampling is performed to similarly avoid sampling 
tumour cells that have been deposited in the CSF at the time of surgery and 
misinterpreting this as evidence of metastasis.   
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Chang Stage Classification criteria 
M0 No evidence of metastasis 
M1 
Microscopic evidence of metastasis 
with tumour cells found in CSF 
M2 
Metastatic spread beyond the primary 
site, but remaining within the brain. 
M3 
Metastatic seeding into the spinal 
subarachnoid space 
M4 Metastasis outside of the CNS 
Table 1.7. Chang metastasis staging system. Classification of CNS-PNET metastasis 
based on the Chang staging system originally devised for medulloblastoma staging. 
Classification is based on cerebrospinal fluid (CSF) cytological examination and 
magnetic resonance imaging (MRI) scanning of the central nervous system (CNS) 
encompassing both brain and spinal cord. Table adapted from (Zeltzer, Boyett et al. 
1999). 
 
1.4.5 Treatment  
1.4.5.1 Introduction 
The management of children with CNS-PNETs requires multimodal therapy 
incorporating surgery, radiotherapy and chemotherapy as will be discussed in sections 
1.4.5.2, 1.4.5.3 and 1.4.5.4 respectively. Currently there are no pathological or 
biological features that are used in treatment stratification.  Age at diagnosis, with 
infants and young children under the age of 3-5 years depending on the series, 
remains the only parameter used to determine the treatment strategy. The 
management strategy employed in the UK currently is outlined in Figure 1.17.  
In the UK, children under the age of 3 years are treated using guidelines that apply for 
children with either infratentorial or supratentorial PNETs. Current treatment requires 
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assessment of disease extent with MRI neuroaxis imaging and CSF cytology, and 
upfront surgery to resect as much of the tumour as possible.  Following recovery from 
surgery, children receive 6 cycles of induction high-dose intensive chemotherapy with 
cyclophosphamide, carboplatin and vincristine with granulocyte colony stimulating 
factor (GCSF) support. The use of craniospinal radiotherapy after induction 
chemotherapy is, as will be discussed in 1.4.5.3, controversial but may be offered to 
some patients before a 6 month course of consolidation chemotherapy comprising 4 
cycles of vincrsitine, lomustine (CCNU) and cisplatin (“Packer chemotherapy” (Packer, 
Sutton et al. 1994)).  
For children diagnosed with a CNS-PNET over the age of 3 years in the UK since the 
discontinuation of the most recent UK CNS-PNET trial (UKCCSG HART SPNET) due to 
inadequate registration, the approaches used for children with high-risk 
medulloblastoma are employed. The recommended treatment in the UK follows the 
Milan approach (Massimino, Gandola et al. 2006)  which is summarised in Table 1.8. 
Treatment involves surgery to remove the bulk of the tumour, followed by sandwich 
chemotherapy with methotrexate, cyclophosphamide, etoposide and carboplatin. 
Following recovery from the chemotherapy course the patient receives radiotherapy 
both to the tumour bed, and also to the entire craniospinal axis. In the UK 
conventional radiotherapy is used in preference to hyperfractionated accelerated 
radiotherapy (HART) as used in the Milan study and investigated in the UK HART SPNET 
study, at conventional doses with 20Gy to the tumour bed and 35Gy to the 
craniospinal axis that have been used in previous PNET studies (SIOP PNET 4) 
(Lannering and Kortmann 2004). Treatment is consolidated with 2 courses of high dose 
chemotherapy with thiotepa and peripheral blood autologous stem cell rescue (AuSCR). 
A few centres in the UK (personal communication Dr Barry Pizer, CCLG CNS division) 
may use the St Jude strategy (Chintagumpala, Hassall et al. 2009) which utilises a 
comparable radiotherapy strategy, does not include sandwich chemotherapy, and uses 
4 cycles of cisplatin, cyclophosphamide and vincristine with peripheral blood AuSCR as 
part of a high dose consolidation strategy. The treatment strategies are summarised in 
Table 1.8.  
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Figure 1.17. Current UK management recommendations for intracranial PNETs. 
*Average risk medulloblastoma patients treated suing conventional radiotherapy and 
Packer chemotherapy used in the SIOP/ CCLG PNET4 study. ** The UK CCLG CNS 
division recommendation for the management of high risk MB and CNS-PNET is to use 
high dose chemotherapy with autologous haematopoietic stem-cell rescue (AuHCR) as 
published by the Italian group (Massimino, Gandola et al. 2006) 
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Protocol Milan St Judes UKCCSG HART SPNET SIOP PNET4 
Sandwhich 
chemotherapy 
Methotexate 8g/m2 Topotecan (Optional) No Weekly Vincristine 1.5mg/m
2  
 (x 8 doses) prior to, and during 
radiotherapy 
Etoposide 2.4g/m2     
Cyclophosphamide 4g/m2     
Carboplatin 800mg/m2     
Radiotherapy 
(Start 8 weeks after surgery if 
recovered from chemotherapy) 
(Start within 4-6 weeks from 
surgery) 
(Start within 4-6 weeks 
from surgery) 
(Start within 4-6 weeks from surgery) 
Randomisation 
HART Conventional HART A B 
31.2 - 39 Gy CSI  36-39.6 Gy CSI  39.7Gy CSI Conventional HART 
with 1.3 Gy fractions bd PTB (55.8 Gy total) 22.3 Gy PTB 23.4 Gy CSI  36 Gy CSI 
21-29 Gy PTB (Max 60 Gy total)   1.24 Gy fractions bd 30.6 Gy PTB 32 Gy PTB 
with 1.5 Gy fractions bd     1.8 Gy fraction od 1 Gy fraction bd 
Post- 
radiotherapy 
Chemotherapy 
2 High dose cycles with PBSCT 4 High dose cycles with PBSCT  "Packer Chemotherapy" "Packer Chemotherapy" 
Thiotepa 300mg/m2 Cisplatin 75mg/m2 8 x 6 weekly cycles 8 x 6 weekly cycles 
  Cyclophosphamide 4g/m2  Lomustine 75mg/m2 Lomustine 75mg/m2 
  Vincristine 1.5mg/m2 Cisplatin 70mg/m2 Cisplatin 70mg/m2 
    Vincristine 1.5mg/m2 x3  Vincristine 1.5mg/m2 x3 doses 
Table 1.8. CNS PNET treatment following surgery in children over the age of 3 years. Protocols: Milan (Massimino, Gandola et al. 2006), St 
Judes (Chintagumpala, Hassall et al. 2009), UKCCSG HART SPNET (Saran, Taylor et al. 2004) and SIOP PNET 4 (Lannering and Kortmann 2004). 
Abbreviations: HART: hyperfractionated accelerated radiotherapy; Gy: Gray, od: once daily; bd: bis die (twice daily); CSI: cranial spinal 
radiotherapy; PTB: primary tumour boost; PBSCT: peripheral blood stem cell transplant. “Packer chemotherapy” as originally described in 
(Packer, Sutton et al. 1994).
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1.4.5.2 Surgery 
CNS-PNETs are often located close to the meningeal surface and may become firmly 
attached. Patients with meningeal involvement at the time of surgery are at a higher 
risk of developing progressive disease (Jakacki 1999). Gross total surgical resection is 
possible in only a minority of cases due to the large size of the tumours at presentation 
and their proximity or involvement of important structures. These tumours may also 
occur deep within the brain in thalamic, hypothalamic and paraventricular sites, which 
pose a significant challenge for their safe resection (Dai, Backstrom et al. 2003). It has 
been shown that with post operative residual disease measuring less than 1.5cm2 (as 
judged by post operative imaging) that 4 year survival was 40% (± 22%), compared to 
13% (± 8%) if residual tumour measuring more than 1.5cm2 remains (Albright, Wisoff 
et al. 1995). The need for complete surgical resection does however remain 
controversial. In the HIT 88/89 German series patients with an incomplete resection 
fared as well as those who underwent macroscopically complete resection 
(Timmermann, Kortmann et al. 2002). Current surgical recommendations are therefore 
to attempt maximal surgical resection, aiming for a tumour residuum of less than 
1.5cm2, whilst minimising morbidity and mortality. 
 
1.4.5.3 Radiotherapy 
CNS-PNETs are radiosensitive tumours. Radiotherapy treatment targeted at the 
tumour bed is employed following surgery to improve local disease control. In the HIT 
88/89 study for example, 60% of patients with a CNS-PNET relapsed, and of these in 
almost three-quarters (71%) disease recurred at the primary site only (Timmermann, 
Kortmann et al. 2002). These findings have been subsequently corroborated in the 
SIOP PNET 3 trial in which local failures occurred in 72% of relapsed patients (23/32) 
(Pizer, Weston et al. 2006), and in the CCG921 study where a local failure rate of 42% ± 
8.5%, twice that seen in medulloblastomas, was reported (Hong, Mehta et al. 2004). 
These tumours do however also exhibit a propensity for leptomeningeal spread 
through the subarachnoid space and therefore irradiation of the entire craniospinal 
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axis (CSRT)  in addition to the tumour bed is recommended (Timmermann, Kortmann 
et al. 2002). In the HIT 88/89 and 91 studies a significant 3year PFS advantage was 
observed in those receiving CSRT (43.7% v 14.3%, p=0.012) (Timmermann, Kortmann 
et al. 2002). The dose administered is important with a loss of local control observed 
with doses less than 54Gy (Hong, Mehta et al. 2004; Jakacki 2005). The use of 
radiotherapy, as reviewed in Saran 2004,  in the treatment of this disease is however,  
determined by a number of factors including the patient’s age, the anatomical location 
and extent of the tumour, availability of paediatric radiotherapy and allied supporting 
facilities, as well as patient, parental and physician attitudes towards and assent to 
treatment (Saran 2004). 
Severe neurotoxicity, including profound deterioration in intelligence quotient (IQ) 
scores, have been shown to result from the use of radiotherapy in infants (Spunberg, 
Chang et al. 1981; Danoff, Cowchock et al. 1982; Jannoun and Bloom 1990; Mulhern, 
Kepner et al. 1998). In one large series that followed up 165 children under the age of 
3 whose treatment for a brain tumour included radiotherapy found disabling long-
term morbidity in 58%, and a poorer neurological outcome for those with 
supratentorial tumours (p<0.001)(Syndikus, Tait et al. 1994). The neurological toxicity 
observed is in particular related to the extent of white matter loss (Mulhern, Palmer et 
al. 2001). The use of radiotherapy in infants and very young children for these reasons 
in contemporary management is limited.  
To avoid the devastating neurological consequences of delivering radiotherapy to the 
CNS of infants, strategies which delay or omit the use of radiotherapy have been 
developed. The use of intensive induction chemotherapy, as discussed in section 
1.4.5.4 has been used in these strategies with some limited success (Marec-Berard, 
Jouvet et al. 2002; Timmermann, Kortmann et al. 2006).  
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1.4.5.4 Chemotherapy 
The use of adjuvant chemotherapy in CNS-PNET management has arisen through 
“intracranial PNET” studies involving both medulloblastomas and supratentorial PNETs 
to eradicate minimal residual disease, and the observation that benefit is derived in 
those with high risk tumours. Whilst in medulloblastoma chemotherapy strategies 
have been shown to improve survival (Packer, Sutton et al. 1994; Taylor, Bailey et al. 
2003), the effectiveness of a similar regimen in CNS-PNET is uncertain. In the 
SIOP/CCLG PNET3 trial no benefit was derived in either EFS or OS with the addition of 
chemotherapy (Pizer, Weston et al. 2006), raising doubt as to the effectiveness of 
Packer chemotherapy in this disease (Biswas, Burke et al. 2009).  High dose 
chemotherapy has been employed in predominantly limited institutional series in this 
disease, but its role as discussed in 1.4.5.6, is currently under investigation. 
In infants, chemotherapy has been used to delay or avoid the use of radiotherapy and 
its associated sequelae. In a paediatric oncology group (POG) study, 21 infants under 
the age of 3 years were treated with  2 cycles of vincristine and cyclophosphamide 
following surgery which resulted in a complete or partial response in 6 (29%), and 
stable disease in 9 (43%) (Duffner, Horowitz et al. 1993). Similar findings were 
observed in the Headstart I + II trials, in which 18/22 (82%) of patients treated with an 
intensive induction chemotherapy regimen comprising vincristine, etoposide, 
cyclophosphamide and (in Headstart II) methotrexate achieved a complete or partial 
response (Fangusaro, Finlay et al. 2008). In a further study, a 5 year EFS of 17 ± 6% was 
observed in a study of CNS-PNETs treated with surgery and induction chemotherapy 
only (Geyer, Sposto et al. 2005). 
 
1.4.5.5 Recurrent or refractory disease 
If tumours recur they tend to recur early, typically within 2 years of diagnosis. In 1955 
Collins et al, proposed “Collins’ Law” which states that these tumours recur within 
“nine months plus the age at which they were diagnosed” (Collins, Loeffler et al. 1956). 
55 
 
This has been largely supported in three subsequent studies by Paulino et al, Brown et 
al, Hong et al which showed that this law was upheld in between 93.3%, and 100% of 
cases (Brown, Tavare et al. 1995; Paulino and Melian 1999; Hong, Mehta et al. 2005). 
This law also supports the finding that relapses in younger children occur earlier as 
well as more frequently. In the largest study of CNS-PNETs (CCG 921)  the median time 
to failure for children under the age of 3 was 0.38 years (range: 0.15 – 1.15 years) 
compared to 0.9 years (range: 0.4 - 5.8 years) for older children (Hong, Mehta et al. 
2005). In the same study treatment failure also occurred earlier in those with 
metastatic disease (median age of 0.21 versus 0.41 years for those with metastatic and 
localised disease respectively).   
The outcome for children with recurrent CNS-PNET is dismal. High dose chemotherapy 
has been used in this context, but with limited success. Studies treating patients with 
high dose chemotherapy for recurrent CNS-PNET have always to date been undertaken 
in combination with medulloblastomas, as reviewed in (Gajjar and Pizer 2010). High 
dose carboplatin, etoposide and thiotepa was used in two promising studies from the 
Memorial Sloan Kettering Cancer centre and Children’s Cancer group incorporating 17 
supratentorial PNETs including 9 CNS-PNETs (Broniscer, Nicolaides et al. 2004). In only 
one patient who had received upfront radiotherapy was a second durable remission 
attained (101 months), whilst in all 4 patients who had not received radiotherapy in 
first remission were alive at 40-123 months. Other studies however including the UK 
relapsed PNET and German HIT studies have not replicated these findings, and in total 
only 4.2%  (5/118) patients treated with high dose chemotherapy have become event 
free survivors (Gajjar and Pizer 2010). In combination this suggests that second 
remission may be possible in a subgroup who has not received maximal initial therapy 
with aggressive surgery and radiotherapy, but relapsed patients who have received 
this as part of their upfront therapy continue to have a very poor outcome. 
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1.4.5.6 Clinical Studies of CNS-PNET 
Recent reported clinical studies of CNS-PNETs are summarised in Table 1.9. These 
studies include a number of institutional reviews (Mason, Grovas et al. 1998; Yang, 
Nam et al. 1999; Reddy, Janss et al. 2000; Paulino, Cha et al. 2004; Massimino, Gandola 
et al. 2006; Chintagumpala, Hassall et al. 2009) in addition to clinical trials (Duffner, 
Horowitz et al. 1993; Albright, Wisoff et al. 1995; Cohen, Zeltzer et al. 1995; Marec-
Berard, Jouvet et al. 2002; Timmermann, Kortmann et al. 2002; Hong, Mehta et al. 
2004; Pizer, Weston et al. 2006; Timmermann, Kortmann et al. 2006; Fangusaro, Finlay 
et al. 2008; Grundy, Wilne et al. 2010). In all cases the reported results of CNS-PNETs 
were part of a larger study that incorporated previously classified other intracranial 
PNETs including medulloblastomas or pineoblastomas. The numbers of CNS-PNETs 
included in individual studies are typically small and the distinction in particular 
between pineoblastomas and CNS-PNETs historically is not always recorded. 
The results for infants are consistently dismal and inferior to those achieved in older 
patients. The UKCCSG 9204 baby brain study reported a 0% event free survival (EFS) at 
1 year (Grundy, Wilne et al. 2010), whilst the POG, Societѐ Française Oncologie 
Pѐdiatrique (SFOP) and HIT SKK 87+92 studies resulted respectively in only a 19% 
progression free survival (PFS) at 2 years, 14% overall survival at 5 years, and  a 17% 
PFS at 3 years (Duffner, Horowitz et al. 1993; Marec-Berard, Jouvet et al. 2002; 
Timmermann, Kortmann et al. 2002). An EFS of 43% at 2 years has been achieved in 
one study, but this was a single institutional study and included both pineoblastomas 
and CNS-PNETs and included children up to the age of 5 years (Mason, Grovas et al. 
1998). Their approach however of using high dose chemotherapy with AuSCR following 
tumour resection forms the basis of current treatment in this age group. 
In older children, CNS-PNET clinical studies combined with medulloblastomas using 
surgery, radiotherapy and chemotherapy have been undertaken, but yielded a 
consistently poorer outcome in those children with a CNS-PNET. In the UK for example, 
54 patients with a CNS-PNET were treated on the PNET3 study. An inferior EFS of 41% 
at 5 years was achieved in this study, compared with 74% at 5 years in children treated 
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on the same protocol for medulloblastoma (Taylor, Bailey et al. 2003; Pizer, Weston et 
al. 2006). To date, the best reported results in children over the age of 3 years with 
CNS-PNET’s were derived from a multi-institutional study using cycles of non-
myeloablative chemotherapy and autologous stem cell rescue following tumour 
resection and radiotherapy (Chintagumpala, Hassall et al. 2009). An event free survival 
at 5 years of 78 ± 14% was reported. In  this study, and for the first time patients were 
stratified as either being of “average” or “high” risk based on the presence of 
metastatic disease and degree of tumour resection. The craniospinal radiotherapy 
dose administered to those of average risk was lowered in this study. The 5 year EFS 
was 75% and 60% respectively for the average and high risk patients, suggesting that a 
reduction in CSI and its late effects may be achievable in this disease without 
compromising on survival.  The series, however comprised of only 9 CNS-PNET cases 
and therefore needs to be replicated in a larger multi-institutional cohort. 
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Trial / series Enrolment Tumour Cases PFS (%) Age (years) Reference 
POG 1986-1990 PB + CNS-PNET 36 19 ± 12 @ 2 yr <3 (Duffner, Horowitz et al. 1993) 
CCG 921 1986-1992 CNS-PNET 27 33 @ 3yrs 1.5 -19 
(Albright, Wisoff et al. 1995; Cohen, Zeltzer 
et al. 1995; Hong, Mehta et al. 2004)  
 Memorial Sloan Kettering Cancer   1991-1995 PB 3  43 @ 2yr*  <5 (Mason, Grovas et al. 1998) 
 Center  Institutional Study   CNS-PNET 11       
Institutional study 1986-1995 PB 3 38 @ 5 yrs <17 (Yang, Nam et al. 1999) 
(Seoul University)   CNS-PNET 25       
Institutional study (CNMC + CHP) 1981-1986 CNS-PNET 9 33 @ 5yrs 3-18 (Reddy, Janss et al. 2000) 
HIT 88/89, 91 1988-1998 CNS-PNET 52 34 @ 3yrs 3-18 (Timmermann, Kortmann et al. 2002) 
SFOP 1990-1997 PB 4 14 @ 5yrs** <5 (Marec-Berard, Jouvet et al. 2002) 
    CNS-PNET 21       
Institutional study (UoI + LUMC) 1980-2001 PB 7 36 @ 5yrs 1-32 (Paulino, Cha et al. 2004) 
    CNS-PNET 18       
PNET3 1992-2000 CNS-PNET 54 41 @ 5 yrs 3 -16 (Pizer, Weston et al. 2006) 
Milan 1997 PB 3 54 ± 14 @ 3yrs 3-18 (Massimino, Gandola et al. 2006) 
    CNS-PNET 12     
HIT-SKK 87 +92 1987-1997 PB 2 17 @ 3yrs < 3 (Timmermann, Kortmann et al. 2006) 
    CNS-PNET 27     
Headstart I+II 1991-2002 CNS-PNET 30 48 ± 9 @ 5 yrs*  <10 (Fangusaro, Finlay et al. 2008) 
Multi institutional study*** 1996-2003 CNS-PNET 9 78 ± 14 @ 5yr* 3-21 (Chintagumpala, Hassall et al. 2009) 
UKCCSG CNS 9204 1993-2003 PB 3 0 @ 1yr* <3 (Grundy, Wilne et al. 2010) 
(Baby Brain)   CNS-PNET 8       
Table 1.9. Outcomes from clinical trials and studies of CNS-PNETs.  POG, Pediatric Oncology Group; PB, pineoblastoma; CNS-PNET, central 
nervous system primitive neuroectodermal tumours; CCG, Children’s Cancer Group; SFOP, Societѐ Française Oncologie Pѐdiatrique; CNMC, 
Children's National Medical Center; CHP, Children's hospital of Philadelphia;  UoI, University of Iowa; LUMC, Loyola University Medical Center; 
*event free survival (EFS); **overall survival (OS); ***Texas Children's hospital, USA; Melbourne Royal Children's hospital, Australia; Brisbane 
Royal Children's Hospital, Australia; St Jude Children's Research Hospital, Memphis, USA.
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1.4.5.7 Treatment outcome 
Survival from a CNS-PNET remains poor and inferior to that achieved for those with a 
medulloblastoma. An EFS of 78 ± 14% has been achieved in one pilot study involving 
children over the age of 3 years (Chintagumpala, Hassall et al. 2009), but larger studies 
have consistently shown a poorer outcome with a 3 year EFS of 33-54% (Yang, Nam et 
al. 1999; Reddy, Janss et al. 2000; Timmermann, Kortmann et al. 2002; Paulino, Cha et 
al. 2004; Massimino, Gandola et al. 2006; Pizer, Weston et al. 2006; Fangusaro, Finlay 
et al. 2008). The outcome for infants and children under the age of 3 remains bleak 
with a 3 year EFS of 0 - 19% (Duffner, Horowitz et al. 1993; Timmermann, Kortmann et 
al. 2006; Grundy, Wilne et al. 2010). 
In addition to age, the presence of metastatic disease also affects outcome and may be 
present in up to a third of cases at diagnosis (Timmermann, Kortmann et al. 2002; Pizer, 
Weston et al. 2006; Fangusaro, Finlay et al. 2008). Five year EFS has been shown to fall 
from 64.3% to 36.4% in those with M0 or M1+ disease respectively (Pizer, Weston et al. 
2006). Studies of large series of CNS-PNET are however required to investigate this 
relationship further. 
 
1.4.5.7.1 Long-term therapy associated sequelae 
Survival following a childhood brain tumour is known to be associated with a number 
of adverse sequalae. In a large survey of 342 survivors of childhood brain tumours with 
479 sibling controls, survivors were found to be more than ten times less likely to be 
employed, and almost 30 times less likely to be able to drive a car (Mostow, Byrne et al. 
1991). Young age at diagnosis, the use of cranial or CSI radiotherapy and a 
supratentorial location were all shown to be adverse factors. The association with a 
poorer outcome in those with a supratentorial compartment tumour has also been 
replicated in a recent study that followed 120 patients with a brain tumour (aged 2 – 
24 years)(Kiehna, Mulhern et al. 2006).  Increased cognitive dysfunction was observed 
in those with supratentorial tumours (p=0.035). Furthermore, tumours arising in the 
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dominant hemisphere (left sided cortical tumours, in right-handed people) are 
associated with increased cognitive dysfunction (Hahn, Dunn et al. 2003; Kiehna, 
Mulhern et al. 2006). 
In a recent Childhood Cancer Survivor Study incorporating 818 adult survivors of 
childhood CNS tumours, radiation doses ≥ 30Gy to the temporal region were 
associated with a greater propensity for memory impairment, whilst radiotherapy to 
the frontal lobe was associated with physical performance limitations. (Armstrong, Jain 
et al. 2010). In addition survivors who had received temporal lobe radiotherapy 
reported dose dependent higher rates of poor general health and social functioning.  
Radiotherapy, and in particular CSI in addition to the cognitive and neurological deficits 
is also associated with hearing loss, neuroendocrine defects including hypothalamic 
axis, pituitary and thyroid dysfunction, pneumonitis, cardiotoxicity, scoliosis and 
secondary malignancies.(Schell, McHaney et al. 1989; Holm 1990; Silber, Littman et al. 
1990; Constine, Woolf et al. 1993; Jakacki, Zeltzer et al. 1995; Bieri, Sklar et al. 1997; 
Adams, Lipshultz et al. 2003; Gleeson and Shalet 2004). The risk to benefit balance of 
the use of RT, particularly CSRT, is therefore the major determinant influencing 
treatments used in CNS-PNET. 
Adjuvant chemotherapy may also cause late effects including peripheral neuropathy 
following cisplatin and vincristine administration; nephrotoxicity and subfertility 
following the use of cisplatin or CCNU; deafness with cisplatin; and an increased risk of 
secondary malignancies, and in particular leukaemias following lomustine (CCNU) or 
etoposide administration (Skinner, Wallace et al. 2005). Chemotherapy may also 
potentiate radiation induced defects including cardiac toxicity, growth retardation and 
hearing loss (Gleeson and Shalet 2004). The reduction of late effects arising from the 
surgery, radiotherapy, chemotherapy, or in combination therefore remains a key 
challenge in current management. 
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1.4.5.8 Emerging therapies 
Whilst CNS-PNETs are radiosensitive tumours the late effects derived from the use of 
radiotherapy has limited its role in treatment strategies, particularly in infants and very 
young children under the age of 3 years. The use of conformal radiotherapy has 
enabled a reduction in such toxicities (Saran 2004), but to potentially avoid these risks 
further, proton beam radiotherapy, which enable radiation to be targeted to the 
tumour whilst delivering  a reduced dose to surrounding normal structures, has been 
developed (Greco and Wolden 2007). Proton therapy has already become the “gold 
standard” for some tumours including base of skull chordoma and chondrosarcoma, 
and its use in paediatric and in particular childhood brain tumours is being investigated 
(St Clair, Adams et al. 2004; Bouyon-Monteau, Habrand et al. 2010). 
The use of ifosfamide and temozolamide in CNS-PNET has been suggested, based on 
the hypothesis that as some of these tumours show similarities with glioblastoma 
which benefit from these therapies, a similar beneficial effect may be derived in 
patients with CNS-PNET (Biswas, Burke et al. 2009). In support of this, Temozolamide 
has been successfully used in an adult patient with a CNS-PNET (Terheggen, Troost et 
al. 2007). 
 
1.4.6 CNS-PNET: The clinical challenge 
Current therapeutic strategies for CNS-PNETs are derived from adjusted strategies for 
medulloblastomas based on the historical concept of an intracranial “PNET”. These 
strategies result in a poorer prognosis for patients with CNS-PNET irrespective of 
disease spread or their age. In addition, survivors of this disease are frequently left 
with significant toxicities as a result of the treatment which confers further lifelong 
health and social disadvantages. There is therefore a very clear and urgent need to 
improve the outcomes for these patients, by improving the treatments they receive. 
Advancements could be made through the development of molecularly targeted 
therapies, or through the identification of disease sub-groups which may in turn permit 
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a stratified therapeutic approach. Both of these approaches have been successfully 
employed in the treatment of other cancers including the use of the tyrosine kinas 
inhibitor imatinib mesylate in the management of BCR-ABL chronic myeloid 
leukaemia(Baccarani, Dreyling et al. 2009), and in the management of childhood acute 
lymphoblastic leukaemia (ALL) a risk-adapted stratified approach is used based on a 
combination of clinical and molecular criteria (Moorman, Ensor et al. 2010). The 
fundamental clinical challenge of improving outcome is however itself restrained by 
the current poor understanding of the biological mechanisms involved in the 
development of a CNS-PNET as a result of a paucity of research into this tumour. To 
address the CNS-PNET challenge a programme of research into these tumours is 
therefore now required. 
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1.5 Molecular genetics of CNS-PNET  
1.5.1 Introduction 
To date, research into the biological basis of CNS-PNET tumorigenesis has been limited, 
and correspondingly our understanding of the molecular basis for these tumours is 
poor. Studies into the molecular characterisation specifically of CNS-PNETs, and the 
discovery of disease distinct events have rarely been undertaken. Insights into the 
development of these tumours have been derived from tumours developed in children 
with genetic predisposition syndromes (section 1.5.2), but have predominantly come 
from larger intracranial PNET studies, which have included only a limited number of 
CNS-PNETs, and comparison with defects observed in medulloblastomas.  
 
1.5.2 Genetic predisposition to CNS-PNET 
1.5.2.1 Introduction 
A number of different familial conditions are associated with the development of brain 
tumours, summarised in Table 1.10. Li Fraumeni syndrome, Turcot syndrome, and 
Gorlin syndrome however are all associated with the development of intracranial 
PNETs. 
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Syndrome Gene Chromosome CNS tumours 
Neurofibromatosis type 1 
  
  
  
NF1 
  
  
  
17q11 
  
  
  
Neurofibroma 
MPNST* 
Optic pathway glioma (OPG) 
Astrocytoma 
Neurofibromatosis type 2 
  
  
  
  
NF2 
  
  
  
  
22q12 
  
  
  
  
Bilateral vestibular schwannoma 
Meningioma 
Meningioangiomatosis 
Spinal ependymoma 
Astrocytoma 
Von Hippel-Lindau VHL 3p25 Hemangioblastoma 
Tuberous sclerosis 
  
TSC1 9p34 Subependymal giant cell astrocytoma 
TSC2 16p13   
Li-Fraumeni 
  
TP53 
  
17p13 
  
Primitive neuroectodermal tumour 
Astrocytoma 
Turcot  
  
  
APC 5q21 Medulloblastoma 
hMLH1 3p21 Glioblastoma 
hPSM2 7p22   
Cowden PTEN 10q23 
Dysplastic gangliocytoma of the 
cerebellum (Lhermitte-Duclos) 
Gorlin** PTCH 9q31 Medulloblastoma 
Rhabdoid tumour 
predisposition syndrome INI1 22q11.2 Atypical teratoid rhabdoid tumour 
Table 1.10. Familial brain tumour predisposition syndromes.  *MPNST: Malignant 
peripheral nerve sheath tumour, ** Gorlin syndrome, is also known as nevoid basal 
cell carcinoma syndrome (NBCCS). Table adapted from (Louis, Ohgaki et al. 2007) 
 
1.5.2.2 Li Fraumeni Syndrome 
Li Fraumeni syndrome (LFS) is an autosomal dominantly inherited disorder 
characterised by the development of multiple tumours in childhood and in adult life. 
Tumours that develop may include soft tissue sarcomas, osteosarcomas, breast cancer, 
leukaemia, adrenocortical tumours and brain tumours (Li, Fraumeni et al. 1988). The 
incidence of LFS ranges from 1 in 5000, to 1 in 20,000 live births (Lalloo, Varley et al. 
2006; Gonzalez, Noltner et al. 2009). LFS families are defined as those where a patient 
develops a sarcoma before the age of 45 years, a first degree relative develops cancer 
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before the age of 45, and an additional first degree relative develops a cancer before 
the age of 45 or a sarcoma at any age (Li, Fraumeni et al. 1988). A Li-Fraumeni like 
syndrome (LFLS) has also been described where a childhood tumour, brain or 
adrenocortical tumour occur before the age of 45 in addition to a first or second 
degree relative developing any cancer before the age of 60 (Hottinger and Khakoo 
2009). LFS results from mutation in the TP53 gene (discussed in detail in section 1.5.5.1) 
in 70% of cases, whilst mutations in TP53 (Kleihues, Schauble et al. 1997) are observed 
in only 20-40% of families with LFLS (Hottinger and Khakoo 2009). 46% of the 
mutations observed were missense and located at codons frequently mutated “hot-
spot” codons in cancer 175, 213, 245, 248, 273, and 282 (Olivier, Goldgar et al. 2003). 
Brain tumours occur in 10-15% of people with LFS, typically before the age of 45. The 
majority of these tumours are gliomas, but in up to a third medulloblastomas and CNS-
PNETs develop (Taylor, Mainprize et al. 2000). Unfortunately almost half of all patients 
who are successfully treated for a cancer will develop a second cancer within 30 years 
(Birch, Alston et al. 2001). In patients with Li-Fraumeni Syndrome it is therefore 
recommended that ionising radiation therapy where possible is avoided to reduce the 
risk of further tumours (Evans, Birch et al. 2006). 
 
1.5.2.3 Turcot syndrome 
Turcot syndrome is an autosomal dominantly inherited condition characterised by 
adenomatous colorectal polyps or colonic carcinomas in addition to brain tumours. 
There are two forms of Turcot syndrome. In type 1 Turcot syndrome, glioblastomas 
occur in the presence of germline mutations of mismatch repair genes (hPMS2, hMSH2 
or hMLH1) or hereditary non-polyposis colorectal carcinoma (HNPCC). In type 2 Turcot 
syndrome medulloblastomas occur in patients with familial adenomatous polyposis 
(FAP) or with germ line mutations of APC (5q21). The risk of developing a brain tumour 
with Turcot syndrome is 92 times greater than in the general population (Hamilton, Liu 
et al. 1995). Turcot syndrome has also been described in children who develop CNS-
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PNETs with mutations in germline PMS2 and MSH2 described (De Vos, Hayward et al. 
2006; Jeans, Frayling et al. 2009). 
 
1.5.2.4 Gorlin syndrome 
Gorlin syndrome, or naevoid basal cell carcinoma syndrome (NBCCS) is an autosomal 
dominant disease characterised by a spectrum of developmental abnormalities and 
neoplasms, reviewed in (Lo Muzio 2008).  It is caused by germline mutations of the 
PTCH gene, located on chromosome 9 (9q22.3) and in the UK affects 1 in 55,000 to 
57,000 of the population (Farndon, Del Mastro et al. 1992; Evans, Ladusans et al. 1993). 
90% of affected individuals develop multiple skin basal cell carcinomas in early 
childhood and also keratocysts of the jaw within the first three decades of life (Evans, 
Ladusans et al. 1993). Palmar and plantar dyskeratoses and congenital abnormalities 
including macrocephaly, cleft lip and/ or palate, and skeletal defects may also occur. 
Within the CNS ectopic calcification and cyst development may occur (Stavrou, 
Dubovsky et al. 2000). The development of medulloblastoma in young children under 
the age of 2 years is also a feature of Gorlin syndrome. These tumours have been 
associated with desmoplasia and the medulloblastoma with extended nodularity 
(MBEN) subtype and a superior prognosis (Amlashi, Riffaud et al. 2003; Garre, Cama et 
al. 2009). In addition to the histopathological and prognostic associations, it has been 
suggested that the identification of patients with Gorlin syndrome may increasingly 
have a therapeutic significance (Choudry, Patel et al. 2007). Patients with Gorlin 
syndrome have an increased risk of radiation induced tumours and therefore it may be 
in the future that the judicious use of radiotherapy in the management of these “less 
aggressive” medulloblastomas may be warranted (Choudry, Patel et al. 2007). 
 
67 
 
1.5.3 Cytogenetic abnormalities in CNS-PNET 
There have been very few studies to characterize cytogenetic abnormalities in CNS-
PNET. As with nearly all genetic studies in this disease, when performed these studies 
have usually been as a part of an overarching “PNET” characterization study involving 
medulloblastomas and pineoblastomas, or as part of a paediatric brain tumour study. 
A series of studies have characterised the karyotype of 23 CNS-PNETs in total, 
(Chadduck, Boop et al. 1991; Fujii, Hongo et al. 1994; Bhattacharjee, Armstrong et al. 
1997; Bigner, McLendon et al. 1997; Burnett, White et al. 1997; Bayani, Zielenska et al. 
2000; Roberts, Chumas et al. 2001; Uematsu 2003), as summarised in Table 1.11. The 
most common abnormalities were found with chromosome 11 in 10/23 (43%) cases. 
These chromosome 11 cytogenetic abnormalities includes gains (1/23, 4%), losses 
(3/23, 13%), translocations (4/23, 17%) and other abnormalities (duplications, 
deletions and gain of additional material) in 4/23 (17%). A gain of chromosome 7 was 
observed in 4/23 (17%) and loss of chromosome 13 also in 4/23 (17%).  
The most common cytogenetic abnormality seen in medulloblastoma is loss of the p-
arm of chromosome 17 occurring in up to 40% of tumours (McDonald, Daneshvar et al. 
1994; Burnett, White et al. 1997). This may occur in association with a gain of 17q and 
the formation of an isochromosome (i17q) or may arise as an isolated defect. 17p loss 
or i17q formation was not found in any of the CNS-PNET cases described, however 
chromosome 17 loss and a deletion of 17q21.3 were both observed in isolated cases 
(Bayani, Zielenska et al. 2000; Roberts, Chumas et al. 2001).  
In a third of cases (8/23) a normal karyotype was found. Karyotyping may however not 
detect more subtle cytogenetic alterations, and therefore comparative genomic 
hybridization (CGH) studies have also been undertaken in a small number of cases. A 
study by Nicholson et al reported the cytogenetic features by CGH of 4 paediatric CNS-
PNETs  (Nicholson, Wickramasinghe et al. 2000). In one case no abnormality was 
detected, but in the other 3 cases a series of genetic losses and gains were observed, 
including in common with the previous karyotyping studies, frequent gains on 
chromosome 7 (2/4, 50%). Unfortunately in CGH studies by Russo et al, Avet-Loiseau et 
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al and Inda et al, involving 18 SPNETs the distinction between pineoblastomas and 
CNS-PNETs was not made, and therefore these findings cannot reliably be used to 
characterize CNS-PNET disease (Avet-Loiseau, Venuat et al. 1999; Russo, Pellarin et al. 
1999; Inda, Perot et al. 2005). 
More recently, three studies (summarised in Table 1.12 and Table 1.13) have 
interrogated CNS-PNETs by array-CGH, which has provided an enhanced resolution of 
genetic abnormalities observed in these tumours (Kagawa, Maruno et al. 2006; 
McCabe, Ichimura et al. 2006; Pfister, Remke et al. 2007). Even with the superior 
resolution that array CGH provides, in keeping with the previous karyotyping studies in 
3 cases (3/20, 15%) no abnormality was observed suggesting that alternative 
tumourigenic mechanisms (see section 1.2) may be implicated in at least a sub-group 
in this disease.  In total genetic gains were observed in 35% (7/20) involving 
chromosome 12, 30% (6/20) with chromosome 7q, and 20% (4/20) for both 
chromosomes 17q and 2p.  
Interestingly, in the Pfister series loss of 17p was seen in 2 cases (2/10, 20%), and the 
region of loss (17p11.2-pter) occurred at the breakpoint similar to that which has been 
observed in medulloblastomas (Biegel, Janss et al. 1997; Scheurlen, Seranski et al. 
1997). This finding was not observed however in either the McCabe et al, or Kagawa et 
al studies. In a recent large medulloblastoma study 25% (47/190) of medulloblastomas 
were shown to have loss of 17p (Ellison, Kocat et al. 2011). This finding, (as will be 
discussed in chapter 3 and summarised in table 3.28) has only rarely been observed in 
CNS-PNETs, but very limited small studies only have previously been performed and a 
dedicated study of 17p defects in CNS-PNETs has not previously been undertaken.   
Finally, using a high resolution single nucleotide polymorphism (SNP) array on 39 CNS-
PNETs,  Li et al in common with the previous array CGH studies identified recurrent 
gains (8/39, 21%) on chromosome 2 incorporating the MYCN locus and also a novel 
amplicon on chromosome 19 (19q13.42) incorporating a micro RNA cluster (8/39, 21%) 
(Li, Lee et al. 2009). Amplification at this locus was shown to confer an adverse 
69 
 
prognosis (4 +/- 1.3 months in amplified cases versus 44 +/- 12.8 months in non-
amplified cases; p<0.0001). 
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Reference 
Age 
(Years) 
Karyotype 
 (Chadduck, Boop et al. 1991) <1 Normal 
<1 Normal 
<1 Normal 
<1 45, XY,-22 
 (Fujii, Hongo et al. 1994) 9 Normal 
11 
43-44;XY;+2,-6;der(10)t(10;11)(q26;q21),del(11)(q21,-12,-
13=mar,(8)/84/90,XXYY,der(10)t(10;11)(q26:21),der(10;11)(q26:q21),del(11)(q21),+2mar/(8) 
14 Normal 
 (Bhattacharjee, Armstrong et al. 1997)   46,XY,i(1)(q10);-9,t(9;11)(q34;q13)<8?/90; idemx2, -X,Y1/46;XY 
 (Bigner, McLendon et al. 1997) 2 46,XY,t(6:9)(q21;q13),del(10)(q22)2/34. idem, t(11;13)(q15;q11)-13 
  Normal 
  Normal 
  Normal 
 (Burnett, White et al. 1997) 
 
 
 
(Bayani, Zielenska et al. 2000) 
 
 
7 
49,XX,add(3)(q23 or q24),+5,+8,dup(11)(q12q22.3 or 
q13q23),del(16)(q22q24),add(19)(p13),+21[8]/49.idem,add(13)(q34[1] 
16* 
90,XX,add(X)(p22)x2,dic(1;9)(q42;p21)x2,dic(4;9)(q3?5;p2?2),6,add(6)(p24), 
9,add(11)(p15)x2,add(16)(q2?2),+mar1,+mar2[11] 
3 70-103 chromosomes, dmins and double rings 
3 55-75,XX,-X,del(1)(p22),i(4)(p10),-5,+6,+add(7)(q36),add(9)(p21),-11,-13,-17,add(18)(q23),-19,-19,+13mars+dmins 
4 46,X,?rea(X),?rea(10p),?rea(14q),add(19q),+?add(22q),22q 
6 46,XY,t(6;13)(q25;q14) 
 (Roberts, Chumas et al. 2001)   46,XX,del(2)(p22.2-2p23.1),del(5)(q33-q35)/46,idem,del(17)(q21.3q21.3) 
  der(9:15)(q10;q10)x2,+11,+13,+18,+20,+56-59,Xc,+X<+1,+1,+1,add(1)(p?),add(1)(q?),+2,del(2)(p24),+7,+8,add(8)(q?) 
  69~75XX,-X,add(10(q42)x2,-4,-4,add(4)(q3?),-10,-11,del(11)(q2?),-13,-16,-18,+7~13mar,dmin(cp7)dmins 
 (Uematsu, Takehara et al. 2002) 7 52,XX,+1x2,add(3)(q25)+7x2,add(11)(q25)x2,+21x2 
Table 1.11. Reported karyotypes of CNS-PNETs. Karyotypes described using International System for Cytogenetic Nomenclature (ISCN) 1995 
(Mitelman 1995), * relapse tumour sample.
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Reference 
 
Case 
 
Age 
(years) 
Gain 
 
Loss 
 
 (Kagawa, 
Maruno et al. 
2006) 
1 <1 MSH2 (2p22.3-p22.1), ERBB2 (17q11.2-q12), BCR (22q11.23) (none) 
2 2 Ch 7, MYCN (2p24.1), MSH3 (5q11.2-q13.2), EGFR (7p12.3-p12.1), RFC2 
(7q11.23), PTCH (9q22.3), DMBT1 (10q25.3-q26.1), GLI (12q13.2-q13.3), 
ERBB2 (17q11.2-q12) , TK1 (17q23.2-q25.3), STK6 (20q13.2-q13.3) 
Chr 6q, MSH2 (2p22.3-p22.1) 
3 3 MSH2 (2p22.3-p22.1), EGFR (7p12.3-p12.1), RFC2 (7q11.23), DBCCR1 
(9q33.2), CDK2 & ERBB3 (12q13), BRCA1 (17q21), STK6 (20q13.2-q13.3) 
APC (5q21-q22), SNRPN (15q12), HRAS (11p15.5), GLI 
(12q13.2-q13.3) 
 (McCabe, 
Ichimura et al. 
2006) 
4 - FIP1L1-CHIC2 (4q12) 13q14.11qter 
5 - FOXQ1-FOXF2 (6p25.3), ALDH8A1-MYB (6q23.3), PHACTR2-SF3B5 (6q24.2) RASA3 (13q34) 
6 - CACNG8-LILRB5 (19q13.42) RASA3 (13q34) 
7 - (none) Chr 13q 
8 - (none) CDKN2A/CDKN2B (9p21.3) 
9 - (none) (none) 
10 - (none) (none) 
 (Pfister, 
Remke et al. 
2007) 
11 1 (none) (none) 
12 1 ADAM8 (10q26.3) (none) 
13 2 UNC5B/CDH23 (10q22.1) (none) 
14 3 PRDM16 (1p36.32), CNTNAP2 (7q35), NOS3 (7q36.1), URP2 (11q13.1), 
DACH1 (13q22), TNFRSF6B (20q13.33) 
UNC5C (4q22.3) 
15 3 TNFRSF6B (20q13.33) AJAP (1p36.13), IGSF21 (1p36.13), GRM2 (3p21.1), 
TAF6L/HRASLS3 (11q13) 
16 6 TMEM/MGC33556 (1p34.1), MM-1 (12q13.13), NULL (12q23) NULL (1q31.1), UNC5C (4q22.3), GPR116 (6p12.3) 
17 7 RHOB (2p24.1), MAP3K7 (6q16), MM-1 (12q13.13), NULL (12q23), DACH1 
(13q22) 
AJAP (1p36.13), IGSF21 (1p36.13), HRG (3q27.3), DOK7 
(4p16.2), DUSP8 (11p15.5), RHOG (11p15.4), JAM3 (11q25) 
18 7 CNTNAP2 (7q35), NOS3 (7q36.1) GPR116 (6p12.3), MED4 (13q14.2) 
19 11 LMO1/STK33 (11p15.4) MGMT (10q26.3), DUSP8 (11p15.5), RHOG (11p15.4), 
TAF6L/HRASLS3 (11q13), GRM5 (11q14.2), JAM3 (11q25) 
20 12 IGFB2/5 (2q35), TNFRSF6B (20q13.33), PDGFB (22q13.1) MED4 (13q14.2) 
Table 1.12. Losses and gains in CNS-PNET tumour samples by array CGH. Genes names in italics:  www.ensembl.org/Homo_sapiens. NULL: Gene 
unspecified. Regions of gains or losses <3MB only are shown for cases 11-20 from the Pfister et al study. 
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Chromosome Loss or Gain Number Frequency (%) 
13q Gain 5 25 
20q Loss 5 25 
2p Gain 4 20 
7q Gain 4 20 
12q Gain 4 20 
10q Gain 3 15 
11p Loss 3 15 
11q Loss 3 15 
17q Gain 3 15 
Table 1.13. Summary of the most frequent chromosomal abnormailities by array CGH in 
CNS-PNETs. The most frequent nine abnormalities observed in 20 CNS-PNETs investigated by 
array CGH in three studies (Kagawa, Maruno et al 2006; McCabe, Ichimura et al 2006; and 
Pfister, Remke et al 2007).
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1.5.3.1 19q13.42 amplification and ETMR 
In 2009, Pfister et al reported the results of an array CGH performed on the tumour 
sample taken from a 2 year old girl with a CNS-PNET(Pfister, Remke et al. 2009). An 
amplification at 19q13.42 was detected which has been subsequently been identified 
from two further studies in an additional 48 cases (Li, Lee et al. 2009; Korshunov, 
Remke et al. 2010). This amplification appears to be specific to CNS-PNETs, and did not 
occur in an additional 300 paediatric brain tumours screened for this amplicon 
(Korshunov, Remke et al. 2010). The histopathological feature of the original case and 
72% (8/11) of the Li et al, series were consistent with the proposed embryonal tumour 
with multilayered rosettes (ETMR) subtype (see section 1.3.3), whilst all of the tumours 
investigated by Korshunov et al, were of the ETMR subtype, and the 19q13.42 
amplicon was present in 93% (37/40). In addition to the histopathological correlation, 
these tumours also appear to occur in children under the age of 3 and associated with 
an inferior outcome compared with other children with CNS-PNETs. 
 
1.5.4 Gene specific defects in CNS-PNET 
The development of CNS-PNETs in those with cancer predisposition syndromes has 
suggested a role of a number of cell signalling pathways, including wnt/wingless, p53, 
sonic hedgehog and Notch, in CNS-PNET tumorigenesis. Aberrations of components of 
these pathways have subsequently been shown to be implicated in this disease, as is 
discussed in section 1.5.5. Cytogenetic studies, as discussed in section 1.5.3, have also 
identified a number of loci associated with CNS-PNET development including CDKN2A 
(section 1.5.5.1) and the MYCC and MYCN (section 1.5.4.1). 
 
1.5.4.1 MYC family genes 
The MYC family of oncogenes comprises 3 genes (MYCN, MYCC and MYCL) which are 
involved in cell growth, proliferation, differentiation and apoptosis (Pelengaris, Khan et 
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al. 2002). In humans MYCC, MYCN and MYCL are mapped to 8q24.1, 2p24 and 1p34 
respectively, and have similar gene structures (Ryan and Birnie 1996). 
 
1.5.4.1.1 The functional role of MYC 
The MYC genes are essential for normal development. In murine models knockdown of 
either c-myc or n-myc is lethal within 10.5 and 12.5 days respectively (Charron, Malynn 
et al. 1992; Davis, Wims et al. 1993). Germ-line mutation and deletions of MYCN have 
also been shown to be associated with a number of developmental defects including 
oesophageal atresia, duodenal atresia, congenital cardiac defects, macrocephaly and 
learning difficulties as part of Feingold syndrome (FES) (van Bokhoven, Celli et al. 2005).  
In cancer, MYC is implicated in promoting cell growth, vasculogenesis, reducing cell 
adhesion, increasing genomic instability and promoting metastasis (summarised in 
Figure 1.18) (Adhikary and Eilers 2005; Vita and Henriksson 2006). Cell growth is 
promoted through the role of MYC enabling  G0/1 to S phase cell cycle progression 
(Meyer and Penn 2008). MYC messenger RNA (mRNA) and protein levels increase 
during cellular proliferation, but are absent in differentiated quiescent cells. Sustained 
up-regulation of MYC expression conversely has been shown to be associated with an 
inhibition of cellular differentiation and the promotion of tumour development 
including tumours that resemble human PNETs (Su, Gopalakrishnan et al. 2006). 
Genomic instability has been shown to result from up-regulated MYC expression (Mai, 
Hanley-Hyde et al. 1996), occurring through a variety of mechanisms including 
alteration in chromosomal structure, the promotion of DNA strand breaks  with 
increased levels of reactive oxygen species, and bypassing the p53 checkpoint through 
repression of p53 (Prochownik and Li 2007). The role of MYC in angiogenesis has also 
been demonstrated in cell line and murine models (Ngo, Gee et al. 2000; Prochownik 
and Li 2007). In addition to its effect on growth, MYC family members may also 
promote apoptosis through p53 dependent and independent pathways (Prochownik 
and Li 2007; Meyer and Penn 2008).
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Figure 1.18. Cellular control by MYC during normal conditions and tumorigenesis. Myc is a key regulator of many biological activities and the 
deregulation of Myc may result in apoptosis, genomic instability, uncontrolled cell proliferation, escape from immune surveillance, growth 
factor independence, and immortalization. Figure taken from (Vita and Henriksson 2006).
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1.5.4.1.2 MYC genes in human cancers 
The involvement of MYCC, MYCN and MYCL have are all implicated in human cancer 
development.  MYCC is up-regulated in approximately 70% of all human tumours 
(reviewed in (Vita and Henriksson 2006) but most frequently occurs in Burkitt’s 
lymphomas which is characterized by a translocation incorporating the MYCC locus 
which results in MYCC over-expression in 91% of cases (Vita and Henriksson 2006). 
MYCC amplification may also occur in many human tumours including osteosarcomas, 
melanoma and ovarian, beast, bladder, prostate, cervical, colonic, lung, gastric and 
hepatocellular carcinomas (Vita and Henriksson 2006).  Amplification, particularly at a 
high level, is frequently associated with a poorer prognosis (Nesbit, Tersak et al. 1999; 
Takei, Nguyen et al. 2009). MYCN amplification in contrast with MYCC amplification is 
associated with predominantly paediatric tumours including neuroblastoma, 
rhabdomyosarcoma, medulloblastoma and retinoblastoma (Nesbit, Tersak et al. 1999). 
It is however also associated with a more aggressive phenotype and a poorer prognosis. 
MYCN amplification was the first genetic marker used in the management of 
neuroblastoma which is associated with a reduced 5 year overall survival from 98% to 
36% in MYCN amplified cases (Lu, Pearson et al. 2003; Vasudevan, Nuchtern et al. 
2005). The MYCL gene has been less commonly associated with tumours in humans 
compared to the MYCC and MYCN homologues, but has been seen in ovarian 
carcinoma and  small cell lung carcinoma (Vita and Henriksson 2006). The impact of 
MYCL amplification on clinical outcome has however not been established. 
 
1.5.4.1.3 MYC genes in medulloblastoma and CNS-PNET 
MYCC and MYCN amplification occur in 15-25% of medulloblastomas, are associated 
with large cell anaplastic subtype and an unfavourable outcome (Leonard, Cai et al. 
2001; Lamont, McManamy et al. 2004; Vita and Henriksson 2006; Pfister, Remke et al. 
2009). Few studies however have investigated MYC family amplification in CNS-PNETs. 
In murine models CNS-PNETs have been shown to develop with increased c-myc 
expression. In a study involving 43 p53 deficient mice, CNS-PNETs developed in 35% 
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(15/43) of cases, located in the periventricular region in 53% (Momota, Shih et al. 
2008). In human studies 54 CNS-PNET tumour samples analysed across three clinical 
cohorts revealed MYCC and MYCN amplification in 5% cases (MYCN amplification 1/54, 
MYCC amplification 5/54) (Fruhwald, O'Dorisio et al. 2000; Pfister, Remke et al. 2007; 
Behdad and Perry 2010). However in CNS-PNETs unlike in medulloblastomas, no 
clinicopathological correlation with MYC expression has been derived. In summary, the 
previous studies in CNS-PNET show that the MYC family genes are implicated in CNS-
PNET development, and demands further investigation. 
 
1.5.5 Developmental pathways disrupted in CNS-PNET  
1.5.5.1 The p53 pathway 
Located on chromosome 17 at 17p13.1, TP53 was one of the first tumour suppressor 
genes discovered four decades ago (Linzer and Levine 1979). TP53 codes for a 393 
amino acid phosphoprotein transcription factor found at low levels in all healthy 
tissues, and has a number of critical roles that has lead to it being referred to as “the 
guardian of the genome” (Lane 1992). Cellular stresses including DNA damage, hypoxia, 
growth factor depletion, oncogenic activation and microtubule disruption result in the 
stabilisation and nuclear accumulation of activated p53 (Figure 1.19). Activated p53 is 
then able to induce a number of responses including cell cycle arrest and apoptosis 
(Vousden and Lu 2002).  
During embryogenesis up to 50% of neurones undergo apoptosis under the control of 
p53 as they fail to differentiate correctly (Oppenheim 1991). The pro-apoptotic 
functions of p53 are however potentially lethal and are therefore tightly regulated 
(Figure 1.19). MDM2, an E3 ubiquitin ligase, is a critical negative regulator of p53. 
MDM2 itself is induced in response to p53 activation and therefore forms a tightly 
regulated negative feedback loop. Deletion of mdm2 in the mouse model is lethal in 
early embryonic development (Marine, Francoz et al. 2006). In addition the tumour 
suppressor p14ARF, both negatively regulates MDM2 and inhibits the p53-MDM2 
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interaction by binding to MDM2 within the nucleolus facilitating p53 accumulation and 
enabling p53 induced transcriptional activity (Sionov, Coen et al. 2001). P53 levels are 
highest in G1 phase, and accumulate in the nucleus in S phase (Shaulsky, Goldfinger et 
al. 1990) 
Post translation modifications of p53 may arise in response to stress and  may include 
the addition of a functional group to p53 by phosphorylation, ubiquitylation, 
acetylation, sumolyation, glycosylation, ribosylation and methylation and direct 
whether apoptotic genes or those involved in cell cycle arrest are transactivated 
(Vousden and Lu 2002). Subcellular location is another important component of p53 
regulation. Whilst p53 may readily shuttle in a cell cycle dependent manner between 
the nucleus and cytoplasm, translocation to the nucleus is essential for it to undertake 
its transcriptional activity (Jimenez, Khan et al. 1999; Sionov, Coen et al. 2001).  
Targets of p53 may inhibit cell cycle progression leading to G1 or G2 arrest and include 
p21WAF1 and GADD45. p21WAF1 is an inhibitor of cyclin dependent kinases (CDKs) and by 
binding to cyclin-CDK complexes blocks cell cycle progression from G1 to S phase 
(Levine 1997; Vogelstein, Lane et al. 2000). GADD45 directly inhibits G2M transition 
through binding with B1-Cdc” complexes (Zhan, Antinore et al. 1999). 
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Figure 1.19. Overview of the p53 pathway. The cellular response of p53 to DNA 
damage and stresses includes cell cycle arrest enabling either apoptosis or DNA repair. 
Control of the pathway is influenced by MDM2 by negative feedback inhibition. Levels 
of MDM2 are themselves controlled by p14ARF and both MYCC and MYCN. Figure 
adapted from (Carr, Bell et al. 2006). 
 
1.5.5.1.1 The TP53 gene and cancer 
The TP53 gene encodes a 393 amino acid phosphoprotein and is comprised of five 
functional domains (Vousden and Lu 2002). Amino acid residues 1-42 at the N-
terminus form the transcriptional activation domain (TAD) where interaction with 
basal transcriptional machinery results in transactivation of downstream target genes. 
It is at this site where negative regulators such as MDM2 bind to inhibit p53 mediated 
transcriptional activity. A second domain is located at codons 40-92 and contains a 
series of repeated proline residues and a second transactivation domain. The amino 
acid residues 101-306 constitute the (central) DNA binding domain (DBD). DNA binds 
to p53 at this site, and it is within the DBD where TP53 is commonly mutated. An 
oligomerization domain at codons 307-355 is involved in the formation of p53 dimers. 
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The final carboxy-terminus of p53 (amino acid residues 356-393) contains 3 nuclear 
localization signals (NLS) and a non-specific DNA binding domain that binds to 
damaged DNA. This region is also involved in downregulation of DNA binding to the 
central domain (DBD). 
TP53 is frequently mutated in human cancers, and occurs in over a third of non- 
melanomatous skin (80%), lung (70%), head and neck (60%), colonic (60%), ovarian 
(60%), bladder (60%), gastric (45%) and oesophageal (40%) cancers (data from 
http://p53.free.fr/p53). TP53 mutation most commonly occurs at residues R175, G245, 
R248, R249, R273 and R282, accounting for 30% of all TP53 mutations (Figure 1.20) 
and result in damage to the structural integrity of the DBD (Greenblatt, Bennett et al. 
1994; Levine 1997). The majority of TP53 mutations result in a single amino acid 
substitution; 75% are missense and 7% nonsense (http://www-p53.iarc.fr/). Mutation 
results in the accumulation of an inactive mutant protein although in some cases a 
gain of function has been demonstrated (Lang, Iwakuma et al. 2004; Olive, Tuveson et 
al. 2004; Soussi and Lozano 2005). Germline mutations of TP53 result in the Li 
Fraumeni cancer predisposition syndrome (see section 1.5.2.2). 
 
Figure 1.20. Genetic location of TP53 mutations in human cancers. In 30% of tumours 
mutations arise in the DNA binding region at 6 codons (175, 245, 248, 273 and 282). 75% 
of these mutations are missense substitutions, 9% frameshift and deletions, 7% are 
nonsense mutations and in 5% mutations are silent. Data and figure adapted from the 
IARC TP53 Database (http://www-p53.iarc.fr/, R13, November 2008) and (Petitjean, 
Mathe et al. 2007) 
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1.5.5.1.2 The p53 pathway in cancer 
The importance of the p53 pathway in cancer development was demonstrated in 
murine models where a high incidence of tumours developed in mice deficient in p53 
(Donehower, Harvey et al. 1992). Mutations of TP53 are the most common cause of 
p53 pathway dysregulation, but the pathway may be disrupted through a variety of 
other mechanisms. The aberrant  accumulation of the MDM2 protein for example, 
occurs in many tumours (Onel and Cordon-Cardo 2004). This accumulation may arise 
as a result of amplification of the MDM2 gene, which occurs in 7% of all cancers, or 
increased genetic transcription (Momand, Jung et al. 1998; Michael and Oren 2002). 
Aberrant expression of p14ARF may also result in tumour development. Alternative 
splicing of CDKN2A at 9p21 produces both p16INK4A and p14ARFand the homozygous 
deletion of CDKN2A has been shown to occur in a number of tumours including in up 
to 40% of glioblastomas (Schmidt, Ichimura et al. 1994) including paediatric cases 
(Newcomb, Alonso et al. 2000). The MYC family of genes also play a role in the 
regiulation of p53, as shown in Figure 1.19, the role of the MYC genes in cancer 
development is described in further detail in section 1.5.4.1. 
 
1.5.5.1.3 The role of the p53 pathway in CNS-PNET 
Germ line mutations in TP53 resulting in Li-Fraumeni syndrome are known to be 
associated with an array of tumours including CNS-PNETs (Malkin, Li et al. 1990; 
Orellana, Martinez et al. 1998; Reifenberger, Janssen et al. 1998). In addition mice 
models have provided further evidence for the importance of p53 in CNS-PNET 
tumorigenesis with the development of CNS-PNETs as well as medulloblastomas in 
p53-/- mice (Tong, Ohgaki et al. 2003). CNS-PNETs have also been shown to develop 
within 3 months in p53 deficient murine models with c-myc and/ or β-catenin 
(Momota, Shih et al. 2008).  
Reviewed in Ellison 2002, mutations in TP53 have been shown to occur in less than 10% 
of medulloblastomas (Ellison 2002)(Ellison 2002)(Ellison 2002)(Ellison 2002)(Ellison 
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2002)(Ellison 2002)(Ellison 2002)(Ellison 2002)(Ellison 2002)(Ellison 2002) which was 
confirmed recently in a large study investigating 310 medulloblastomas in which TP53 
mutations were observed in 6.8% (21/310) (Pfaff, Remke et al. 2010). The clinical 
significance of TP53 mutations has not been established. In a recent study mutation 
was associated with a universally poor outcome (p<0.001) (Tabori, Baskin et al. 2010), 
but in the Pfaff et al 2010 study no correlation with survival was observed (p=0.63) 
(Pfaff, Remke et al. 2010). To date, few CNS-PNET tumours have been investigated for 
TP53 mutations. In five studies a total of 46 CNS-PNET tumour samples were screened 
for TP53 mutations, and identified in 7 cases (Table 3.30)(Ho, Hsieh et al. 1996; Burnett, 
White et al. 1997; Zagzag, Miller et al. 2000; Kraus, Felsberg et al. 2002; Zakrzewska, 
Rieske et al. 2004). Evidence of p53 pathway dysregulation appears however to be a 
common event in CNS-PNET and appears to occur significantly more frequently than in 
medulloblastomas (Eberhart, Chaudhry et al. 2005). In the Eberhart et al study, p53 
dysregulation, assumed with the immunohistochemical accumulation of p53, occurred 
in 88% (7/8) CNS-PNETs, but only 18% (8/44) classic medulloblastomas (p<0.001).  
The involvement of MDM2 in CNS-PNET has been investigated in one study. Kraus et al 
2002, reported the results of 12 CNS-PNETs, and found no evidence of MDM2 
amplification (Kraus, Felsberg et al. 2002). In the same study evidence of CDKN2A 
(p14ARF) deletion was also investigated, and not found to be a feature. However more 
recently a series of studies have reported a role of CDKN2A in CNS-PNET disease. Array 
CGH studies identified loss of the CDKN2A locus at 9p21.3 in 3 tumours (McCabe, 
Ichimura et al. 2006; Pfister, Remke et al. 2007). Using fluorescence in situ 
hybridisation (FISH) in a second cohort Pfister et al showed loss of CDKN2A in a total of 
7/21 (33%) of CNS-PNETs, and reported an associated trend with metastatic disease 
(p=0.07). An investigation of the role of p53 pathway dysregulation, TP53 mutations, 
MDM2 amplification and CDKN2A loss in a large series of CNS-PNETs is required to 
determine the role of this pathway in CNS-PNET tumorigenesis. 
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1.5.5.2 Wingless signalling pathway 
1.5.5.2.1 Overview of Wingless (WNT) signalling 
The wingless (WNT) pathway is a critical developmental signal transduction pathway 
involving a group of lipid-modified signaling proteins, collectively known as Wnt 
proteins, in the proliferation, fate specification, polarity, and migration of cells (Willert, 
Brown et al. 2003; Logan and Nusse 2004). Signal transduction may occur via either a 
β-catenin dependent (canonical) or an independent pathway. 
Under normal conditions cytoplasmic β-catenin is degraded by a protein complex 
comprising axin, APC and glycogen synthase kinase-3β (Axin-APC-GSK3β complex). 
GSK-3β phosphorylates β-catenin which is then available for proteosomal degradation. 
β-catenin, through its degradation, is prevented from translocating into the nucleus to 
replace Groucho to permit Wnt target gene expression and therefore expression is 
repressed (Kalderon 2002). 
In the canonical Wnt signalling pathway, Wnt signalling (Figure 1.21) is initiated 
through the binding of Wnt proteins to a transmembrane receptor complex. The 
transmembrane receptor complex comprises one of the seven Frizzled (Fz) proteins 
and the low density lipoprotein receptor-related protein (LRP). The binding results in 
phosphorylative activation of LRP and the cytoplasmic recruitment of Axin in addition 
to phosphorylation of Dishevelled (Dsh) by (Fz). The resulting Axin-APC-GSK-3β 
complex inhibits the phosphorylation of β-catenin by GSK-3β. The hypophosphorylated 
β-catenin is unsuitable for proteosomal degradation in this state which results in its 
cytoslic accumulation and translocation into the nucleus. In the nucleus it replaces 
Groucho and in a partnership with T-cell –specific transcription factor (TCF) and 
lymphoid enhancer factor (LEF) activates gene expression including cmyc, cyclin D1 
and Axin 2 (He, Sparks et al. 1998; Shtutman, Zhurinsky et al. 1999; Tetsu and 
McCormick 1999; Jho, Zhang et al. 2002; Lustig, Jerchow et al. 2002). 
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Figure 1.21. Overview of canonical WNT signalling. (a) In cells not exposed to Wnt, β-
catenin associates with a complex comprising Axin, APC, and GSK-3. Phosphorylation of 
β-catenin occurs which targets it for degradation. Wnt target genes are in this state are 
repressed by the association of TCF with Groucho. (b) Wnt binds to the Fz and LRP 
receptors which induces phosphorylation of LRP and recruitment of Axin. Dsh is also 
phosphorylated, and the Axin·APC·GSK-3 complex is inhibited, leading to accumulation 
of cytosolic β-catenin. Accumulated β-catenin then translocates to the nucleus, 
replaces Groucho from TCF, and activates target genes. Abbreviations: APC, 
adenomatous polyposis coli; GSK3, glycogen synthase kinase 3β; TCF, T-cell specific 
transcription factors; Fz, Frizelled; LRH, lipoprotein receptor related protein; Dsh, 
Dishevelled (Figure adapted from (Gordon and Nusse 2006)). 
 
1.5.5.2.2 WNT signalling in medulloblastoma and CNS-PNET  
Aberrant Wnt signalling resulting from germ line defects in the Wnt signalling pathway 
may give rise to medulloblastoma or CNS-PNET development, as has been described in 
Turcot syndrome (see section 1.5.2.3).  In clinical trials, aberrant Wnt signalling, 
identified by β-catenin accumulation has been shown to occur in 16% of patients with 
medulloblastomas (Ellison, Kocat et al. 2011). In this study, mutations in exon 3 at 
codons 33,34 and 41 in CTNNB1, that affect the binding site for the β-transducin 
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repeat-containing protein (β-TRCP) which promotes the degradation of β-catenin in 
the proteosome (Gilbertson 2004), were found to occur in 10% of medulloblastomas. 
There have however only been two previous small studies in which Wnt pathway 
disruption has been investigated in CNS-PNETs, and in total 16 tumours were screened 
for CTNNB1 mutations and 33 for β-catenin nuclear accumulation by 
immunohistochemistry (Koch, Waha et al. 2001; Rogers, Miller et al. 2009). In these 
studies only a single case of CTNNB1 mutation was observed. Unlike in 
medulloblastoma where a favourable prognostic phenotype has been repeatedly and 
convincingly demonstrated with Wnt pathway disruption (Ellison, Onilude et al. 2005; 
Gajjar, Chintagumpala et al. 2006; Fattet, Haberler et al. 2009; Ellison, Kocat et al. 
2011), the effect of CTNNB1 mutations and β-catenin accumulation in CNS-PNET has 
not been determined. Further study of this pathway is now required in this disease to 
clarify its role in CNS-PNET development and to establish whether it may be exploited 
in the future for treatment stratification, as is being proposed currently for the 
management of children with medulloblastomas (Pizer and Clifford 2009). 
 
1.5.5.3 Sonic hedgehog pathway 
The sonic hedgehog signalling (shh) pathway is involved in the development of the 
brain and in particular the external granular layer of the cerebellum. The SHH gene is 
located at 7q36 and produces a ligand that binds to the patched receptor to initiate 
shh pathway signalling (Figure 1.22). The patched gene (PTCH1) is situated on 
chromosome 9q22.3 and is responsible for medulloblastoma tumour development as 
part of the Gorlin syndrome when mutant (section 1.5.2.4). 
Activation of the SHH ligand results in dissociation of PTCH from SMO, releasing SMO  
to activate Gli which, following nuclear translocation, induces target gene expression, 
including those that are involved in angiogenesis (components of the platelet derived 
growth factor (PDGF) and vascular epithelial growth factor (VEGF) pathways), and in 
controlling cell proliferation (cyclin D, cyclin E, and MYC) (di Magliano and Hebrok 
2003). 
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Mouse models have shown that transgenic Ptc+/- mice and a transgenic mouse model 
with mutant SmoA1 both develop medulloblastoma tumours (Goodrich, Milenkovic et 
al. 1997; Hallahan, Pritchard et al. 2004). Mutations in the PTCH, SMO and SUFU genes, 
have been shown to be important in the development of medulloblastomas and in 
particular the nodular desmoplastic subtype (Xie, Murone et al. 1998; Taylor, Liu et al. 
2002). In murine models, downstream effectors of Shh signalling (Gli 1-3) have been 
identified in the cerebral cortex and midbrain in addition to the cerebellum, suggesting 
that Shh signalling may also be implicated in brain development outside of the 
infratentorial compartment (Dahmane, Sanchez et al. 2001). The role of the shh 
pathway in CNS-PNET pathogenesis has however not been extensively investigated, 
but in a series of 3 CNS-PNET tumours all were shown to express the downstream 
target of the Shh-Gli pathway, MYCN (Moriuchi, Shimizu et al. 1996). In an additional 
study 3 out of 8 CNS-PNETs harboured mutations at the PTCH gene locus, at 9q22.3, 
Vorechovsky, Tingby et al. 1997), suggesting that aberrant shh signalling could be a 
feature in a small subset of CNS-PNETs.  
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Figure 1.22.  The sonic hedgehog signalling pathway. (a) In the absence of ligand, the 
sonic hedgehog signaling pathway (shh) is inactive. The transmembrane protein 
receptor Patched (Ptch) inhibits the activity of Smoothened (Smo) and the 
downstream transcription factor Gli is prevented from entering the nucleus to activate 
transcription through interactions with cytoplasmic proteins Fused and Suppressor of 
fused (Sufu). (b) Pathway activation. Binding of the hedgehog ligand  (Hh) to Ptch 
results in the removal of Smo repression and activation of a cascade that leads to the 
translocation of activated Gli to the nucleus. Nuclear Gli activates target gene 
expression, including those that are involved in angiogenesis (components of the 
platelet-derived-growth-factor (PDGF) and vascular-epithelial-growth-factor (VEGF) 
pathways), and in controlling cell proliferation (cyclin D, cyclin E, and MYC). Figure 
taken from (di Magliano and Hebrok 2003). 
 
1.5.5.4 The Notch signalling pathway 
The Notch signalling pathway is involved in the regulation of mechanisms that control 
multiple cell differentiation processes during both embryonic and adult life using cell 
to cell communication. Large transmembrane proteins (Notch 1-4) are encoded by the 
NOTCH genes which act as receptors for ligands expressed by neighbouring cells and 
activation of this pathway results in the release of the notch intracellular domain 
(NICD) and activation of the Hes(1-3) target genes (Kume 2009) as illustrated in Figure 
1.23. Signalling plays an important role in the normal development of many tissues 
effects cellular differentiation, survival, and proliferation. The pathway has also been 
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shown to be involved in the regulation of normal neurogenesis (Ishibashi, Ang et al. 
1995; Gaiano and Fishell 2002). 
Aberrant Notch signalling, first observed in T-cell leukaemias with a translocation 
involving the NOTCH1 locus on chromosome 9 (t(7;9)) (Reynolds, Smith et al. 1987), 
has been shown to be involved in many cancers including small cell lung cancer, basal 
cell skin cancer, prostate cancer, neuroblastoma and cervical cancer (reviewed in 
(Allenspach, Maillard et al. 2002). To date there has been limited research on the 
NOTCH signalling pathway in intracranial PNET development but activation of this 
pathway has been shown in two studies suggesting that it may play a role in CNS-PNET 
development (Rostomily, Bermingham-McDonogh et al. 1997; Fan, Mikolaenko et al. 
2004). Rostomily et al, demonstrated differential expression of hASH1, a basic helix-
loop-helix protein inhibited by NOTCH signalling, in CNS-PNETs. In the subsequent Fan 
et al study, differential expression of NOTCH 1 and 2 was interestingly shown in CNS-
PNET and MB with high levels of NOTCH 2 detectable in CNS-PNETs.  Inactivation and 
associated cell growth retardation in the CNS-PNET cell line PFSK, provided further 
support for the role of NOTCH 2 in CNS-PNET tumorigenesis (Fan, Mikolaenko et al. 
2004). 
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Figure 1.23. Overview of the Notch signalling pathway. Upon Notch ligand binding, a 
two-step proteolysis cleavage process (small arrows) is catalyzed by a member of the 
disintegrin and metalloproteases (ADAMS) family and the γ-secretase containing 
complex. Notch intracellular domain (NICD) is then released from the membrane and 
translocates to the nucleus, where it forms a transcriptional activation complex with 
CSL and coactivators (CoA), and induces transcription of target genes. Figure taken 
from (Kume 2009). 
 
1.5.6 Epigenetic events in CNS-PNET 
The role and mechanisms of epigenetic modification in CNS-PNET are currently poorly 
understood. A number of recent studies investigating micro RNAs in CNS-PNET have 
however provided significant insights into CNS-PNET tumourigeneis and have 
supported the hypothesis that this disease may in fact consist of a number of entities. 
In a case report in 2009, Pfister et al, reported the molecular features of a 2 year old 
girl with an ETANTR CNS-PNET (Pfister, Remke et al. 2009). Molecular analysis revealed 
a 19q13.42 amplicon containing C19MC, a known microRNA cluster.  In a subsequent 
study by Li et al, 45 CNS-PNET tumours were investigated and a similar amplification of 
C19MC within the 19q13.41 amplicon was identified in 24% (11/45) (Li, Lee et al. 2009). 
Expression of miR-520g and miR-517c from within this cluster were found to be 
significantly elevated in the amplified cases, and in both in vivo and in vitro models 
associated with oncogenic effects including promoting cell survival. 
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Changes in DNA methylation patterns appear also to be a significant feature of 
intracranial PNETs, and studies have estimated that aberrant hypermethylation occurs 
in up to 1% of CpG islands in primary PNET tumours (Fruhwald, O'Dorisio et al. 2001). 
To date there have however been few studies investigating DNA methylation 
epigenetic modification in CNS-PNET. Reported DNA methylation events in CNS-PNET, 
in common with genetic aberrations, have been identified as a part of wider brain 
tumour or intracranial PNET cohorts, rather than specific CNS-PNET studies. These 
studies have investigated a selected group of genes and reported evidence of aberrant 
methylation in a subset, as summarised in Table 1.14.  
Methylation of the p14ARF promoter has been shown to be a feature of supratentorial 
PNETs in one study, occurring in 50% (3/6) of analysed tumours (Inda, Munoz et al. 
2006) . In contrast, in this study p14ARF promoter hypermethylation was seen in only 14% 
(3/21) of medulloblastomas. A subsequent study however did not corroborate this 
finding (Muhlisch, Bajanowski et al. 2007).  Promoter hypermethylation of CASP8 has 
been observed in a third of CNS-PNETs (8/24) (Muhlisch, Schwering et al. 2006), and in 
a further study by Chang et al, promoter hypermethylation of FHIT and sFRP1 was 
detectable in 22% (2/9) and 11% (1/9) of cases respectively (Chang, Pang et al. 2005). 
Promoter hypermethylation of the tumour suppressor DLC-1 was identified in a single 
CNS-PNET case (9%, 1/11) (Jesse Chung-Sean, Qing et al. 2005).  In a study that 
screened the largest number of genes in CNS-PNET, only CDH1 was found to be 
frequently methylated in 60%, but the investigative cohort only comprised of 5 CNS-
PNET tumours (Muhlisch, Bajanowski et al. 2007). In this study evidence of methylation 
for DAPK1, DUTTI1, p16INK4A, P15INK4B and SOCS1 was not seen in any of the 
primary CNS-PNET tumours.  
The most commonly methylated gene identified in CNS-PNET to date is RASSF1A. In 
total, 39 CNS-PNETs have been investigated in three small studies for 
hypermethylation of the RASSF1A promoter (Chang, Pang et al. 2005; Muhlisch, 
Schwering et al. 2006; Inda and Castresana 2007). Overall, RASSF1A promoter 
hypermethylation was shown to occur in 77% (30/39) of cases, but these findings 
require validation in larger series.  
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Gene 
Hypermethylation 
Frequency 
Reference 
CASP8 8/24 (33%) (Muhlisch, Schwering et al. 2006) 
CDH1 3/5 (60%) (Muhlisch, Bajanowski et al. 2007) 
DAPK1 0/5 (0%) (Muhlisch, Bajanowski et al. 2007) 
DLC-1 1/11 (9%) (Jesse Chung-Sean, Qing et al. 2005) 
DUTTI 0/5 (0%) (Muhlisch, Bajanowski et al. 2007) 
FHIT 2/9 (22%) (Chang, Pang et al. 2005) 
p14ARF 
0/4 (0%) (Muhlisch, Bajanowski et al. 2007) 
3/6 (50%) (Inda, Munoz et al. 2006) 
p15INK4B 0/2 (0%) (Muhlisch, Bajanowski et al. 2007) 
p16INK4a 
0/5 (0%) (Muhlisch, Bajanowski et al. 2007) 
1/6 (17%) (Inda, Munoz et al. 2006) 
RASSF1A 
6/9 (67%)  (Chang, Pang et al. 2005) 
19/24 (79%) (Muhlisch, Schwering et al. 2006) 
5/6 (83%) (Inda and Castresana 2007) 
sFRP1 1/9 (11%)  (Chang, Pang et al. 2005) 
SOCS1 0/3 (0%) (Muhlisch, Bajanowski et al. 2007) 
TIMP3 1/5 (20%) (Muhlisch, Bajanowski et al. 2007) 
Table 1.14 Promoter hypermethylation in CNS-PNET primary tumours. 
 
1.5.6.1 RASSF1A 
The RASSF1 (Ras Association Domain Family Protein 1) gene is located on chromosome 
3p21.3 and encodes a protein of 38.8kD which is expressed in all tissues. It contains 2 
promoters and produces 7 different transcripts (RASSF1A-G) using different 
combinations of alternative splicing and promoters. The RASSF1 locus has CpG islands 
associated with its two promoter regions, and the first CpG island includes the 
promoter region for RASSF1A (Pfeifer and Dammann 2005).  
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RASSF1A is a tumour suppressor gene which promotes cell cycle arrest, apoptosis, 
microtubule stability and proliferation (Agathanggelou, Cooper et al. 2005). Expression 
of RASSF1 proteins has been shown to promote cell cycle arrest and apoptosis (Feig 
and Buchsbaum 2002), and the discovery that RASSF1A -/- cells are more sensitive to 
depolymerization and induced microtubule damage by nocodazole has provided 
evidence for its role in microtubule stability (Liu, Tommasi et al. 2003).  
 
1.5.6.1.1 RASSF1A in cancer 
Evidence supporting epigenetic suppression of RASSF1A leading to tumorigenesis 
originates from mouse models. The first mice developed lacking rassf1a were 
engineered by Smith et al, (Smith, Xian et al. 2002).  Tommasi and colleagues later 
engineered a knockout mouse model, deleting exon 1α and thus Rassf1a, and tumours 
developed in the mice included lymphomas, lung adenomas and a breast 
adenocarcinoma (Tommasi, Dammann et al. 2005). RASSF1A promoter methylation 
has subsequently been observed in multiple tumour types including a range of 
paediatric malignancies, summarised in Table 1.15 (Agathanggelou, Cooper et al. 2005).  
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Tumour Type RASSF1A Methylation 
  % Tumours 
Ewings Sarcoma 0 0/8 
Hepatoblastoma 19 5/7 
Medulloblastoma 79 27/34 
Neuroblastoma 55 37/67 
Osteosarcoma 0 0/11 
Rhabdomyosarcoma 61 11/18 
Retinoblastoma 59 10/17 
Wilm's tumour 71 22/31 
Table 1.15. RASSF1A promoter methylation in primary paediatric tumours. 
Summarised from data in the review by (Agathanggelou, Cooper et al. 2005). 
 
1.5.6.1.2 RASSF1A promoter methylation in PNET 
RASSF1A promoter methylation has been shown to be a prominent feature in 
intracranial PNETs. In six studies incorporating 129 medulloblastoma tumour samples 
RASSF1A methylation occurred in 79-100% of cases (Table 1.16)(Harada, Toyooka et al. 
2002; Lusher, Lindsey et al. 2002; Horiguchi, Tomizawa et al. 2003; Lindsey, Lusher et 
al. 2004; Chang, Pang et al. 2005; Inda and Castresana 2007). Methylation of the 
RASSF1A promoter is not known however to confer a survival bias or be associated 
with any clinicopathological feature (Harada, Toyooka et al. 2002; Lindsey, Lusher et al. 
2004). Three small studies have investigated RASSF1A promoter methylation in CNS-
PNET, and determined rates of methylation of 67% (6/9), 79% (19/247) and 83% 
(5/6)(Chang, Pang et al. 2005; Muhlisch, Schwering et al. 2006; Inda and Castresana 
2007). In limited series, RASSF1A methylation is therefore the most common 
epigenetic event detected in CNS-PNET to date, but both validation of this finding and 
the determination of any clinic-pathological correlates needs to be established. Taken 
together, these data also suggest a role for methylation events in CNS-PNET, which 
now requires further investigation.  
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Reference 
Cohort size Methylation 
Size Age (yrs) Freq 
(Lusher, Lindsey et al. 2002) 34 1-11 27/34 (79%) 
(Harada, Toyooka et al. 2002) 16 <16 14/16 (88%) 
(Horiguchi, Tomizawa et al. 2003) 5 - 5/5 (100%) 
(Lindsey, Lusher et al. 2004) 28 0-68 27/28 (96%) 
(Chang, Pang et al. 2005) 25 3-69 25/25 (100%) 
(Inda and Castresana 2007) 21 2-87 19/21 (91%) 
Table 1.16. RASSF1A promoter hypermethylation in medulloblastoma tumours. 
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1.6 Project summary and aims 
CNS-PNETs are embryonal malignant brain tumours that arise particularly in young 
children. The tumours are treated aggressively according to their age with multi-modal 
therapy including surgery, radiotherapy and chemotherapy. However, whilst there has 
been an improvement in the outcome for children with cancer as a whole over the last 
few decades, with over 75% of all children now surviving beyond 5 years (ONS 2010), 
the outcome for children with a CNS-PNET remains dismal. Fewer than half of the 
children who develop this tumour survive. Improving the chance of cure remains the 
most critical goal in the clinical management of patients with this disease.   
Establishing the diagnosis of a CNS-PNET remains both a significant challenge and 
controversial. Whilst the introduction of routine INI1 staining has aided in the 
differentiation between ATRTs and other CNS tumours including CNS-PNETs, no 
specific test is currently available to confidently classify a tumour as a CNS-PNET. On 
histopathological examination, a CNS-PNET appears as a highly malignant tumour but 
may exhibit a diverse array of non-specific features which frequently overlap with, and 
may be misclassified as other diagnoses, and in particular high grade gliomas. New 
approaches are therefore essential to assist in the diagnosis of this tumour.  
The PNET concept, devised by Harte and Earle in 1973, classified together tumours 
throughout the CNS with similar histopathological features. The hypothesis that 
histopathologically similar tumours would respond to a similarly unified treatment 
approach has directed international management in these tumours for over three 
decades. The consistent disparity in outcome however, between intracranial PNETs 
arising from the cerebellum (medulloblastoma), and those arising elsewhere in the 
CNS has led to renewed controversy in the PNET concept. The contemporary 
hypothesis is that despite histopathological similarities, the differences in outcome 
seen in children with intracranial PNETs at different sites reflect diversity at the 
molecular genetic level. 
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A well characterised series of molecular events have now been shown to be implicated 
in medulloblastoma development. The most frequent aberration in this disease is 
RASSF1A promoter methylation, which has been shown to occur in 79-100% of cases. 
The development of medulloblastomas in patients with cancer predisposition 
syndromes including Li-Fraumeni, Turcot and Gorlin syndromes, suggested that 
aberrant p53, Wnt and sonic hedgehog signalling respectively is involved in the 
pathogenesis of this disease, and dysregulation of these pathways are frequently 
observed in tumour samples. In addition, large clinical trial based cohorts in this 
disease have more recently revealed the prognostic impact of some of these events 
which are now being exploited clinically to provide stratified treatment regimens.  
To date, research into CNS-PNET has been very limited. The few studies that have been 
undertaken typically have arisen as part of either a paediatric brain tumour or 
intracranial PNET study and have shown extensive molecular heterogeneity in the CNS-
PNETs.  Consequently, studies have commonly lacked sufficient power or specific focus 
to detect novel insights into the pathogenesis of CNS-PNETs.  Investigation of 
molecular events frequently observed in other intracranial PNETs in a large and well 
characterised CNS-PNET cohort is required to determine the role of these events in this 
disease, and to define the relationship with medulloblastomas. 
The overall objective of this project was to investigate in comparison with 
medulloblastomas the molecular mechanisms that may be involved in the 
development of a CNS-PNET and to determine their clinical and histopathological 
significance, by attending to the following specific aims: 
 
1.  To investigate in a large cohort of primary CNS-PNET tumour samples and cell 
lines the role of common genetic features associated with medulloblastomas, 
and to identify clinical and histopathological correlates (Chapter 3). 
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2.   To follow up the findings of recent large-scale genome-wide genetic studies in 
brain tumours in which novel candidate genes have been identified to 
determine their role in CNS-PNET (Chapter 4). 
 
3.  Undertake a systematic investigation of the CNS-PNET methylome in a cohort 
of primary tumours, to investigate the role of DNA methylation epigenetic 
modification in CNS-PNETs, to identify new genetic markers in CNS-PNET and 
their clinico-pathological significance, and also to compare and contrast the 
CNS-PNET methylome with medulloblastomas and other paediatric brain 
tumours (Chapter 5). 
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2.1 Clinical cohort 
2.1.1 Primary CNS-PNET tumour samples 
The cohort of primary CNS-PNET samples for this study was collected in the Northern 
Institute for Cancer Research (NICR) tumour bank at Newcastle University. Tissue was 
stored in accordance with the Human Tissue Act 2004 (Human Tissue Act, 2004) and 
the Human Tissue Authority (HTA) code of practice (Human Tissue Authority, 2009). 
Ethical approval for the registration, storage, access and study of samples was 
obtained from the Newcastle and North Tyneside Local Research Ethics Committee. All 
clinical data was anonymised. 
The cohort consisted of 39 primary CNS-PNETs. The samples (frozen tumour material 
in 21 cases and formalin fixed and paraffin embedded in a further 18) were kindly 
provided from local, national and international sources including the Newcastle Upon 
Tyne NHS Trust pathology archive, the Children Cancer and Leukaemia Group (CCLG) 
tumour bank, Professor Richard Grundy (Nottingham University, UK), Professor 
Michael Fruhwald and Dr Martin Hasselblatt (University Hospital of Munster, Germany), 
and Dr Peter Hauser (Semmelweis University, Budapest, Hungary). All cases underwent 
a central pathological review. Cases were reviewed in three review sessions by UK 
neuropathologists involved in providing central pathological review for the UK Children 
Cancer and Leukaemia Group (CCLG) brain tumour studies, and included Professor 
David Ellison (formerly Northern Institute Cancer Research, Newcastle University, UK 
and now, St Judes Children’s Research Hospital, Memphis, USA), Dr Keith Robson and 
Dr Jim Lowe (University of Nottingham, UK), and Dr Tom Jacques (Great Ormond Street 
Hospital, London, UK).  
The characteristics of the cohort are summarised in Table 2.1. The metastatic stage for 
each tumour is given using the Chang staging system score (see section 1.4.4). 
Tumours in the cohort collected prior to the routine clinical assessment of CSF to 
ascertain evidence of microscopic metastatic disease and therefore where no CSF 
results is available are classified by convention as stage M0/1, and are considered as 
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being non-metastatic (Pizer, Weston et al. 2006). Additional details of the tumour 
samples used in each study will be given in the methods section of each results chapter. 
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Tumour 
sample 
ID 
Diagnosis Site Sex 
Age at 
diagnosis 
(Months) 
Metastasis 
Stage 
(Chang) 
Status 
Follow up 
(months) 
Investigated 
in studies in 
chapter 
3 4 5 
SP3 CNS-PNET Parieto-occipital lobes Male 48 M0/1 Dead 17       
SP4 CNS-PNET Parietal lobe Female 78 M0/1 Alive 121       
SP7 CNS-PNET Intraventricular Female 75 M0 Dead 7       
SP10 CNS-PNET 3rd Ventricle Male 158 M0/1 Alive 112       
SP13 CNS-PNET Cerebral Male 106 M0/1 Dead 71       
SP14 CNS-PNET Parietal lobe Female 105  - Alive 100       
SP21 CNS-PNET Left tempoparietal lobes Male 65   Dead 25       
SP23 CNS-PNET Cerebral Male 126 M0/1 Alive 108       
SP24 CNS-PNET Cerebral Male 31  - Dead 7       
SP28 CNS-PNET Right frontal lobe Female 23 M0/1 Dead 9       
SP40 CNS-PNET Right parietal lobe Female 348 M0/1  -  -       
SP41 CNS-PNET Left Fronto-temporal lobes Male 56 M0/1 Dead 24       
SP42 CNS-PNET Right temporal lobe Female 288 M0/1 Alive 24       
SP43 CNS-PNET Left parietal lobe Male  - M0/1  -  -       
SP45 CNS-PNET Right parietal lobe. Female 11 M0/1  -  -       
SP46 CNS-PNET Left frontal lobe Female 312 M0/1 Dead 36       
SP47 CNS-PNET Left frontal lobe Female 87 M0/1 Alive 132       
SP49 CNS-PNET Right temporal lobe Female 15 M2 Alive 36       
SP50 CNS-PNET Left tempoparietal lobes Female 36 M0/1 Dead 15       
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SP51 CNS-PNET Cerebral Female 360  - Dead 55       
SP52 CNS-PNET Left parietal lobe Male 127 M0/1 Alive 43       
SP54 CNS-PNET Infra + Supratentorial Female 26 M0/1 Dead 3       
SP55 CNS-PNET Temporal lobe Male 77 M0/1 Dead 15       
SP57 CNS-PNET Frontal + temporal lobes Male 21 M0/1 Alive 39       
SP58 CNS-PNET Right (superficial) parietal lobe Female 223 M0 Alive 17       
SP101 CNS-PNET Right parietal lobe Female 10 M2 Dead 41       
SP103 CNS-PNET Right frontal lobe Female 20 M0 Dead 0       
SP104 CNS-PNET Right parietal lobe Male 122 M0 Alive 52       
SP106 CNS-PNET Right frontal lobe Male 141 M3 Dead 30       
SP108 CNS-PNET Left cerebral hemisphere Male 107 M2 Dead 71       
SP110 CNS-PNET Right temporal Lobe Male 37 M4 Dead 6       
SP111 CNS-PNET Right frontal, temporal & parietal lobes Female 53 M0 Alive 36       
SP113 CNS-PNET Sub thalamic, left lateral & 3rd ventricle  Male 142 M0 Dead 0       
SP115 CNS-PNET Right frontoparietal Lobes Female 71 M0 Dead 5       
SP116 CNS-PNET Left frontal lobe Male 61 M0 Dead 21       
SP117 CNS-PNET Midline frontal region Male 59 M2 Dead 9       
SP124 CNS-PNET Suprasellar Female 14 M2 Alive 24       
SP125 CNS-PNET Suprasellar Female 144 M0 Alive 3       
SP126 CNS-PNET Right parietal lobe Male 84 M1 Dead 1.6       
Table 2.1. Clinical characteristics of CNS-PNETs used in studies. Highlighted boxes indicate cases investigated in studies described in specific 
chapters of this thesis.
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2.1.2 Normal brain tissue cohort 
A panel of normal brain tissue samples were also investigated (Table 2.2) which was 
derived from Newcastle Upon Tyne NHS Trust post-mortem specimens. The conditions 
in which the samples were collected and stored were as described in section 2.1.1 for 
the tumour cohort assembly. 
 
ID Site Age Sex 
cbll17 Cerebellum prenatal* male 
cbll18 Cerebellum prenatal* male 
cbll19 Cerebellum  -  - 
cbll20 Cerebellum 67 years male 
cbll21 Cerebellum newborn female 
cbll22 Cerebellum 60 years male 
cbll23 Cerebellum prenatal* female 
cbll24 Cerebellum prenatal* male 
Table 2.2. Clinical characteristics of normal brain samples used in this study. 
*Prentatal samples from foetuses as 18-22 weeks gestation. 
 
2.1.3 CNS-PNET cell lines 
Two immortalised cell lines of CNS-PNETs were investigated (PFSK and CHP707m), and 
these were both kindly donated by Dr Michael Grotzer (University Children’s Hospital, 
Zurich, Switzerland) and cultured for experiments. PFSK was derived from a 22 month 
old boy with a right frontal lobe CNS-PNET. He underwent a subtotal resection and 
received postoperative chemotherapy, but died within 4 months of diagnosis from 
extensive disease. (Fults, Pedone et al. 1992). The second cell line, CHP707m, was 
derived from a 33 year old man with a right frontal lobe CNS-PNET. He also underwent 
a subtotal resection and this was followed by radiotherapy to the tumour bed and the 
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craniospinal axis. He relapsed at 11 months and the cell line was derived from a bone 
marrow metastatic deposit at this time. (Baker, Reddy et al. 1990). The clinical and 
cytogenetic features of PFSK and CHP707m are summarised in Table 2.3. 
The CHP707m cell line contains a t(11;22) translocation. This is however a 
characteristic feature of Ewing’s sarcomas and peripheral PNETs (Nagao, Ito et al. 1997) 
and is not observed in CNS-PNETs. Indeed, the presence of a t(11;22) has been used to 
distinguish peripheral PNETs from CNS-PNETs when these tumours may rarely arise in 
the central nervous system (Dedeurwaerdere, Giannini et al. 2002; Ohba, Yoshida et al. 
2008). There is therefore some doubt as to the true nature of the CHP707m cell-line 
and caution with interpreting results based on experiments using this, as it may in fact 
have arisen from a peripheral PNET/ Ewings rather than a CNS-PNET. 
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PFSK CHP707m 
Sex Male Male 
Patient age 22 months 33 years 
Location Right Frontal lobe Right Frontal lobe 
Surgery Subtotal Subtotal 
Radiotherapy No Tumour bed + C/S axis 
Chemotherapy Vincrisine, Cyclophosphamide, Methylprednisolone No 
Relapsed 
At 3 months, metastasising into both cerebral 
hemispheres At 11 months, metastatic to bone marrow 
Died At 4 months from diagnosis At 21 months after diagnosis 
Cell line From primary tumour at diagnosis From metastatic deposit at relapse 
Cytogenetics 81,XXYY,t(Xp;8q), del(1)(p22), -2, -3, del(4)(p14), -5, 
-8, -9, -9, -13, -13, -14, -14, -16, -20, -22 
n52XY,+Y, -1,-3,+8,-11,+13, -14, +17, -20, -22, +i(1q), 
+der(3), del(5)(q31), del(7)(q21q32), +del(7)(q11.2), 
t(9;18)(q13;q11.2), +der(11ins) t(11,22) 
Table 2.3. Clinical and cytogenetic features summary of supratentorial CNS-PNET cell lines. 
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2.1 CNS-PNET cell line in vitro culture 
2.1.1 Principles of in vitro cell culture 
Cell culture is the culture of dispersed cells taken from the original tissue and was first 
devised in 1902 by Haberlandt (Freshney 2000). Tissue culture is used as a means of 
studying the behaviour of cells at relatively low cost whilst the physicochemical 
environment is controlled. A primary cell culture is started from cells taken directly 
from an organism and may be propagated into a cell line. A continuous cell line has the 
capacity for infinite survival and is therefore also referred to as being “established” or 
“immortalised” as described by George Gey, in 1952,  with the production of the first 
continuous human (uterine cervix cancer) cell line, HeLa(Jones, McKusick et al. 1971).  
All tissue culture experiments were performed in a Class II tissue culture hood 
(Streamline lab) using standard sterile techniques and pipettes.  
 
2.1.2 Resurrection of cells from liquid nitrogen 
Cryopreservation tubes (Nunc, Denmark) containing the frozen cells were removed 
from liquid nitrogen and placed on ice. Tubes were thawed rapidly in a 37°C water 
bath. The thawed cells were then transferred to pre-cooled 25ml universal tubes kept 
on ice. Ice-cold Fetal Calf Serum (FCS) (Sigma-Aldrich, UK) was added drop-wise to the 
cells; the cell suspension was mixed gently and left on ice for 20 minutes to allow the 
dimethylsulphoxide (DMSO) to diffuse out of the cells. The universal tube was then 
centrifuged for 5 minutes at 1000g in a MSE Mistral 2000R centrifuge (MSE 
Incorporation, USA) and the supernatant was discarded. The cell pellet was 
resuspended in fresh medium containing 10% (v/v) FCS and transferred to a sterile 
tissue culture flask (Corning, USA) and placed in a humid incubator (SANYO) to culture. 
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2.1.3 Cell line maintenance and sub culture 
Cells were grown in optimal growth conditions at 37°C with air containing 5% carbon 
dioxide within a humid incubator (SANYO). The cells growing in culture were passaged 
twice weekly to optimise growth potential and nutrient availability. The flasks were 
first inspected for contamination and growth status assessed by cell density under a 
phase contrast inverted light microscope (Nikon E400) at x100 magnification. The 
colour of the medium was used as an additional guide as to when replenishment of 
medium was necessary since it contained phenol red which becomes progressively 
more yellow with a  fall in pH, seen with the accumulation of metabolic waste products 
(Sambrook and Russell 2001). 
 
2.1.3.1 Maintenance and subculture of PFSK 
Cells were grown in RPMI 1640 media (Sigma) containing 10% (v/v) FCS and 1% (v/v) 
sodium pyruvate (Sigma-Aldrich).  1% (v/v) streptomycin / penicillin (sigma-Aldrich, UK) 
was also added to protect against bacterial contamination. To passage cells excess 
media was gently aspirated off the cells, which were then washed with 5-15ml of 
sterile phosphate buffered saline (PBS) at 37°C to remove traces of FCS. PBS was then 
drawn off the cells and 1-3ml of 1xEDTA- trypsin solution (Sigma-Aldrich, UK) was 
added to detach cells from the flask. Cells were incubated for 5 minutes at 37C, and 
microscopy was used to gauge detachment. An equal volume of prepared media was 
used to neutralise the trypsin and then the cells were transferred to a 25ml universal 
tube. The universal tube was centrifuged at 1000g for 5 minutes in a MSE Mistral 
2000R centrifuge (MSE Incorporation, USA) and the supernatant was discarded. The 
cell pellet was resuspended in 10ml fresh media pre-warmed to 37°C, before being 
split into 3-4 aliquots. Each aliquot was transferred using sterile pipettes into a 
separate sterile flask and made up to 25ml with fresh media at 37°C. 
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2.1.3.2 Maintenance and subculture of CHP707m 
Cells were again grown in RPMI 1640 media (Sigma-Aldrich, UK)) containing 10% (v/v) 
FCS, 1% Sodium pyruvate, and 1% (v/v) streptomycin / penicillin. CHP707m grows as a 
non-adherent culture and so to passage the cells the contents of the flask were 
centrifuged at 1000g in a MSE Mistral 2000R centrifuge (MSE Incorporation, USA) for 5 
minutes in a 25ml sterile universal container. The supernatant was discarded and the 
cells pelleted at the bottom were washed in 20ml sterile PBS at 37°C. The PBS was 
removed by centrifugation at 1000g for 5 minutes. The resulting cell pellet was 
resuspended in 10ml fresh media pre-warmed to 37°C, before being split into 3-4 
aliquots. Each aliquot was transferred using sterile pipettes into a separate sterile flask 
and made up to 25ml with fresh media at 37°C. 
 
Cell line CHP707m PFSK 
Growth characteristics Non- adherent Adherent 
Media RPMI 1640 R8758 RPMI 1640 R8758 
   + 10% Fetal Calf Serum  + 10% Fetal Calf Serum 
   + 1% Sodium Pyruvate  + 1% Sodium Pyruvate 
  
 + 1% Penicillin/ 
streptomycin 
 + 1% Penicillin/ 
streptomycin 
Table 2.4. Supratentorial CNS-PNET cell lines growth characteristics and media 
requirements. 
 
2.1.3.3 Mycoplasma testing 
Unlike bacterial and fungal contamination, infection with mycoplasma is not readily 
identified by the naked eye. Cultures were tested every 2 months for mycoplasma 
infection using the MycoAlert® mycoplasma detection kit (Lonza, UK) following the 
manufacturer’s instructions, by DR E Matheson in the Northern Institute for Cancer 
Research. Any mycoplasma positive cultures identified would be discarded.  
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2.1.3.4 Cell number assessment 
To determine the concentration of cells, the suspension was firstly gently pipetted to 
remove clumping and to generate a suspension containing single cells. A 10µl aliquot 
of suspension was then drawn under the cover-slip on a haemocytometer (Sigma-
Aldrich, UK) by capillary action.  The haemocytometer had 2 chambers each comprising 
9 large grids of 25 squares. The area of each grid was 1mm2 with depth of 0.1mm with 
a resultant volume of 0.1mm3 (1x10-4ml).  Using a light microscope cells contained in 
four large grids were counted, including those cells on the top and left borders only, to 
avoid counting the same cell twice. The number of cells was subsequently divided by 
four to produce an average number of cells in each grid, and finally multiplied by 104 to 
ascertain the total number of cells/ ml in suspension. 
 
2.1.4 Harvesting cells for DNA extraction 
Cell suspensions were generated and removed from the tissue culture flask into 25ml 
universal tubes as previously described (section2.1.3). Cell numbers were assessed as 
described in section 2.1.3.4. The cell suspension was centrifuged at 1000g in a MSE 
Mistral 2000R centrifuge (MSE Incorporation, USA). The supernatant produced was 
discarded and the resulting cell pellet was resuspended in 20ml of ice-cold PBS. The 
suspension was again centrifuged at 1000g for 5 minutes before the supernatant was 
gently aspirated away from the cell pellet which was resuspended in PBS to yield a 
final concentration of 5x106 cells/ ml. Aliquots contacting 1ml of cell suspension were 
transferred into 1.5ml microfuge tubes and centrifuged at 12000g using an Eppendorf 
5147R centrifuge (eppendorf). The supernatant was gently aspirated from the tubes 
without dislodging the cell pellet which was snap-frozen with liquid nitrogen and 
stored until DNA extraction, at -80°C. 
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2.1.5 Long-term cryopreservation of cell lines 
The cell suspension from the tissue culture flask was transferred into a 25ml universal 
tube and centrifuged at 1000rpm for 5 minutes. The supernatant was discarded and 
the cells were resuspended at a concentration of 5-6x106 cells/ml in ice cold FCS and 
left on ice for 10 minutes. Pre-cooled FCS containing 20% DMSO was added drop wise 
to minimise shock to the cells in an equal volume to the cell suspension. To allow the 
DMSO to permeate the cells, the universal tube was left on ice for 30 minutes. The cell 
suspension was transferred to pre-cooled cryopreservation tubes and stored overnight 
at -80C, before being transferred into liquid nitrogen for long-term storage. 
 
2.2 DNA extraction 
2.2.1 Primary tumour DNA extraction 
DNA from formalin fixed-paraffin embedded material (FFPE) was extracted using the 
QIAamp DNA FFPE Tissue Kit (Qiagen, UK). The FFPE tissue was first dewaxed and 
digested using 1-2x25µm curls according to the manufacturer’s instructions. For 
samples where frozen material was available the DNeasy kit (Qiagen, UK) was 
employed, and extraction was achieved following the manufacturer’s instructions. 
 
2.2.2 Cell line DNA extraction 
DNA from cell line pellets was extracted using the DNeasy kit (Qiagen, UK) according to 
the manufacturer’s instructions and stored in the EB elution buffer provided.  
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2.2.3 Quantification of extracted DNA 
The concentration and quality of extracted DNA was evaluated using the NanoDropTM 
Spectrophotometer (Thermo scientific). Using 1µl of sample the spectrophotometer 
assessed the UV light absorbency (optical density (OD)) at OD260 and OD280. DNA 
molecules show maximum UV light absorbance at OD260 and therefore the amount of 
light absorbed at OD260 reflects the concentration of DNA in a sample, and the ratio 
with OD280 give an indication of the DNA quality. Using spectrophotometry to estimate 
DNA concentration is reviewed by Sambrook et al (Sambrook and Russell 2001). 
Working stocks of 25ng/µl were prepared and stored at -20°C, and concentrated 
stocks were stored at -80°C. 
 
2.3 Polymerase chain reaction (PCR) 
2.3.1 Introduction 
The polymerase chain reaction (PCR) was devised by Mullis and colleagues in 1984, 
and is a method for the in vitro amplification of DNA fragments (Mullis and Faloona 
1987). A sample containing DNA is first heated to 95oC so that 2 single strands are 
produced (denaturation step). The reaction mixture is then cooled so that short 
amplimers (oligonucleotides of 15-30 bases) hybridise to the target sequence 
(annealing step). The optimal temperature for the primer annealing depends on the 
melting temperature of the primers used (50-65oC). The next step (extension step) 
utilises a thermostable DNA polymerase to catalyse the addition of deoxynucleotides 
(dNTPs) to the new double strand DNA in a 5’ to 3’ direction at a rate of 1000 bases per 
second at 72oC. This cycle yields 2 copies of the targeted DNA, a further cycle will 
result in 4 double stranded copies. The process is repeated for 30- 40 cycles resulting 
in an exponential accumulation of PCR product. 
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Figure 2.1. The three steps of a PCR reaction. During the first step a) the double 
stranded DNA is denatured by the reaction being heated to 95°C. The temperature is 
then lowered b) to enable specific primers to anneal to either strand of the single 
stranded DNA. In the final extension step c) the temperature is raised to 72°C and the 
DNA polymerase adds complementary dNTPs to synthetise new DNA strands. Figure is 
adapted from (http://commons.wikimedia.org/wiki/File:PCR_Steps.JPG) 
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Figure 2.2. The exponential amplification of PCR. From a single starting template after 
35 cycles of a PCR reaction 68 billion copies are produced (adapted from: 
users.ugent.be/~avierstr/principles/pcrsteps.gif). 
 
2.3.2 Primer design 
A set of two primers were designed for each PCR reaction which contained 
complimentary sequences to the region of DNA to be amplified. One primer was 
designed to bind to the forward DNA strand, and another to the reverse to which DNA 
polymerase would attach to promote the synthesis of new complimentary DNA strands 
in the 5’ to 3’ direction.    
Primers were optimised considering the following factors to contain a G/C content of 
approximately 50%, be of 20-25 nucleotides in length, to avoid complementary regions 
between the primer pair, and to avoid repetitive sequences to prevent the formation 
of hairpin loops. All designed primers were reviewed using BLAST 
(http://blast.ncbi.nlm.nih.gov) and BLAT (http://genome.ucsc.edu) searches to ensure 
that the resultant amplified PCR products would contain only the correct and unique 
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sequence. Details of primers used in particular studies are given in the methods of the 
relevant chapter (see sections 3.2, 4.2 and 5.2). 
 
2.3.3 Standard PCR protocol 
For each sample to be tested, 25μl reactions mixtures were set up and volumes were 
doubled if sequencing was to be performed in PCR tubes containing 2.5l each of 
10M Forward and Reverse Primer (Invitrogen), 2.5l of Amplitaq Gold 10 x PCR Buffer 
(Applied Biosystems), 1.0l of 5mM dNTPs (Amersham Biosciences), 1.5l of 25mM 
MgCl2 (Applied Biosystems), 0.3l Amplitaq Gold (Applied Biosystems) and 12.7l of 
sterile water to a final volume of 22l. Two microlitres of each cell line or tumour DNA 
(25ng/l) were added to individual tubes as outlined in Table 2.5. The tubes were then 
placed in a GeneAmp PCR System 9700 machine (Applied Biosystems) programmed to 
perform automated cycles using parameters optimised for each reaction as shown in 
Table 2.6. 
 
Reagent Volume 
Final 
Concentration 
Source 
  (µl)   
Forward primer (10µM) 2.5 1µM Invitrogen 
Reverse primer (10µM) 2.5 1µM Invitrogen 
10 PCR buffer 2.5  - Applied Biosystems 
Magnesium chloride (25mM) 1.5 1.5mM Applied Biosystems 
dNTP (5mM) 1 0.2mM Amersham Biosciences 
Distilled water 12.7  -  ELGA, UK 
AmpliTaq Gold (5U/µl) 0.3 0.06U/µl Applied Biosystems 
Genomic DNA (25ng/µl) 2 2ng/µl  -  
Total 25     
Table 2.5. Standard PCR reaction reagents. Reagents were added as listed to make a 
final volume of 25µl. 
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Stage 1 
Stage 2 
Stage 3   Step 1 Step 2 Step 3 
Process Denaturation Denaturation Annealing Extension Elongation 
Temperature 95°C 95°C 50-65°C 72°C 72°C 
Duration (mins)  5-10 0.5 -1 0.5-1 0.5-1 7 
No. Of cycles 1 30-40 1 
Table 2.6. Standard PCR conditions. The PCR reactions can be divided into 3 main 
stages. During the first stage the double stranded DNA is denatured and the Taq 
polymerase activated. The second stage consists of three steps (denaturation, 
annealing and extension) which are repeated in 30- 40 cycles. In stage 3 the extension 
step is elongated to enable the completion of all newly synthesised single stands. 
Following the completion of the PCR the product is cooled for storage to 4°C. 
 
2.3.4 Fast-PCR protocol 
Some PCR reactions were performed using a contemporary rapid methodology. The 
GeneAmp® Fast PCR system (Applied Biosystems) uses a hot start polymerase system 
that has been optimised to reduce the overall amplification time, reducing the time 
taken to perform a PCR from 2-3 hours to 20 -30 minutes. For a standard reaction , 
10µl of GeneAmp® Fast PCR Mix (2X) was added to 2µl of both 10µM forward and 
reverse oligonucleotide primers, 50ng DNA template and made up to 20µl with water 
(Elga). The samples were placed in a GeneAmp PCR System 9800 machine (Applied 
Biosystems) and the PCR reaction run using the settings shown in Table 2.7. During 
cycling there is a combined annealing and extension step. The temperature for this 
step is dependent on the melting temperature of the primers but must be set between 
62-72°C for the optimal performance of the GeneAmp Fast PCR Master Mix. The 
duration of this step is determined by the PCR product length and is set at 25 seconds 
for every 1000 bases. Details of primers and cycling conditions for each experiment are 
given in the method sections of chapters 3,4 and 5.  
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Step 1 2 3 4 
Denaturation 
& 
Taq activation 
PCR Amplification 
(30-40 cycles) 
Elongation HOLD 
Denature Annealing &  
Extension 
Temp  95oC 94oC 62-72oC 72oC 4oC 
Time  10-60 sec 0 sec 25 seconds / Kb 10-60 sec  
Table 2.7. Fast PCR standard conditions. Conditions programmed into a GeneAmp PCR System 9800 machine (Applied Biosystems). A 
combined annealing and denaturation step is set at a temperature in between a conventional PCR extension temperature of 72°C and an 
annealing temperature based on the melting point of the oligonucleotide primers and is set to continue for a period based on the 
predicted amplification product size.
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2.3.5 PCR product purification 
The products obtained after a PCR reaction contain not only the desired amplified 
sequence but also some low molecular weight sequences including primer excess and 
additional primer dimer structures. These sequences may impede subsequent 
sequence analysis and were removed using the PureLinkTM PCR Purification Kit 
(Invitrogen, UK) according to the manufacturer’s instructions. The purified PCR 
products were stored at -20°C before processing.   
 
2.4 Agarose gel electrophoresis 
2.4.1 Introduction 
Agarose gel electrophoresis is a technique used to separates the product of a PCR 
reaction, DNA fragments, according to their size.  The negatively charged DNA 
molecules are transported across the agarose gel by the application of an electric 
current.  The migration of larger fragments is reduced by the gel’s polysaccharide 
matrix resulting in separation based on molecular size which may be referenced 
against DNA ladders producing bands of known sizes. The DNA is visualised by adding 
ethidium bromide to the gel which intercalates between the bases of the DNA and 
fluoresces under ultraviolet light illumination. 
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Figure 2.3. Image of a electrophoresis gel stained with ethidium bromide under UV 
light. Comparing the size of the bands against the standard size marker ladder 
(Invitrogen, UK) in lane 1 shows the products in lanes a) i 2 and 3 to be 210 base pairs, 
b) 5 and 6 to be 336 base pairs and c) 8 and 9 260 base pairs. No PCR product is seen in 
lanes 4 and 7 (arrows). 
 
2.4.2 Standard protocol 
Agarose gels were produced at a 2% (w/v) concentration in 1 x TBE buffer. 150ml of 
0.1mM Tris, 1M Boric acid, 10mM EDTA buffer (1 x TBE buffer) was added to 3g of 
agarose (Invitrogen), this solution was heated in a microwave. Two drops of ethidium 
bromide was added to the molten agarose when cooling which was then set in a gel-
casting tray (Gibco) with combs in position to produce wells once the gel set. The PCR 
product was mixed (4 parts to 1) with Orange G loading buffer (800l Glycerol, 40l 
0.5M EDTA pH 8.0, 1160l water and a pinch of Orange G (Sigma)) before being loaded 
into an individual well on the gel. A Power Pac 3000 (Bio-Rad) was used to run the gel, 
immersed in a gel tank containing 1 x TBE (see appendix), at 100 volts. Band sizes were 
determined using a 100bp marker (125l of 1g/l 100bp marker (Invitrogen), 250l 
of bromophenol blue loading dye and 875l 1 x Tris EDTA (TE)) and the gels were 
photographed using a Bio Vision UV trans-illuminator (Biogene Limited). 
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2.5 Direct sequencing 
2.5.1 Introduction 
This method of sequencing, illustrated in Figure 2.4, was devised by Frederick Sanger in 
1974 (Sanger, Nicklen et al. 1977).  A short oligonucleotide primer first attaches to the 
DNA template. DNA polymerase and dNTPs are added to the mix so that 
complementary strands can be produced. In addition however dideoxynucleoside 
triphosphates (ddNTPs) are added which are dideoxy analogues that lack the 3’OH 
group necessary for chain elongation. 
The new strand synthesis continues until it is terminated by the incorporation of a 
ddNTP lacking the necessary hydroxyl group for chain elongation. Using the 4 different 
dideoxy analogues the new strands formed will terminate at all the possible nucleotide 
positions. The resultant mix will contain new strands of every length. For automated 
DNA sequencing the ddNTPs are labelled using different fluorescent probes. The 
sample is passed across a gel and separated according to size by electrophoresis. The 
samples pass across a laser detector which interprets the fluorescence wavelength and 
assigns a base at that position. 
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Figure 2.4. Sanger sequencing. The steps involved in sequencing are shown. (a) DNA sequence to be analysed. (b) A mixture of 
nucleotides are added including labelled dideoxynuceoside triphosphates (ddNTPs) which lack a hydroxyl group necessary for chain 
elongation so that (c) when incorporated in to the sequence result in sequence termination. The pool of sequences of various lengths, are 
then (d) passed across an electrical current. Smaller chains pass across first and the terminal labelled ddNTP is detected by a fluorescence 
detector and (e) an electrophoregram of the sequence is generated.  
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2.5.2 Standard protocol 
PCR reactions were carried out and purified as detailed above (section 2.3). 
Sequencing reactions were carried out using CEQ 2000 Dye Terminator Cycle 
Sequencing (DTCS) with Quick Start Kit (Beckman Coulter). The following reagents 
were added to 0.2ml thin-walled PCR tubes (Abgene): 8l of DTCS Quick Start Master 
Mix, 0.5l of 8M forward or reverse primer (as used for the original PCR reaction), 
and 11.5l of DNA purified using the QIAquick Gel Extraction Kit. The tubes were run 
on the following cycle using a GeneAmp PCR System 9700 machine: 
96C for 20 seconds, 50C for 20 seconds and 60C for 4 minutes, for a total of 30 
cycles, followed by a holding step of 4C.  
The sequencing products were precipitated using the CEQ 2000 DTCS Kit. Four 
microlitres of stop solution (1.5M NaOAc and 50mM EDTA, prepared by adding equal 
volumes of 3M NaOAc and 100mM EDTA (Sigma-Aldrich)) and 1l of 20mg/ml 
glycogen (Beckman Coulter) were added to 1.5ml eppendorph tubes. The sequencing 
reactions were transferred to the appropriately labelled tubes and vortexed. Sixty 
microlitres of ice-cold 95% (v/v) ethanol was added to the tubes, which were 
immediately centrifuged at 10000g 4C for 20 minutes in an Eppendorf 5417R 
Centrifuge. The supernatant removed and the pellets were rinsed twice with 200l of 
70% ice-cold ethanol. The samples were centrifuged at 12000g for 3 minutes and the 
supernatant carefully removed in between each washing. The pellets were vacuum 
dried for approximately 40 minutes, to remove all remaining ethanol. Each sample was 
resuspended in 30l of sample loading solution (SLS, Beckman Coulter). 
Samples were loaded into the appropriate wells on the CEQ sample plates (Beckman 
Coulter). One drop of light mineral oil (Beckman Coulter) was added to the surface of 
each sample on the plate. The plate was loaded into the CEQ 8000 Genetic Analysis 
System and processed using the appropriate method program for the size of the PCR 
product. Sequence traces were analysed using the CEQ analysis software.  
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2.6 Quantitative real-time PCR (qRT-PCR)  
2.6.1 Introduction 
A PCR reaction goes through three phases: exponential, rate-limiting and plateau. 
Quantitative real-time PCR (qRT-PCR) was devised in 1992 to take advantage of these 
properties to enable the simultaneous amplification and quantification of PCR 
products (Higuchi, Dollinger et al. 1992). At the start of a PCR reaction reagents are 
plentiful and the DNA template is at a low concentration so as not to interfere with 
primer binding, and therefore the PCR amplification proceeds at an exponential rate 
(the exponential phase).  Eventually, when reagents become limited and the 
concentration of DNA template inhibits primer binding and further template synthesis, 
the reaction enters a rate-limiting phase. The point at which the reaction exits the 
exponential phase and enters the rate limiting phase is variable. Finally the formation 
of product stops and the reaction enters the terminal plateau phase. Analysis of PCR 
products in the plateau phase can identify the presence or absence of a particular 
product as in conventional PCR (see section 2.4), but cannot determine the quantity of 
starting template. Measurement however of the amount of product during the 
exponential phase of a PCR reaction permits the estimation of the template quantity. 
Higushi et al  first demonstrated that a PCR method could both simultaneously amplify 
and quantify PCR products exploiting the characteristics of the exponential phase of a 
PCR reaction with the addition of ethidium bromide to the reaction reagents (Higuchi, 
Dollinger et al. 1992). Ethidium bromide intercalates into double-stranded DNA so that 
the intensity of fluorescence emitted is proportional to the quality of double stranded 
DNA produced. The fluorescence emitted at the end of every PCR cycle is plotted and a 
graph plotted which identifies the exponential, rate-limiting and plateau phases, as 
illustrated by Figure 2.5. If a threshold is set in the exponential phase, then the number 
of cycles taken to reach a given threshold will be less in samples with a higher 
concentration of template DNA. The number of cycles required to achieve this 
threshold is defined as the Ct (cycle threshold). Modern quantitative real-time PCR 
(qRT-PCR) protocols in preference to ethidium bromide use less toxic chemistries such 
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as TaqManTM probes (Applied Biosystems) and SYBRTM green (Molecular Probes) to 
intercalate with double stranded DNA. Computerised automated platforms also now 
exist to systematically calculate the level of fluorescence after each cycle. For reviews 
of qRT-PCR, see (Valasek and Repa 2005; Kubista, Andrade et al. 2006). 
 
2.6.2 Absolute quantification (AQ) 
qRT-PCR can be employed to determine the absolute quantity (copy numbers, ng, 
mRNA) of specific genes within a particular sample using an absolute quantification 
(AQ) , or standard curve method (reviewed in(Bustin 2000). For this approach a sample 
of known concentration is first serially diluted to produce a series of samples of known 
concentration. A standard curve is then generated for each target gene and 
endogenous control by plotting the initial concentration of each sample against the 
qRT-PCR cycle number at which the Ct is reached (Figure 2.6). The quantity of a specific 
gene in an unknown sample can then be calculated by interpolation of the standard 
curve using the Ct value of the target gene and endogenous control in the unknown 
sample. The target gene is normalised to the endogenous control to account for 
sampling issues and then determine the absolute quantity of the target gene in the 
unknown sample.  
The slope of the standard curve can be used to measure the efficiency of the reaction 
primers. If the primers are 100% efficient the amount of PCR product should double 
with every cycle in the exponential phase. If then the results from a 10-fold serial 
dilution are plotted, as on a standard curve, the individual Ct values should differ by 
3.32 cycles. The slope of a standard curve from -3.2 to -3.6 therefore represents primer 
efficiencies in the range of 90-100%. 
Following the PCR reaction the AQ method performs a dissociation step which can be 
used to assess primer specificity (Figure 2.7). During this step the PCR products are 
heated from 60°C by 1°C every 15 seconds up to 95°C and the amount of 
fluorescence recorded. When the new double stranded molecules become denatured 
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the fluorescence intensity falls and a bell shaped dissociation plot produced. Due to 
the unique biochemical properties of individual sequences each PCR product has a 
specific dissociation temperature (Tm). Using non-specific primers will therefore result 
in multiple dissociation curves for each product produced rather than the single curve 
seen when primers bind to a single specific template region.  
 
2.6.3 qRT-PCR primer design 
Primers were designed with Dr Sarra Ryan (Northern Institute Cancer Research) to 
cover all transcript variants of a specific gene found using the NCBI and Ensembl 
genomic databases (www.ncbi.nlm.nih.gov, www.ensemble.org). PrimerExpress® 
software (Applied Biosystems, UK) was used to design the qRT-PCR primers with 
amplicons of 50-150 base pair, a Tm of 58-60°C, and have a G/C content of 30-80%. 
The primers were then checked using BLAST (www.ncbi.nlm.nih.gov) and BLAT 
(www.genome.ucsc.edu) searches to determine their uniqueness. Concentrated 
primer stocks (Sigma, UK) were made up to 100nmol with Purelab Ultra water (ELGA, 
UK) and stored at -80°C, and 10nmol working solutions aliquots were stored at -20°C. 
Primer specificity was initially assessed by performing a conventional PCR (section 
2.3.3) and identifying products on an electrophoretic gel (section 2.4.2). A dissociation 
curve was subsequently generated using the AQ method (section 2.6.2) to test for non-
specific products. Nucleic acid sequences of primers used in this study will be provided 
in the relevant methods sections. 
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Figure 2.5. An amplification plot produced from a qRT-PCR assay. The number of 
cycles required to achieve the cycle threshold (Ct) for samples (a) and (b) repeated in 
triplicate is shown. The Ct is set during the exponential phase of product amplification. 
Sample (a) consistently requires fewer cycles to achieve Ct compared to (b) which 
suggests an elevated initial sample template.  
 
 
Plateau 
Exponential 
Threshold 
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Figure 2.6. The development of a standard curve in a qRT-PCR assay.  (A) qRT-PCR is 
performed on a serial dilution of a control sample at a known concentration which 
results in the samples with a higher-fold initial template achieving the cycle threshold 
(Ct) with fewer PCR cycles. (B) A standard curve for the primer set shown in (A). The 
slope coefficient is -3.2 showing the PCR efficiency to be almost 100%. The number of 
cycles required to achieve the Ct value is plotted on the y-axis and the amount of 
template DNA on the x-axis. Plots in red record the results of test samples with an 
unknown starting template concentration which can now be calculated by 
interpolating the standard curve.   
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Figure 2.7. A dissociation curve produced from a qRT-PCR assay. The dissociation 
curve for a single gene repeated in triplicate on one sample is shown. A single product 
is produced with a Tm of 78°C.  
 
 
2.6.4 Standard protocol 
QRT-PCR was performed on an ABI PRISM 7900HT instrument (Applied Biosystems, UK) 
using the reagents and reagent concentrations shown in Table 2.8. The assays were 
performed in 384-well plates (Applied Biosystems, UK) which were covered with 
adhesive lids (Applied Biosystems, UK). All samples were assessed in triplicate in a 
single experiment, and where copy number alterations were observed the experiment 
was repeated on two further occasions to corroborate the finding. On each plate a 
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negative control containing Purelab Ultra water (ELGA, UK) and a cell-line DNA positive 
control was added. Standard cycling conditions were as outlined in Table 2.9. The data 
generated was analysed using SDS version 2.2 (Applied Biosystems) and converted into 
Excel®2007 (Microsoft) format for normalisation and further analysis.  
 
Reagent 
Volume 
Final Concentration Source 
(µl) 
SYBR green (+Rox) 5.1  -  Invitrogen, UK 
Forward primer 0.2  - VhBio, UK 
Reverse primer 0.2 0.2µM VhBio, UK 
Purelab Ultra Water 0.5 0.2µM ELGA, UK 
Genomic DNA 4 variable ng/µl  - 
Total 10     
Table 2.8. Standard qRT-PCR reaction reagents. The addition of the Rox reference dye 
reduces the background noise by normalising non-PCR fluorescent fluctuations   
 
 
 
 
131 
 
 
Stage 1 Stage 2 
Stage 3 
Stage 4 
 
Step 1 Step 2 
Process 
UDG 
Activation 
Denaturation 
& Taq 
activation Denaturation 
Annealing & 
Extension Dissociation 
Temperature 50°C 95°C 95°C 60°C 95°C 60°C 95°C 
Duration 2 min 10 min 15 sec 1min 15sec 20 sec 15 sec 
No. Of cycles 1 1 40 1 
Table 2.9. Standard qRT-PCR conditions. 
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2.7 Loss of heterozygosity (LOH) assessment 
2.7.1 Introduction to LOH 
Loss of heterozygosity (LOH) is a frequent finding in tumours and indicates the loss of 
one of the two alleles of a gene in a cell. By screening paired blood and tumour 
samples and identifying differences, genome-wide scanning techniques which identify 
regions of LOH have been used to identify narrow regions of chromosomal loss for 
further investigation which in turn may harbour tumour suppressor genes (Strachan 
and Read 2004). The identification of LOH can be undertaken using polymorphic 
microsatellite markers. Microsatellites are short polymorphic nucleotide repeat 
sequences consisting of di-, tri-, or tetra- nucleotide repeats (eg; CACACACA, or 
CAGCAGCAGCAG, or CAGTCAGTCAGTCAGT). The number of repeats present is 
polymorphic and therefore for a given microsatellite the number of repeats inherited 
on each allele is likely to be different. If this region were amplified by using flanking 
primers in a PCR reaction, yielding two products would suggest the retention of both 
alleles, whilst the production of a single product in a tumour sample where two are 
seen in the constitutive DNA, would indicate a loss of heterozygosity. 
 
2.7.2 The HOMOD method 
Homozygous mapping of deletions (HOMOD) is a technique used to identify LOH 
without using constitutive DNA as a comparator. HOMOD uses a statistical approach to 
identify extended regions of homozygosity (ERH) with polymorphic satellite markers. 
The frequency of heterozygosity for each marker in the general population is known 
and details may be obtained from databases including the Marshfield Clinic Research 
Foundation (http://research.marshfieldclinic.org/genetics/GeneticResearch/). The 
probability of a number of consecutive markers being homozygous is calculated by 
multiplying the homozyosity scores (1 - heterozygous probability) of each marker 
together. LOH is recorded when the probability of homozygosity at contiguous markers 
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is ≤0.001, which is typically equivalent to ≥5 adjacent homozygous markers (Goldberg, 
Glendening et al. 2000). 
 
2.7.3 Primer design 
Polymorphic markers covering the chromosomal region to be investigated were 
identified from the Marshfield Research Foundation website 
(http://research.marshfieldclinic.org/genetics/GeneticResearch/). The markers were 
then entered into the National Center for Biotechnology Information (NCBI) Uni-STS 
database from which details of the nucleotide primer sequences and PCR product sizes 
for each marker were derived. The forward oligonucleotide primer of each set was 
labelled with a fluorescent dye, WeLLRED, at the 5’ end (Sigma-Proligo, France). 
Further details of the primers used in HOMOD studies are described in (section 3.2.6) 
 
2.7.4 Standard protocol 
PCR products for each marker were generated using primers described in section 3.2.6 
and methods described in section 2.3.3. Products were subsequently analysed using 
the CEQ 8000 Genetic Analysis System (Beckman Coulter) by loading 0.5µl PCR product 
onto a 96 well plate (Beckman Coulter) and adding 40µl sample loading solution (SLS, 
Bekman Coulter), and 0.5µl 400 size standard (Beckman Coulter). A fragment analysis 
installed programme was run (Frag-4) according to the manufacturer’s instructions. As 
described in paragraph 2.5.2 and illustrated on Figure 2.4, this system involved the PCR 
products travelling across a fluorescent sensor during electrophoresis. Smaller 
products labelled with the WeLLRED dye were detected by the sensor at an earlier 
stage, resulting in a peak in fluorescent intensity. By labelling different PCR primers of 
different sizes with altering coloured WeLLRED tags up to 3 samples were loaded into 
the same well of a plate and analysed together (Figure 2.8). A fragment analysis 
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programme was subsequently run on the CEQ8000 Analysis System (Beckman Coulter) 
to convert the raw data into interpretable traces. 
 
2.7.5 Interpretation of results 
The results are interpreted by recognising the specific pattern that each polymorphic 
microsatellite produces as shown in Figure 2.9, In addition the pattern of nucleotide 
repeats for each microsatellite (mono, di, tri, tetra) is also considered. The presence of 
a single major peak suggests homozygosity at that marker.  More than one peak may 
however still be interpreted as homozygous, if it is the characteristic pattern of a 
particular marker to produce a number of minor peaks to represent a major peak.  
Minor peaks always occur within 2, 3 or 4 base-pairs of the major peak of a mono, di, 
tri, or tetra nucleotide repeat marker respectively. In addition, a second peak is only 
considered to be a major peak if it is at least 30% of the size of the main peak. Taken 
together samples are assigned as being homozygous for a particular marker if there is 
a single peak, or if additional peaks are less than 30% of the size of the major peak. 
Heterozygosity is assigned if two peaks whose height measure within 50% of each 
other are observed. Where the peak heights fall between 30 and 50% of each other a 
non-informative assignment is made, and the experiment for that sample repeated.  
Details of the polymorphic microsatellite markers used in this study are described in 
section 3.2.6. 
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Figure 2.8. HOMOD trace. For this sample two different polymorphic microsatellite markers have been analysed simultaneously. D17S969 
(black) shows 2 major peaks (128.8 and 137.1) more than 3 base pairs apart indicating a retention of heterozygosity at this locus. The trace in 
blue shows the result for the tetra-nucleotide marker D17S1866. This marker produces a characteristic pattern of 4 minor peaks. These minor 
peaks constitute a single major peak suggesting homozygosity at this locus. Standard size markers are shown in red. 
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Figure 2.9. Fragment analysis traces at a polymorphic microsatellite site. Analysis using dinucleotide polymorphic microsatellite marker 
D17S974.(a) A single major peak (206.7) is produced suggesting homozygosity at this locus. (b) Heterozygous trace. The marker produces a 
major peak for each allele positioned more than 3 base pairs apart (203.1 and 211.3).  Standard size markers are shown in red. 
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2.8 Multiplex ligation-dependent probe amplification 
(MLPA) 
2.8.1 Introduction 
Multiplex ligation-dependent probe amplification (MLPA) is a multiplex PCR based 
method first described in 2002 that can be employed to detect abnormalities in 
genomic DNA or RNA copy number (Schouten, McElgunn et al. 2002). Probes can also 
be designed to incorporate known mutation sites and epigenetic methylation changes 
using methylation-specific MLPA (MS-MLPA)(Eldering, Spek et al. 2003). Crucially 
because it is a multiplex technique up to 50 different sequences may be interrogated 
within a single reaction with only 20-100ng DNA or RNA template. 
The MLPA reaction is divided into five steps: (1) DNA denaturation and hybridisation of 
MLPA probes, (2) ligation reaction, (3) PCR reaction, (4) separation of amplification 
products by electrophoresis, and (5) data analysis, as shown in Figure 2.10. The DNA is 
first denatured and hybridized with two separate oligonucleotide MLPA probes. The 
two oligonucleotide probes are designed to hybridize at immediately adjacent regions 
on the template DNA and also contain one of the PCR primer sequences. A ligation 
reaction is then performed. Crucially only ligated sequences will contain both PCR 
primer sequences, and therefore only these will be amplified and produce a signal in 
the subsequent PCR reaction (see section 2.3). 
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Figure 2.10. The 5 stages of MLPA. (a)DNA denaturation and hybridisation of MLPA probes: Two probes with a complementary sequence to 
the target DNA hybridise adjacent to each other. Attached towards the 3’ end of the probe is a non-hybridising stuffer sequence which 
elongates the final product to a pre-determined length. At the 5’ and 3’ ends are common MLPA primers; (b) Ligation: The adjacent probes are 
joined together (c) PCR amplification: The ligated sequence is the amplified using the common PCR primers (X and Y), (d) Electrophoresis: The 
MLPA product is run on a Beckman-Coulter Genetic analysis system and each product length is determined using a fragment analysis 
programme. (e) Data analysis: The results are subsequently analysed in comparison to normal controls using GeneMarker®software to 
determine copy number changes. (Figure adapted from (Schouten, McElgunn et al. 2002))
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2.8.2 Primer design 
The sequences of genes to be investigated were obtained from 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene. Probes were designed with Dr 
Matthew Allan (Northern Institute for Cancer Research) following the guidance 
provided by MRC-Holland (MRC-Holland 2009) and manufactured by Metabion 
(Germany). Each MLPA probe consisted of a left probe oligonucleotide (LPO) and a 
right probe oligonucleotide (RPO). The MLPA probes were designed to be 100-140 
nucleotides in length, with the length of each probe being at least 4 nucleotides 
different from any other probe to facilitate distinct fragment separation and avoiding 
lengths of probes already contained in the normalisation probe mix.  Each MLPA probe 
contained PCR primers comprising 42 base pairs and therefore the left and right 
hybridising sequences (LHS and RHS) combined with a stuffer sequence were designed 
to be 58-98 base pairs in length (optimal MLPA probe length – PCR primer length) . The 
structure of an MLPA probe is outlined in Figure 2.11. The LHS and RHS sequences 
were reviewed using BLAST (http://blast.ncbi.nlm.nih.gov) and BLAT 
(http://genome.ucsc.edu) searches to ensure that following hybridisation and 
subsequent PCR amplification that the resultant products would comprise only the 
correct and unique sequence. Details of the MLPA probes designed and used in the 
study are given in (sections 3.2.7.4 and 3.2.8.5). 
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Figure 2.11. Schematic representation of a MLPA probe. An optimal MLPA probe 
following ligation is between 100 and 140 nucleotides in length. It comprises two 
standard PCR primers (a) and (e) of 42 nucleotide in length. The combination of the (b) 
left hybridising sequence (LHS), with the (c) right hybridising sequence (RHS), and a 
stuffer sequence (d) must measure between 58 and 98 nucleotides. 
 
2.8.3 Standard protocol 
All probes and reagents used in the MLPA reactions were supplied by MRC-Holland. 
The probes were provided at a concentration of 20nM and were diluted with 200µl TE 
(see Appendix) to make 100µM stock solutions which were stored at -20°C. Working 
aliquots of 1 µM of each probe were made by diluting 10µl stock solution with 1ml TE 
and stored at -20°C. 
In the first step, 50-200ng (5µl) sample DNA was first denatured by heating aliquots in 
PCR tubes in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) to 
98°C for 5 minutes. This was then left to cool to room temperature before the MLPA 
SALSA probe mix was added (detailed in Table 2.10). In a GeneAmp PCR System 9700 
thermal cycler (Applied Biosystems) the mix was incubated at 95°C for 1 minute, and 
then heated at 60°C for 16 hours to enable hybridisation to occur. Following 
hybridisation the temperature of the thermal cycler was reduced to 54°C and 32µl of 
ligation mix (Table 2.10) was added which was then incubated at 54°C for 15 minutes 
followed by 98°C for 5 minutes in the thermal cycler. In a separate PCR tube a mix 
containing 4µl SALSA PCR buffer and 26µl of PureLab Ultra water (ELGA, UK) was 
prepared to which 10µl of the ligation reaction product was added. The tubes were 
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incubated in a GeneAmp PCR System 9700 thermal cycler at 60°C to which 10µl of a 
polymerase mix (Table 2.10) was added before proceeding with the MLPA PCR 
programme  (Table 2.11). Samples containing 40µl sample loading solution (Beckman 
Coulter), 0.5µl 400 size marker (Beckman Coulter) and 1µl PCR product were 
subsequently loaded into the appropriate wells on the CEQ sample plates (Beckman 
Coulter). One drop of light mineral oil (Beckman Coulter) was added to the surface of 
each sample on the plate. The plate was loaded into the CEQ 8000 Genetic Analysis 
System and processed using the MLPA installed software programme (MLPA). The 
data generated was downloaded and analysed initially using GeneMarker® version 
1.75 (Softgenetics). The peak intensity of all probes including the control probes within 
a sample was derived. This data was then transferred to an Excel® 2007 (Microsoft) 
format and the intensities of the test probes relative to a series of control probes 
calculated. Details of the probes used can be found in (sections 3.2.7.4 and 3.2.8.5). 
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Table 2.10. Reaction reagents prepared on ice in a standard MLPA experiment. (a) 
Constituents of a hybridisation reaction to which 5µl denatured DNA template is added. 
Following hybridisation a ligation reaction is performed to which the (b) ligation mix is 
added. After ligation a PCR step is performed requiring a 10µl ligation reaction product 
aliquot to be combined with (c) a polymerase mix.  
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  Stage 1 
Stage 2 Stage 3   Step 1 Step 2 Step 3 
Process Denaturation Annealing Extension Elongation Hold 
Temperature 95°C 60°C 72°C 72°C 15°C 
Duration 30 seconds 30 seconds 1 minute 20 minutes ∞ 
No. Of cycles 35 1 ∞ 
Table 2.11. MLPA PCR program conditions. Prior to commencing the PCR program 
samples were kept at 60°C whilst a polymerase mix was added.  
 
2.9 Fluorescence in situ hybridisation (FISH) 
2.9.1 Introduction 
Fluorescence in situ hybridisation (FISH) is a cytogenetic technique employed to detect 
the presence or absence of chromosomal abnormalities including changes in copy 
number and structural rearrangements which affect the DNA sequence. Probes are 
designed to be complimentary to the specific region under investigation. The 
technique then involves hybridizing, either directly or indirectly the fluorescently 
labelled DNA probes to interphase nuclei or metaphase chromosomes. Using a 
fluorescence microscope the detection of genetic sequences may then be viewed 
within a cellular context. 
Probes may be labelled directly or indirectly with fluorophores by a variety of methods. 
In a technique referred to as nick translation some of the nucleotides from a DNA 
sequence are replaced using DNA Polymerase I with fluorescently labelled analogues.  
In addition to direct labelling techniques which involve the attachment of fluorophores 
to a nucleic acid probe indirect techniques may be employed where the nucleic acid 
probe binds to a non-fluorescent molecule such as biotin and digoxigenin. With 
indirect techniques following in situ hybridisation of non-fluorescent probes to cells, a 
fluorophore-labelled antibody or avidin is applied which provides the fluorescent signal. 
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The steps involved in a typical FISH experiment are illustrated in Figure 2.12. For a 
detailed review of FISH, see (Fan 2002; Gorczyca 2008).  
Bacterial artificial chromosomes (BACs) are vectors derived from E.coli bacteria which 
are often used to develop probes for FISH studies. The BACs contain foreign DNA 
fragments of 100-200kb into which probe DNA sequences can be incorporated and 
subsequently inserted into E.coli bacteria by electroporation. The advantage of this 
system is that with growth the transformed bacteria will produce a large amount of 
cells containing the probe in a short period which can be harvested when the cells are 
lysed and the DNA content purified. For a detailed review of BAC cloning, see (Birren, 
Green et al. 1999) 
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Figure 2.12. Scheme showing the principle of indirect FISH.  a) A DNA probe is labelled with a non-fluorescent molecules preparation and a 
slide is prepared b) with fixed cells, to which c) the probe hybridizes. Antibodies to the probe are then applied d) which are linked to 
fluorescent molecules which allows the material to be viewed under a fluorescent microscope. (Adapted from 
www.en.wikipedia.org/wiki/fluorescent_in_situ_hybridization).
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Figure 2.13. Fluorescence in situ hybridisation composite image showing a normal 
cellular diploid copy number of MYCN. Image captured using a fluorescence 
microscope with a excitation wavelength of 540nm to capture the Texas red labelled 
centromeric probe, and a 490nm to capture the MYCN Fluorecein isothiocyanate 
labelled (green) probe. 
 
2.9.2 Slide preparation 
All FISH studies were performed using FFPE material. Where available 10µm sections 
were cut from a FFPE tissue block and fixed to microscope slides (Nunc) by baking at 
60°C for 5 minutes. Before using in the FISH studies the fixed sections were dewaxed 
by placing them in xylene for 5 minutes and rehydrating them through an alcohol 
graded series of ethanol baths (100% (v/v), 80% (v/v), 70% (v/v), 50% (v/v)) for a 
minute each. To each slide 400µl of 0.5% pepsin (Sigma-Aldrich, UK) in 0.1M HCl was 
applied. The slides were then incubated in a humidified chamber for 2 hours at 37°C 
before being washed in 37°C water and immersed in PBS (see Appendix) for 5 minutes 
at 37°C. The slides were then rehydrated by descending through a series of ethanol 
baths (95% (v/v), 85% (v/v) and 75% (v/v)) and left to dry for 5 minutes before applying 
the probe. 
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To perform FISH on isolated nuclei a single 25µm section curl of FFPE tissue was placed 
in a 1.5ml microfuge tube containing xylene to dewax. The xylene was then aspirated 
and the tissue resuspended in ethanol before being centrifuged at 12000g for 5 
minutes in an Eppendorf 5147R centrifuge (Eppendorf). This process was repeated to 
facilitate the removal of all xylene from the suspension. The cycle was repeated a third 
time with the tissue resuspended in PBS before being passed through a 70µm mesh 
cell strainer (Fisher) at 1000g in a pre-cooled to 4°C Eppendorf 5147R centrifuge 
(Eppendorf) for 10 minutes. The resultant isolated nuclei were then centrifuged at 
1000g for 10 minutes onto microscope slides (Nunc) using a Cytospin 2 centrifuge 
(Thermal Scientific).  The slides were stored at -20°C until used at which time they 
were warmed in a 37°C water bath for 10 minutes before 100-200µl of pepsin (Sigma-
Aldrich) solution (4mg/ml HCl) was applied and incubated in a 37°C humidified 
chamber for 16 minutes. The slides were then washed in 37°C water and placed in PBS 
(see Appendix) for 5 minutes at 37°C before finally being rehydrated with passage 
through a series of ethanol baths (95% (v/v), 85% (v/v), and 75% (v/v)) and left to dry.  
 
2.9.3 Standard protocol 
The labelled probe was placed in a water bath at 37°C for 20 minutes and then 2.5µl 
was pipette onto the pre-prepared slides (section 2.9.2). A small cover slip (Nunc, 
Denmark) was placed over the top which was then sealed to the slide with a rubber 
cement (Marabo, Germany). Slides were placed onto a hot plate and heated to 75°C 
for 5 minutes to denature the genomic and probe DNA before being left overnight in a 
humidified incubator at 37°C. The following morning, the cover slips were taken off by 
removing the rubber seal and then gently agitating the slides in 2x saline-sodium 
citrate buffer (SSC, Becton Dickinson) at 37°C.  To remove any unbound DNA 
molecules the slides were then washed twice in 30% (v/v) formamide (Sigma-Aldrich) 
in 1xSSC at 43°C for 5 minutes. The slides were then placed in 2xSSC at 37°C for 5 
minutes, followed by incubation in 4xSSC (see Appendix) in a humidified chamber at 
37°C for 15 minutes. The slides were then incubated at 37°C for 20 minutes in a 
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humidified chamber with 50-100µl of six different antibodies washed twice in 4xSSC 
for 5 minutes in between each antibody exposure. The antibodies were added in the 
following order: 
1) 1:20 anti-digoxigenin fluorescence fab fragments (FITC, (Roche)) 
2) 1:50 rabbit anti-sheep IgM (DAKO) 
3) 1:40 anti-rabbit FITC (DAKO) 
4) 1:500 Texas red avidin (Vector) 
5) 1:100 goat biotinalated anti-avidins (Vector) 
6) 1:500 Texas red avidin (Vector) 
The slides were subsequently washed for 4 minutes with 2xSSC twice and with PBS for 
2 minutes once before being rehydrated through an ethanol gradient series (95%, 85%, 
and 75%). The slides were then left to dry in the dark for 15 minutes before being 
counterstained with a drop of DAPI (Vector) and protected with a cover slip (Nunc) 
sealed with nail varnish. The probes were then visualised with a DM300 Fluorescence 
Microscope (Leica) using the appropriate probe excitation wavelengths as shown in 
Table 2.12. 
 
Probe 
Wavelenth (nm) 
Excitation Fluorescent emission 
Fluorecein isothiocyanate (FITC) 490 520 
Texas red 590 620 
Table 2.12. FISH probe excitation and fluorescent emission wavelengths. 
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2.10 Immunohistochemistry (IHC) 
2.10.1 Introduction 
Immunohistochemisty (IHC) is an established process which identifies cellular proteins 
or antigens in tissues by using labelled antibodies and observing antigen-antibody 
interactions with marker fluorescent dyes or enzymes. The visualisation of an antigen-
antibody interaction may use a fluorophore, as first described in 1941 by Albert Coons 
(Coons, Creech et al. 1941), or by conjugation of an antibody to an enzyme that 
catalyses a colour producing reaction (Nakane and Pierce 1966). IHC enables the 
distribution and location of specific cellular components to be identified within intact 
cells. Specific molecular markers may be associated with particular cellular process or 
disease states and therefore this technique is widely used to discern normal from 
abnormal cells, and in particular the demonstration of cancerous cells. 
 
2.10.2 Antibodies for antigen detection in IHC 
Antibodies used in IHC can be either polyclonal or monoclonal (mAb). Typically 
polyclonal antibodies are generated by injecting an animal with an antigen and then 
harvesting the antibodies that are produced in response. Polyclonal antibodies 
therefore comprise a hetergenous mix of antibodies to a variety of epitopes. 
Monoclonal antibodies differ as they are monospecific, created by the overproduction 
of a unique immunoglobulin against a particular antigen. This method was first devised 
in 1975 with the creation of a hybridoma using a mouse myeloma to produce an 
antibody from an immunised donor (Kohler and Milstein 1975). This approach can now 
be used to selectively produce specific antibodies to defined antigens. 
Antibodies may be further sub-classified as being primary or secondary.  Primary 
antibodies are raised against an antigen of interest and are usually unlabelled 
(unconjugated), while secondary antibodies are raised against primary antibodies and 
identify immunoglobulins of a particular species.  
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Antigens may be detected through either a direct or indirect method (see Figure 2.14). 
In the direct method a single labelled antibody reacts directly with the antigen. Whilst 
simple this method has the disadvantage of poor signal amplification and is 
comparatively expensive.  More commonly an indirect approach is used. In this 
method the primary antibody again reacts with a specific antigen but is unlabelled. A 
secondary labelled antibody is then applied which reacts with the primary antibody. 
Importantly, the same labelled secondary antibody may be used with many different 
primary antibodies derived from the same species which makes this a particularly 
economical approach. 
To facilitate visualisation the secondary antibody is conjugated to biotin, or a reporter 
enzyme, or fluorescent dyes such as alkaline phosphatase or horseradish peroxidase 
(HRP). Commonly a biotinylated secondary antibody is coupled with a streptavidin 
tagged horseradish peroxidase enzyme which is reacted with diaminobenzidine (DAB) 
to produce colorimetric reaction. The resultant brown staining identifies and localises 
the antigen under investigation and the signal intensity is typically amplified as the 
secondary antibody is able to react with a number of epitopes on the primary antibody.  
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Figure 2.14. Immunohistochemical (IHC) approaches. (a) The direct method: A single labelled antibody (red inverted Y) binds to a specific cell 
antigen (A), and not to other cellular proteins (B and C). (b) The Indirect Approach: A primary antibody is applied which binds to a specific 
cellular antigen. A second antibody (purple inverted Y) is then applied which is labelled and reacts with the primary antibody. (redrawn from: 
http://en.wikipedia.org/wiki/Immunohistochemistry).
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2.10.3 Standard protocol 
Slides were placed in an oven at 60°C for 30 minutes before being transferred into a 
xylene bath for 10 minutes to dewax. The slides were then passed through a 
descending ethanol gradient to rehydrate for 30 seconds in each bath (100% (v/v), 100% 
(v/v), 95% (v/v), 95% (v/v), 75% (v/v), water). The slides were placed in a non metallic 
polyacetal slide rack trough (Thermo Scientific) and submerged in a citrate buffer pH6 
(see Appendix) before being microwaved at full energy for 5 minutes. The slides were 
then inspected to ensure that they continued to be submerged in citrate buffer which 
was replenished as necessary before being microwaved at full energy for a further 5 
minutes. The slides and buffer were then left to cool for 20 minutes before being 
rinsed in water. The slides were then placed into a coplin jar (Fisher Scientific) for 20 
minutes containing 100ml 6% hydrogen peroxide (Sigma-Aldrich). The slides were then 
rinsed initially in water and then using 10x TBS-Tween (see Appendix). The slides were 
then placed on a slide hydration tray (Fisher Scientific) containing 1ml of water in each 
lane and 100-200µl of the antibody solution depending on the area of the section was 
applied. The tray was covered and left to incubate at room temperature for 1 hour. 
After an hour excess antibody was rinsed off using 0.05M TBS (see Appendix). To 
ensure the complete removal of all free antibody the slides were then placed in a 
coplin jar containing TBS and rinsed. This was repeated a second time with TBS before 
the slides were placed in 10x TBS-Tween. To enable antibody detection the 
MenapathTMpolymer-HRP detection kit (Menarini Diagnostics) was used according to 
the manufacturer’s instructions. 1-2 drops of the MenapathTM universal probe was 
applied to cover the tissue on each slide and left in a hydration tray for 30 minutes. 
The slides were then rinsed with TBS to remove any excess which was repeated twice 
further in a coplin jars containing TBS. Excess solution was removed and then 1-2 drops 
of MenapathTM HRP-polymer was applied and left in a hydration tray for 20 minutes. 
Excess solution was removed by rinsing the slides in running water for 20 minutes. A 
solution containing 1ml DAB dilutent and 1 drop of chromagen liquid DAB was 
prepared and 1-2 drops were dropped on each slide and left for 3-4 minutes. The slides 
were then rinsed in water before being counterstained with haematoxylin for 30 
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seconds, rinsed again in water, and dipped into an acid/ alcohol bath. The slides were 
then rinsed again in water before being placed in a solution of Scott’s water for 10 
seconds and then re-ascending a gradient of ethanol baths (75% (v/v), 95% (v/v), 100% 
(v/v)). The tissue was finally fixed with xylene, mounted in DPX and protected with a 
cover slip (Nunc) before placing at 4°C for storage. Details on the preparation of the 
counterstains may be found in the Appendix. 
 
2.11   DNA methylation analysis 
2.11.1 Introduction 
DNA methylation is an enzyme-mediated chemical modification that adds methyl (CH3) 
groups to the carbon-5 position of the cytosine base (C) and occurs in approximately 3-
5% of the cytosine residues in genomic DNA (Ehrlich et al, 1982). Almost 60% of genes 
contain regions of DNA with a high content of cytosine and guanosine (G+C) 
nucleotides and a high frequency of the CpG dinculeotide, known as CpG islands. 
These CpG islands frequently arise upstream to transcriptional start sites or promoter 
regions and methylation may result in chromatin remodelling into a transcriptionally 
repressive structure, and therefore act as an epigenetic modification by altering 
transcription without affecting the nucleotide sequence, as discussed in section 1.2.6. 
Methods to assess DNA methylation often require an initial modification to reveal the 
methylation status at a particular locus, including bisulphite modification. 
 
2.11.2 Bisulphite modification of DNA 
Bisulphite modification is a technique employed to detect whether methylation of CpG 
diucleotides is present by introducing a sequence alteration between methylated and 
hypomethylated states. In this process all unmethylated cytosines are deaminated and 
sulphonated by the sodium bisulphite treatment which converts them to uracils. 
Methylated cytosines are resistant to this treatment, and therefore the sequence at 
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this residue remains unaltered. In subsequent PCR amplification the uracils are 
replaced by thymines as outlined in Figure 2.15 and Figure 2.16. 
 
2.11.3 Sequencing of bisulphited DNA  
Following bisulphite treatment the DNA sequence is transformed to produce altered 
sequences for both methylated and unmethylated DNA. To determine these 
sequences PCR amplification is performed. Oligonucleotide primers are generated to 
amplify the converted sequences, and are therefore different to those that would be 
employed to amplify the same locus in the original untreated DNA template. Primers 
need to be able to amplify both unmethylated and methylated sequences and 
therefore the primers are designed not to contain any CpG dinucleotides. Primer 
design is undertaken using MethPrimer 
(http://www.urogene.org/methprimer/index1.html), an online tool that initially in 
silico bisulphite converts a genomic sequence, and then computes appropriate primer 
pairs. The details of oligonucleotide primers are provided in sections 3.2.5 and 5.2, and 
were synthesised by Invitrogen.  
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Figure 2.15. Sodium bisulphite modification of DNA.Treatment of DNA with sodium bisulphite selectively deaminates unmethylated cytosine 
(C) residues (green) converting them to uracil (U). When methylated (closed red circle) methylcytosine residues (red) remain unaffected by the 
bisulphite modification. The modified DNA sequences can then be analysed for sequence variation using PCR techniques.   
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Figure 2.16. Electrophoregrams demonstrating the effect of methylation following bisulphite modification. Reverse trace sequences for 
RASSF1A on two samples are shown. (a) Methylated sequence, showing the preservation of CG dinucleotides following bisulphite treatment. 
The first CpG (1) is shown to be fully methylated, but the 2nd CpG (2) shows evidence of partial methylation with an adenine peak in addition to 
the guanine in this reverse sequence. (b) Unmethylated sequence. Bisulphite conversion has deaminated all non-methylated cytosines resulting 
in CA dinucleodide at both CpG sites. 
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2.11.4 Standard protocol 
Bisulphite conversion was performed on 500ng of genomic DNA using the EpiTect® 
(Qiagen) kit, following the manufacturer’s instructions. Converted DNA was eluted in 
EB buffer (Qiagen) and stored in two 20µl aliquots at -80°C until used. PCR reactions 
were performed as described in section 2.3.3, visualised by gel electrophoresis as 
described in section 2.4.2 and purified using the PureLink® (Invitrogen) system (section 
2.3.5). Purified products were subsequently sequenced as previously outlined in 
section 2.5.2and the methylation status assigned by interrogating each CpG 
dinucleotide on the electrophotegrams and scoring as being either methylated, 
partially methylated or hypomethylated.   
 
2.12 Illumina GoldenGate methylation array 
2.12.1 Introduction 
The GoldenGate® methylation array (Illumina) platform is a high-throughput method 
that enables the methylation status of up to 96 samples to be simultaneously 
evaluated (Bibikova, Lin et al. 2006; Fan, Gunderson et al. 2006). Using the 
GoldenGate® Methylation Cancer Panel I 1505 CpG sites across 807 genes are assessed. 
The genes incorporated in this panel have been selected as they are either tumour 
suppressor genes, oncogenes, genes involved in DNA repair, or genes that regulate cell 
cycle control or apoptosis or cell differentiation. In the panel 28.6% of the genes are 
represented by a single CpG on the array, 57.3% with 2 CpGs and 14.1% by 3 or more 
CpG dinucleotides.  
An outline of the Illumina GoldenGate methylation array process is shown in Figure 
2.17. Genomic DNA is first bisulphite treated to deaminate non-methylated cytosines 
and has been previously described (section 2.11.2). The transformed sequences are 
then hybridised with probe pairs designed for unmethylated and methylated 
sequences. Each probe pair contains an allele-specific oligonucleotide (ASO) and locus-
158 
 
specific oligonucleotide (LSO). The probes anneal to the modified target DNA at the 
ASO and LSO. A ligation reaction is then performed which extends the ASO to the 
corresponding LSO, to form a PCR template. Universal PCR primers attached to both 
the 5’ and 3’ the ends of the probes are used to amplify the resulting sequence. The 
PCR primers also contain fluorophores, different for methylated and unmethylated 
sequences. Following PCR amplification the sequence are hybridised to a bead with a 
complementary sequence and the fluorescence intensity of both fluorophores 
generated at each bead recorded by the BeadArray reader (Illumina). Each of the 1505 
sites is represented up to 30 times on different beads on the Sentrix Array Matrix 
(SAM). The intensity of the 2 wavelengths for each bead is registered and an average 
(mean) value for each CpG generated (average delta beta). The average delta beta 
scores range from 0 (fully unmethylated) to 1 (fully methylated). 
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Figure 2.17. GoldenGate methylation array flow process.The steps involved in the 
Illumina GoldenGate methylation array for methylated (left) and unmethylated (right) 
sequences are shown. (a) Genomic sequences showing methylation (closed red circle) 
at CpG dinucleotides. (b) Sequence transformation following bisulphite treatment.(c) 
For each CpG site two pairs of probes are designed: an allele-specific oligonucleotide 
(ASO (orange)) and locus-specific oligonucleotide (LSO (green)) probe pair for the 
methylated and unmethylated states. The pooled oligonucleotides anneal to the target 
DNA. (d) Extension in the LSO direction. (e) Ligation (purple) of the extended ASO to 
the corresponding LSO to create a PCR template. The ligated products are then PCR 
amplified using fluorescently labelled common primers (grey) and (f) hybridise to a 
bead array bearing the complementary sequence (blue). Two fluorophores are then 
used to distinguish methylated and unmethylatyed loci. (redrawn from: 
www.illumina.com/technology/goldengate_methylation_assay.ilmn) 
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2.12.2 Sample plate preparation 
Methylation analysis on the Illumina GoldenGate Methylation array platform was 
performed by the Wellcome Trust Centre for Human Genetics (Oxford, UK). For each 
sample to be analysed 750ng of genomic DNA was prepared. The clinical details of 
tumours and controls used in this study are given in section 5.2) 
 
2.12.3 Quality control assessment 
2.12.3.1  BeadStudio Methylation Module quality control assessment 
The raw data was first subjected to a quality control assessment using BeadStudio 
Methylation Module, version 3.0 (Illumina). A control summary graph was produced to 
evaluate each step of the methylation process. These steps included a quality control 
assessment of bisulphite conversion, a determinant of gender specific methylation, 
allele specific extension, contamination, hybridisation to the DNA template, secondary 
hybrisdaiation to the array beads and negative controls following the manufacturer’s 
instructions (Illumina) and illustrated in Figure 2.18 and Figure 2.19. Samples that 
failed these quality control steps were excluded from subsequent analyses. 
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Figure 2.18. Illumina GoldenGate Methlyation array control panel (A) summary. (a) 
Bisulphite conversion: The efficiency of bisulphite conversion is verified by checking for 
the presence of genomic DNA (red) compared to bisulphite converted DNA (green) in 
the assay using two primers (868 and 1742) designed to amplify genomic DNA at the 
same locus. (b) Negative controls: A panel of 22 negative control probes are included 
in the oligonucleotide pool which target bisulphite converted sequences but should 
not produce a signal as they do not contain an ASO and will not be PCR amplify. Any 
signal produced therefore represented a background signal resulting from cross-
hybridisation, or non-specific binding of dye. (Note the intensity scale is 10-fold lower 
with minimal signals detected). (c) Gender specific methyaltion: The sex of the samples 
was verified using two X-linked genes (G6PD (1878) and ELK1 (2911)). These genes are 
known to exhibit DNA dose compensation by becoming partially methylated when two 
X chromosomes are present. Only a Cy3 (green) signal in males and both Cy3 and Cy5 
(red) signals in females should be observed. (d) Contamination: PCR contamination 
was detected using four control oligonucleotides (1968, 1992, 2980, 3433). Only one 
was added to each oligonucleotide pool and so the presence of more than one 
suggests contamination. 2980 was added to the pool shown which shows no evidence 
of contamination. 
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Figure 2.19. Illumina GoldenGate Methylation array control panel (B) summary. Cy3 
unmethylated signals are shown in green, Cy5 methylated signals in red. (a) First 
hybridisation: Hybridisation of the allele-specific oligonucleotide (ASO) to the DNA 
template specificity is assessed using 2 different control probes. 962 should provide 
only a Cy3 and 1209 a Cy5 signal if hybridisation has occurred successfully. (b) Allele-
specific extension: The allele-specific extension control test uses 3 sequences (272, 329 
and 1142) to ensure that a Cy5 methylation signal is observed only when a specific ASO 
is applied and that methylation is not being non-specifically detected. Only a Cy3 signal 
should be observed. (c) Extension gap: Tests the efficiency of extending 15 bases from 
the ASO to the locus-specific oligonucleotide (LSO) to produce an intense (yellow) 
signal. (d) Second hybridisation: Hybridisation of generated products to the array 
beads was tested with a panel of known methylated (044/0278), partially methylated 
(1112/1632) and unmethylated (0501/1003) control sequences that should produce 
Cy5 only, Cy5 and Cy3, and CY3 only signals respectively. 
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2.12.3.2 BASH analysis quality control assessment 
Following the BeadStudio quality control analysis the raw data from the BeadArray 
reader (Illumina) was then input into “beadarray”((Dunning, Smith et al. 2007), 
downloaded from Bioconductor (www.bioconductor.org/). Using this package the 
fluorescent intensities of both wavelengths (red and green) for each bead and their 
geographical location on the SAM were analysed to detect any spatial artefacts. 
Artefacts may result because of a damaged chip or from a speck of dust which distorts 
the fluorescent intensities from being read by the BeadArray reader (Illumina). Due to 
the random placement of up to 30 multiple beads for each CpG on the array the effect 
of an erroneous reading from a single bead on the average delta beta methylation 
value will be negligible. Larger defects affecting a number of beads may however make 
the result unreliable.    
Three types of defect have been described: Extended, compact and diffuse ((Cairns, 
Dunning et al. 2008). Extended defects occur where a significant variation in intensities 
between different chips is observed, suggesting a chip fault; compact defects occur 
when small connected clusters of outlying values are seen; and diffuse defects contain 
small regions where more outliers than expected are observed.    
The BeadArray Subversion of Harshlight (BASH) programme within the beadarray 
package was used to produce an “error image” for each sample and discover any 
spatial artefacts. Small (<20%) defects were “masked” from inclusion in the generation 
of average delta beta values for each probe and compared with the raw data values as 
illustrated in Figure 2.20. These corrected values were used in subsequent studies. 
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Figure 2.20. BASH analysis plots. (a) BeadArray reader scan (Left) of a sample with a 
segmental defect, with (right) area identified and masked (red) in BASH analysis. (b) 
Normal read and BASH analysis plots with small focal defects. (c) Plot of unmethylated  
(G, green) and methylated (R, red) intensities across all 1505 CpG dimnucleotides for a 
sample. Left: Normal result with a bimodal distribution (results are methylated or 
unmethylated at most loci with partial methylation occurring at few loci). Right: 
Sample failure, as a paucity of methylation (R) signal detected. 
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2.12.4 Bioinformatic analyses 
BASH adjusted data were analysed in a series of in-silico experiments using the R 
project for statistical computing (http://www.r-project.org/). To describe the variation 
and recognise patterns within this dataset unsupervised analysis using cluster and 
principal component analysis (PCA) was undertaken. Details of the programming 
scripts used in these analyses may be found in the Appendix.  
 
2.12.4.1 Principal component analysis (PCA) 
Principal component analysis reduces the number of characters within a dataset by 
producing new characters that are a combination of contributions from the original 
characters. In this way the relationship between objects with complex 
characterisations comprising more than 3 components, and therefore cannot normally 
be visualised, may be reduced to form data that can be plotted and inspected in 2 or 3 
dimensions. PCA analysis of the methylation dataset was undertaken within R using 
the stats package within the gplots (version 2.8.0) package and the rgl (version 
0.92.798) package to create 3 dimensional plots downloaded from Comprehensive R 
Archive Network (CRAN) (http://cran.r-project.org/). 
 
2.12.4.2 Cluster analysis 
In contrast to PCA, in cluster analysis complex data is managed to facilitate pattern 
recognition by reducing the number of objects rather than characters. In cluster 
analysis objects are grouped by their relatedness (Kapetonovik IM 2004). In the 
methylation analysis hierarchical clustering was employed which uses a ‘bottom up’ 
method of clustering in which each sample begins in its own cluster before successive 
agglomeration of similar pairs resolves all of the samples into a single cluster.  In order 
to determine the extent of sample relatedness in clusters, the Euclidean distance 
between them was measured (Quackenbush 2001). Cluster analysis was performed 
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within R using the pvclust (version 1.2-2) package downloaded from CRAN 
(http://cran.r-project.org/). 
 
2.13   Statistical analysis 
Statistical analyses were performed using Prism 4 (GraphPad software). Significance 
was tested using Fisher Exact tests, t-tests, and chi-squared tests where appropriate. 
Survival analyses were measured using Kaplan-Meier survival curves, and tested using 
univariate (log-rank) and multivariate (Cox proportional hazard tests). The p-value was 
used as a threshold for determining significance and Benjamini-Hochberg corrections 
applied with multivariate testing. Further details of the statistical analyses employed 
are given in the relevant results chapters. 
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3.1 Introduction 
The CNS-PNET is an aggressive embryonal tumour predominantly affecting young 
children. These tumours, in contrast with medulloblastoma, arise at sites outside of 
the cerebellum within the CNS. Their similar immunohistochemical appearance to 
medulloblastoma has resulted in the suggestion that these tumours share a common 
origin and the term “PNET” applied to refer to both groups of tumours (Rorke 1983). 
Patients with intracranial “PNETs” have been treated along parallel lines as it has been 
assumed that the mechanisms underlying their development, in view of their similar 
morphological phenotype, are likely to be correspondingly analogous. The results from 
a series of international clinical studies have consistently shown an adverse outcome 
with an extra-cerebellar intracranial PNET and raised doubt as to whether the 
fundamental concept of a “PNET” entity remains valid (discussed in detail in chapter 1). 
There have been few studies investigating the molecular basis of CNS-PNETs. Where 
investigation has occurred, this has typically been in the context of a combined study 
with medulloblastoma, in which a few cases of CNS-PNET have been analysed in 
addition, but seldom are the focus of the study. This has meant that the molecular 
characterisation of CNS-PNETs and the extent to which they may share similar features 
with their cerebellar counterparts remains yet to be clearly characterised.  
The frequent molecular events in medulloblastoma that characterise this disease are 
summarised in Table 3.1. Promoter methylation of RASSF1A (section 1.5.6) is the most 
frequent event in medulloblastoma (Lindsey, Lusher et al. 2004), whilst loss of the p-
arm on chromosome 17 (section 1.5.3) is the most common karyotypic abnormality 
(McDonald, Daneshvar et al. 1994; Burnett, White et al. 1997). The most common 
biological pathways demonstrated to be involved in tumourigenisis are the TP53 and 
Wnt pathways (discussed in detail in section 1.5.5), with disruption associated with an 
aggressive and favourable phenotype respectively (Eberhart, Chaudhry et al. 2005; 
Tabori, Baskin et al. 2010; Ellison, Kocat et al. 2011). In addition amplification of the 
MYC family of oncogenes (see section 1.5.4) are frequently observed (Ellison, Kocat et 
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al. 2011). The involvement of these defects in CNS-PNET is however unclear and needs 
investigation.
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Defect Manifestation 
Medulloblastoma 
Reference 
Frequency* Significance 
RASSF1A methylation 
Promoter 
hypermethylation 
54/62 (87%) 
Most common 
medulloblastoma tumour 
specific event. 
(Lindsey, Lusher et al. 2004) 
MYC family gene 
amplification 
MYCC amplification 6/292 (2%) 
Associated with a more 
aggressive phenotype. 
(Ellison, Kocat et al. 2011) 
MYCN amplification 16/292 (5%) 
Associated with a more 
aggressive phenotype. 
Chromosome 17 defects 17p loss 47/190 (25%) 
Associated with a more 
aggressive phenotype. 
(Megahed 2010)  
TP53 pathway disruption 
Nuclear p53 
immunopositivity by 
immunohistochemistry 
17/64 (27%)** 
15/49 (30%)** 
Associated with a more 
aggressive phenotype. 
(Eberhart, Chaudhry et al. 
2005; Tabori, Baskin et al. 
2010) 
TP53 mutation 8/49 (16%)** 
Associated with a more 
aggressive phenotype. 
(Tabori, Baskin et al. 2010)  
Wnt signalling disruption 
β-catenin nuclear 
immunopositivity by 
immunohistochemistry 
33/206 (16%) Favourable prognosis 
(Ellison, Kocat et al. 2011) 
CTNNB1 mutations  20/195 (10%) Favourable prognosis 
Table 3.1. Summary of medulloblastoma molecular defects to be investigated in CNS-PNET. *Based on equivalent studies in local 
Newcastle (Northern Institute for Cancer Research) cohorts. **Based on studies reported in the literature.
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The overall aim of studies reported in this chapter was to determine whether the 
significant medulloblastoma defects outlined in Table 3.1 are features of CNS-PNET 
disease. 
The following specific aims were investigated. 
1. Investigation of RASSF1A promoter methylation status in CNS-PNET primary 
tumours and cell lines. 
2.  Analysis of the frequency of MYCC and MYCN amplification in CNS-PNET 
primary tumours by qRT-PCR, using MLPA and FISH validation. 
3.   Determine whether loss of the short of chromosome 17 is a feature of CNS-
PNET disease. 
4.   Investigate whether defects in the TP53 pathway are observed in CNS-
PNET primary tumour samples. Defects studies included abnormal nuclear p53 
protein accumulation, mutation analysis of TP53, MDM2 amplification and 
homozygous loss of CDKN2A. 
5.   To investigate whether aberrant Wnt signalling is a feature of CNS-PNETs. 
6.  Determine any clinicopathological correlations with identified defects. 
7.   Compare and contrast the genetics of CNS-PNET with medulloblastoma. 
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3.2 Materials and methods 
3.2.1 CNS-PNET cell lines 
Two CNS-PNET cell lines (PFSK and CHP707m) were investigated in this study. Further 
details regarding these cell lines and their culture may be found in sections 2.1.2 and 
2.2 . Genomic DNA was extracted from the cell lines as described previously in section 
2.3.2. 
3.2.2 Control cell lines 
Two medulloblastoma and a neuroblastoma cell line were used in this study to provide 
control DNA. The medulloblastoma cell line DNA was generously provided by Dr Sara 
Ryan (Northern Institute Cancer Research, Newcastle University, UK), and that from 
the neuroblastoma cell line from Dr Jane Carr (Northern Institute Cancer Research, 
Newcastle University, UK). Details of these cell lines are given in Table 3.2.  The 
medulloblastoma cell lines were cultured as reported by Langdon et al (Langdon, 
Lamont et al. 2006). The establishment of IMR-32 is described (Tumilowicz, Nichols et 
al. 1970). 
 
Cell line Derivation Source Reference 
D341 Med Medulloblastoma 
American Type Culture 
collection 
 (Friedman, Burger 
et al. 1988) 
MHH-MED1 
Medulloblastoma 
metastatic cells 
present in the CSF. 
Dr T Pietsch.              
(University of Bonn 
Medical centre, Bonn 
Germany). 
 (Pietsch, 
Scharmann et al. 
1994) 
IMR-32 Neuroblastoma 
American Type Culture 
collection 
(Tumilowicz, 
Nichols et al. 1970) 
Table 3.2. Control cell lines used in this study. 
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3.2.3 Normal brain control cohort 
To provide reference DNA a cohort of 6 normal brain samples was used. Clinical details 
of these samples is given in Table 3.3. 
 
Sample ID Location Age Material 
N3 Cerebral cortex 4 years FFPE 
N9 Right temporal lobe 14 years FFPE 
N18 Temporal lobe 34 years FFPE 
N21 Cerebral cortex Adult FFPE 
N26 Frontal lobe 14 years FFPE 
CB3 Cerebellum  -  FFPE 
Table 3.3. Normal brain samples cohort. FFPE: Formalin fixed paraffin embedded 
material 
 
3.2.4 CNS-PNET primary tumour cohort 
A total of 25 primary CNS-PNETs were investigated in this study. All samples had 
undergone a central pathological review as described in section 2.1.1. Clinical details of 
these tumours are given in Table 3.4. The cohort included material from 11 male and 
14 female cases enrolled on a number of different studies who underwent different 
treatment strategies. The patients were aged 11 – 360 months (0.92 – 30 years), with a 
median age of 77.5 months (6.5 years) at diagnosis. A single case had evidence of 
metastatic disease on neuroimaging at diagnosis. Genomic DNA was extracted as 
described in section 2.3.1.  
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Tumour 
ID 
Diagnosis Site Sex 
Age at 
diagnosis 
(Months) 
Metastasis 
Stage 
(Chang) 
Status 
Follow 
up 
(months) 
SP3 CNS-PNET Parieto-occipital lobes M 48 M0/1 Dead 17 
SP4 CNS-PNET Parietal lobe F 78 M0/1 Alive 121 
SP7 CNS-PNET Intraventricular F 75 M0 Dead 7 
SP10 CNS-PNET 3rd Ventricle M 158 M0/1 Alive 112 
SP13 CNS-PNET Cerebral M 106 M0/1 Dead 71 
SP14 CNS-PNET Parietal lobe F 105  - Alive 100 
SP21 CNS-PNET Left temporo-parietal lobes M 65  - Dead 25 
SP23 CNS-PNET Cerebral M 126 M0/1 Alive 108 
SP24 CNS-PNET Cerebral M 31  - Dead 7 
SP28 CNS-PNET Right frontal lobe F 23 M0/1 Dead 9 
SP40 CNS-PNET Right parietal lobe F 348 M0/1  -  - 
SP41 CNS-PNET Left fronto-temporal lobes M 56 M0/1 Dead 24 
SP42 CNS-PNET Right temporal lobe F 288 M0/1 Alive 24 
SP43 CNS-PNET Left parietal lobe M  - M0/1  -  - 
SP45 CNS-PNET Right parietal lobe. F 11 M0/1  -  - 
SP46 CNS-PNET Left frontal lobe F 312 M0/1 Dead 36 
SP47 CNS-PNET Left frontal lobe F 87 M0/1 Alive 132 
SP49 CNS-PNET Right temporal lobe F 15 M2 Alive 36 
SP50 CNS-PNET Left temporo-parietal lobes F 36 M0/1 Dead 15 
SP51 CNS-PNET Cerebral F 360  - Dead 55 
SP52 CNS-PNET Left parietal lobe M 127 M0/1 Alive 43 
SP54 CNS-PNET Infra + Supratentorial F 26 M0/1 Dead 3 
SP55 CNS-PNET Temporal lobe M 77 M0/1 Dead 15 
SP57 CNS-PNET Frontal + temporal lobes M 21 M0/1 Alive 39 
SP58 CNS-PNET Right parietal lobe F 223 M0 Alive 17 
Table 3.4. Clinical details of CNS-PNET primary tumour samples used in 
medulloblastoma defect comparison study. M: Male, F: female.
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3.2.5 Analysis of RASSF1A methylation status 
3.2.5.1 Bisulphite conversion of genomic DNA 
To determine RASSF1A methylation status 500ng of genomic DNA of each tumour 
sample was bisulphite treated as described in section 2.12.2. 
 
3.2.5.2 PCR amplification of RASSF1A promoter 
To determine RASSF1A methylation status primers were designed in the RASSF1A 
promoter region, using the CpG plot program (http://www.ebi.ac.uk/emboss/cpgplot/ ) 
to determine the promoter region and MethPrimer 
(http://www.urogene.org/methprimer/index1.html) to design primers, as described in 
section 2.12.3 and shown in Figure 3.1. The PCRs were performed using the standard 
method and conditions described in section 2.4.3. Details of the primers used and 
annealing temperature are given in Table 3.5. 
 
3.2.5.3 Sequencing of RASSF1A products 
PCR products were purified prior to further analysis as described in section 2.4.5. 
RASSF1A purified products were sequenced using methods described in section 2.6, 
and the methylation status at each CpG dinucleotide assessed as either being 
methylated, partially methylated or hypomethylated as discussed in section 2.12.3. 
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-1000                             -500                                     0                       +500                              +1000
-1000                             -500                                     0                       +500                              +1000
-1000                             -500                                     0                       +500                              +1000
RASSF1A RASSF1C
CpG
AGTCCCTGCACCCAGGTTTCCATTGCGCGGCTCTCCTCAGCTCCTTCCCGCCGCCCAGTCTGGATCCT
GGGGGAGGCGCTGAAGTCGGGGCCCGCCCTGTGGCCCCGCCCGGCCCGCGCTTGCTAGCGCCCAA
AGCCAGCGAAGCACGGGCCCAACCGGGCCATGTCGGGGGAGCCTGAGCTCATTGAGCT
a)
b)
c)
 
Figure 3.1. Identification of RASSF1A promoter associated CpG island and bisulphite 
sequencing primers. a) Section of chromosome 3 containing the RASSF1 gene 
(ensemble gene ID ENSG00000068028). Blue boxes denote exons, the promoter 
regions and CpG islands marked. b). In silico identification of the RASSF1A CpG island 
using the CpG plot program (http://www.ebi.ac.uk/emboss/cpgplot/ ). The observed 
vs expected (obs/exp) ratio of the frequency of the CpG dinucleotide, percentage G/C 
content and CpG islands predicted by this program. The first 100bp of the gene and 
1000bp upstream flanking sequence are shown and the base pairs relative to the 
transcriptional start site are recorded.  (c). Section of RASSF1A CpG island between -
162 to +29 bps relative to the transcriptional start site. Methylated bisulphite 
converted sequence is shown. Primers were designed using MethPrimer 
(http://www.urogene.org/methprimer/index1.html), and are shown underlined, CpG 
sites shown in red type, and the transcriptional start site in bold italic. 
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Gene 
Primer 
location Forward sequence Reverse sequence 
Product 
size 
(bp) 
Annealing 
temperature 
(°C) 
PCR 
method 
RASSF1A Promoter* 5'-GTTTTATAGTTTTTGTATTTAGGTTTTTAT-3' 5'-AACTCAATAAACTCAAACTCCCC-3' 191 56 Standard 
Table 3.5. Primers used in the PCR analysis of RASSF1A methylation status. DNA was amplified using a standard 40 cycle PCR reaction 
using the annealing temperatures given. *The promoter location between -162 to +29 bps relative to the transcriptional start site was 
identified using the CpG plot program (http://www.ebi.ac.uk/emboss/cpgplot/). 
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3.2.6 HOMOD assessment of the p-arm of chromosome 17 status 
3.2.6.1 PCR amplification of 17p microsatelites 
PCR primers to amplify polymorphic microsatellite sites on the short arm of 
chromosome 17 were designed as described in section 2.8.3. The location of the 
regions that were amplified by the seven primer sets are shown in Figure 3.2. PCRs 
were performed using the “fast” method as described in section 2.4.4, using a 
combined annealing/ extension temperature of 62°C. The primer sequences, location 
and product sizes are given in Table 3.6. 
 
 
 
 
Figure 3.2. Chromosome 17 ideogram showing the location of 7 polymorphic 
microsatelite markers. Markers were designed and location ascertained using 
Marshfield Research Foundation website 
(http://research.marshfieldclinic.org/genetics/GeneticResearch/).
182 
 
Marker 
Chromosome 
location 
NCBI-STS 
map location 
(bp) Forward sequence Reverse sequence 
Product 
size 
(bp) 
Annealing 
temperature 
(°C) 
PCR 
method 
D17S2196 17p11.2 
17016698 - 
17016842 5'-CCAACATCTAGAATTAATCAGAATC-3' 5'-ATATTTCAATATTGTAACCAGTCCC-3' 139-163 62 Fast 
D17S936 17p12-p11.2 
13328455 - 
13328553 5'-ATTTGAAACCACAACAGCA-3' 5'-AGGTATATGCCCACCCC-3' 93-103 62 Fast 
D17S969 17p12  
11746071 - 
11746198 5'-ATCTAATCTGTCATTCATCTATCCA-3' 5'-AACTGCAGTGCTGCATCATA-3' 116-140 62 Fast 
D17S974 17p13.2 
10418376 - 
10418583 5'-AGACCCTGTCTCAGATAGATGG-3' 5'-TAAAATAGAAAGTGCCCCTCC-3' 201-217 62 Fast 
D17S1840 17p13.3 
867416 - 
867610 5'-GCCTGGGCGACAGAGTGA-3' 5'-TGGGGCAGACTTGGTCCTT-3' 173-225 62 Fast 
D17S1308 17p13.3 
533715 - 
534016 5'-TGTGAAACTTTGTCATCACTATACC-3' 5'-TTGGTGACAAAGAAAGTCTCC-3' 304-318 62 Fast 
D17S1866 17p13.3 
102127 - 
102307 5'-TGGATTCTGTAGTCCCAGG-3' 5'-GGTTCAAAGACAACTCCCC-3' 154-185 62 Fast 
Table 3.6. PCR primers used to investigate chromosome 17p polymorphic microsatelites. For each polymorphic microsatellite marker the 
primer pair nucleotide sequence, PCR product size range and amplification settings are given. The location on chromosome 17 for each marker 
is shown using the National Center for Biotechnology Information sequence Tagged Sites (NCBI-STS) database as recorded in the Marshfield 
Research Foundation website (http://research.marshfieldclinic.org/genetics/GeneticResearch/). 
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3.2.6.2 Fragment analysis of 17p products 
PCR products were analysed on a CEQ 8000 Genetic Analysis System (Beckman Coulter) 
as previously described (section 2.8.4). Traces were assessed as being homozygous, 
heterozygous or indeterminate at each locus in all samples and the presence of an 
extended region of homozygosity (ERH) determined as outlined in section 2.8.5 using 
the homozygous probability values from the Marshfield Research Foundation 
(http://research.marshfieldclinic.org/genetics/GeneticResearch/data/info/info17.txt) 
and given in Table 3.7. The probabilities returned from the Marsfield Reserach 
Foundation maps have been constructed on the basis of nearly 1 million genotypes 
and incorporated over 8,000 short tandem-repeat polymorphisms (Broman, Murray et 
al. 1998). 
 
Marker 
Probability  
 Heterozygous Homozygous 
D17S936   0.6 0.4 
D17S974  0.64 0.36 
D17S969 0.64 0.36 
D17S2196  0.81 0.19 
D17S1866  0.79 0.21 
 D17S1308  0.62 0.38 
D17S1840 0.83 0.17 
Table 3.7. Chromosome 17 p-arm polymorphic microsatellite markers population 
probability scores. The probability of a heterozygous or homozygous result for each 
marker locus as given in the Marshfield Research Foundation 
(http://research.marshfieldclinic.org/genetics/GeneticResearch/data/info/info17.txt) 
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3.2.7 Investigation of MYCC and MYCN amplification 
3.2.7.1 Polymerase chain reaction validation of real-time PCR primers 
Primers to be used in subsequent real-time PCR (RT-PCR) studies were designed as 
previously described in section 2.7.3. In addition to MYCC and MYCN primers a further 
three primer sets were designed to be used as endogenous controls. These primers 
were designed to amplify chromosome regions which rarely harbour copy number 
aberrations in either medulloblastomas (Bayani, Zielenska et al. 2000; Eberhart, Kratz 
et al. 2002; Rossi, Conroy et al. 2006) or CNS-PNET (Li, Bouffet et al. 2005). The three 
endogenous controls comprised TBP (chromosome 6), RPLPO (chromosome 12) and 
B2M (chromosome 15). Validation PCRs were performed using standard conditions as 
described previously in section 2.7.4. The PCR annealing temperature was set at 60°C 
to correspond with the annealing temperature that would be used in subsequent RT-
PCR experiments. Nucleotide sequences of the RT-PCR primers, location and the 
resultant product length are summarised in Table 3.8 for each analysed gene. PCR 
products were initially analysed by agarose gel electrophoresis as described in section 
2.5 and the size of the bands determined by comparison with a 100bp DNA ladder 
(Invitrogen, UK). 
 
3.2.7.2 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR), described in section 2.7, was used to validate 
the copy number determination produced from the MLPA screen of CNS-PNET 
tumours and cell lines for MYCC and MYCN. All samples were analysed in triplicate. A 
standard curve was derived using a panel of six dilutions (100ng, 50ng, 10ng, 5ng, 1ng 
and 0.5ng) of a medulloblastoma cell line DNA (MHH-Med1), which has previously 
been shown to have a diploid copy number of both MYCC and MYCN (Langdon, Lamont 
et al. 2006). The cycle threshold (Ct) was determined during the exponential phase of 
the PCR reaction as previously discussed (section 2.7.2). For each gene investigated a 
negative control was added (Ultrapure water (Elga, UK)) in addition to two additional 
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medulloblastoma cell line positive controls (IMR-32 (MYCN amplified;(Carr, Bown et al. 
2007)) and D341-MED (MYCC amplified; (Bigner, Friedman et al. 1990)). 4ng of 
Genomic DNA (1ng/µl) from the unknown samples to be tested was added to each 
reaction as previously described (section 2.7.4). The results for MYCC and MYCN for 
each sample processed in triplicate were first averaged and then measured relative to 
the three endogenous controls (TBP, RPLPO, B2M) to generate an average copy 
number for both MYCC and MYCN for each unknown sample. Samples that showed an 
elevation in copy number relative to two or three of the control genes were reanalysed 
on a further two separate replicates to corroborate the finding. 
 
3.2.7.3 Determining elevated MYCC or MYCN copy number by qRT-PCR 
The values derived from section 3.2.7.2 were compared with a reference cohort to 
determine whether a tumour sample had an elevated MYCC or MYCN copy number. A 
reference cohort comprising of 6 normal brain samples (section 3.2.3) which had been 
processed equivalently to the tumour samples was used. Each reference sample was 
investigated as previously described (section 2.7.2). The average copy number of MYCC 
and MYCN for this reference panel was derived and designated to represent a copy 
number of one to which the value for each test sample would be normalised to. The 
elevation detection value (EDV) was defined as the reference panel mean + 3 standard 
deviations. Tumour samples with a MYCC or MYCN copy number greater than the EDV 
measured relative to at least 2 of the endogenous controls in all 3 independent 
replicates were classified as showing an elevated copy number. 
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Gene Location Forward sequence Reverse sequence 
Product 
size 
(bp) 
Annealing 
temperature 
(°C) 
PCR 
method 
MYCC Intron 1-2 5'-CTTTCGAGATTTCTGCCTTATGAAT-3' 5'-CCCAAAACCCAGAGAGCAATT-3' 95 60 Standard 
MYCN Intron 2-3 5'-AAACTTGGTGATAAGCCTCCAGT-3' 5'-AAGTGCTTCCTCACCAAAAGCT-3' 83 60 Standard 
TBP Intron5-6 5'-TCTCTCTGACCATTGTAGCGGTT-3' 5'-CCGTGGTTCGTGGCTCTCT-3' 64 60 Standard 
B2M Intron 1-2 5'-TCTAGGCGCCCGCTAAGTT-3' 5'-TCGCGTGCTGTTTCCTCC-3' 81 60 Standard 
RPLPO Intron 2-3 5'-ATAAACGGGCTCAGGCAAGTT-3' 5'-CGCGCTCTTTTAGAAGCCAG-3' 81 60 Standard 
       Table 3.8. Primers used in the RT-PCR assessment of MYCC and MYCN.
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3.2.7.4 Multiplex ligation-dependent probe amplification (MLPA) 
MLPA, which has been previously described in section 2.9, was used to determine the 
copy number of MYCC and MYCN genes in the cohort of CNS-PNET primary tumour 
samples and cell lines. Probes for 2 control genes (TBP and B2M), MYCC and MYCN 
were designed to produce products of different sizes as described in section 2.9.2. The 
nucleotide sequences and product lengths for the MLPA probes are given in Table 3.9. 
MLPA was undertaken on all tumour samples as described in section 2.9.3. The results 
for MYCC and MYCN for each sample were measured relative to two of the 
endogenous control genes used in the qRT-PCR study (TBP and B2M) in addition to a 
further 2 control probes (Table 3.10) supplied in the MLPA P200 (MRC Holland) 
reaction mix to generate an average copy number for both MYCC and MYCN for each 
unknown sample. Samples that showed an elevation in copy number relative to three 
or four of the control genes were reanalysed to corroborate the finding. 
 
3.2.7.5 Determining elevated MYCC or MYCN copy number by MLPA 
The values derived from 3.2.7.4 were compared with the normal brain reference 
cohort (Table 3.3) to determine whether a tumour sample had an elevated MYCC or 
MYCN copy number. The average copy number of MYCC and MYCN for this reference 
panel was derived and designated to represent a copy number of one to which the 
value for each test sample would be normalised to. The elevation detection value (EDV) 
was defined as the reference panel mean + 3 standard deviations. Tumour samples 
with a MYCC or MYCN copy number greater than the EDV measured relative to at least 
2 of the endogenous controls in all 3 independent replicates were classified as showing 
an elevated copy number. 
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Gene 
Stuffer 
Length 
(nt) 
Probe 
Length 
(nt) Left hybridising sequence Right hybridising sequence 
B2M 7 90 5'-CTGACAGCATTCGGGCCGA-3' 5'-GATGTCTCGCTCCGTGGCCTTA-3' 
TBP 4 96 5'-TCATGGATCAGAACAACAGCCTGCCAC-3' 5'-CTTACGCTCAGGGCTTGGCCTCC-3' 
MYCN 24 110 5'-GAGCTGGGTCACGGAGATGCT-3' 5'-GCTTGAGAACGAGCTGTGGGGCA-3' 
MYCC 25 116 5'-GTGCCACGTCTCCACACATCAGCACAA-3' 5'-CTACGCAGCGCCTCCCTCCACT-3' 
Table 3.9. Primers used in the MLPA analysis of MYCC and MYCC. 
 
Name Probe 
Probe length 
(nt) 
Location 
Ctrl 1 3578-L02939 172 7q31 
Ctrl 2 3139-L02607 178 14q22 
Table 3.10. Control MLPA probes supplied in the P200 kit (MRC Holland). 
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3.2.7.6 Fluorescence in situ hybridisation (FISH) 
Where material was available FISH was performed on cases showing an elevated copy 
number of MYCN. Nuclear preparations and unstained sections were prepared and 
used as described in sections 2.12.2 and 2.12.3. A probe to chromosome 2p24.3 
corresponding to the MYCN locus (MYCN, bA355H10) was compared with a probe to 
the centromere of the same chromosome (pBSD4D).  Both probes were kindly 
provided by Dr Kieran O’Toole (Northern Institute for Cancer Research, Newcastle 
University UK) from DNA isolated from BAC clones as previously described and 
validated by Lamont et al (Lamont, McManamy et al. 2004). 
The genetic status of each cell was assigned based on the ENQUA recommended 
criteria (Ambros, Benard et al. 2003) which is summarised in Table 3.11. Tumour 
samples were considered as showing MYCN amplification if the test probe to 
centromeric probe ratio was equal or greater than 4. The presence of either speckling 
or clumping within the cells consistent with double minute (DM) or homogenously 
staining region (HSR) formation respectively was also  considered to show evidence of 
amplification as has been previously described (Bown 2001; Mathew, Valentine et al. 
2001; Lamont, McManamy et al. 2004; Yoshimoto, Bayani et al. 2006). 
 
Status Test probe copy number Test probe: Centromeric control ratio 
Monosomy 1 1 
Diploid 2 1 
Trisomy 3 1 
Tetrasomy 4 1 
Ploidy >4 1 
Gain >4 >1 to <4 
Amplification >4 ≥4 
Table 3.11. Criteria to define genetic status of cells by FISH. In this study a probe to 
the centromere of chromosome 2 was used as a control and that to MYCN as the test 
probe.  
190 
 
3.2.8 Investigation of TP53 pathway defects 
3.2.8.1 Immunohistochemistry 
Slides were prepared from FFPE material as has been previously described (section 
2.11.3) using Dako High pH Target Retrieval Buffer (Dako, USA) (see appendix A). 
Disruption of the p53 pathway was assessed using the M7001 clone D-07 antibody 
(Dako, USA) used in previous medulloblastoma and CNS-PNET studies (Jaros, Lunec et 
al. 1993; McLendon, Friedman et al. 1999; Eberhart, Chaudhry et al. 2005; Tabori, 
Baskin et al. 2010).  A 1/2000 dilution of the M7001 clone D-07 p53 antibody was 
applied and detected using the methods previously detailed (section 2.11.3). Slides 
were viewed under a light microscope and scored according to nuclear staining 
according to previously described scoring system (Ng, Lo et al. 1994) with three 
categories of positive results and a negative score with the absence of nuclear staining 
as shown in Table 3.12.  
 
Score 
p53 nuclear 
positive cells (%) 
0 0 
 +  1-25 
 ++ 26-50 
 +++ >50 
Table 3.12. Scoring of p53 immunohistochemical slides.  
 
3.2.8.2 Polymerase chain reaction 
PCR primers were designed as described previously (section 2.4.2) to amplify the 
commonly mutated TP53 exons 4-9. To investigate the presence of a homozygous 
deletion of CDKN2A (p14) primers were designed to amplify exon 1β of this gene. The 
CDKN2A primer pair were amplified in a duplex PCR reaction with the addition of a 
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previously described control primer pair to SCN4A (Frank, Hernan et al. 2004; Carr, Bell 
et al. 2006). Details of the primers and PCR reactions are given in Table 3.13. The TP53 
exons were amplified using reaction mixes, given previously in section 2.4.4. For the 
CDKN2A duplex PCR 2µl of each of the 4 primers (10µM) was added to 10µl of the 
GeneAmp® Fast PCR Master Mix and 50ng of DNA template to yield a final volume of 
20µl. PCR amplification was performed using a 40 cycle reaction using the fast method 
(section 2.4.4) with an annealing and extension step of 10 seconds.  
 
3.2.8.3 Sequencing of TP53 products 
PCR products were purified prior to further analysis as described in section 2.4.5. prior 
to  sequencing on an ABI 3730 (Applied Biosystems) by DBS genomics (Durham 
University, Durham, UK). Raw data was returned for subsequent mutational analysis. 
 
3.2.8.4 Agarose gel electrophoresis 
The PCR products from the p14 duplex PCRs were separated on an agarose gel by 
electrophoresis as has been previously described (section 2.5). Evidence of p14 loss 
was determined by the absence of a CDKN2A-1β band in the presence of a band 
generated from the control gene (SCN4A). Abnormal results were repeated to confirm 
the finding. 
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Gene 
Location 
(Exon) Forward sequence Reverse sequence 
Product 
size 
(bp) 
Annealing 
temperature 
(°C) 
PCR 
method 
TP53 4 5'-GGCTGAGGACCTGGTCCTCTGA-3' 5'-GCCAGGCATTGAAGTCTCATGG-3' 371 64 Fast 
TP53 5 5'-ATCTGTTCACTTGTGCCCTG-3' 5'-CAACCAGCCCTGTCGTCTCTC-3' 275 64 Fast 
TP53 6 5'-GCCTCTGATTCCTCACTGAT-3' 5'-GGAGGGCCACTGACAACCA-3' 203 64 Fast 
TP53 7 5'-AAGGCGCACTGGCCTCATCTT-3' 5'-CAGGGGTCAGAGGCAAGCAGA-3' 220 64 Fast 
TP53 8 5'-GAGCCTGGTTTTTTAAATGG-3' 5'-TTTGGCTGGGGAGAGGAGCT-3' 344 64 Fast 
TP53 9 5'-AGCGAGGTAAGCAAGCAGG-3' 5'-GCCCCAATTGCAGGTAAAACAG-3' 267 64 Fast 
CDKN2A 1β 5'-CTGTGGCCCTCGTGCTGATGCTAC-3' 5'-AATGCGCCCCGGACTTTTC-3' 103 64 Fast 
SCN4A 24 5'-TCGGCATCTGCTTCTTCTGCA-3' 5'-TCGAACTTCTCCCATGTCTCG-3' 166 64 Fast 
Table 3.13. TP53 pathway studies PCR primers
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3.2.8.5 MLPA assessment of MDM2 amplification 
To determine the copy number of the MDM2 gene in the cohort of CNS-PNET primary 
tumour samples and cell lines, MLPA was used as detailed in section 2.9.3. Four 
reference control probes were used (as discussed in 3.2.7.5) in addition to a probe set 
for MDM2 (Table 3.10 and Table 3.14). Samples that showed an elevation in copy 
number relative to three or four of the control genes were reanalysed to corroborate 
the finding. 
 
Gene MDM2 
Stuffer Length (nt) 1 
Probe Length (nt) 123 
Left hybridising sequence 5'-GATCAGTTTAGTGTAGAATTTGAAGTTGAATCTCTCGACT-3' 
Right hybridising sequence 5'-CAGAAGATTATAGCCTTAGTGAAGAAGGACAAGAACTCTC-3' 
Table 3.14. MLPA probe for MDM2 copy number ascertainment. nt: nucleotides. 
 
3.2.8.6 Determining elevated MDM2 copy number by MLPA 
The values derived from 3.2.8.4 were compared with the normal brain reference 
cohort as has been described for the MYC genes in section 3.2.7.5. The elevation 
detection value (EDV) was defined as the reference panel mean + 3 standard 
deviations. Tumour samples with a MDM2 copy number greater than the EDV 
measured relative to 3 or 4 of the endogenous controls were classified as showing an 
elevated copy number. 
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3.2.9 Wnt pathway defects investigation 
3.2.9.1 Immunohistochemistry 
Slides were prepared from FFPE material as has been previously described (section 
2.11.3) using freshly prepared citrate Buffer see appendix A). Disruption of the Wnt 
pathway was assessed using β-catenin antibody (610514, BD Transduction labs, USA) 
as described in section 2.11.3 and used in previous medulloblastoma studies (Ellison, 
Onilude et al. 2005; Clifford, Lusher et al. 2006; Ellison, Kocat et al. 2011). Slides were 
viewed under a light microscope and scored according to nuclear accumulation of β-
catenin. Nuclear immunohistochemical status was scored using the same criteria as 
used in the aforementioned studies, summarised in Table 3.15. 
 
β-catenin nuclear immunohistochemistry 
Description Score Classification 
No nuclear staining 0 Negative 
<10% nuclear staining  + Negative 
Widespread nuclear staining  ++ Positive 
Patchy nuclear staining >10%  ++ Positive 
Table 3.15. β-catenin immunohistochemistry scoring system. 
  
3.2.9.2 Polymerase chain reaction (PCR) amplification of CTNNB1  
PCR products spanning the GSK-3β phosphorylation domain of β-catenin (see section 
1.5.5.2) were generated for subsequent sequencing and mutational screening. PCRs 
were performed using a standard 40 cycle reaction as described in section 2.4.3 using 
the previously described CTNNB1 primers (Ellison, Onilude et al. 2005). Primer details 
and PCR conditions are given in Table 3.16. 
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Gene CTNNB1 
Primer location Exon 3 
Forward sequence 5'-TCCAATCTACTAATGCTAATACTG-3' 
Reverse sequence 5'-TAAGGCAATGAAAAATAATACTC-3' 
Product size (bp) 293 
Annealing temperature (°C) 53 
PCR method Standard 
Table 3.16. CTNNB1 mutation analysis PCR primers. 
 
 
3.2.9.3 Sequencing of CTNNB1 
All PCR products were purified prior to further analysis as described in section 2.4.5. 
prior to  sequencing on an ABI 3730 (Applied Biosystems) by DBS genomics (Durham 
University, Durham, UK). Raw data were returned for subsequent mutational analysis
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3.3 Results 
3.3.1 RASSF1A promoter methylation in CNS-PNET 
3.3.1.1 Investigation of RASSF1A promoter methylation in CNS-PNET 
cell lines and primary tumours 
Methylation of the RASSF1A promoter was determined in 2 control samples, 2 CNS-
PNET cell lines and in 25 primary CNS-PNET tumour samples. Illustrative 
electropherograms from the methylated DNA and unmethylated DNA control samples 
are shown in Figure 3.3 and Figure 3.4 respectively. Within each amplicon, 15 CpG 
dinucleotides were analysed.  The methylation status at each CpG dinucleotide within 
the amplified sequence for the CNS-PNET cell lines and tumour samples is shown in 
Figure 3.3. 
Both CNS-PNET cell lines (PFSK and CHP707) investigated were found to exhibit 
RASSF1A promoter methylation. RASSF1A methylation results were not obtained in 3 
samples (SP7, SP10 and SP13). In the remaining 22 samples, 18 (82%) exhibited 
promoter methylation and 4 (18%) were hypomethylated.  
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Figure 3.3. Methylated control electrophoregram of RASSF1A promoter amplified sequence. Antisense sequence following bisulphite 
conversion shown. CpG dinucleotides are marked  A to O.  
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Figure 3.4. Unmethylated control electrophoregram of RASSF1A promoter amplified sequence. Antisense sequence following bisulphite 
conversion shown. CpG dinucleotides are marked A to O. The unmethylated cytosines are converted to uracils with bisulphite treatment, seen 
as an adenine substitution when sequenced using the RASSF1A antisense primer.  
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Figure 3.5. RASSF1A promoter methylation in CNS-PNET primary tumours and cell lines. The methylation status at each CpG dinucleotide (A 
to O) of 2 control samples (black bar), including an unmethylated control (UC) and a methylated control (MC), 2 CNS-PNET cell lines (orange bar) 
and samples from 22 primary CNS-PNETs (green bar). Methylation status at each CpG dinucleotide is given as hypomethylated (open circle), 
partially methylated (half closed circle) and methylated (closed circle).   
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3.3.1.2 Comparison of CNS-PNET and medulloblastoma RASSF1A 
promoter methylation. 
Lindsey et al observed a frequency of methylation in a total cohort of 62 primary 
medulloblastoma samples of 87% (54/62) using equivalent methods (Lindsey, Lusher et 
al. 2004). Methylation of the RASSF1A promoter occurred at a similar rate (82%, 18/22) 
in this cohort of CNS-PNET primary tumour samples (p=0.50, Fisher’s exact test). 
 
3.3.2 Investigation into chromosome 17p loss in CNS-PNET 
3.3.2.1 HOMOD investigation of 17p loss 
Investigations to determine the status of the p-arm of chromosome 17 were 
undertaken in 2 CNS-PNET cell lines and the panel of tumours shown in Table 3.1. The 
7 polymorphic microsatellite markers were amplified and assessed as showing 
homozygous or heterozygous state at each locus as shown in Figure 3.6.  Retention of 
heterozygosity was observed for both CNS-PNET cell lines as shown in Figure 3.7.  The 
results for 23/25 primary tumour samples are given in Figure 3.8. Results are not 
available for samples SP3 or SP7. No evidence of entire chromosome 17p loss was seen 
in any of the primary tumour samples or cell lines. However, in 2 cases (SP46 and SP55) 
an extended region of homozygosity (ERH) was observed with the identification a loss 
of heterozygosity (homozygous state) at 6 consecutive polymorphic markers 
(p=0.00064) consistent with segmental loss of chromosome 17p. 
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Figure 3.6. Chromosome 17p polymorphic microsatelite marker CEQ traces. Standard 
size markers are shown in red. (a) and (b): Fragment analysis traces for tetra-
nucleotide repeat marker D17S969; (a) Two sets of two minor peaks 4 base pairs apart 
constitute two major peak indicating a heterozygous trace, (b) Homozygous trace with 
a single major peaks. (c) and (d): Fragment analysis traces for di-nucleotide repeat 
marker D17S1866 and (e) and (f) fragment analysis traces for di-nucleotide repeat 
marker D17S936. (c) and (e) Three minor peaks 2 base pairs apart are shown to 
constitute a major peak in these heterozygous traces, (d) and (f) homozygous traces. (g) 
and (h): Heterozygous and homozygous traces respectively for tetra-nucleotide repeat 
polymorphic microsatellite marker D17S974. (i) and (j): Heterozygous and homozygous 
traces respectively for D17S2196. (K) and (l). Mono-nucleotide repeat marker 
D17S1840 using green fluorescence to enable to discern this result from the 
simultaneous assessment of other markers. (K) example of a heterozygous trace,  (l) 
homozygous status. (m) and (n): Traces for D17S1308 producing the largest product 
size (304-318 base pairs) of all the markers used. (m) heterozygous and (n) 
homozygous status. 
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Figure 3.7. CNS-PNET cell line results from chromosome 17 p-arm homozygosity of 
deletion (HOMOD) mapping. The location of each of the 7 polymorphic microsatelite 
markers on the p-arm of chromosme 17 is shown with the result for both CNS-PNET 
cell lines (PFSK and CHP707). Closed circle: Homozygous, open circle: heterozygous. 
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Figure 3.8. Chromosome 17p Homozygosity mapping of deletions (HOMOD) in primary CNS-PNET. The results for 23 primary CNS-PNET 
samples are shown for each marker - homozygous (closed circle), and heterozygous (open circle). An extended region of homozygosity (ERH) 
with more than 5 consecutive markers displaying a homozygous status was observed in both SP46 and SP55.
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3.3.2.2 Comparison of chromosome 17p loss in CNS-PNET and 
medulloblastoma. 
In a large study by Megahed (Megahed 2010), who undertook an identical approach to 
investigate chromosome 17 status in 190 primary medulloblastoma samples, 25% 
(47/190) were found to have lost the p-arm of chromosome 17 (data not shown). This 
result however does not differ statistically significantly with these results in the CNS-
PNET study where 17p loss was observed in 2/23 of the primary tumour samples 
(p=0.08, Fisher’s exact test).  
 
3.3.3 Investigation of MYCC  and MYCN gene amplification 
3.3.3.1 Development of the qRT-PCR assay 
Primers designed to amplify B2M, RLPO, TBP, MYCC and MYCN genes were tested 
using a standard PCR reaction and assessed on an agarose gel to confirm that single 
products of the correct size were produced as given in Table 3.8. Dissociation plots for 
each primer pair were generated by qRT-PCR to confirm that the qRT-PCR reaction 
resulted in a single product with a specific melting temperature (Tm) as shown in 
Figure 3.9. 
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Figure 3.9. Dissociation curves for genes used in qRT-PCR MYC family study. (a) Dissociation curve generated using the MYCC primers. i) 
multiple replicates resulting in ii) a single PCR product following denaturation, without any products being produced using i ii) negative controls 
(water). (b-e) Unique products produced for all the genes used in the qRT-PCR study, (b) B2M, (c) MYCN, (d) TBP, (e) RPLPO.
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3.3.3.2 Development of elevated copy number thresholds for MYCN and 
MYCC by qRT-PCR using a reference cohort 
The results from qRT-PCR of a panel comprising of the DNA extracted from FFPE 
material from 6 normal brain samples was used as a reference cohort as described in 
3.2.7.3. The copy numbers of MYCC and MYCN were measured relative to the three 
internal control genes (TBP, B2M and RPLPO). The average copy number of MYCC and 
MYCN was measured in three independent replicates and the mean, standard 
deviation (SD) and coefficient of variation (Cv) determined as shown in Table 3.17. The 
elevation detection value (EDV) determined by calculating the mean +3SD for MYCC 
and MYCN of the reference cohort was  used as a cut-off to identify samples in the test 
series with an elevated copy number. Details of the EDV for MYCC and MYCN 
compared to each of the reference genes in the reference cohort are shown in Table 
3.17. 
 
  
MYCC MYCN 
TBP B2M RPLPO TBP B2M RPLPO 
Mean  0.8097 1.0775 0.7342 3.8287 5.1932 3.5703 
SD 0.2234 0.2270 0.1482 0.7000 0.9258 0.7966 
EDV 1.4799 1.7587 1.1788 5.9288 7.9705 5.9600 
Log10 EDV 0.1702 0.2452 0.0715 0.7730 0.9015 0.7752 
Table 3.17. qRT-PCR of MYCN and MYCC copy number in the reference cohort and 
derivative values. Mean, standard deviation (SD) and elevation detection values (EDV) 
for both MYCC and MYCN compared to three reference genes (TBP, B2M and 
RPLPO).The EDV was set at mean + 3SD. 
 
The capacity for the qRT-PCR assay to detect MYCC or MYCN copy number changes 
was confirmed as discussed in section 3.2.7.2 with the inclusion of 2 cell lines known to 
exhibit MYCN (IMR-32) and MYCC (D384) amplification and shown in Figure 3.10. 
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Figure 3.10. MYCC and MYCN amplification in qRT-PCR positive control cell lines. (a) MYCC amplification in medulloblastoma cell line D384. (b) 
MYCN amplification in neuroblastoma cell line IMR-32. A copy number greater than the elevation detection value (EDV) when compared with 
at least 2 control genes (TBP, B2M or RPLPO) denotes a gain. The EDV for TBP, B2M and RPLPO are shown by the blue, red and green dotted 
lines respectively.
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3.3.3.3 Assessment of MYCC and MYCN copy number in CNS-PNET cell 
lines and primary tumour samples. 
Two CNS-PNET cell lines and 25 primary CNS-PNET samples were investigated for copy 
number changes of the MYC family genes by qRT-PCR. PFSK and CHP707 were both 
found to have a raised copy number of MYCC when compared relative to the three 
internal control genes (TBP, B2M and RPLPO) and were validated in three independent 
replicates. This finding was not observed in any of the primary tumour samples (0/25) 
as shown in Figure 3.11. A gain in MYCN copy number was not present in either cell 
line. In 3/25 (12%) primary tumours investigated, a gain in MYCN copy number was 
observed in comparison to the control genes, which was validated in three 
independent replicates Figure 3.12.   
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Figure 3.11. MYCC copy number in CNS-PNET by qRT-PCR. MYCC copy number in 2 CNS-PNET cell lines and 25 primary CNS-PNET tumours 
measured relative to 3 internal control genes (TBP, B2M and RPLPO). Copy number elevation in both CNS-PNET cell lines (PFSK and CHP707) as 
denoted by values above the elevation detection values (EDV) for all 3 control genes (TBP, blue dotted line; B2M, red dotted line; and RPLPO, 
green dotted line). A normal copy number was observed in all primary tumours (relative copy number <EDV when compared with 1> control 
gene). 
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Figure 3.12. Log10 MYCN copy number in CNS-PNET by qRT-PCR.  Log10 MYCN copy number is shown in 2 CNS-PNET cell lines and 25 primary 
CNS-PNET tumours measured relative to 3 internal control genes (TBP, B2M and RPLPO). A normal copy number was observed in both CNS-
PNET cell lines (PFSK and CHP707) as denoted by values below the elevation detection values (EDV) for 2 or 3 control genes (TBP, blue dotted 
line; B2M, red dotted line; and RPLPO, green dotted line). A MYCN copy number elevation was observed in 3 primary CNS-PNET tumour 
samples (SP21, SP42 and SP46). 
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3.3.3.4 Development of the elevated copy number thresholds to be 
used for the MLPA validation of the qRT-PCR results 
The reference cohort used in determining the qRT-PCR EDV for both MYCC and MYCN 
was used to determine the EDV for the MLPA analysis. The copy numbers of MYCC and 
MYCN were measured relative to four internal control genes (TBP, B2M Ctrl and Ctrl2). 
TBP and B2M as previously described (section 3.2.7.5) had product lengths smaller 
than the test genes, whilst Ctrl1 and Ctrl2 produced products greater than the MYC 
products (as shown in Figure 3.13). The elevation detection value (EDV) was 
determined by calculating the mean +3 SDs for MYCC and MYCN as shown in Table 
3.18. 
Gene ratio Mean SD EDV Log10 EDV 
MYCN/B2M 1.2023 0.3306 2.1942 0.3413 
MYCN/TBP 1.2812 0.4155 2.5277 0.4027 
MYCN/Ctrl1 1.0857 0.1636 1.5766 0.1977 
MYCN/Ctrl2 1.4050 0.3263 2.3838 0.3773 
MYCC/B2M 1.1936 0.1535 1.6540 0.2185 
MYCC/TBP 1.2454 0.1915 1.8198 0.2600 
MYCC/Ctrl1 1.1109 0.1919 1.6866 0.2270 
MYCC/Ctrl2 1.4056 0.2063 2.0244 0.3063 
Table 3.18. MLPA reference cohort MYCC and MYCN copy number derived values. 
Mean, standard deviation (SD) and elevation detection values (EDV) for both MYCC 
and MYCN compared to four reference genes (TBP, B2M, Ctrl1 and Ctrl2 ).The EDV was 
set at mean + 3SD. 
 
The capacity for the MLPA assay to detect MYCC or MYCN copy number changes was 
confirmed as discussed in section 3.2.7.2 with the inclusion of 2 cell lines known to 
exhibit MYCN (IMR-32) and MYCC (D384) amplification and shown in Figure 3.14. 
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Figure 3.13. MLPA analysis raw traces. (a) Raw trace from control sample N9. Normal 
size control peaks (blue) for B2M (88.1bp), TBP (99.3bp), Ctrl1 (172.4bp) and Ctrl2 
(178.1bp). In between these peaks are three test peaks for MYCN (108.6bp), MYCC 
(113.2bp) and MDM2 (121.1bp). Additional peaks of molecular size greater than Ctrl2 
reflect redundant additional probes in the MRC-Holland P200 probemix. Reference size 
marker (red). (b) MYCN amplification in SP42. Signal intensity for the MYCN probe 
(108.6bp) is ten-fold greater than the panel of reference and other test probes. 
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Figure 3.14. MYCC and MYCN amplification in MLPA positive control cell lines. (a) 
MYCC amplification in medulloblastoma cell line D384. (b) MYCN amplification in 
neuroblastoma cell line IMR-32. A copy number greater than the elevation detection 
value (EDV) when compared with at least 3 control genes (TBP, B2M, Ctrl1 or Ctrl2) 
denotes a copy number elevation. The EDV for B2M, TBP, Ctrl1 and Ctrl2 are shown by 
the blue, red, green and purple dotted lines respectively. 
 
3.3.3.5 Assessment of MYCC and MYCN copy number in CNS-PNET cell 
lines and primary tumour samples by MLPA. 
The reference cohort EDV was used as a cut-off to identify samples in the test series 
with an elevated copy number. The qRT-PCR cohort comprising two CNS-PNET cell 
lines and 25 primary CNS-PNET samples were investigated for copy number changes of 
the MYC family genes by MLPA. CHP707 was found to have a raised copy number of 
MYCC (1/2 CNS-PNET cell lines) when compared relative to the control genes. This 
finding was not observed in any of the primary tumour samples (0/25) as shown in 
Figure 3.15. A gain in MYCN copy number was not present in either cell line. In 3/25 
(12%) primary tumours investigated a gain in MYCN copy number was observed (Figure 
3.16).
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Figure 3.15. MYCC copy number in CNS-PNET by MLPA. MYCC copy number in 2 CNS-PNET cell lines and 25 primary CNS-PNET tumours 
measured relative to 4 internal control genes (TBP, B2M, Ctrl1 and Ctrl2). Copy number elevation was observed in CHP707 as denoted by 
values above the elevation detection values (EDV) for all 4 control genes (B2M, blue dotted line; TBP, red dotted line; and Ctrl1, green dotted 
line; and Ctrl2, purple dotted line). A normal copy number was observed in all primary tumours (relative copy number <EDV when compared 
with 1> control gene). 
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Figure 3.16. Log10 MYCN copy number in CNS-PNET by MLPA. Log10 MYCN copy numbers are shown in 2 CNS-PNET cell lines and 25 primary 
CNS-PNET tumours measured relative to 4 internal control genes (TBP, B2M, Ctrl1 and Ctrl2). Normal copy numbers were observed in both 
CNS-PNET cell lines (PFSK and CHP707) as denoted by values below the elevation detection values (EDV) for 3 or 4 control genes (B2M, blue 
dotted line; TBP, red dotted line; Ctrl1, green dotted line and; Ctrl2, purple dotted line). MYCN copy number elevation was observed in 3 
primary CNS-PNET tumour samples (SP21, SP42 and SP46). 
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3.3.3.6 FISH validation of MYCN amplification 
Material was available in two of the cases with evidence of MYCN copy number 
elevation (SP21 and SP46), to be used for FISH validation in addition to a reference 
cohort diploid sample (N9) which was used as a diploid normal copy number reference 
control. A normal diploid signal for both the centromeric and MYCN probes was 
observed in the reference sample. MYCN signals for both SP21 and SP46 demonstrated 
clumps of varying sizes consistent with HSR formation and confirming MYCN 
amplification (MYCN probe: control centromeric probe ratio ≥4) in these cases, as 
shown in Figure 3.17.  Based on these results, and the equivalent copy numbers 
observed for the three cases with evidence of MYCN copy number elevation, it may be 
inferred that the copy numbers observed for sample SP42, for which suitable material 
for FISH analysis was not available, are consistent with gene amplification.  
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Figure 3.17. MYCN amplification by fluorescence in situ hybridisation. (a) N9: Normal diploid status. Two (red) centromeric signals are seen in 
each cell (closed arrow head), and two MYCN (green) signals (arrow). (b) SP21: Two centromeric signals are seen indicating that the cells 
contatin 2 copies of chromosome 2, but innumerable additional green signals are also observed indicating MYCN amplification. (c) MYCN 
amplification in SP46. Some cells have additional copies of chromosome 2 with up to 6 centromeric signals in each cell. The MYCN signal 
exceeds 6 copies, again confirming MYCN amplification. 
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3.3.3.7 Summary of MYCN and MYCC amplification findings in CNS-PNET 
primary tumour samples 
An elevation of MYCC copy number was not observed in any of the primary CNS-PNET 
tumour samples (0/25, 0%). This finding was confirmed by both qRT-PCR and MLPA. An 
elevation in copy number (>5) consistent with amplification was observed in 3/25 (12%) 
primary tumour samples by both qRT-PCR and MLPA with 100% concordance. In two 
of these cases appropriate material was available to confirm this finding by FISH. A 
summary of these results is given in Table 3.19. 
 
3.3.3.8 MYCN and MYCC amplification in CNS-PNET in comparison with 
medulloblastoma 
The results from a large study by (Ryan 2009) undertaken using a qRT-PCR approach to 
investigate MYC family gene amplification in 292 primary medulloblastoma samples 
showed MYCC amplification in 2% (6/292) and MYCN amplification in 5.5% (16/292) of 
cases. These findings are consistent with those identified in the current CNS-PNET 
study (p=0.53 and 0.23 respectively, Fisher’s exact test).  
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ID 
MYCN copy number 
qRT-PCR MLPA FISH 
SP3 Diploid Diploid  - 
SP4 Diploid Diploid  - 
SP7 Diploid Diploid  - 
SP10 Diploid Diploid  - 
SP13 Diploid Diploid  - 
SP14 Diploid Diploid  - 
SP21 Amplified Amplified Amplified (HSR) 
SP23 Diploid Diploid  - 
SP24 Diploid Diploid  - 
SP28 Diploid Diploid  - 
SP40 Diploid Diploid  - 
SP41 Diploid Diploid  - 
SP42 Amplified Amplified  - 
SP43 Diploid Diploid  - 
SP45 Diploid Diploid  - 
SP46 Amplified Amplified Amplified (HSR) 
SP47 Diploid Diploid  - 
SP49 Diploid Diploid  - 
SP50 Diploid Diploid  - 
SP51 Diploid Diploid  - 
SP52 Diploid Diploid  - 
SP54 Diploid Diploid  - 
SP55 Diploid Diploid  - 
SP57 Diploid Diploid  - 
SP58 Diploid Diploid  - 
Table 3.19. Summary of MYCN copy number elevation determined by different 
molecular techniques summary. Copy number results derived from quantitative real-
time PCR (qRT-PCR), multiplex ligation dependent probe amplification (MLPA) and 
fluorescence insitu hybridisation (FISH) are shown. An amplified result by qRT-PCR or 
MLPA denotes a relative copy number ≥5. HSR: homogenously staining region. 
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3.3.4 Investigation of TP53 pathway defects in CNS-PNET 
3.3.4.1 Assessment of p53 nuclear accumulation in CNS-PNET cell lines 
and primary tumour samples. 
Assessment of p53 nuclear accumulation was made in 22 primary CNS-PNET tumours 
where suitable material was available (Not performed on SP3, SP21 or SP51). No 
evidence of p53 accumulation was observed in 2 cases (2/22, 9%), low level 
accumulation (1-25% of cells) in 23% (5/22), moderate accumulation in 32% (7/22) and 
evidence of nuclear accumulation in more than 50% nuclei in 36% (8/22). These results 
are summarised in Table 3.20, Figure 3.18, Figure 3.19 and Table 3.20. 
 
ID 
p53 nuclear 
immunohistochemistry 
score 
SP4  + 
SP7  ++ 
SP10 0 
SP13 0 
SP14  ++ 
SP23  + 
SP24  + 
SP28  ++ 
SP40  + 
SP41  ++ 
SP42  +++ 
SP43  +++ 
SP45  ++ 
SP46  +++ 
SP47  +++ 
SP49  +++ 
SP50  +++ 
SP52  +++ 
SP54  ++ 
SP55  +++ 
SP57  ++ 
SP58  + 
Table 3.20. p53 nuclear accumulation in primary CNS-PNET tumours. 
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Figure 3.18.Immunohistochemical analysis of p53 pathway activation. (a) Score: 0. No evidence of pathway activation. (b) Score: +. 1-25% of 
cells show evidence of nuclear accumulation. (c) Score: ++. 25-50% of cells show nuclear accumulation. (d) Score: +++. Intense staining of 
greater than 50% nuclear accumulation.  
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Figure 3.19. p53 nuclear accumulation in TP53 mutant CNS-PNET primary tumours. (a)SP4: Showing 10-15% positive cells; (b) 
SP46: Intense nuclear staining in all tumour cells; (c) SP47: Widespread accumulation with intense staining in some nuclei 
(arrow); (d) SP55. Widespread accumulation with intense staining in some nuclei (arrow). 
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3.3.4.2 CNS-PNET TP53 mutation analysis 
TP53 mutation analysis of exons 4-9 was successfully performed on 2 CNS-PNET cell 
lines (PFSK and CHP707) and 22 primary CNS-PNET tumour samples. A total of 5 non-
synonymous point mutations were discovered in 4 tumour samples (4/22, 18%). No 
mutation was seen in either cell line.  In SP47 a substitution mutation was detected in 
exon 5 (471G>T, V157F), a substitution (823T>G, C275G) in exon 8 of SP4 and a further 
substitution mutation in exon 8 of SP46 (817C>T, R273C) as shown in Figure 3.20, 
Figure 3.22 and Figure 3.23. In SP55 homozygous substitutions in both exons 5 and 8 
are observed (460G>A (G154S) and 847C>T, (R283C)), shown in Figure 3.21 and Figure 
3.24. All identified mutations were confirmed on independent repeat sequencing and, 
were cross-correlated with the International Agency for Research in Cancer (IARC) 
TP53 database and p53 Mutation Manual, and were confirmed to have been 
previously described in cancer (Petitjean, Mathe et al. 2007; Hjortsberg L, Rubio-
Nevado J.M et al. 2010). 
 
Figure 3.20. Electrophoregrams of TP53 exon 5 showing a mutation in SP47 in 
comparison with a wild type sequence.  (a) and (b) wild type sequences in sense and 
anti-sense direction respectively. (c) and (d) Corresponding region in SP47 in both 
sense and antisense directions respectively showing a non-synonymous heterozygous 
codon 157 GTC to TTC point mutation (arrow). 
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Figure 3.21. Electrophoregrams of TP53 exon 5 showing a mutation in SP55 in 
comparison with a wild type sequence.  (a) and (b) wild type sequences in sense and 
anti-sense direction respectively. (c) and (d) Corresponding region in SP55 in both 
sense and antisense directions respectively showing a non-synonomous homozygous 
codon 154 GGC to AGC point mutation (arrow). 
 
 
Figure 3.22. Electrophoregrams of TP53 exon 8 showing a mutation in SP4 in 
comparison with a wild type sequence. (a) and (b) wild type sequences in sense and 
anti-sense direction respectively. (c) and (d) Corresponding region in SP4 in both sense 
and antisense directions respectively showing a non-synonomous homozygous codon 
275 TGT to  GGT point mutation (arrow). 
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Figure 3.23. Electrophoregrams of TP53 exon 8 showing a mutation in SP46 in 
comparison with a wild type sequence.  (a) and (b) wild type sequences in sense and 
anti-sense direction respectively. (c) and (d) Corresponding region in SP46 in both 
sense and antisense directions respectively showing a non-synonomous homozygous 
codon 273 CGT to TGT point mutation (arrow). 
 
 
Figure 3.24. Electrophoregrams of TP53 exon 8 showing a mutation in SP55 in 
comparison with a wild type sequence.  (a) and (b) wild type sequences in sense and 
anti-sense direction respectively. (c) and (d) Corresponding region in SP55 in both 
sense and antisense directions respectively showing a non-synonomous homozygous 
codon 283 CGC to TGC point mutation (arrow). 
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3.3.4.3 MDM2 amplification in CNS-PNET 
A reference cohort comprising the same samples used in the MYC study was used in a 
study to determine the EDV for an MLPA analysis investigating MDM2 amplification. 
The copy number of MDM2 was measured relative to four internal control genes (TBP, 
B2M, Ctrl and Ctrl2). TBP and B2M as previously described (section 3.2.7.5) had 
product lengths smaller than the test genes, whilst Ctrl1 and Ctrl2 produced products 
greater than the MDM2 products (as shown in Figure 3.13a). The elevation detection 
value (EDV) was determined by calculating the mean +3 SDs for MDM2 as shown in 
Table 3.21. 
 
  MDM2/B2M MDM2/TBP MDM2/Ctrl1 MDM2/Ctrl2 
Mean 1.6471 1.7155 1.5518 1.9351 
SD 0.1859 0.2308 0.3652 0.2145 
EDV 2.2048 2.4079 2.6475 2.5787 
Log10 EDV 0.3434 0.3816 0.4228 0.4114 
Table 3.21. MLPA reference cohort MDM2 derived copy number values. Mean, 
standard deviation (SD) and elevation detection values (EDV) for MDM2 relative to 
four reference genes (TBP, B2M, Ctrl1 and Ctrl2 ).The EDV was set at mean + 3SD. 
 
Two CNS-PNET cell lines and 25 primary CNS-PNET samples were examined for 
evidence of MDM2 amplification. A normal MDM2 copy number was detected for both 
PFSK and CHP707. A copy number elevation of MDM2 was observed in a single (SP40) 
CNS-PNET primary tumour sample (1/25, 4%) as shown in Figure 3.25. 
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Figure 3.25. MDM2 copy number in CNS-PNET by MLPA. MDM2 copy number in 2 CNS-PNET cell lines and 25 primary CNS-PNET tumours 
measured relative to 4 internal control genes (TBP, B2M, Ctrl1 and Ctrl2). Normal copy numbers were observed in both CNS-PNET cell lines 
(PFSK and CHP707) as denoted by values below the elevation detection values (EDV) for 3 or 4 control genes (B2M, blue dotted line; TBP, red 
dotted line; Ctrl1, green dotted line and; Ctrl2, purple dotted line). A MDM2 copy number elevation was observed in a single primary CNS-PNET 
tumour samples (SP40). 
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3.3.4.4 Investigation of CDKN2A homozygous deletion in CNS-PNET 
Results were obtained for both CNS-PNET cell lines and CNS-PNET primary tumour 
samples examined (25/25). Evidence of homozygous deletion of CDKN2A was found in 
one of the cell lines was observed (CHP707). PFSK and CHP707 were both subsequently 
used when investigating the primary tumour cohort for CDKN2A deletion as positive 
controls, as shown in Figure 3.26. There was no evidence of a homozygous deletion of 
CDKN2A in any of the primary tumours investigated (0/25, 0%). 
 
 
Figure 3.26. CDKN2A homozygous deletion analysis in CNS-PNET by duplex PCR. 
Primers to both CDKN2A and control gene SCN4A were amplified in a duplex PCR 
reaction and run on an agarose electrophoretic gel. Duplex bands for both SCN4A and 
CDKN2A using PFSK and a single band for SCN4A with CHP707 indicates a retention and 
a homozygous loss of CDKN2A in these 2 cell line samples, respectively.  CDKN2A 
homozygous loss was not observed in any of the CNS-PNET primary tumour samples. 
 
3.3.4.5 Summary of TP53 pathway defects in CNS-PNET and 
comparison with medulloblastoma 
The results of the investigation into TP53 pathway in CNS-PNET are summarised in 
Table 3.22. Nuclear accumulation of p53 was identified in 20/22 (91%) primary CNS-
PNET samples. In medulloblastoma cohorts, p53 nuclear accumulation have been 
reported to occur at rates of ranging from 9-31% in previous studies (Eberhart, 
Chaudhry et al. 2005; Pfaff, Remke et al. 2010; Tabori, Baskin et al. 2010). In these 
previous studies p53 nuclear accumulation has been assumed to indicate pathway 
dysfunction. The frequency of p53 nuclear accumulation in CNS-PNET primary tumour 
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samples is thus significantly greater than in medulloblastoma (p=0.0001, Fisher’s exact 
test), and may be associated with a higher prevalence of pathway dysfunction. In 53% 
of cases in the Tabori et al study, p53 nuclear accumulation in medulloblastoma was 
associated with a TP53 mutation (Tabori, Baskin et al. 2010), and Pfaff et al reported 
p53 nuclear accumulation in 82% of those with TP53 mutations (Pfaff, Remke et al. 
2010). In the current study of CNS-PNET, mutations occurred in a lower frequency of 
4/20 (20%) of cases with p53 nuclear accumulation (p=0.071, Fisher’s exact test). TP53 
mutations were not observed in cases without p53 nuclear accumulation.. 
To identify alternative mechanisms resulting in disruption of TP53 pathway both 
MDM2 amplification and homozygous loss of CDKN2A (p14ARF) were investigated. 
There was no evidence of homozygous loss of CDKN2A in the cohort studied, and 
MDM2 amplification was observed in only a single case. MDM2 amplification occurred 
in the presence of p53 nuclear accumulation, but unfortunately suitable material was 
not available to permit FISH validation of the MDM2 status in this case. These findings 
suggest that MDM2 amplification may play a role in p53 pathway disruption in a 
subset of CNS-PNETs, but that additional alternative mechanisms are responsible for 
the frequency of p53 nuclear accumulation and possible TP53 pathway disruption in 
CNS-PNET, which requires further investigation. 
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ID TP53 mutation 
p53 nuclear 
immunohistochemistry 
score 
MDM2 
copy 
number 
CDKN2A 
homozygous 
deletion 
SP4 
Homozygous mutation: 
275 TGT>GGT 
 + Diploid No 
SP7 wt  ++ Diploid No 
SP10 wt 0 Diploid No 
SP13 wt 0 Diploid No 
SP14 wt  ++ Diploid No 
SP23  -  + Diploid No 
SP24 wt  + Diploid No 
SP28 wt  ++ Diploid No 
SP40 wt  + Elevated No 
SP41 wt  ++ Diploid No 
SP42 wt  +++ Diploid No 
SP43 wt  +++ Diploid No 
SP45 wt  ++ Diploid No 
SP46 
Homozygous mutation: 
273 CGT>TGT 
 +++ Diploid No 
SP47 
Heterozygous mutation: 
157 GTC>TTC 
 +++ Diploid No 
SP49 wt  +++ Diploid No 
SP50 wt  +++ Diploid No 
SP51 wt - Diploid No 
SP52 wt  +++ Diploid No 
SP54 wt  ++ Diploid No 
SP55 
Homozygous mutations: 
154 GGC>AGC 
283 CGC>TGC 
 +++ Diploid No 
SP57 wt  ++ Diploid No 
SP58 wt  + Diploid No 
Table 3.22. Summary of TP53 pathway defects in CNS-PNET primary tumour samples. 
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3.3.5 Investigation of defects in the Wnt signalling pathway in 
CNS-PNET. 
3.3.5.1 Accumulation of nuclear β-catenin in CNS-PNET primary 
tumour samples. 
Assessment of β-catenin nuclear accumulation was made in 22 primary CNS-PNET 
tumours where suitable material was available. No evidence of β-catenin accumulation 
was observed in 18 cases (18/22, 72%), low level accumulation (1-10% of cells) in 9% 
(2/22), and evidence of intense nuclear accumulation in more than 10% nuclei in two 
cases, SP10 and SP13 (2/22, 9%). These results are summarised in Table 3.23 and 
Figure 3.27 and Figure 3.28.
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ID 
β-catenin nuclear immunohistochemistry 
Description Score 
SP4 Negative Staining 0 
SP7 Negative Staining 0 
SP10 Widespread (100%) & strong intensity staining  ++ 
SP13 Patchy (50%) & strong intensity staining  ++ 
SP14 Negative Staining 0 
SP23 Negative Staining 0 
SP24 Negative Staining 0 
SP28 Negative Staining 0 
SP40 Negative Staining 0 
SP41 Negative Staining 0 
SP42 Negative Staining 0 
SP43 Negative Staining 0 
SP45 Negative Staining 0 
SP46 Negative Staining 0 
SP47 Negative Staining 0 
SP49 Negative Staining 0 
SP50 5% Weak intensity staining  + 
SP52 Negative Staining 0 
SP54 Negative Staining 0 
SP55 Negative Staining 0 
SP57 5% weak intensity staining  + 
SP58 Negative Staining 0 
Table 3.23. Nuclear β-catenin accumulation in primary CNS-PNET tumours. Scoring: 
Nuclear accumulation in 0% cells, 0 (negative); 1-10%, + (weakly positive); and >10% of 
cells, ++ (strongly positive). 
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Figure 3.27. Immunohistochemistry analysis of β-catenin nuclear accumulation and Wnt pathway activation. (a) Positive: Nuclear staining in 
all cells in SP10, (b) Negative staining in SP40. Some cytoplasmic staining but absent β-catenin nuclear accumulation.
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Figure 3.28. β-catenin immunohistochemical analysis of SP13. Sample contained regions with evidence of differential Wnt pathway activation 
(a) nuclear accumulation, and (b) normal status with only β-catenin antibody cytoplasmic staining.  
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3.3.5.2 CTNNB1 mutation analysis in CNS-PNET cell lines and primary 
tumour samples. 
CTNNB1 exon 3 mutation analysis was performed on both CNS-PNET cell lines (PFSK and 
CHP707) in addition to 25 CNS-PNET primary tumour samples. Both cell lines exhibited a wild 
type sequence. A heterozygous point mutation in codon 34 (100G>C, (G34R)) was detected 
in a single primary tumour sample (1/25, 4%) resulting in an amino acid change from glycine 
to arginine (Figure 3.29). This mutation was observed in SP13 which also exhibited 
immunohistochemical β-catenin nuclear accumulation. No mutation of CTNNB1 was 
however detected in the only other case in the CNS-PNET cohort that exhibited β-catenin 
nuclear accumulation (SP10).  
 
 
Figure 3.29. Electrophoregrams of CTNNB1 showing a mutation in SP13 compared with a 
wild-type sequence. (a) and (b) wild type sequences in sense and anti-sense direction 
respectively. (c) and (d) Corresponding region in SP13 in both sense and antisense directions 
respectively showing a non-synonomous heterozygous codon 34 GGA to CGA point mutation 
(arrow). 
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3.3.5.3 CNS-PNET Wnt pathway defects in comparison with 
medulloblastoma. 
Defects in the Wnt pathway were detected in 2/22 primary CNS-PNETs. The frequency of β-
catenin nuclear accumulation was comparable (p=0.542, Fisher’s exact test) with that 
reported in medulloblastoma (33/206, 16%, (Ellison, Kocat et al. 2011)). No mutation in 
CTNNB1 was observed in the absence of nuclear β-catenin accumulation, but this finding did 
not reach statistical significance (p=0.09, Fisher’s exact test). 
 
3.3.6 Analysis of clinical features of investigated medulloblastoma 
defects in CNS-PNET 
A series of defects frequently observed in medulloblastoma cohorts were investigated in 
CNS-PNET primary tumour samples. The results of these investigations are summarised in 
Table 3.24. 
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ID 
RASSF1A 
meth1 
17p 
loss2 
Amplification TP53 Pathway defect 
Wnt pathway 
defect 
MYCC MYCN 
p53 
IHC3 
TP53 
mutation 
MDM2  
elev4 
CDKN2A 
deletion 
β-
catenin 
IHC5 
CTNNB1 
mutation 
SP3 No - No No - - No  No No No 
SP4 Yes No No No Yes Yes No  No No No 
SP7 - - No No Yes No No  No No No 
SP10 - No No No No No No  No Yes No 
SP13  - No No No No No No  No Yes Yes 
SP14 Yes No No No Yes No No  No No No 
SP21 No No No Yes - - No  No - No 
SP23 Yes No No No Yes - No  No No No 
SP24 Yes No No No Yes No No  No No No 
SP28 Yes No No No Yes No No  No No No 
SP40 Yes No No No Yes No Yes No No No 
SP41 Yes No No No Yes No No No No No 
SP42 Yes No No Yes Yes No No No No No 
SP43 Yes No No No Yes No No No No No 
SP45 Yes No No No Yes No No No No No 
SP46 Yes ERH No Yes Yes Yes No No No No 
SP47 Yes No No No Yes Yes No No No No 
SP49 Yes No No No Yes No No No No No 
SP50 Yes No No No Yes No No No No No 
SP51 Yes No No No - No No No - No 
SP52 Yes No No No Yes No No No No No 
SP54 Yes No No No Yes No No No No No 
SP55 Yes ERH No No Yes Yes No No No No 
SP57 No No No No Yes No No No No No 
SP58 No No No No Yes No No No No No 
Total 
18/22                 
(81%) 
2/23 
(9%) 
0/25          
(0%) 
3/25          
(12%) 
20/22         
(91%) 
4/22        
(18%) 
1/25 
(4%) 
0/25 
(0%) 
2/23       
(9%) 
1/25        
(4%) 
Table 3.24. Summary of common medulloblastoma defects investigated in CNS-PNET. 
Cohort comprises 25 primary CNS-PNET samples. 1 RASSF1A promoter methylation, 2 Loss of 
the p-arm of chromosome 17, 3 p53 immunohistochemistry nuclear accumulation, 4 MDM2 
copy number elevation, and 5 β-catenin nuclear positivity in >10% cells. 
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An initial analysis of survival in relation to the presence of identified medulloblastoma 
defects in CNS-PNET showed no survival correlations with any of the identified defects 
(Table 3.25).  
 
Molecular defect Frequency 
Survival 
statistical 
analysis 
Significance 
(pval) 
RASSF1A methyaltion 18/22 Log-rank 0.664 
Chromosome 17p loss 2/23  Log-rank  0.526 
MYCN amplification 3/25 Log-rank 0.624 
MYCC amplification 0/25  -  - 
p53 nuclear 
immunohistochemistry 
(0) 2/22, (+) 5/22, 
(++) 7/22, (+++) 8/22   
Cox 
regression 0.525 
TP53 mutation 4/22 Log-rank 0.580 
MDM2 amplification 0/23  -  - 
CDKN2A homozygous 
deletion 0/23  -  - 
β-catenin nuclear 
immunohistochemistry  
(0) 2/22, (+) 2/22, 
(++) 18/22 
Cox 
regression 0.691 
CTNNB1 mutation 1/25 Log-rank 0.940 
Table 3.25. Summary of investigated medulloblastoma defects in primary CNS-PNET 
survival analyses.  
 
The presence of metastatic disease and age at diagnosis are the two clinical features known 
to be associated with outcome in CNS-PNET disease. The study cohort comprised of only a 
single case with metastatic disease (SP49), whilst in 4 cases the metastatic status was 
unknown (Table 3.4). An analysis of association between detected medulloblastoma defects 
and metastatic status was therefore not feasible using this cohort. In the cohort, 6 of the 
patients were diagnosed as infants (age<3yrs), 13 as children (3-18 years old) and 5 as adults 
(age >18 years). Information on age at diagnosis was not available for SP43 and therefore 
was excluded from the age related analyses. The relative frequencies of the investigated 
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medulloblastoma defects which occurred in more than one case at different ages are given 
in Table 3.26. No statistically significant association was found between age at diagnosis and 
the presence of RASSF1A promoter methylation (p=0.83), MYCN amplification (p=0.16), 
positive p53 nuclear accumulation (p=0.69), chromosome 17p loss (p=0.45), TP53 mutation 
(p=0.41), or β-catenin nuclear accumulation (p=0.69). There was however a tendency 
towards significance when considering MYCN amplification in adults compared with all 
paediatric cases (1/18 v 2/5, p=0.10 Fisher’s exact test). 
 
Molecular defect 
Age Significance 
(pval) Infant 
(<3yrs) 
Child                   
(3-18 yrs) 
Adult 
>18yrs 
RASSF1A methylation 
5/6 (83%) 8/10 (80%) 4/5 (80%) 0.83 
MYCN amplification 
0/6 (0%) 1/13 (8%) 2/5 (40%) 0.16 
Chromosome 17p loss 
0/6 (0%) 1/12 (8%) 1/5 (40%) 0.45 
Positive p53 nuclear 
immunohistochemistry 6/6 (100%) 9/11 (72%) 4/4 (100%) 0.69 
TP53 mutation 
0/6 (0%) 3/13 (23%) 1/5 (20%) 0.41 
Positive β-catenin nuclear 
immunohistochemistry  0/6 (0%) 2/11 (18%) 0/4 (0%) 0.69 
Table 3.26. Common medulloblastoma defects in CNS-PNET patients at different ages. 
Information on the age at diagnosis was available in 24 cases. Positive β-catenin 
immunohistochemistry includes cases where β-catenin nuclear accumulation was present 
in >10% cells. Statistical significance was determined by Fisher’s exact test using the 
multitest package (Pollard, Gilbert et al. 2010) in the R statistical software program. 
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3.4 Discussion 
3.4.1 RASSF1A methylation in CNS-PNET 
Methylation of the RASSF1A promoter was identified in 81% of primary CNS-PNETs which 
represents one of the most frequent molecular defects detected in this disease. Few studies 
have previously investigated RASSF1A methylation in CNS-PNET (Chang, Pang et al. 2005; 
Muhlisch, Schwering et al. 2006; Inda and Castresana 2007) and have found comparable 
rates of methylation in these series as shown in Table 3.27. In the Chang et al study the 
RASSF1A methylation status of 25 medulloblastomas was compared with that of 9 CNS-
PNETs. All of the medulloblastomas were methylated in this series and a statistically 
significant difference between the 2 tumour groups reported (p=0.014, Fisher’s exact test). 
In this current larger study RASSF1A promoter methylation in 22 CNS-PNETs compared with 
a large cohort of medulloblastomas (n=62) does not corroborate this finding.  
 
Reference 
Cohort RASSF1A methylation 
Number Age (yrs) Frequency Method 
Chang et al,  2005 9  1-26  6/9 (67%) MSP 
Muhlisch et al, 2006 24  1-40 19/24 (79%) MSP & BS 
Inda et al,  2007 6  4-49 5/6 (83%) MSP 
Table 3.27. RASSF1A methylation in published CNS-PNET series. RASSF1A promoter 
methylation ascertained using methylation specific PCR (MSP) and direct bisulphite 
sequencing (BS). 
 
In some tumour groups, RASSF1A methylation has been shown to be associated with clinical 
correlates including poorer survival (Astuti, Agathanggelou et al. 2001; Burbee, Forgacs et al. 
2001; Harada, Toyooka et al. 2002; Tomizawa, Iijima et al. 2004; Yang, Zage et al. 2004; 
Banelli, Gelvi et al. 2005; Michalowski, de Fraipont et al. 2008). However in common with 
previous studies including  medulloblastoma (Lindsey, Lusher et al. 2004; Muhlisch, 
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Schwering et al. 2006) and general paediatric malignancy  studies (Wong, Chan et al. 2004) 
no such correlation in CNS-PNET was identified. The cohort size in this investigation was 
however limited, and the study was not powered to determine whether a lack of correlation 
was statistically significant, and therefore further study is required to determine whether 
RASSF1A methylation is associated with clinical correlates. 
 
3.4.2 RASSF1A methylation as a diagnostic marker 
Studies have shown that RASSF1A promoter methylation is a tumour specific event and not 
seen in the normal brain cerebral or cerebellar tissue (Lusher, Lindsey et al. 2002; Chang, 
Pang et al. 2005; Muhlisch, Schwering et al. 2006). The tumour specific nature and frequency 
of RASSF1A methylation make it an ideal candidate to be used as a tumour marker. RASSF1A 
promoter methylation has however been identified as a frequent event in a range of 
malignant and benign brain tumours including glioma (Horiguchi, Tomizawa et al. 2003; Gao, 
Guan et al. 2004; Hesson, Krex et al. 2008), glioblastoma (Piperi, Themistocleous et al. 2010) , 
medulloblastoma (Lusher, Lindsey et al. 2002; Horiguchi, Tomizawa et al. 2003; Chang, Pang 
et al. 2005; Lindsey, Anderton et al. 2005; Inda and Castresana 2007), meningioma 
(Horiguchi, Tomizawa et al. 2003) and ependymoma (Hamilton, Lusher et al. 2005; 
Michalowski, de Fraipont et al. 2006) and therefore its role as a novel marker is limited to 
being a non-specific tumour marker. 
In addition to assaying methylation profiles within tumour specimens, RASSF1A has also 
been investigated in non-invasive clinical material and has suggested a role for RASSF1A as a 
screening tool for tumours. In non-small cell lung cancer (NSCLC) RASSF1A methylated DNA 
can be found in broncheoalveolar lavage fluid (Topaloglu, Hoque et al. 2004; Grote, 
Schmiemann et al. 2006), and in sputum (Honorio, Agathanggelou et al. 2003) . Methylated 
RASSF1A can also be found in nipple fluid in patients with breast adenocarcinoma 
(Krassenstein, Sauter et al. 2004), and urine in patients with kidney(Battagli, Uzzo et al. 
2003), bladder (Chan, Chan et al. 2003; Dulaimi, Uzzo et al. 2004) and prostate cancers 
(Roupret, Hupertan et al. 2007). RASSF1A methylation in CSF samples potentially could 
therefore be used to detect brain tumours including CNS-PNET. 
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Patients with cancer have increased levels of circulating free DNA within their blood serum 
(Leon, Shapiro et al. 1977; Stroun, Anker et al. 1989). Methylated tumour DNA can also be 
detected in serum samples (Muller, Fiegl et al. 2004; Hauser, Zahalka et al. 2010) and may be 
used to detect disease and potentially to identify those with high risk neoplasms. More 
recently RASSF1A methylation has been used in models to detect papillary thyroid carcinoma 
(Mohammadi-Asl, Larijani et al. 2010), non-familial breast cancer(Jing, Yuping et al. 2010) 
and prostate cancer (Ahmed 2010). The persistence of methylation markers may also be 
used to assess treatment response. In a breast cancer study RASSF1A was used as a 
surrogate marker for response to Tamoxifen®, with the persistence or resolution of RASSF1A 
methylation in blood sera indicating treatment resistance or a good response respectively 
(Fiegl, Millinger et al. 2005).  
The precedent for the potential to use methylation markers in the management of brain 
tumours has recently been reported in a study in glioma (Liu, Cheng et al. 2010). In this study 
the methylation profile of a combination of 4 genes (MGMT, P16INK4a, TIMP-3 and THβS1) 
from CSF and serum samples was used to predict prognosis, and was found to be 100% 
specific in this series. However the limitation of using non-invasive rather than tumour 
material is exemplified by two recent studies. Firstly, in a case-control study involving 
RASSF1A in combination with three other markers (GSTP1, APC and RARβ2), the test failed to 
distinguish breast carcinoma from normal tissue using pre-diagnostic serum samples (Brooks, 
Cairns et al. 2010). In a second study in prostate cancer in which the specificity of using 
RASSF1A as a serum marker was found to be 100%, the test however was only 28% sensitive 
(Sunami, Shinozaki et al. 2009) again limiting its potential clinical utility.  
This study has shown that RASSF1A is a highly frequent event in CNS-PNET development. 
Further studies are however now required to determine the role of RASSF1A methylation in 
CNS tumorigeneis and whether this may be exploited therapeutically, potentially as a 
disease marker. Moreover the role of epigenetics in CNS-PNET development as discussed in 
(section 1.5.6) is currently poorly understood. This current study however highlights the 
potential for identifying events to further advance our understanding of these tumours and 
may provide novel clinical application opportunities. A study to investigate epigenetic 
methylation events and determine the “CNS-PNET methylome” is now required.  
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3.4.3 Loss of chromosome 17p in CNS-PNET 
The most common cytogenetic abnormality seen in medulloblastoma is loss of the p-arm of 
chromosome 17, occurring in up to 40% of tumours (McDonald, Daneshvar et al. 1994; 
Burnett, White et al. 1997). This may occur in association with a gain of 17q and the 
formation of an isochromosome (i17q) or may arise as an isolated defect. The absence of 
17p loss in both CNS-PNET cell lines is consistent with previously reported karyotpe and FISH 
studies of these cell lines (Cohen, Betts et al. 2004). Investigation of 17p loss in CNS-PNET 
has not previously been performed in a large cohort of CNS-PNET tumours. In the current 
study, 17p loss, as evidenced by an extended region of homozygosity, was observed in 9% 
(2/23) primary CNS-PNETs, compared with a rate of 17p loss of 25% (47/190) in a panel of 
medulloblastomas analysed using an identical approach (Megahed 2010). This result whilst 
not statistically significant (p=0.08, Fisher’s exact test) is in keeping with the findings of a 
number of published small studies incorporating 49 cases in total where 17p status has been 
investigated, summarised in Table 3.28. Chromosome 17p loss was identified in only a single 
isolated case (Bayani, Zielenska et al. 2000) amongst these 49 CNS-PNETs. The findings from 
this current comprehensive study and their consistency with previous reports suggest that 
unlike in medulloblastoma chromosome 17p loss is not a frequent feature of CNS-PNET 
disease. Accordingly, tumour suppressor genes thought to be located at 17p13.1, telomeric 
to the TP53 locus, and important in the development of medulloblastomas (Biegel, Burk et al. 
1992; Giangaspero, Bigner et al. 2000), may only be a feature in the development of CNS-
PNETs in a small subset. The HOMOD method however, can only detect comparatively large 
chromosomal losses and therefore may not detect a localised regional loss confined to 
17p13.1. 
Whilst this study has confirmed that 17p loss is an infrequent feature of CNS-PNET the role 
of 17q still requires evaluation. Moreover the frequency, nature and clinical correlates of 
cytogenetic aberrations in CNS-PNET still need to be determined. As discussed in (section 
1.5.3) those studies published to date have been in small series and produced inconsistent 
findings. Studies of large cohorts of pathologically reviewed CNS-PNETs, as used in this study, 
are necessarily required. 
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Reference 
Cohort  Chromosome 17p loss 
Number Age (yrs) Frequency Method 
(Thomas and Raffel 1991) n=5  1-12 0/5 RFLP 
(Burnett, White et al. 1997) n=8  0-16 0/8 RFLP 
(Scheurlen, Schwabe et al. 1998) n=2 6-12  1/2 LOH 
(Russo, Pellarin et al. 1999) n=7 1-31 0/7 CGH 
(Bayani, Zielenska et al. 2000) n=5 2-6 1/5 CGH 
(Kraus, Felsberg et al. 2002) n=12 2-9 0/12 LOH 
(Kagawa, Maruno et al. 2006) n=3 0.6-3 0/3 aCGH 
(McCabe, Ichimura et al. 2006) n=7 2.7-23 0/7 aCGH 
(Pfister, Remke et al 2007) n=10 0.6-13 2/10 aCGH 
Table 3.28. Loss of chromosome 17 p-arm in CNS-PNET. Chromosome 17p loss detected 
using different methodologies. Restriction fragment length polymorphism (RFLP), loss of 
heterozygosity (LOH), comparative (or chromosomal) genomic hybridisation (CGH), array 
CGH (aCGH). 
 
3.4.4 Regional deletion on chromosome 17p is a feature of CNS-PNET 
Whilst a complete loss of chromosome 17p was not demonstrated, a deletion of a region in 
a subset is suggested by the resultsusing the HOMOD method in this study. In two tumours, 
SP46 and SP55, an extended region of homozygosity (ERH) not extending to the telomere 
was observed. FISH or CGH studies for validation to confirm the presence and map the 
extent of this regional loss were not part of this current study as unfortunately further 
suitable material to undertake these studies was not available. The TP53 locus (17p13.1) 
however is situated within this ERH and, in both cases, homozygous mutations of TP53, were 
identified which are consistent with an allelic partial loss on 17p. In a third case (SP4) a TP53 
homozygous mutation was also identified without evidence of an ERH. Interestingly the 
polymorphic microsatellite markers either side of the TP53 locus in this case revealed 
retention of heterozygousity (D17S974, (17p13.2) and D17S969 (17p12)) suggesting that 
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regional loss was not an initiating feature in this case, although cannot exclude a restrictive 
deletion incorporating the TP53 locus. Array-CGH studies in larger cohorts of CNS-PNETs 
would be helpful in determining whether smaller restrictive losses rather than complete 
17p11.2-17pter deletions are a consistent feature in a subset of CNS-PNETs. The 17p11.2 
breakpoint, as described in medulloblastoma (Biegel, Janss et al. 1997; Scheurlen, Seranski 
et al. 1997), may therefore play a role in CNS-PNET. 
 
3.4.5 Involvement of MYC family gene amplification in CNS-PNET 
MYCC and MYCN amplification was not observed in either of the two CNS-PNET cell lines, 
PFSK or CHP707, studied. This finding is consistent with the previously reported molecular 
characterisation of these cell lines (Cohen, Betts et al. 2004). The analysis in primary tumours 
showed no evidence of MYCC amplification but amplification of MYCN in 12% (3/25).  These 
findings were not statistically significantly different to a comparable study in 
medulloblastoma (Ryan 2009), or in relation to previous studies in CNS-PNET as summarised 
in Table 3.29. In a study by Fruhwald et al profiling 5 CNS-PNET samples, a single case of both 
MYCN and MYCC amplification was observed (Fruhwald, O'Dorisio et al. 2000). Of note, the 
MYCC and MYCN amplification was observed within the same sample which was taken at 
relapse 2 years after the original treatment. In a further recently published study (Behdad 
and Perry 2010) assessment of MYCC and MYCN in a cohort of both paediatric and adult 
CNS-PNETs observed amplifications of both MYCC (3/28) and MYCN (9/28) by FISH. 41% of 
the paediatric samples were found to exhibit MYCN amplification. The frequency of MYCC 
and MYCN amplification do not differ significantly from the current study (p=0.24 and p=0.11 
Fisher’s exact tests respectively) but a real difference may nonetheless exist as a result of the 
different methodological approaches employed.  
The qRT-PCR and MLPA approaches taken in the current study are not able to determine the 
copy number of a gene in a given cell, but instead return an average result from the 
amplified DNA extracted from many cells within a tumour sample. If, as has been shown in a 
study by Lamont et al with MYCC gene amplification, there is heterogeneity of copy number 
amongst the tumour cells in a sample(Lamont, McManamy et al. 2004), qRT-PCR and MLPA 
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may fail to detect this, but would be identified using FISH. This observation has been 
previously reported with respect to MYCC and MYCN amplification in medulloblastoma 
(McManamy, Lamont et al. 2003) . In the current study therefore there may have been cases 
where MYCC or MYCN amplification occurred in sub-populations of tumour cells but not 
sufficiently frequently to alter the overall “average” result. The potential importance of 
identifying MYC gene amplification in tumour subpopulations is exemplified  in a 
neuroblastoma case report where amplification of MYCN was identified within a metastatic 
deposit but only gain within the primary tumour (Noguera, Canete et al. 2003). This suggests 
that MYCN amplification was present in a minority of primary tumour cells from which the 
metastic depost was derived. Suitable material was not available in the current study to 
validate the copy number results in all samples using FISH based methods and so the 
presence of small populations of undetected MYCN or MYCC amplification may have been 
present in some of these tumours. 
Finally, determining the downstream effects of MYC gene amplification in the three 
amplified cases needs to be determined to elucidate its role in CNS-PNET development. 
However, as has been shown in medulloblastoma studies, the biological effect of up-
regulation may be dependent on the activating mechanism with Myc expression resulting 
from Wnt pathway activation associated with a favourable phenotype, whilst Myc 
expression resulting from MYCC amplification is often associated with a large cell anaplastic 
and more aggressive phenotype (Ellison, Onilude et al. 2005; Takei, Nguyen et al. 2009). This 
is an area for further study. 
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Reference 
Analysis 
Method 
Cohort Amplification 
Number 
Age 
(years) 
MYCC MYCN 
(Fruhwald, O'Dorisio et al. 2000) 
RLGS + 
CGH 5  3-6 1/5 1/5 
(Pfister, Remke et al. 2007) 
FISH + 
aCGH 21 0.6 - 18 1/21 0/21 
(Behdad and Perry 2010) FISH 
6 20-61 1/6 0/6 
22 0.5-18 2/22 9/22 
Table 3.29. MYC family gene amplification in CNS-PNET. Abbreviations: Restriction 
landmark genomic scanning (RLGS), fluorescence in situ hybridisation (FISH), comparative 
genomic hybridisation (CGH) and array CGH (aCGH). 
 
3.4.6 Disruption of the TP53 signalling pathway in CNS-PNET 
3.4.6.1 Frequent p53 pathway disruption and p53 accumulation in CNS-
PNETs. 
In 91% of primary tumour samples there was evidence of p53 nuclear accumulation by IHC.  
The frequency of accumulation in CNS-PNET was shown to be higher than in previous 
medulloblastoma series (Eberhart, Chaudhry et al. 2005; Tabori, Baskin et al. 2010). However, 
whilst these studies all used the same p53 antibody, the scoring of p53 positivity differed. In 
the Eberhart et al study, as with the current study, cases with positive staining nuclei within 
tumour cells were classified as positive. In the Tabori et al study, however, cases were only 
scored as positive if p53 staining was both intense and present in at least 50% of nuclei 
which has also been used in another medulloblastoma study (Ray, Ho et al. 2004). Using this 
approach, Tabori et al found that p53 IHC positivity correlated with an adverse outcome. If in 
the present study this scoring system were applied 8 cases (SP42, SP43, SP46, SP47, SP49, 
SP50, SP52, SP55) would be found to be positive, but the association with survival remains 
not significant (p=0.87, Logrank test) (Figure 3.30). This study does not however exclude the 
possibility that a significant association between an adverse outcome and p53 nuclear 
accumulation in CNS-PNET exists. Whilst this is a comparatively large CNS-PNET study the 
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nevertheless low sample numbers and high frequency of censored events resulting from a 
relatively short follow up increases the possibility of a type 1 error, that a real association is 
rejected. 
The high frequency of nuclear p53 accumulation suggests that either the pathway is highly 
active in this disease, or frequently disrupted resulting in an abnormal accumulation. To 
identify whether the pathway is dysfunctional in up to 91% of CNS-PNETs further 
investigation of downstream targets, including p21 (cyclin dependent kinase inhibitor), 
(Shariat, Kim et al. 2003) is required. 
 
 
Figure 3.30. Kaplan-meier curve of CNS-PNET survival in relation to p53 
immunohistochemical nuclear staining. Positive scores obtained only in cases with intense 
nuclear staining in >50% of cells.  
 
3.4.6.2 TP53 mutations in pathway disruption 
TP53 mutations were detected in 18% (4/22) of cases (SP4, SP46, SP47, SP55). All were 
missense mutations and were associated with p53 nuclear positivity on IHC suggesting the 
accumulation of a mutant protein (Figure 3.19). In three of these tumours (SP46, SP47 and 
SP55) mutation was associated with intense and widespread nuclear accumulation. In SP4 
however there was faint staining in a minority of cells suggesting that accumulation of 
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mutant p53 protein was occurring to a lesser degree than in the other mutated cases. 
Variation in p53 accumulation in mutated cases is known to occur (Horiuchi, Kawamata et al. 
2004). In a study of 99 colorectal TP53 mutated tumours, 28% did not show any evidence of 
p53 accumulation on immunohistochemical testing (Kressner, Inganas et al. 1999). In this 
colorectal study, in some cases nonsense mutations predicted the production of a truncated 
protein which may not be detected by the anti-p53 antibody, 18% (15/84) of missense 
mutations were also negative on immunohistochemical testing. Whilst in the current study 
p53 IHC identified all the cases with mutation, the scoring approach used by Tabori et al and 
Ray et al would have not detected ¼ of the cases with defects in the TP53 pathway. Together 
this suggests that p53 IHC cannot be used reliably as a sensitive screening test for defects in 
the TP53 pathway. 
The current study however represents the largest CNS-PNET cohort screened for TP53 
mutations to date. TP53 mutations have previously been identified in CNS-PNET in a number 
of small studies (Table 3.30). Interestingly in the study by Ho et al, 43% (6/14) of adult CNS-
PNET were found to have mutations of the DNA biding domain (Ho, Hsieh et al. 1996). In 
contrast in paediatric studies few mutant cases have been identified (Burnett, White et al. 
1997; Zagzag, Miller et al. 2000; Kraus, Felsberg et al. 2002; Zakrzewska, Rieske et al. 2004). 
In the current study mutations occurred in patients aged 6.4, 6.5, 7.3 and 26 years and was 
not significantly associated with age (p=0.41, Fisher’s exact test). 
Mutations outside of the DNA binding domain as discussed in (section 1.5.5) may occur but 
the frequency of these mutations may have been underestimated as studies usually screen 
only for mutations in the binding domain exons (5-8). A case of such a TP53 mutation 
outside the DNA binding domain has been reported in a CNS-PNET in a study that 
investigated predominantly gliomas but contained a single CNS-PNET case (Kato, Kato et al. 
2000). A nonsense mutation in exon 10 was discovered (1043T>A, L348X). It is possible 
therefore that TP53 mutation may be responsible for additional cases of TP53 pathway 
dysfunction and may be identified if subsequent studies of CNS-PNET incorporated 
sequencing of all exons.  
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Finally, constitutional DNA was not available for a paired parallel analysis for any of the cases 
in the investigated cohort. In addition the clinical details available were not sufficiently 
comprehensive to exclude a family history of cancer and in the context of TP53 mutations in 
a CNS-PNET, to exclude the possibility that tumours arose in individuals with Li-Fraumeni 
Syndrome (LFS).  The outcome for patients with LFS who develop a CNS-PNET (or 
medulloblastoma) is not however known to be different but determining LFS status may 
confer other clinical benefits (discussed in section 1.5.2) 
 
Reference Exons 
Cohort 
Mutation 
frequency Size 
Age 
(years) 
(Ho, Hsieh et al. 1996) 5-9 n=14 19-77 6/14 (43%) 
(Burnett, White et al. 1997) 4-9 n=8 0-16 0/8 (0%) 
(Zagzag, Miller et al. 2000) 5-9 n=7 1-8 0/7 (0%) 
(Kraus, Felsberg et al. 2002) 5-8 n=12 2-9 1/12 (8%) 
(Zakrzewska, Rieske et al. 2004) 4 n=5 1-13 0/5 (0%) 
Table 3.30. TP53 mutations in published series of CNS-PNET. 
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3.4.6.3 Alternative mechanisms of TP53 pathway disruption: MDM2 
and CDKN2A 
The prevalence of p53 expression in the current study, could not be accounted for by 
TP53 mutation in the majority of cases. Alternative mechanisms for pathway 
disruption (discussed in section 1.5.5.1), MDM2 amplification and deletion of CDKN2A 
were therefore investigated. Increased expression of Mdm2 can be observed in the 
presence of p53 over-expression (Barak, Juven et al. 1993) which has been shown to 
occur through MDM2 amplification in many cancer types and in 7% of all cancers 
(Momand, Jung et al. 1998). Mdm2 binds to p53 to promote its degradation and 
therefore prevent it from promoting apoptosis or inhibiting the cell cycle and therefore 
in excess may lead to cancer development. In the current study there was evidence of 
MDM2 copy number elevation in a single case (SP40) out of the 23 primary CNS-PNETs 
investigated (1/23, 4%). These findings are in keeping with a previous study in which 
no evidence of MDM2 amplification was observed in a cohort of 12 CNS-PNETs (Kraus, 
Felsberg et al. 2002). To determine whether this was indeed an MDM2 allelic gain 
rather than a gain of part of chromosome 12 containing the MDM2 locus (12q13-q14) 
FISH probes to MDM2 and chromosome 12 would have ideally been applied, but this 
was unfortunately not possible due to a lack of appropriate material. The effect of 
copy number changes on Mdm2 expression did not form part of the present study, but 
should be investigated further. 
As discussed in section 1.5.5.1, alternative splicing of CDKN2A encodes for 2 different 
proteins including p14ARF which is involved in the regulation of p53 through inhibition 
of Mdm2. Inhibition of p14ARF permits the unchecked expression of Mdm2, subsequent 
proteosomal degradation of p53 and tumour development. Homozygous deletion of 
CDKN2A has been shown to occur in a number of tumours including in up to 40% of 
glioblastomas (Schmidt, Ichimura et al. 1994) including paediatric cases (Newcomb, 
Alonso et al. 2000). In the current study there was no evidence of homozygous 
deletion of CDKN2A being responsible for TP53 pathway disruption which supports the 
combined findings (0/21) of two smaller previous studies in CNS-PNETs (Kraus, 
Felsberg et al. 2002; Inda, Munoz et al. 2006). However a previous CGH study (McCabe, 
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Ichimura et al. 2006) homozygous deletion of the CDKN2A locus was observed in a 
single CNS-PNET  (1/7 studied) and in a second study by Pfister et al homozygous 
deletion of 9p21 was observed using FISH in 2/11 CNS-PNETs (Pfister, Remke et al. 
2007). Heterozygous deletion was found in an additional 3 cases in this study and both 
homozygous and heterozygous deletions were associated with reduced “CDKN2A 
protein” expression and a more aggressive phenotype. In the current study suitable 
material was unfortunately not available to ascertain using FISH whether heterozygous 
deletion of the CDKN2A locus was present in any of the CNS_PNETs in this series.  
Finally Inda et al have shown that epigenetic regulation of CDKN2A in CNS-PNET may 
also be implicated in pathway disruption, (Inda, Munoz et al. 2006)  but this needs 
further evaluation in larger series.  
 
3.4.7 Therapeutic targeting of the TP53 pathway in CNS-PNET 
91% of tumours in this study were shown to exhibit nuclear p53 accumulation which 
may indicate TP53 pathway dysfunction. Apart from tumour development, mutant p53 
protein may therefore also significantly contribute to the dismal prognosis in this 
disease by conferring resistance to vincristine and cisplatin which are used as part of 
current treatment protocols (Hamada, Fujiwara et al. 1996; Shelling 1997; 
Giannakakou, Sackett et al. 2000). On the other hand the prevalence of pathway 
disruption may enable therapeutic exploitation of the aberrant TP53 pathway function 
to provide significant opportunities in CNS-PNET. Currently, as reviewed by Lu et al, a 
number of new agents have been developed as possible new treatments in cancers 
with TP53 pathway disruption (Lu and El-Deiry 2009). Treatments include the 
reintroduction of wild-type p53 using an adenovirus vector; elimination of mutant p53 
by selective adenovirus lysis; p53 degradation inhibition and stabilisation using nutlins 
to displace p53 from Mdm2; activation of other components of the pathway including 
p63 and p73 to substitute for the aberrant p53; and a number of agents designed to 
restore wild-type function. Such therapeutic approaches have not been used in CNS-
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PNET to date, but the current study suggests that such approaches may have a role in 
this disease. 
 
3.4.8 Disruption of Wnt signalling pathway in CNS-PNET 
Disruption of the canonical Wnt signalling pathway as identified with nuclear 
accumulation of β-catenin was determined in 2/22 (9%) primary CNS-PNET cases. In 
one of these cases β-catenin accumulation was associated with a CTNNB1 mutation. 
These findings are not significantly different to those observed in medulloblastoma in 
which nuclear β-catenin immunopositivity and CTNNB1 mutations have been shown to 
occur in 33/206 (16%)  and 20/195 (10%) cases respectively (Ellison, Kocat et al. 2011). 
In two previous studies which have investigated wnt pathway disruption in CNS-PNETs 
a total of 16 tumours were screened for CTNNB1 mutations and 33 for β-catenin 
nuclear accumulation by immunohistochemistry (Koch, Waha et al. 2001; Rogers, 
Miller et al. 2009). In these studies, as summarised in Table 3.31, only a single case of 
CTNNB1 mutation was observed. As in the current study a non-synonomous mutation 
in codon 34 was identified, resulting in a valine substitution at this position (GGA>GTA, 
G34V) rather than an arginine as in the current study. Both of these mutations have 
been identified in previous studies in medulloblastoma (Fattet, Haberler et al. 2009; 
Ellison, Kocat et al. 2011) and are known to affect the β-transducin repeat-containing 
protein (β-TRCP) which promotes the degradation of β-catenin in the proteosome 
(Gilbertson 2004). 
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Reference 
Cohort CTNNB1 
mutation 
frequency 
β-catenin 
nuclear IHC 
positivity Number 
Age 
(years) 
(Koch, Waha et al. 2001) 4 0.1-59 1/4 1/4* 
(Rogers, Miller et al. 2009) 29 0.4-15.5 0/12 9/29** 
Table 3.31. Wnt pathway defects in CNS-PNET. Mutation in CTNNB1 exon 3 studied. (*) 
A CTNNB1 mutation in addition to β-catenin nuclear accumulation was observed. (**) 
9/29 cases showed strong β-catenin nuclear accumulation in >10% of cells, and in an 
additional 3/29 samples low level accumulation (1-10%) was reported. 
 
3.4.9 Targeting Wnt pathway in CNS-PNET 
This study has confirmed that disrupted canonical Wnt signalling is involved in a subset 
of CNS-PNETs. The role this disruption has on tumourignesis now needs detailed 
characterisation and further investigation. In similar studies in medulloblastoma 
(Thompson, Fuller et al. 2006; Kool, Koster et al. 2008) canonical Wnt pathway 
disruption with nuclear β-catenin accumulation has been associated with an up-
regulation of Wnt effector gene expression, and associated with a favourable 
prognostic phenotype (Ellison, Onilude et al. 2005; Gajjar, Chintagumpala et al. 2006; 
Fattet, Haberler et al. 2009; Ellison, Kocat et al. 2011). The effect of CTNNB1 mutations 
and β-catenin accumulation in CNS-PNET however is currently unknown and the total 
numbers of reported Wnt pathway disrupted cases are too few currently to determine 
whether this defect is associated with a favourable phenotype in CNS-PNET. 
Identifying CNS-PNETs with Wnt pathway disruption may lead to the use of novel 
treatment strategies which exploit this pathway in these cases. This approach is 
currently being explored in a number of different tumours including colonic carcinoma 
in which aberrant Wnt signalling is observed in 90% of cases (Barker and Clevers 2006). 
In contrast to medulloblastoma and CNS-PNET, in 80% this is attributable to mutant 
APC (Miyaki 1994; Korinek 1997), and mutations in CTNNB1 or Axin-2 in  a small group 
(Morin 1997; Polakis 2000). In a number of other tumours however, including 
257 
 
hepatocelluar carcinoma; hepatoblastoma; endometrial carcinoma; ovarian carcinoma; 
prostate cancer; melanoma and wilm’s tumour, disruption of Wnt signalling results 
from frequent mutations in CTNNB1 (Polakis 2000). The range of therapeutic 
approaches currently being investigated to exploit Wnt signalling disruption includes 
the use of aspirin and similarly acting drugs (Non-steroidal anti-inflammatory drugs 
(NSAIDs)). Aspirin has been shown to be protective in familial colonic cancer (Thun 
1997; Thun, Henley et al. 2002) and other NSAIDs have been shown to have a similar 
effect(Giardiello 1993; Phillips 2002; Koehne and Dubois 2004). These agents however 
are limited by their toxicity profile. Modified NSAIDS including aspirin which donate 
nitric oxide and induce oxidatitive stress within the tumour cell (Rigas and Williams 
2002; Rigas 2007) have been developed which result in a more potent reduction in 
gene expression by disruption of the β-catenin/TCF complex (Williamson, Lu et al. 
2005), have fewer side effects and have been shown to be effective in a number of 
tumours including colonic carcinoma (Rigas and Williams 2002; Gao, Liu et al. 2005), 
breast cancer (Nath, Vassell et al. 2009) and prostate cancer (Lu, Tinsley et al. 2009). 
Antibody therapies to the Wnt and Fz proteins have also been developed. In many 
tumours these proteins are over-expressed (Katoh, Kirikoshi et al. 2001; Holcombe, 
Marsh et al. 2002; Rhee, Sen et al. 2002; Milovanovic 2004; You, He et al. 2004; You, 
He et al. 2004a), and have been found to be effective in in-vitro models (You, He et al. 
2004; You, He et al. 2004a). Of particular note a recently published study using a small 
molecule inhibitor (OSU03012) resulted in growth inhibition with reduced nuclear β-
catenin and a consequent reduction in both cyclin-D1 and c-myc through repression of 
TCF/LEF transcription in a series of medulloblastoma and CNS-PNET cell lines 
(Baryawno, Sveinbjornsson et al. 2010). Targeting of the Wnt pathway may therefore 
provide a therapeutic option for a subgroup of patients with CNS-PNET and merits 
further investigation. 
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3.4.10 Medulloblastoma molecular defects in CNS-PNET: 
Implications for the “PNET” concept 
In this study a series of molecular events frequently observed in medulloblastomas 
have been investigated in a CNS-PNET cohort. This approach has shown that CNS-
PNETs are a heterogenous group of tumours which may possess a range of molecular 
defects, but important differences with medulloblastomas are observed. 
In common with many other tumour types RASSF1A promoter methylation is a highly 
frequent event in CNS-PNET. This finding suggests that understanding epigenetic 
modification by methylation in CNS-PNET may provide novel insights into the tumour 
development in this disease. Our current understanding of the CNS-PNET methylome is 
however very limited and only populated by the results of a few small studies in which 
candidate markers in other brain tumours are investigated in a few CNS-PNET in 
addition. A systematic study to investigate the CNS-PNET methylome in a large cohort 
of such tumours is now required, and forms the basis of the study reported in chapter 
5. 
As discussed in section 1.3.4, the PNET concept suggests that tumours that have a 
similar histological phenotype share a common origin and despite their diverse 
location within the CNS is a unified entity. The current study of a range of frequent 
medulloblastoma defects does not support this hypothesis. Whilst some defects are 
seen in subgroups of tumours (MYCN amplification and Wnt pathway disruption), both 
the frequency of chromosome 17p loss and TP53 pathway activation or dyrsregulation, 
suggests that different mechanisms underlie the development of CNS-PNET compared 
with medulloblastomas. This study has however investigated only a limited number of 
defects. Further genome-wide studies are now needed to investigate and characterise 
the similarities and differences between these two tumour groups in greater detail. 
This study suggests that progress in our understanding of the molecular basis for this 
group of tumours will be derived from future biological studies and programmes 
investigating CNS-PNET as a distinct entity in addition to studies with 
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medulloblastomas. The benefits of such an approach are illustrated with the 
elucidation of a novel gene identified in CNS-PNET and not in medulloblastoma in 
chapter 4. Adequate material and corresponding clinical data to undertake these 
studies is crucial and as a consequence of their relative rarity the need for further 
international collaboration to achieve this, as will be discussed in further detail in 
chapter 7, is both necessary and provides exciting opportunities.  
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4 Chapter 4 
Chapter 4 
A study of IDH1 mutations 
in CNS-PNET 
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4.1 Introduction 
4.1.1 IDH1 mutations in cancer 
Research into the genetic events involved in CNS-PNET tumorigenesis have evolved 
primarily by extending studies into MB, as has been discussed in detail in section 1.5. 
New genome-wide techniques however provide a different approach and potentially 
novel opportunities to identify critical genetic events. A genome wide screen 
incorporating 20,661 protein coding genes from 22 human glioblastoma multiforme 
(GBM) samples in 2008 identified recurrent mutations in a gene not previously known 
to be associated with GBM tumorigenesis (Parsons, Jones et al. 2008). In this study, 
mutations in isocitrate dehydrogenase-1 (IDH1) were discovered in 5 of an initial panel 
of 22 tumours, which was then expanded to include 149 GBMs, in which a total of 18 
(12%) had IDH1 mutations. The mutation discovered in all cases was a point mutation 
in exon 4 resulting in the substitution of guanine to adenine at position 395, leading to 
arginine being replaced by histidine at residue 132. 
Located on chromosome 2q33.3, IDH1 encodes isocitrate dehydrogenase-1, an enzyme 
that  catalyses the rate-limiting step in the citric acid (Kreb’s) cycle converting 
isocitrate to α-ketoglutarate (α-KG) with the production of nicotinamide adenine 
dinucleotide phosphate (NADPH) (Barnes, Kuehn et al. 1971). It is located in the 
cytoplasm, peroxisomes and endoplasmic reticulum (Geisbrecht and Gould 1999; 
Margittai and Banhegyi 2008) and plays a central role in tissue energy metabolism and 
through the production of NADPH, a role in the cellular control of oxidative damage 
(Lee, Koh et al. 2002). 
Subsequent to the Parsons et al study (Parsons, Jones et al. 2008), there have been a 
number of studies designed to investigate the presence of IDH1 mutations in a series 
of brain tumours (Balss, Meyer et al. 2008; Parsons, Jones et al. 2008; Bleeker, Lamba 
et al. 2009; Watanabe, Nobusawa et al. 2009; Yan, Parsons et al. 2009). In total, 1603 
brain tumours (at the time of undertaking this study) had been assessed, and 
mutations discovered in 37%, as summarised in Table 4.1. Research into this novel 
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event in tumours originating outside of the brain was also undertaken by a number of 
investigators (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009). These studies 
included 1053 tumours from a variety locations and histopathological subtypes, but 
did not reveal any IDH1 mutations, suggesting that these mutations may be implicated 
exclusively in the tumorigenesis of CNS tumours. 
 
4.1.2 IDH1 mutations in CNS-PNET 
In the study by Balss et al (Balss, Meyer et al. 2008), a panel of embryonal tumours 
were screened for IDH1 mutations. In addition to MB samples, this panel included 9 
CNS-PNETs and discovered G395A mutations in a third (3/9). No mutations were seen 
in any of the medulloblastoma samples, which corroborated findings by Yan et al in 
their panel of MB samples (Yan, Parsons et al. 2009). Taken together, 113 MB samples 
have been analysed in addition to 9 CNS-PNETs and IDH1 mutation occurs only in CNS-
PNET embryonal tumours (p=0.0003, Fisher’s exact test). Investigation in a larger 
cohort of CNS-PNET is therefore now required. 
 
4.1.3 Aims 
The aim of this chapter was to investigate the role of IDH1 mutations in CNS-PNET 
tumorigenesis, and determine any correlation with clinicopathological features. 
The specific aims were: 
1. To screen a CNS-PNET cohort for IDH1 mutations 
2. To correlate findings with clinicopathological features
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Number of 
tumours 
analysed 
IDH1 Mutation 
References 
    
Number 
 
Frequency 
(%) 
CNS tumour type         
Astrocytic tumours 917 307 33 
(Parsons, Jones et al. 2008; Bleeker, Lamba et al. 2009; 
Nobusawa, Watanabe et al. 2009; Watanabe, Nobusawa et 
al. 2009; Yan, Parsons et al. 2009) 
Oligodendroglial tumours 241 182 76 
(Balss, Meyer et al. 2008; Bleeker, Lamba et al. 2009; 
Watanabe, Nobusawa et al. 2009; Yan, Parsons et al. 2009) 
Oligoastrocytic tumours 124 101 81 
(Balss, Meyer et al. 2008; Watanabe, Nobusawa et al. 2009; 
Yan, Parsons et al. 2009) 
Embryonal CNS-PNET 9 3 33 (Balss, Meyer et al. 2008) 
  Medulloblastoma 113 0 0 (Balss, Meyer et al. 2008; Yan, Parsons et al. 2009) 
Ependymal tumours 87 0 0 
(Balss, Meyer et al. 2008; Watanabe, Nobusawa et al. 2009; 
Yan, Parsons et al. 2009) 
Sellar region tumour 23 0 0 (Balss, Meyer et al. 2008) 
Cranial & paraspinal nerve tumour 17 0 0 (Balss, Meyer et al. 2008) 
Meningothelial cell tumours 72 0 0 (Balss, Meyer et al. 2008) 
Table 4.1. Summary of IDH1 mutations identified in brain tumours. 
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Number of 
tumours 
analysed 
IDH1 Mutation 
References 
  
Number 
Frequency 
(%) 
Tumour type           
Leukaemia   63 0 0 (Yan, Parsons et al. 2009) 
Bladder   34 0 0 (Bleeker, Lamba et al. 2009) 
Breast   223 0 0 (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009) 
Gastric 
 
57 0 0 (Yan, Parsons et al. 2009) 
Colorectal   267 0 0 (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009) 
Lung   142 0 0 (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009) 
Melanoma   23 0 0 Bleeker, Lamba et al. 2009) 
Thyroid   42 0 0 Bleeker, Lamba et al. 2009) 
Ovary   73 0 0 (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009) 
Pancreas   118 0 0 (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009) 
Prostate   11 0 0 (Bleeker, Lamba et al. 2009; Yan, Parsons et al. 2009) 
Table 4.2. Summary of IDH1 mutations identified in non- central nervous tissue (CNS) tumours.
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4.2 Materials and methods 
4.2.1 CNS-PNET cell lines 
Two CNS-PNET cell lines (PFSK and CHP707m) were investigated in this study. Further 
details regarding these cell lines and their culture may be found in section 2.1.2. 
Genomic DNA was extracted from the cell lines as described in section 2.3.2. 
 
4.2.2 CNS-PNET primary tumours 
A total of 25 primary CNS-PNETs were investigated in this study. All samples had 
undergone a central pathological review as described in section 2.1.1. Clinical details of 
these tumours are given in Table 4.3. The cohort included material from 11 male and 
14 female cases enrolled on a number of different clinical studies who underwent 
different treatment strategies. The patients were aged 11 – 360 months (0.92 – 30 
years), with a median age of 77.5 months (6.5 years) at diagnosis. A single case had 
evidence of metastatic disease on neuroimaging at diagnosis. Genomic DNA was 
extracted as described in section 1.3.1.  
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ID Diagnosis Site Sex 
Age at 
diagnosis 
(Months) 
Metastasis 
Stage 
(Chang) 
Status 
Follow 
up 
(months) 
SP3 CNS-PNET Parieto-occipital lobes M 48 M0/1 Dead 17 
SP4 CNS-PNET Parietal lobe F 78 M0/1 Alive 121 
SP7 CNS-PNET Intraventricular F 75 M0 Dead 7 
SP10 CNS-PNET 3rd Ventricle M 158 M0/1 Alive 112 
SP13 CNS-PNET Cerebral M 106 M0/1 Dead 71 
SP14 CNS-PNET Parietal lobe F 105  - Alive 100 
SP21 CNS-PNET Left tempoparietal lobes M 65  - Dead 25 
SP23 CNS-PNET Cerebral M 126 M0/1 Alive 108 
SP24 CNS-PNET Cerebral M 31  - Dead 7 
SP28 CNS-PNET Right frontal lobe F 23 M0/1 Dead 9 
SP40 CNS-PNET Right parietal lobe F 348 M0/1  -  - 
SP41 CNS-PNET Left fronto-temporal lobes M 56 M0/1 Dead 24 
SP42 CNS-PNET Right temporal lobe F 288 M0/1 Alive 24 
SP43 CNS-PNET Left parietal lobe M  - M0/1  -  - 
SP45 CNS-PNET Right parietal lobe. F 11 M0/1  -  - 
SP46 CNS-PNET Left frontal lobe F 312 M0/1 Dead 36 
SP47 CNS-PNET Left frontal lobe F 87 M0/1 Alive 132 
SP49 CNS-PNET Right temporal lobe F 15 M2 Alive 36 
SP50 CNS-PNET Left tempoparietal lobes F 36 M0/1 Dead 15 
SP51 CNS-PNET Cerebral F 360  - Dead 55 
SP52 CNS-PNET Left parietal lobe M 127 M0/1 Alive 43 
SP54 CNS-PNET Infra + supratentorial F 26 M0/1 Dead 3 
SP55 CNS-PNET Temporal lobe M 77 M0/1 Dead 15 
SP57 CNS-PNET Frontal + temporal lobes M 21 M0/1 Alive 39 
SP58 CNS-PNET Right parietal lobe F 223 M0 Alive 17 
Table 4.3. Clinical characteristics of CNS-PNET tumour samples used in IDH1 study.
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4.2.3 Polymerase chain reaction 
PCRs were performed on both cell line and tumour material suing the Fast PCR method 
as described in section 2.4.4, using a combined annealing and extension temperature 
of 64°C for 10 seconds and cycled 40 times. The primer sequences used were as 
previously described (Balss, Meyer et al. 2008) and are given in Table 4.4. Primer 
sequences were verified using BLAST (http://blast.ncbi.nlm.nih.gov) and BLAT 
(http://genome.ucsc.edu) searches as described in section 2.4.2. PCR products were 
analysed by gel electrophoresis and their size approximated using a 100bp DNA ladder 
(as described in section 2.5.2).  
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Gene 
Name 
Forward primer sequence Reverse primer sequence 
Product 
length 
(bp) 
Location 
IDH1 5'-CGGTCTTCAGAGAAGCCATT-3' 5'-GCAAAATCACATTATTGCCAAC-3' 129 Exon 4 
Table 4.4. IDH1 PCR primers.
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4.2.4 Direct sequencing of IDH1 
PCR products were purified as described in section 2.4.5, before being sent to DBS 
genomics (Durham University) for sequence analysis using an ABI 3730 analyser 
(Applied Biosystems) as described in section 2.6.2. Products were sequenced in both 
forward and reverse directions using the PCR primer set in Table 4.4. The sequence 
data generated was imported and analysed in DNASTAR (DNASTAR Inc, USA). Samples 
showing evidence of IDH1 mutation were repeated to corroborate this finding. 
 
4.3 Results 
4.3.1 IDH1 sequence analysis 
Twenty-five tumour samples were screened for mutations of IDH1 in exon 4. The 
results of the sequence analysis are summarised in Table 4.5. IDH1 mutations were 
identified in 2 cases (8%), and confirmed on repeating the PCR amplification and 
sequencing of products. In both cases a non-synonymous point mutation was observed 
in codon 132 with the substitution of guanine for adenine (G395A) as shown in Figure 
4.1 and a corresponding change to the amino acid residue (R132H). 
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ID IDH1 sequence analysis result 
SP3 wt 
SP4 wt 
SP7 wt 
SP10 wt 
SP13 wt 
SP14 wt 
SP21 wt 
SP23 wt 
SP24 wt 
SP28 wt 
SP40 G391A (heterozygous mutation) 
SP41 wt 
SP42 wt 
SP43 wt 
SP45 wt 
SP46 G391A (heterozygous mutation) 
SP47 wt 
SP49 wt 
SP50 wt 
SP51 wt 
SP52 wt 
SP54 wt 
SP55 wt 
SP57 wt 
SP58 wt 
Table 4.5. IDH1 exon 4 sequence analysis results. (wt = wild type sequence) 
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Figure 4.1. IDH1 exon 4 sequence traces. (a) Normal forward sequence in PFSK, (b) Point substitution (G→A) mutation in codon 132 (red bar) in 
SP40. (c) PFSK wild type sequence confirmed in reverse, and (d) reverse trace confirms mutation in SP40 (arrow).
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4.3.2 Association of IDH1 mutation with clinical characteristics 
The outcome data for one of the cases found to contain an IDH1 mutation are not 
known and therefore it was not possible to correlate mutation status with survival. As 
discussed in section 1.4.4, there are 2 clinical characteristics, age at diagnosis and 
Chang stage, which are known to affect prognosis. Both cases with a G395A mutation 
were recorded as having a Chang metastatic stage of M0/1. The IDH1 cohort however 
contained only 1 case (SP49) with metastatic disease confirmed on imaging at 
diagnosis, and so correlation cannot be made. No case of IDH1 mutation occurred in 
infants or in children. The 2 events were seen in adults cases only (26 and 29 years of 
age). The finding that IDH1 mutation occurred solely in adult cases is significant (2/5 
adult cases (>16years) vs 0/19 child cases (<16years), p = 0.04, Fisher’s exact test). 
 
4.4 Discussion 
4.4.1 IDH1 mutations exclusivity to brain tumours 
The original papers that described IDH1 mutations (discussed in section 4.1.1) 
suggested that these events occurred exclusively in tumours of the central nervous 
system. It has however subsequently been discovered that whilst these events have 
been found to be most prevalent in CNS tumours, in particular occurring in 70-80% of 
secondary GBM (Balss, Meyer et al. 2008; Parsons, Jones et al. 2008; Bleeker, Lamba et 
al. 2009; Hartmann, Meyer et al. 2009; Ichimura, Pearson et al. 2009; Nobusawa, 
Watanabe et al. 2009) and other tumours of glial origin (Ichimura, Pearson et al. 2009), 
that these aberrations may also be detected in extracranial disease. IDH1 mutations 
have been observed in myeloproliferative neoplasms including acute myeloid 
leukaemia (AML) (Pardanani, Lasho et al. 2010; Patnaik, Lasho et al. 2010; Tefferi, 
Lasho et al. 2010; Thol, Weissinger et al. 2010). Interestingly, when in conjunction with 
AML, different mutations at the same locus are seen with up to half associated with a 
R132C mutation (Mardis, Ding et al. 2009; Chou, Hou et al. 2010). IDH1 mutations have 
also been identified in a minority of prostate tumours (2/75, 2.7%) in a screen of 1186 
274 
 
cancers from various sites including 1161 extracranial tumours (Kang, Kim et al. 2009). 
They do not appear however to play a pivitol role in the development of cerebral 
metastases from an extracranial solid tumours (Holdhoff, Parsons et al. 2009). Overall, 
extracranial IDH1 mutations remain an infrequent finding. 
 
4.4.2 IDH1 mutations occur solely in adult CNS-PNET disease 
This study has shown IDH1 mutations to be correlated with the development of CNS-
PNETs in adults. Clinical data pertaining to the CNS-PNET samples  from the original 
brain tumour screening series which also identified IDH1 mutations in CNS-PNET (Balss, 
Meyer et al. 2008) are shown in Table 4.6 (kindly supplied by Professor Andreas 
Deimling).  R132H mutations were observed in 3 cases in this other, and all were in 
adults (26.8, 27 and 32 years old). These data in combination with the results of this 
study confirm the finding that IDH1 mutations appear to occur solely in adult cases 
(combined data: 5/12 adults (>16 years) vs 0/21 childhood tumours (<16years), 
p=0.003, Fisher’s exact test) and represents the only biological aberration to date to be 
associated specifically with the adult CNS-PNET phenotype.  This in turn suggests for 
the first time that tumorigenesis mechanisms within the spectrum of CNS-PNET 
disease may be different at different ages. IDH1 mutations appear also to be one of 
the most common mutational events discovered in CNS-PNET development to date. 
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ID 
Age 
(Months) IDH1 Sequence analysis 
D1 322 G395A (heterozygous mutation) 
D2 676 wt 
D3 664 wt 
D4 40 wt 
D5 325 G395A (heterozygous mutation) 
D6 209 wt 
D7 384 G395A (heterozygous mutation) 
D8 84 wt 
D9 562 wt 
Table 4.6. Details of CNS-PNETs from Balss et al study, 2008. Wt: wild type. (Personal 
communication, data kindly provided by Professor Andreas van Deimling) 
 
 
4.4.3 IDH1 role in tumorigenesis 
The identification of mutations in IDH genes has resulted in a series of investigations 
into its functional role in cancer development. It has been postulated that IDH1 may 
act as a tumour suppressor rather than oncogene (Zhao, Lin et al. 2009) and is 
implicated in cancer development by establishing a cellular environment in which 
carcinogenic events may arise (illustrated in Figure 4.2). 
The first postulated effect of an IDH1 mutation is loss of function (Yan, Parsons et al. 
2009), by approximately 2 –fold (Bleeker, Atai et al. 2010), in the catalysis of isocitrate 
to α-KG. The mutant IDH1 (mIDH1) also however derives a gain of function to produce 
2-hydroxyglutarate (2-HG) by an NADPH-dependent reduction of α-KG (Bleeker, Atai et 
al. 2010) which has been shown to occur in all analysed tumours with an IDH1 
mutation (Dang, White et al. 2010). The reduction of α-KG and accumulation of 2-HG 
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has three main effects.  Firstly, the process requires NADPH and therefore in addition 
to this not being produced through the IDH1 conversion of isocitrate, the cell becomes 
further depleted. The reduction of NADPH increases the risk of oxidative stress 
associated with increased reactive oxygen species (ROS), which in turn may increase 
the risk of cancer development (Kolker, Pawlak et al. 2002; Latini, Scussiato et al. 2003). 
Secondly, the α-KG control on the hypoxia-inducible factor subunit 1α (HIF1α) “ master 
switch” of cellular adaptation is impaired by the reduction of cytoplasmic α-KG (Zhao, 
Lin et al. 2009), resulting in the transcription of genes which may promote 
tumorigenesis by aiding cell mobility, invasion and energy metabolism (Hughes, Groot 
et al. 2010).  Thirdly, accumulation of 2-HG is known to be associated with cancer 
development. 2HG is known to accumulate in 2-hydroxyglutaric aciduria, an autosomal 
recessive inherited metabolic disorder characterized by psychomotor retardation and 
progressive ataxia. This inborn error of metabolism occurs due to the deficiency of 2-
hydroxyglutarate dehydrogenase which converts 2-HG to α-KG (Struys, Salomons et al. 
2005) and is associated with the development of brain tumours (Wajner, Latini et al. ; 
Kolker, Mayatepek et al. 2002; Aghili, Zahedi et al. 2009). mIDH1 has been shown to 
gain the function of catalysing α-KG to 2-HG (Zhao, Lin et al. 2009; Bleeker, Atai et al. 
2010) and, as CNS tissues are uniquely able to uptake glutamate and convert it to α-KG 
(Tsacopoulos 2002) an abundant substrate for mIDH1 is available, thus potentially 
increasing the risk of future tumour development. 
Additional studies to improve our understanding of the role IDH1 plays in tumour 
development are now required. Drugs to inhibit the mIDH1 expression, or that inhibit 
2HG (Sonoda and Tominaga 2010), and drugs currently being developed to target 
HIF1α (Semenza 2003), could have a potential role in the management of this disease. 
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Figure 4.2. The cellular roles of IDH1 and IDH2. Isocitrate dehydrogenase (IDH) enzymes catalyse the conversion of isocitrate to α-
ketoglutarate (α-KG) in the cytoplasm (IDH1) and mitochondria (IDH2). This results in the reduction of nicotinamide adenine dinucleotide 
phosphate (NADP+) and degradation of hypoxia-inducible factor 1α (HIF1α). Mutation of IDH1 results in a reduction of α-KG and the 
transcription of HIF1α genes, a depletion of NADPH and an accumulation of carcinogenic 2-hydroxyglutarate (2-HG). 
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4.4.4 Emergence of IDH2 mutations 
The isocitrate dehydrogenase family comprises 5 members. IDH1 is the only one to be 
located in the cytoplasm, the other isoforms exert their catalytic properties in the 
mitochondria (Geisbrecht and Gould 1999). No mutational events have ever been 
described in the IDH3, IDH4 or IDH5 isoforms but mutations in IDH2, located on 
15q26.1, have now been described in gliomas (Hartmann, Meyer et al. 2009; Sonoda, 
Kumabe et al. 2009; Yan, Parsons et al. 2009) and also myeloproliferative disorders 
(Tefferi, Lasho et al. 2010). In common with IDH1 mutations, these involve an arginine 
residue in the substrate binding site, usually affecting codon 172 (Hughes, Groot et al. 
2010; Tefferi, Lasho et al. 2010). To date, the role of IDH2 mutations in CNS-PNET 
disease has not been investigated, which in light of these recent findings should now 
be considered. 
 
4.4.5 The role of IDH1/2 mutations as biological markers 
IDH1 mutation in low grade oligoastroctytomas and oligodendrogliomas occurs at a 
higher frequency than in grade III tumours (79% and 79% vs 60% and 49% p<0.05) 
(Gravendeel, Kloosterhof et al. 2010) and have been confirmed on review of previous 
series (Hartmann, Meyer et al. 2009; Watanabe, Nobusawa et al. 2009). Unusually the 
presence of mutation is more characteristic of a lower grade tumour. The high 
frequency of mutation in these tumours and the development of a monoclonal 
antibody to detect R132H (Capper, Zentgraf et al. 2009) has led to the suggestion that 
this may be used in the diagnostic clinical setting (Paulus 2009). In particular an IDH1 
antibody could be employed to aid diagnostic challenges which arise, as current 
techniques can fail to distinguish diffuse from pilocytic astrocytoma and differentiate 
simple reactive gliosis from diffuse astrocytoma invasion. 
IDH1 mutation has also been associated with prognosis.  Improved survival in gliomas 
is seen (Parsons, Jones et al. 2008; Sanson, Marie et al. 2009; Gravendeel, Kloosterhof 
et al. 2010) and is associated with increased survival by 1 year on average for patients 
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with GBM (Bleeker, Atai et al. 2010). In contrast, in myelodysplastic syndromes, 
mutation is associated with an increased rate of transformation to AML and poorer 
survival (Tefferi, Lasho et al. 2010; Thol, Weissinger et al. 2010).  
Studies in CNS-PNET disease now need to be expanded to include a larger cohort 
before survival analyses have sufficient power to determine any difference in outcome. 
 
4.4.6 Summary 
The investigation of IDH1 mutational status in CNS-PNET disease has identified IDH1 
mutations to be one of the most common mutational events in this disease and a 
novel mechanism involved in tumorigenesis in a subgroup of cases. For the first time, a 
molecular event has been shown to be associated with patient age. The identification 
of IDH1 mutation in adults also supports the hypothesis that CNS-PNET disease is 
different in patients of varying ages.  The consequences of this mutation may also be 
exploited to aid classification and provides new targets for novel therapeutic 
approaches.  
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5.1 Introduction 
Epigenetic modifications involving alterations in DNA methylation patterns are a 
hallmark of most human cancers (Baylin and Herman 2000). In cancer development, 
genome-wide hypomethylation outside of CpG islands of tumour DNA compared to 
normal tissue DNA has been shown to predominate (Feinberg and Vogelstein 1983). 
Against this background, changes in DNA methylation may also potentially affect any 
of the estimated 45,000 CpG islands (section 1.2.6.3) present in the genome 
(Antequera and Bird 1993). Changes in methylation of CpG islands associated with the 
promoter region may result in aberrant transcriptional silencing of tumour suppressor 
genes or activation of oncogenes, or lead to genomic instability and facilitate tumour 
development and progression (Esteller 2006; Irizarry, Ladd-Acosta et al. 2009). As 
discussed in section 1.2.6.3, DNA methylation alterations of genes involved in critical 
regulatory processes including those responsible for cell-cycle regulation, tumour 
invasion, apoptosis, transcription, DNA repair, cell signalling and chromatin 
remodelling, have been implicated in tumour development.  
Aberrant DNA hypermethylation has been estimated to occur in up to 1% of CpG 
islands in CNS-PNETs (Fruhwald, O'Dorisio et al. 2001). Current understanding of 
methylation patterns in this disease, including which CpG islands are affected and 
specifically which genes are epigenetically modified, however, is limited. The results 
from a series of small studies which have investigated a number of candidate genes 
(table 1.12) have demonstrated aberrant methylation in CNS-PNETs, and support the 
importance of alterations in DNA methylation being implicated in this disease (Chang, 
Pang et al. 2005; Muhlisch, Schwering et al. 2006; Inda and Castresana 2007; Muhlisch, 
Bajanowski et al. 2007). In addition, in chapter 3, methylation of the RASSF1A 
promoter was identified in 81% of primary CNS-PNETs. To date, aberrant methylation 
of the RASSF1A promoter is therefore one of the most frequent molecular events 
identified in this disease. Studies to describe and interpret the CNS-PNET DNA 
methylome in detail and potentially identify additional genes that are implicated in the 
epigenetic development of these tumours are now required. 
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5.1.1 DNA methylation assessment technologies 
Significant progress has been made in the last decade in deciphering the DNA 
methylome with the development of a spectrum of new techniques and technological 
advancements (reviewed in (Laird 2010)). The methodologies used to determine DNA 
methylation can be broadly divided in two categories based on the process used to 
pre-treat the DNA:  segregation and bisulphite conversion. Segregation techniques can 
be further subdivided into those which utilise methylation specific restriction enzymes 
or those that employ processes which enrich and separate out the methylated DNA 
fraction.  Methylation patterns of individual CpG dinucleotides are typically 
determined using locus-specific or gel-based analyses. These techniques however can 
only be employed to determine the methylation status of a limited number of CpG 
dinucleotides. The development of array-based technologies and, more recently, next-
generation sequencing has enabled the automated assessment of large numbers of 
CpG dinucleotides. Whilst each technique has merits and disadvantages, which can be 
exploited in different experimental contexts, the gold standard for determining DNA 
methylation remains methods which use bisulphite-based DNA sequencing (Clark, 
Statham et al. 2006). A summary of the spectrum of approaches that may be used in 
DNA methylation studies is given in Table 5.1. 
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  Analytical step 
Pretreatment 
Locus-specific 
analysis 
Gel-based 
analysis 
Array-based 
analysis 
NGS-based 
analysis 
Enzyme digestion Hpall-PCR Southern blot DMH Methyl-seq 
    RLGS MCAM MCA-seq 
    MS-AP-PCR HELP HELP-seq 
    AIMS MethylScope MSCC 
      CHARM   
      MMASS   
Affinity enrichment MeDIP-PCR   MeDIP MeDIP-seq 
      mDIP MIRA-seq 
      mCIP   
      MIRA   
Sodium bisulphite MethylLight Sanger BS BiMP RRBS 
  EpiTYPER MSP GoldenGate BC-seq 
  Pyrosequencing MS-SNuPE Infinium BSPP 
    COBRA   WGSBS 
Table 5.1. DNA methylation analyses. AIMS, amplification of inter-methylated sites; 
BC-seq, bisulphite conversion followed by capture and sequencing; BiMP, bisulphite 
methylation array profiling; BS, bisulphite sequencing; BSPP, bisulphite padlock probes; 
CHARM, comprehensive high-throughput arrays for relative methylation; COBRA, 
combined bisulphite restriction analysis; DMH, differential methylation hybridisation; 
HELP, Hpall tiny fragment enrichment by ligation PCR; MCA, methylation CpG island 
amplification; MCAM, MCA with microarray hybridisation; MeDIP, mDIP and mCIP, 
methylated DNA immunoprecipitation; MIRA, methylated CpG island recovery assay; 
MMASS, microarray-based methylation assessment of single samples; MS-AP-PCR, 
methylation-sensitive arbitrarily primed PCR; MSCC, methylation-sensitive cut counting; 
MSP, methylation specific PCR; MS-SNuPE, methylation-sensitive single nucleotide 
primer extension; NGS, next generation sequencing; RLGS, restriction landmark 
genome scanning; RRBS, reduced representation bisulphite sequencing; WGSBS, 
whole-genome shotgun bisulphite sequencing. Table taken from (Laird 2010). 
 
 
286 
 
5.1.1.1 DNA methylation analysis using segregation techniques  
DNA methylation may be identified using segregation techniques that rely on either 
restriction endonucleases or methods which can select for “enrichment” of methylated 
loci.  
 
5.1.1.1.1 Segregation by endonuclease digestion  
Commonly employed restriction enzymes include the isoschizomers HpaII / MspI and 
SmaI / XmaI. HpaII and MspI recognise the nucleotide sequences CCGG, whilst 
CCCGGG is the target sequence for SmaI and XmaI. HpaII and SmaI cannot however cut 
when the internal cytosine in the recognition sequence is methylated and therefore in 
combination with their respective isoschizomers can be used to determine the relative 
frequency of methylation at a CpG site. The combination of both HpaII and MspI can 
be used to assess up to 98.5% of CpG islands in the human genome (Oda, Glass et al. 
2009).  
Originally, methylation-sensitive restriction enzymes were used to differentially digest 
methylated and unmethylated DNA which produced fragments of different sizes which 
could be visualised, following PCR amplification, using gel electrophoresis. Methods 
included methylation sensitive arbitrarily primed PCR (MS-AP-PCR), amplification of 
inter-methylated sites (AIMS), restriction landmark genomic scanning (RLGS) and 
Southern blots.  These methods are labour intensive and false positive results may 
arise if there is inadequate digestion by the restriction enzyme which limits the use of 
these techniques (Kaput and Sneider 1979; Frigola, Ribas et al. 2002; Liang, Gonzalgo 
et al. 2002; Allegrucci 2007). 
A number of array-based technologies which reduce labour costs also use endonclease 
digestion in determining methylation profiles, but still require relatively large 
quantities of high quality DNA (reviewed in (Laird 2010)). These technologies include: 
methylated CpG island amplification and array hybridisation (MCAM) in which the 
differential cutting properties of SmaI and XmaI are exploited; differential methylation 
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hybridisation (DMH) where the relative intensities of digested (using MseI) and 
undigested fluorescently labelled DNA at different loci on the array are measured; a 
modification of DMH, MethylScope, in which the methylation-dependent 
endonuclease McrBC is used to improve the sensitivity within methylated regions; 
comprehensive high-throughput arrays for relative methylation (CHARM) which again 
uses the same principle as DMH but, with the optimised workflow, permits a greater 
performance; microarray-based methylation assessment of single samples (MMASS) 
where a cocktail of restriction enzymes are used; and HpaII tiny fragment enrichment 
by ligation-mediated PCR (HELP), which uses a ligation-mediated PCR to amplify 
digested fragments prior to array hybridisation. 
More recently, next generation sequencing (NGS) techniques that exploit 
endonuclease digestion have been developed. The main advantages of these methods 
are that they do not require an appropriately designed array, less DNA is needed and 
they permit allele-specific analysis. These techniques include Methyl-seq and MSCC 
(methylation-sensitive cut counting) which employ NGS following digestion with HpaII 
or MspI compared with randomly sheared products in the former and HpaII and MmeI 
digestion with adaptor ligation in the latter, and an adaption of the HELP assay in 
which the output is analysed by NGS (HELP-seq) (Berman, Weisenberger et al. 2009; 
Brunner, Johnson et al. 2009; Oda, Glass et al. 2009). 
 
5.1.1.1.2 Segregation by enrichment 
Methylated cytosines (5mC) and the proteins that specifically recognize and bind to 
these molecules may be identified using specific antibodies. This has permitted the 
development of immunoprecipitation-based methods for DNA methylation analysis 
which have been used to identify DNA methylation markers in cancer (Weber, Davies 
et al. 2005; Koga, Pelizzola et al. 2009). Hybridisation to an array following enrichment 
by immunoprecipitation forms the basis of a number of techniques (MeDIP, mCIP, 
mDIP and MIRA) which have enabled the methylation profiling on a larger scale (Rauch 
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and Pfeifer 2005; Weber, Davies et al. 2005; Keshet, Schlesinger et al. 2006; Zhang, 
Yazaki et al. 2006). 
Finally, enrichment techniques have recently been combined with next generation 
sequencing, including MeDIP-seq and MIRA-seq. These novel techniques enable rapid 
genome-wide DNA methylation assessment to be made, but unlike the bisulphite 
based methods (section 5.1.1.2) cannot resolve the sequence structure at the 
individual CpG dinucleotide level (Down, Rakyan et al. 2008). 
  
5.1.1.2 DNA methylation analysis using bisulphite treated DNA 
In addition to the segregation methods outlined in section 5.1.1.1, DNA methylation 
analyses may also be undertaken using bisulphite treated DNA. As has been discussed 
in detail in section 2.12, sodium bisulphite treatment, first described by Frommer et al 
in 1992, causes the deamination of unmethylated cytosines whilst methylated cytosine 
residues are unaffected and therefore results in the production of differing sequences 
dependent on the methylation status (Frommer, McDonald et al. 1992). The change in 
sequence may then be identified using sequencing technologies, including Sanger 
sequencing as previously described (section 2.6). 
Mass spectrometry of bisulphite converted DNA has been used in a technique known 
as EpiTYPER to determine methylation status at a given CpG dinucleotide. This 
technique utilises the different size and charge properties of methylated and 
unmethylated CpG DNA to determine the methylation status, and can be combined 
with an array format to assess the methylation status of a series of CpG dinucleotides 
within an amplicon (Coolen, Statham et al. 2007). The methylation status at a 
particular locus may also be ascertained using MethyLight or pyrosequencing. In the 
former process, differentially fluorescently labelled PCR probes are generated for 
unmethylated and methylated sequences for a given locus. A real-time PCR reaction is 
then performed and the quantity of methylation estimated by analysis of the 
fluorescent signal generated (Eads, Danenberg et al. 2000). In pyrosequencing in 
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contrast, four enzymes are used including Luciferase for the sequence structure to be 
identified using a bioluminescence real-time approach (Reviewed in (Ahmadian, Ehn et 
al. 2006)).   
DNA methylation may be analysed using bisulphite converted DNA in gel-based 
systems. In methylation-specific PCR (MSP) primers to unmethylated or methylated 
sequences are designed and the methylation status at a locus determined with the 
presence of bands on gel electrophoresis. Gel electrophoreisis is also employed in 
combined bisulphite restriction analysis (COBRA) to distinguish methylation status 
based on product size following the application of a methylation sensitive restriction 
enzyme. The methylation status at a given CpG dinucleotide may also be determined 
by methylation-sensitive single nucleotide primer extension (MS-SNuPE). The MS-
SNuPE technique uses internal primers which anneal immediately adjacent to the 
nucleotide to be analysed in an amplified PCR product and the methylation status is 
determined with the inclusion of differently labelled dNTPs (Gonzalgo and Jones 1997). 
Finally, Sanger sequencing, described in section 2.6, utilises a gel based method to 
determine the nucleotide sequence identity.   
Array and next generation sequencing-based platforms have also been developed in 
sodium bisulphite pre-treated methylation detection strategies. These permit both 
higher throughput and automation of processing and therefore have the advantage of 
being more cost-effective when large numbers of samples and CpG sites require 
investigation. Methylation analysis of small genomes containing methylation dense 
regions maybe investigated by hybridisation to oligonucleotide arrays in bisulphite 
methylation profiling (BiMP) (Reinders, Delucinge Vivier et al. 2008). Discussed in 
section 2.13.1, Bibikova et al in 2006 reported the development of a high throughput 
DNA-methylation profiling technique using an Illumina bead array (Bibikova, Lin et al. 
2006). In this study 1536 CpG dinucleotides were assessed in 371 selected cancer 
related genes, with each gene represented by 1-9 CpG sites. Subsequently a panel 
incorporating 807 known cancer causing genes, and including 1505 CpG sites was 
developed (Cancer Panel I, Illumina) to be used to investigate the methylation profiles 
of different cancers. Most recently this approach has been further modified with the 
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development of the Illumina Infinium platform, which can profile 27,578 CpG 
dinucleotides using less than 1 microgram of DNA including DNA extracted from FFPE 
material (Bibikova, Le et al. 2009; Thirlwell, Eymard et al. 2010). 
Lately a number of techniques have also been developed which combine next 
generation sequencing with bisulphite treated DNA which enable detailed assessment 
of methylation status within a sample, known as “sequencing based methylation 
profiling” (Zhang and Jeltsch 2010). These technologies include reduced representation 
bisulphite sequencing (RRBS); bisulphite conversion followed by capture and 
sequencing (BC-seq); bisulphite padlock probes (BSPP); and whole genome shotgun 
bisulphite sequencing (WGSBS). Cost however currently limits the use of these 
technologies in screening the methylome in multiple samples (Laird 2010). 
 
5.1.2 Illumina Goldengate methylation arrays in cancer 
As has been described in section 5.1.1, methylation arrays permit the interrogation 
and elucidation of tumour epigenetic characteristics. In the construction of global 
methylation profiles new candidate genes may be discovered that could be utilised to 
predict therapeutic outcomes (Shen, Kondo et al. 2007) and patient survival in cancer 
(Rosenbaum, Hoque et al. 2005). Methylation arrays also facilitate a genetic study 
where adequate material may not be available for expression arrays. In particular the 
Illumina Goldengate methylation array may be employed using DNA extracted from 
FFPE tumour material. The Illumina Goldengate methylation array has been 
successfully used to investigate a series of adult cancers which have been reported in 
recent years. These have included; mesothelioma, glioma, AML, lymphoma, and gastric, 
renal cell, colorectal, ovarian, breast, hepatocellular, pancreatic and urothelial cancers 
(Aik Choon, Antonio et al. 2009; Hinoue, Weisenberger et al. 2009; McRonald, Morris 
et al. 2009; O'Riain, O'Shea et al. 2009; Alvarez, Suela et al. 2010; Christensen, 
Houseman et al. 2010; Christensen, Kelsey et al. 2010; Houshdaran, Hawley et al. 2010; 
Loh, Liem et al. 2010; Milani, Lundmark et al. 2010; Noushmehr, Weisenberger et al. 
2010; Shin, Kim et al. 2010; Wolff, Chihara et al. 2010). Apart from investigation into 
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haematological malignancies including childhood ALL (Milani, Lundmark et al. 2010), to 
date there have been no publications that have specifically investigated paediatric 
malignancies.   
 
5.1.3 Genetic profiling in paediatric embryonal brain tumours 
In recent years, the establishment of array technology has provided critical insights 
into both the molecular development of paediatric brain tumours and how these 
tumours may be sub-classified. In 2002, Pomeroy et al reported the results of an 
expression array of CNS embryonal tumours (Pomeroy, Tamayo et al. 2002). This study 
included 60 children with medulloblastomas, 10 children with ATRTs, 10 young adults 
with malignant gliomas and 8 children with supratentorial PNETs. Overall the 
embryonal tumours were shown to comprise of a heterogeneous group, with the 
medulloblastomas clustering separately from the CNS-PNETs. A sub-analysis of the 
medulloblastoma cohort however identified correlations between the tumour 
expression profiles with clinical features including subtype and outcome. This study 
though was limited by the availability of suitable genetic material, and in particular 
high quality RNA extracted from frozen samples.  
A series of studies in medulloblastoma have now been performed showing that 
between 4 and 6 molecular subtypes exist (Thompson, Fuller et al. 2006; Kool, Koster 
et al. 2008; Cho, Tsherniak et al. 2010; Northcott, Korshunov et al. 2010). In the study 
by Thompson et al in 2006, the gene profiles of 46 medulloblastomas were 
investigated and 5 subgroups identified. Two of these subgroups were associated with 
known genetic events in medulloblastoma development, namely Wnt pathway and 
sonic hedgehog (SHH) pathway disruption (Thompson, Fuller et al. 2006). Kool et al 
investigated the expression profiles of 62 primary medulloblastomas and combined 
this with genomic data in 52 cases. A subgroup containing tumours expressing genes 
associated with Wnt pathway disruption (“group A” or “Wnt group”)  and a second 
group comprising those with SHH pathway disruption (“group B” or “SHH group”) were 
again identified. In addition 3 other groups were identified, which were associated 
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with metastatic disease and a poorer outcome. Expression and molecular features of 
neuronal differentiation were observed in “group C”, photoreceptor differentiation in 
“group E”, and a mixture of both neuronal and photoreceptor differentiation in the 
final group (“group D”). 
Northcott et al combined the DNA copy number and expression data of 103 primary 
medulloblastomas and identified 4 distinct genetic subgroups (Northcott, Korshunov et 
al. 2010). The four groups again comprised both a Wnt and a SHH group in addition to 
2 non-wnt and non-SHH groups referred to as “group C” “group D”, the former 
associated with high MYC levels, CSF dissemination and an inferior outcome. Finally, in 
the largest study to date investigating the expression profiles of medulloblastomas, 
Cho et al reported the expression profiles of 194 primary medulloblastomas and 
identified 6 subgroups (Cho, Tsherniak et al. 2010). In addition to a Wnt and SHH group, 
2 groups of medulloblastomas incorporating genes associated with photoreceptor and 
GABAergic expression, and another 2 groups with tumours with neuronal and 
glutamategic expression were identified. Taken together, these studies have 
consistently identified subgroups associated with Wnt and SHH signalling.  The number 
of non-wnt and non-SHH subgroups and their precise definition and characterisation 
has yet to be fully elucidated. 
Currently unpublished work undertaken by Dr Ed Schwalbe at the Northern Institute 
for Cancer Research at Newcastle University has compared the expression profiles of 
primary medulloblastoma tumours with their methylomic profiles. These data, 
summarised in Figure 5.1, have shown that using methylation profiling a number of 
distinct subgroups can be determined, which correlate with the groups identified by 
expression profiling. In particular, a cluster of samples with aberrant Wnt pathway 
activation (Wnt group), a second cluster with aberrant sonic hedgehog signalling (SHH 
group), and a third cluster without Wnt or sonic hedgehog pathway activation (non-
Wnt, non-SHH) can be identified as distinct entities, in addition to a few outlying 
samples that do cluster with any of three groups.  
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The relationship between molecular events and methylomic profiling has not 
previously been investigated in CNS-PNET disease and to date, no stratification or sub-
classification based on clinical or molecular features has been identified in this disease. 
Methylomic profiling may, as has been demonstrated with medulloblastomas, 
facilitate the discovery of subgroups within this otherwise heterogenous group of 
tumours and provide both critical insights into the genetic development of these 
tumours and a rationale for the development of stratified and potentially targeted 
therapeutic approaches. 
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Figure 5.1. Identification of medulloblastoma subgroups using expression and methylomic analyses. (a)  Bootstrapped cluster dendrogram of 
methylation patterns in 100 medulloblastoma samples. Numbers in red refer to bootstrap percentages of major dendrogram branches. Major 
subgroups are coloured (orange, red, green, blue), with outlying samples marked grey. Heatmap shows methylation scores, from green 
(hypomethylated) to red (fully-methylated). (b) Principal component analysis loadings plot of methylomic data confirming the four distinct subgroups 
identified in (a). (c) Principal component analysis loadings plot of WNT/SHH gene expression signature assay (Schwalbe, Lindsey et al. 2011): WNT 
signature expressing (red), SHH signature expressing (blue).  (d) Molecular correlates and relation to methylomic subgroup assignment. Subgroups 
are coloured as in (a).  Line 1: CTNNB1 activating mutation, CTNNB1 mutation (red); no mutation (white) (p=2.7 X 10-16). Line 2: Chromosome 6 loss 
of heterozygosity (LOH), LOH detected (red); no LOH (white) (p=9.4 X 10-16). Line 3: Signature - activation of WNT and SHH pathways by gene 
expression, WNT (red), SHH (blue) pathway activation; WNT/SHH independent (white) (p=2.1 X 10-26). Grey hatching – DNA/ RNA unavailable. All p 
values derived using chi-squared tests. Adapted figures and data kindly supplied by Dr Ed Schwalbe, Northern Institute Cancer Research, UK.  
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5.1.4 Study Aims 
To date understanding of the CNS-PNET DNA methylome is limited. A detailed 
description and understanding of the CNS-PNET methylome and its role in 
tumorigenesis is now required. This approach may afford the potential to develop a 
sub-classification within this heterogenous group of tumours, identify novel 
methylation events for further investigation and investigate the relationship with other 
highly malignant paediatric brain tumours including medulloblastomas and high-grade 
gliomas. 
The specific aims of this study were: 
1.  To determine the global methylation patterns in CNS-PNET primary tumours in 
comparison with those observed within the normal brain. 
2.  To identify tumour-specific markers in CNS-PNET and to develop a model to enable 
the identification of CNS-PNET tumour from normal brain using methylation markers. 
3. To correlate methylation events observed with known clinical, pathological and 
genetic features in CNS-PNET and discover possible sub-groups within this disease. 
4. To compare and contrast the methylation profiles of CNS-PNET with other 
aggressive paediatric brain tumours and examine any molecular interrelationships that 
may exist between the different tumour groups. 
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5.2 Materials and methods 
5.2.1 CNS-PNET primary tumour cohort 
Thirty-nine primary CNS-PNET samples were available for inclusion in the methylation 
array study. The clinical characteristics of these samples have been previously given in 
Table 2.1.  DNA was extracted from the tumour samples and processed using the 
Illumina Goldengate Methylation array, using methods previously described (Section 
2.3.1 and section 2.13.1). 
 
5.2.2 Control brain cohort 
The methylation profiles of normal control brain samples were established from two 
sources. DNA was extracted from normal brain samples from the Northern Institute for 
Cancer Research (Table 2.3) and processed using the Illumina Goldengate methylation 
array, as has been previously described (Section 2.3.1 and section 2.13.1). The 
methylation results from a published series of normal cerebellar and cerebral samples 
was also included (Ladd-Acosta, Pevsner et al. 2007). Additional clinical information 
shown in Table 5.2 pertaining to this published series was kindly made available by Dr 
Potash (Research Director, Mood Disorders Center Meyer, Baltimore, USA) in a 
personal communication. In total 43% of the samples (16/37) were derived from the 
cerebrum and 57% (21/37) from the cerebellum. Samples were obtained from a wide 
range of cases of different ages incorporating both infant cases under the age of 3 
years (9/37, 27%), and adult cases (27/37, 73%). The age of the patient was not 
available for one of the samples (3%).  The clinical features of the normal brain cohort 
are summarised in Table 5.3. 
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Array ID Site Age (years) Sex Source 
cbll1 cerebellum 25 female Ladd-Acosta 
cbm1 cerebrum 25 female Ladd-Acosta 
cbll2 cerebellum 24 male Ladd-Acosta 
cbm2 cerebrum 24 male Ladd-Acosta 
cbll3 cerebellum 28 male Ladd-Acosta 
cbm3 cerebrum 28 male Ladd-Acosta 
cbll4 cerebellum 2 female Ladd-Acosta 
cbm4 cerebrum 2 female Ladd-Acosta 
cbll5 cerebellum 21 male Ladd-Acosta 
cbm5 cerebrum 21 male Ladd-Acosta 
cbm6 cerebrum 26 male Ladd-Acosta 
cbll6 cerebellum 26 male Ladd-Acosta 
cbm7 cerebrum 21 male Ladd-Acosta 
cbll7 cerebellum 21 male Ladd-Acosta 
cbm8 cerebrum 19 male Ladd-Acosta 
cbll8 cerebellum 19 male Ladd-Acosta 
cbm9 cerebrum 30 male Ladd-Acosta 
cbll9 cerebellum 30 male Ladd-Acosta 
cbm10 cerebrum 30  - Ladd-Acosta 
cbll10 cerebellum 30  - Ladd-Acosta 
cbm11 cerebrum 22 male Ladd-Acosta 
cbll11 cerebellum 22 male Ladd-Acosta 
cbm12 cerebrum 2 female Ladd-Acosta 
cbll12 cerebellum 2 female Ladd-Acosta 
cbm13 cerebrum 20 male Ladd-Acosta 
cbll13 cerebellum 20 male Ladd-Acosta 
cbm14 cerebrum 42 male Ladd-Acosta 
cbm15 cerebrum 72 male Ladd-Acosta 
cbm16 cerebrum 67 male Ladd-Acosta 
cbll17 cerebellum prenatal* male Newcastle 
cbll18 cerebellum prenatal* male Newcastle 
cbll19 cerebellum  -  - Newcastle 
cbll20 cerebellum 67 male Newcastle 
cbll21 cerebellum newborn female Newcastle 
cbll22 cerebellum 60 male Newcastle 
cbll23 cerebellum prenatal* female Newcastle 
cbll24 cerebellum prenatal* male Newcastle 
Table 5.2. Normal brain control samples used in methylation array. Newcastle 
samples were derived from the Northern Institute for Cancer Research archive. The 
Ladd-Acosta samples describe those used in their published series (Ladd-Acosta, 
Pevsner et al. 2007). Clinical details for the Ladd-Acosta samples were kindly provided 
by Dr Potash (personal communication). * prenatal samples from foetuses at 18-22 
weeks gestation. 
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Criteria Category n (%) 
Site Cerebrum 16 (43%) 
  Cerebellum 21 (57%) 
      
Age <3 years 9 (24%) 
  3-18 years 0 (0%) 
  >18 years 27 (73%) 
  Unknown 1 (3%) 
      
Sex Male 26 (70%) 
  Female 8 (22%) 
  Unknown 3 (8%) 
      
Table 5.3. Methylation array normal brain control samples clinical characteristics 
summary. 
 
5.2.3 Malignant brain tumour comparator cohorts 
5.2.3.1 Pineoblastoma 
Four pineoblastomas confirmed on central pathological review using the current WHO 
classification system (Louis, Ohgaki et al. 2007) were included in the study.  DNA was 
extracted from the cases, as has been previously described (Section 2.3.1). The clinical 
features of the four pineoblastoma cases used in the study are given in Table 5.4. 
Array ID Sex 
Age 
(months) 
Metastasis 
(Chang stage) 
Follow-up 
(months) Status 
PB1 F 300 M3 Unknown Unknown 
PB4 F 45 Unknown 35 DOD 
SP2 F 73 M0 124 ADF 
SP114 F 13 M3 10 DOD 
Table 5.4. Clinical characteristics of methylation array pineoblastoma cohort. DOD, 
died of disease; ADF, alive and disease free.  
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5.2.3.2 Medulloblastoma 
The methylation profiles of 100 medulloblastomas processed concurrently with the 
CNS-PNET study using the Illumina GoldenGate platform, confirmed on central 
histopathological review according to the current WHO classification by Prof David 
Ellison (St Judes Research hospital, Memphis, Tennessee, USA), was kindly made 
available for use in this study by Dr Ed Schwalbe from the Northern Institute for Cancer 
Research, Newcastle University, UK. A summary of the pathological subgroup and 
clinical features of these tumour samples is given in Table 5.5. 
 
Medulloblastoma characteristic 
 
Category 
 
No 
 
Classification subgroup Classic 72 
  Nodular desmoplastic 17 
  Large cell / anaplastic 10 
  MBEN 1 
Sex Male 63 
  Female 37 
Age (years) <3 15 
  3-16 78 
  >16 7 
Metastasis (Chang score) M0 47 
  M0/1 8 
  M1 7 
  M2 8 
  M3 12 
  M4 0 
  Unknown 18 
Status Alive, disease free 60 
  Alive, with disease 5 
  Died of disease 30 
  Died of other cause 2 
  Unknown 3 
Molecular features* Wnt/ Wingless 10 
  SHH 20 
  Non-Wnt/ Wingless & Non-SHH 59 
  Unknown 11 
Table 5.5. Clinical and molecular characteristics of the medulloblastoma primary 
tumour cohort. 100 primary medulloblastoma tumour samples in the cohort. MBEN, 
medulloblastoma with extended nodularity; SHH, sonic hedgheohog pathway; *data 
kindly supplied by Dr Ed Schwalbe, Northern Institute for Cancer Research at 
Newcastle University.  
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5.2.3.3 High grade glioma 
The methylation profiles, processed using the Illumina GoldenGate platform, of 29 high 
grade gliomas (HGG), confirmed on pathological review, were very kindly made 
available for use in this study by Dr Martyna Adamowicz and Professor Richard Grundy 
from the Children's Brain Tumour Research Centre (CBTRC), University of Nottingham, 
UK. Further clinical details for these samples are not available. 
 
5.2.4 Array sample preparation 
Control and tumour samples to be investigated using the Illumina GoldenGate 
Methylation array platform were prepared and processed as has been previously 
described in section 2.13.2. 
 
5.2.5 Quality control assessment 
The data produced by the Wellcome Trust Centre for Human Genetics (Oxford, UK) 
from processing the Illumina GoldenGate microarrays were subjected to a quality 
control assessment. Firstly, the data was analysed in the BeadStudio Methylation 
Module (version 3.0 (Illumina)) as has been described in section 2.13.3.1. The data was 
also subjected to a further quality control assessment using the BeadArray Subversion 
of Harshlight (BASH) programme within the BeadArray package, as has been described 
in section 2.13.3.2. The methylation data from samples that successfully passed both 
quality control assessments were used in subsequent analyses. 
 
5.2.6 Methylation array platform validation 
The methylation values obtained using the Illumina methylation array platform were 
validated by comparing the methylation scores obtained for 18 tumour samples on the 
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array at a number of differentially methylated loci with the methylation status 
identified by direct bisulphite sequencing. A panel of loci of seven genes were analysed 
comprising ASCL2, CCKAR, COL1A2, HFE, MSH2, NOS2A and SPDEF. PCR primers to 
amplify regions containing the relevant methylation array probe loci were designed 
using methods previously described (section 2.12.3) and are given in Table 5.6. 
Standard PCR reactions were performed as described in section 2.4.3, and the 
resultant PCR product purified and sequenced using Sanger sequencing (see sections 
2.4.5 and 2.6). Anonymised traces for each sample were scored using direct visual 
inspection and the percentage methylation ranging from 0% (unmethylated) to 100% 
(fully methylated) at each CpG locus under investigation estimated. The validation 
study was performed with Dr Janet Lindsey at the Northern Institute for Cancer 
Research at Newcastle University. 
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Gene Array probe ID Forward primer (5’-3’) Reverse primer (5’-3’) 
HFE HFE_E273_R  GGTAATAGTTGTAGGGTGATTTTTG  CAAATCCTCCAAAATTAACAAACTC 
ASCL2 ASCL2_P360_F  GGGAATTTGAATTTTTTATTT  AAACTAAATTCCTACTAAACCCC 
NOS2A NOS2A_E117_R  AAAAATAATTTTTTGGATGGTATGG  TTACAACTAACTACACTACCTCCCC 
CCKAR CCKAR_P270_F ATTGTTTTTTTATAAGGAGGTAGAATATA CTAAATACAAACAACCTAACTACCC 
SPDEF SPDEF_P6_R TTGTTTGTGGTTTGAGGTAAGTAAG CCCTCAAAAAATAACCCTCTAAAAT 
MSH2 MSH2_P1008_F GGTAGAAGATTTTTTGGGTTTAAA CACCATCCTAAACAACATAATAAAAC 
COL1A2 COL1A2_E299_F AGGTATTTTAGGGTTAGGGAAATTTT ATTACTACAAACAACAACAAAATCC 
Table 5.6. PCR primers used in the array validation study.
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5.2.7 Methylation status classification ascertainment 
β-values provided by the Illumina GoldenGate microarray were used to determine the 
methylation status of a sample for a probe at a given locus. The reported β-values 
ranged from 0 (fully unmethylated) to 1 (fully methylated). β-values greater than 0.67 
were classified as being methylated, less than 0.34 as unmethylated and between 
these values (0.34-0.67) as showing partial methylation at a given locus. Differentially 
methylated probes were categorised as those in which the methylation scores across 
the cohort varied in a range of more than 0.34 (Δβ>0.34). 
 
5.2.8 Comparison of the methylation profiles of the normal brain 
and CNS-PNET 
5.2.8.1 Methylation profile ascertainment in the normal brain 
The methylation profile of the normal brain was established using methylation scores 
derived from the Illumina Goldengate methylation platform (see section 2.13) in the 
normal brain cohort (section 5.2.2). The data were processed using unsupervised 
techniques (section 2.13.4) to establish any patterns of methylation within this cohort. 
 
5.2.8.2 Methylation profile ascertainment in CNS-PNET 
The methylation profile of the CNS-PNET cohort was established using methylation 
scores derived from the Illumina Goldengate methylation platform (see section 2.13) in 
the CNS-PNET cohort (section 5.2.1). The data was processed using unsupervised 
techniques (section 2.13.4) to establish any patterns of methylation within this cohort. 
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5.2.8.3 Methylation profile comparison 
Comparison of the methylation profiles of the 37 cerebellar and cerebral normal brain 
samples (section 5.2.2) was made with the 31 CNS-PNET cohort (section 5.2.1) using 
unsupervised approaches previously described (section 2.13.4). Comparison of the 
methylation status in different sample groups of probes situated within and outside of 
CpG islands was made using the probe location data supplied by Illumina (data not 
shown). 
 
5.2.9 Assessment of aberrant methylation in CNS-PNET 
5.2.9.1 Identification of aberrantly methylated genes in CNS-PNET 
To identify aberrant methylation in CNS-PNET, the methylation profile of the control 
cohort was firstly analysed and the probes found in all samples to be consistently 
either methylated (β>0.67) or hypomethylated (β<0.34) recorded. Probes that were 
found to be consistently methylated or hypomethylated in all samples were 
designated as “invariant”. The methylation values of the invariant probes were then 
investigated in the CNS-PNET cohort. A probe was shown to exhibit an aberrant 
methylation profile if the average β value of the CNS-PNET cohort differed significantly 
from that observed in the normal brain. Assessment of significant difference was made 
using the Mann-Whitney test, and a multi-test Benjamini-Hochberg false discovery rate 
correction applied. 
The most significant aberrantly methylated probes in CNS-PNET were determined by 
requiring the difference in the average β-values between the tumour and normal brain 
cohorts to be greater than the reported limit of detection on the Illumina Goldengate 
Methylation array platform (Δβ>0.17) (Bibikova, Lin et al. 2006), as has been previously 
used in published reports by separate groups (Archer, Mas et al. 2010). 
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5.2.9.2 Ontological analysis of aberrantly methylated genes in CNS-
PNET 
To determine whether CNS-PNET development is associated with the involvement of 
particular functional pathways, processes or cellular mechanisms, an ontological 
analysis was performed. The functional classification tool (FCT) within the web-based 
database for annotation, visualisation and integrated discovery (DAVID) ontological 
analysis tool, was used (http://david.abcc.ncifcrf.gov/gene2gene.jsp). The DAVID FCT 
uses an algorithm which classifies highly related genes into functionally related groups. 
Each gene may be represented in a number of different biological pathways or 
processes and is compared with the DAVID FCT tool to reduce the list of genes to be 
investigated into organised classes of related genes or biology (Reviewed in  (Huang, 
Sherman et al. 2009b; Huang, Sherman et al. 2009)). A list of most differentially 
methylated genes in CNS-PNET was generated, as has been previously described 
(section 5.2.9.1), and compared using the DAVID FCT with the list of 807 genes 
represented on the methylation array as a background panel.  
 
5.2.9.3 Investigating associations between aberrant methylation in 
CNS-PNET and clinical features  
A young age at diagnosis (<3 years) and the presence of metastatic disease are the 
only two clinical variables known to influence survival in CNS-PNET.  To determine 
whether aberrant methylation of specific genes is associated with either of these 2 
clinical features the most aberrantly methylated genes in CNS-PNET (see section 
5.2.9.1) were investigated. A Mann-Whitney test was performed and the Benjamini-
Hochberg correction applied to ascertain any significant differences in the methylation 
of the aberrantly methylated genes in those patients diagnosed before or after 3 years 
of age, and in those with (M1-M4) and without (M0 or M0/1) metastatic disease at 
diagnosis. Analyses were performed using the “R” statistical computer package, as has 
been previously described (section 2.13.4). 
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5.2.9.4 Investigating associations between aberrant methylation in 
CNS-PNET and survival 
To determine whether any aberrantly methylated genes are associated with survival 
outcomes, the list of most aberrantly methylated genes (see section 5.2.9.1), were 
analysed for associations with outcome using the ‘R’ statistical package (see section 
2.13.4).  Univariate analysis was performed and the most significant genes (p<0.05) 
from this analysis were entered into a multivariate Cox-model analysis to determine 
whether any of these probes were independently prognostically significant. 
 
5.2.10 Comparison of the methylation profiles of CNS-PNET with 
other malignant brain tumours 
The methylation profile of CNS-PNETs was compared with that observed in other 
malignant brain tumours using unsupervised approaches previously described (section 
2.13.4). Comparison of the methylation profiles of the 37 normal brain samples 
(section 5.2.2) and the 31 CNS-PNETs (section 5.2.1) was made with 4 pineoblastomas 
(section 5.2.3.1 ), 100 medulloblastomas (section 5.2.3.2) and 29 high-grade gliomas 
(section 5.2.3.3). Comparisons were made in triplicate utilising firstly the methylation 
scores of all 1505 probes on the array, secondly using only differentially methylated 
probes (see section 5.2.7), and thirdly using the methylation scores arising from 1421 
probes targeting genes not located on the X-chromosome.  
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5.3 Results 
5.3.1 Array quality control 
Thirty-nine primary CNS-PNET cases that had undergone central pathological review 
were included in the CNS-PNET cohort. As outlined in Figure 5.2, tumour material was 
available in 34 of these to be included on the methylation array. The data obtained 
from the methylation array was subjected to a quality control assessment. Beadstudio 
quality control assessment found that SP42, SP49 and SP55 were quality control 
failures (Figure 5.3). In all 3 cases, abnormal signals were detected in the negative 
control analysis and significant levels of contamination were observed in the analysis 
of both SP42 and SP49. Bisulphite conversion was found to be borderline in SP42, and 
SP55 failed this quality control requirement. In addition SP55 failed tests on both the 
first and secondary hybridisation steps, and SP49 failed the quality control analysis on 
the secondary hybridisation and allele-specific extension steps. The quality control 
process findings were confirmed using a second technique. On BASH assessment SP42, 
SP49 and SP55 failed the analysis (Figure 5.4), and these 3 samples were subsequently 
removed from the analysis. The clinical features of the final cohort of 31 primary CNS-
PNET tumour samples that passed the quality control assessment and were used in the 
subsequent methylation analyses are given in Table 5.7. DNA had been extracted from 
frozen material in 20 of these cases (20/31, 65%), and formalin fixed paraffin 
embedded (FFPE) material in 11 cases (11/31, 35%). In the three cases that failed the 
quality control analysis, DNA had been extracted from frozen material in one (SP55) 
and from FFPE in 2 cases (SP42 and SP49).
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Figure 5.2. CNS-PNET cohort ascertainment. FFPE, Formalin fixed paraffin embedded material; QC, Quality control.  
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Figure 5.3 Beadstudio quality control analysis. Data shown includes the combined results of two methylation array plates (Array index 1-96 
(plate 1), 97-192 (plate 2)). CNS-PNET cohort: array index cases 1-36 (excluding 11 and 22). Red line indicates cut-off for quality control (QC) 
pass. Red numbers indicate samples failing the QC analysis for the different QC parameters (1) SP42 (CNS-PNET), (2) SP55 (CNS-PNET), (3) index 
case 11 (medulloblastoma), (4) index case 22 (medulloblastoma) (5) SP49 (CNS-PNET): a) First hybridisation; b) Contamination (note failures are 
below red line for 2nd plate); c) Negative control; d) Bisulphite conversion; e) Second hybridisation; f) Allele specific extension.
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Figure 5.4. BASH analysis plots. Methylated (R, red) and unmethylated (G, Green) 
intensities across all 1505 CpG probes for individual tumour samples are shown. a) A 
normal plot passing the quality control process showing a bimodal distribution 
(consistent with most loci being either methylated or unmethylated with partial 
methylation at only a few loci. Three samples were excluded from the study as the red 
(methylated) channel failed to detect signals in b) SP42, c) SP55 and d) SP49. 
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Clinical characteristic 
 
Number (Frequency %) 
Sex Male 15 (48%) 
  Female 16 (52%) 
Age at diagnosis Infant (<3 years) 8 (26%) 
  Child (3-16 years) 18 (58%) 
  Adult (>16 years) 4 (13%) 
  Unknown 1 (3%) 
Metastasis (Chang score) M0/1 21 (68%) 
 
M1 1 (3%) 
  M2 4 (13%) 
  M3 1 (3%) 
  M4 1 (3%) 
  Unknown 3 (10%) 
Survival Alive  9 (29%) 
  Died 19 (61%) 
  Unknown 3 (10%) 
Table 5.7. Clinical characteristics of the quality control approved CNS-PNET 
methylation array cohort. In total 31 CNS-PNET primary tumour samples passed the 
methylation array quality control requirements and the methylation data from these 
tumours were used in the subsequent studies. 
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5.3.2 Validation for methylation array results 
The methylation values obtained on the Illumina Goldengate methylation array were 
validated by direct bisulphite sequencing, using a panel of 18 tumour samples to assess 
7 differentially methylated loci which were present on the array. The direct bisulphite 
sequencing traces were inspected, and a numerical score between 0 (fully 
unmethylated) and 1 (fully methylated) recorded by measuring the peak heights of the 
methylated (a) and unmethylated (b) traces at each locus and calculating the 
proportion of methylation present (a/a+b). The results, shown in Figure 5.5, revealed a 
high concordance between the two approaches. The mean difference was 0.006, and 
standard deviation of 0.167. In only 10/126 (7.9%) of cases did a difference greater 
than 2 standard deviations (>0.34) between the methylation array and direct bisulphite 
sequencing occur. 
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Figure 5.5. Validation of methylation array β values. For 18 tumour samples at 7 
differentially methylated loci (ASCL2, CCKAR, COL1A2, HFE, MSH2, NOS2A, SPDEF), the 
methylation status of the interrogated CpG dinucleotide reported from the 
methylation array was compared against estimates from bisulfite sequencing. The 
distribution of differences between array and bisulfite values across all 7 loci, for all 18 
samples, is summarised in the density plot. The mean difference was 0.006, and 
standard deviation was 0.167. Samples lying more than 2 standard deviations from the 
mean (10/126, 7.9%) are shaded red. 
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5.3.3 Methylation patterns in the normal brain 
The methylation pattern across 1505 probes associated with 807 genes implicated in 
cancer development using the Illumina Goldengate cancer panel I was assessed in 37 
control normal brain samples. 28.1% of the genes are represented by 1 probe, 57.3% 
by 2 probes and 14.1% of the genes have 3 or more probes on the array. The mean 
methylation for each probe across the control cohort was calculated and 64.2% 
(966/1505) of probes were hypomethylated, 28% (422/1505) were fully methylated 
and 7.8% (117/1505) were partially methylated. Overall, the methylation values in the 
normal brain control group cohort exhibited a bimodal distribution, as shown in Figure 
5.6. The normal brain samples were shown to exhibit variable methylation (β range > 
0.34) with 28% (421/1505) of the probes on the array, but the majority (72%, 
1084/1505) of probes were therefore invariantly methylated (β range < 0.34). 
The normal brain cohort comprised a diverse range samples from the cerebellum and 
cerebrum, including samples from across the age spectrum (prenatal, paediatric and 
adult) as well as from both male and female patients. Unsupervised hierarchical 
clustering of the normal brain cohort (Figure 5.6c) showed two main branches 
associated with the site of origin of the sample (p= 0.0005, Fisher’s exact test). 
Clustering was not found to be statistically significantly associated with age at biopsy 
(p=0.47, Fisher’s exact test). 
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Figure 5.6. Methylation patterns in the normal brain. Assessment of the methylation 
patterns using 1505 probes on the methylation array of 37 normal brain samples. (a) 
Density plot showing the bimodal distribution of average methylation β-values in the 
normal brain. (b) Unsupervised hierarchical clustering heatmap. Green, 
hypomethylated; black, partially methylated and red, fully methylated. (c) clinical 
characteristics of the normal brain samples. Top bar, sample site; middle bar, sex; 
bottom bar, age at biopsy. 
 
 
 
 
 
316 
 
5.3.4 Methylation patterns in CNS-PNET 
The methylation patterns of 31 CNS-PNET primary tumour samples were next 
investigated using the Illumina Goldengate Cancer panel I. The methylation or β-values 
at each locus for the 1505 probes on the array are graphically represented in Figure 5.7. 
The experiment was repeated using only the 1065 probes that exhibited variable 
methylation (β range > 0.34) in CNS-PNET and also repeated excluding those probes on 
the X chromosome, with similar results obtained (data not shown). 
Four of the CNS-PNET samples were shown to be outliers (SP54, SP126, SP40 and SP24) 
and did not cluster with other CNS-PNETs. In contrast to the normal brain (Figure 5.6) 
the unsupervised hierarchical clustering of the remaining samples did not yield 
discrete clusters or sub-groups from which associations with clinical characteristics 
could be determined, but demonstrated methylation heterogeneity within the CNS-
PNET cohort. 
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Figure 5.7. Methylation profile of 31 CNS-PNET primary tumour samples using the 
Illumina Goldengate methylation array. (a) Heatmap showing the methylation profiles 
of the CNS-PNET cohort across 1505 probes. Fully methylated (red), partially 
methylated (black) and unmethylated (green). (b) Unsupervised hierarchal clustering 
dendrogram of the bootstrapped methylation profiles of 31 CNS-PNETs.  Numbers in 
red indicate the percentage frequency at which individual branches occur. CNS-PNET 
clinical characteristics. Sex: male (blue), female (pink); Age at diagnosis: Infant (green), 
child (amber), adult (red); metastatic disease:  present (red), absent (green); status: 
died of disease (red), alive (green). No result available (blank). 
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5.3.5 Comparison of CNS-PNET methylation patterns with normal 
brain 
Comparison was next made between the CNS-PNET samples and the methylation 
profile of the normal brain.  In total, 1044 of the 1505 probes (69%) on the Cancer I 
panel used with the methylation array were located within CpG islands, defined 
according to the criteria described by Takai and Jones (Takai and Jones 2002). An 
additional 461 probes (31%) hybridised to CpG dinucleotides outside of CpG islands. As 
shown in Figure 5.8, methylation of the 1044 probes within CpG islands was 
significantly greater in the CNS-PNET tumours compared with the normal brain 
(interquartile range 100-151 and median 120 probes in CNS-PNET vs interquartile 
range 96-106 and median of 101 probes in the control samples; p=0.002). In contrast 
methylation of the 461 probes located outside of CpG islands was greater in the 
control sample cohort (interquartile range 235-303 and median 269 probes in CNS-
PNET vs interquartile range 325-335 and median of 330 probes in the control samples 
(p<0.0001). The variability amongst samples also differed. In the tumour cohort the 
standard deviation of methylated probes inside and outside of CpG islands was 46.5 
and 44.9 respectively, compared to only 8.2 and 8.9 in the normal brain cohort. Taken 
together these data show that methylation profiles of primary CNS-PNET differ 
significantly to those observed in normal brains both with respect the frequency and 
variablity of methylation. Tumour-specific methylation is therefore a feature of CNS-
PNET, although the methylation profiles of a minority of tumours may more closely 
resemble those observed in the normal brain (Figure 5.9). 
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Figure 5.8. Box and whisker plots comparing methylation patterns at and outside of 
CpG island sites in normal brain tissue and in CNS-PNET. (a) methylated, and (b) 
hypomethylated probe comparison. 
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Figure 5.9. Comparison of CNS-PNET methylation profiles with normal brain. (a) Principal component analysis showing the co-clustering of 
normal brain samples and CNS-PNET heterogeneity. (b) Unsupervised hierarchical clustering bootstrapped dendrogram. SP124 (red arrow) is 
shown to have a methylation profile closely related to the normal brain samples.
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5.3.6 Identification of tumour-specific methylation events in CNS-
PNET  
The identification of probes that are significantly aberrantly methylated in CNS-PNETs 
was derived as has been detailed in section 5.2.9.1, and the process summarised in 
Figure 5.10. In the normal brain, 52.1% (784/1505) of probes were found to be 
invariantly hypomethylated and 17.4% (262/1505) of probes were found to be 
invariantly fully methylated. Of the invariantly fully methylated and hypomethylated 
probes 138 and 418 probes respectively were found to exhibit significantly different 
methylation in the CNS-PNET cohort. In total 76 probes were identified that exhibited 
the most significantly aberrant methylation, 24 of which have an invariantly 
hypomethylated profile and 52 of which have an invariantly fully methylated profile in 
the normal brain (Figure 5.11). These significant aberrantly methylated probes in CNS-
PNET target in total 63 different genes as summarised in Table 5.8 and Table 5.9. 
In these 76 probes, aberrant methylation occurs in 16-77% (5/31 – 24/31) of CNS-PNET 
cases (Figure 5.12). The KLK11_P103_R and HLADPB1_E2_R probes are the two most 
frequently aberrantly hypo-methylated probes in CNS-PNET that are fully methylated 
in the normal brain (aberrantly methylated in 77% and 74% of CNS-PNETs respectively). 
The two most frequently aberrantly hyper-methylated probes in CNS-PNET which are 
hypomethylated in the normal brain are RASSF1_E116_F and FZD9_E458_F (aberrantly 
methylated in 68% and 61% of CNS-PNETs respectively). 
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Figure 5.10. Ascertainment of aberrantly methylated probes in CNS-PNET. 
*Invariantly fully methylated (β>0.67) and hypomethylated (β<0.34) probes showed 
consistent values in all normal brain samples. **The average methylation in the normal 
brain and CNS-PNET samples differed significantly (p<0.05, Mann-Whitney testing after 
multi-test correction), and ***magnitude of difference exceeded the limit of 
detectability on the methylation array platform (Δβ>0.17).  
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Figure 5.11. Heatmaps of gene probes significantly differentially methylated between CNS-PNETs and the normal brain. (a) Consistently 
methylated probes (β > 0.66) in all normal brain samples with a significant variation in CNS-PNET samples. (b) Consistently hypomethylated 
probes (β < 0.34) in all normal brain samples with a significant variation in CNS-PNET samples. In (a) and (b), median β in CNS-PNET is 
significantly different (p<0.05, Mann-Whitney test and Benjamin-Hochberg correction.  Methylation β values shown: Green, hypomethylated; 
black, partially methylated; red, fully methylated. Black bar, normal brain; Green bar, CNS-PNET.
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Aberrant 
No (%)
Hypo       
No (%)
ACTG2_E98_R 15 (48%) 8 (26%)
ACTG2_P346_F 14 (45%) 6 (19%)
AFP_P824_F 5 (16%) 2 (6%) AFP 4 transfer/ carrier protein, mesoderm development
AGXT_P180_F 7 (23%) 4 (13%) AGXT 2 transaminase, cellular amin aocid and derivative metabolism
ATP10A_P524_R 13 (42%) 9 (29%) ATP10A 15 cation transporter, hydrolase activity, cation transmebrane transporter activity
CARD15_P302_R 13 (42%) 8 (26%) CARD15 16 intracellular receptor, immune system process, apoptosis induction
CCL3_E53_R 14 (45%) 5 (16%) CCL3 17 chemokine, immune response, cell-cell  signaling, cell  surface receptor l inked signal transduction
CD1A_P6_F 12 (39%) 7 (23%) CD1A 1 immunoglobulin receptor, B cell mediated immunity
CEACAM1_P44_R 10 (32%) 5 (16%) CEACAM1 19 cell adhesion molecule, signal transduction, cell-cell  adhesion
CHI3L2_P226_F 10 (32%) 4 (13%) CHI3L2 1 glycosidease, hydrolase activity, hydrolysing N-glycosyl compounds
CSF3R_P472_F 5 (16%) 3 (10%) CSF3R 1
signaling molecule,  B cell mediated immunity, cell  surface receptor l inked signal transduction,  
ectoderm/ mesoderm & nervous system development,  haemopoiesis
CXCL9_E268_R 17 (55%) 12 (39%) CXCL9 4
chemokine,  cellular defence response, IFNγ response, angiogenesis, mesoderm development, cell-
cell  signaling, signal transduction,  macrophage activation
DLC1_E276_F 11 (35%) 8 (26%)
DLC1_P695_F 18 (58%) 14 (45%)
DSG1_P159_R 11 (35%) 3 (10%) DSG1 18 cell junction protein, cell-cell  adhesion, signal transduction, calcium ion binding
EMR3_E61_F 21 (68%) 14 (45%)
EMR3_P1297_R 15 (48%) 8 (26%)
EMR3_P39_R 18 (58%) 11 (35%)
FGF7_P44_F 15 (48%) 10 (32%) FGF7 15
FGF signaling pathway receptor, ectoderm & nervous system development, cell  cycle, cell-cell  
signaling, intracellular signaling cascade
HLA-DPB1_E2_R 23 (74%) 17 (55%) HLA-DPB1 6
major histocompatibility complex antigen, antigen processing & presentation, cellular defense 
response
IFNG_E293_F 15 (48%) 8 (26%)
IFNG_P188_F 12 (39%) 4 (13%) IFNG 12
interferon glycoprotein, interferon gamma signaling pathway, cellular defense response, cell-cell  
signaling, natural kil ler cell  activation, apoptosis regulation
DLC1 8 G-protein modulator, PDGF signaling pathway
EMR3 19
G-protein coupled receptor, synaptic transmission, B cell mediated immunity, mesoderm & heart 
development, angiogenesis, signal transduction
ACTG2 2 actin-like protein, structural constituent of cytoskeleton
Probe
Methylation
Gene Chr Function(s)
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IL10_P85_F 12 (39%) 4 (13%) IL10 1
interleukin cytokine, cellular defense response, modulate inflammation and immunity by regulating 
growth, mobility and differentiation of lymphoid cells
IL2_P607_R 11 (35%) 5 (16%) IL2 4
interleukin cytokine, cellular defense response, modulate inflammation and immunity by regulating 
growth, mobility and differentiation of lymphoid cells
IL8_P83_F 17 (55%) 12 (39%) IL8 4
chemokine, cellular defense response,  inflamation mediated by chemokine & cytokine signaling 
pathway, , IFNγ response, angiogenesis, mesoderm development
ITK_P114_F 10 (32%) 4 (13%) ITK 5
transmembrane receptor protein kinase, ectoderm/ mesoderm & nervous system development, cell  
cycle & apoptosis, cell-cell  signaling & adhesion
KLK11_P103_R 24 (77%) 16 (52%) KLK11 19
serine protease, blood coagulation, immune system processing, ectoderm & nervous system 
development, cell  cycle
LAT_E46_F 14 (45%) 6 (19%) LAT 16 adapter protein, T-cell activation pathway
MMP19_E274_R 8 (26%) 2 (6%) MMP19 12 metalloprotease, protein metabolism processing
MMP9_E88_R 8 (26%) 4 (13%) MMP9 20 metalloprotease, protein metabolism processing
MPO_E302_R 9 (29%) 3 (10%) MPO 17 peroxidase, immune response, oxygen species metabolic process
NAT2_P11_F 14 (45%) 2 (6%) NAT2 8 acetyltransferase, metabolism
NOS2A_E117_R 8 (26%) 3 (10%) NOS2A 17 nitric oxide synthase
NOTCH4_P938_F 19 (61%) 6 (19%) NOTCH4 6
transcription factor, ectoderm & nervous system development, cell-cell  signaling & adhesion, 
signal transduction
PECAM1_P135_F 10 (32%) 5 (16%) PECAM1 17
immunoglobulin receptor, B cell mediated immunity, natural kil ler cell  & macrophage activation, 
cell  adhesion, signal transduction
PGR_P456_R 9 (29%) 4 (13%)
PGR_P790_F 15 (48%) 5 (16%)
PI3_E107_F 8 (26%) 5 (16%) PI3 20 serine protease inhibitor, protein metabolism
PTK6_E50_F 11 (35%) 3 (10%) PTK6 20
transmembrane receptor protein kinase, ectoderm/ mesoderm & nervous system development, cell  
cycle & apoptosis, cell-cell  signaling & adhesion
PTPRH_E173_F 14 (45%) 7 (23%) PTPRH 19
receptor, hydrolase & phosphatase activity, ectoderm & nervous system development, cellular 
glucose homeostasis, mitosis, immune system process, cell-cell  & cell-matrix adhesion
SFTPB_P689_R 9 (29%) 6 (19%) SFTPB 2 surfactant, l ipid metabolism and transport, blood circulation
SIN3B_P514_R 6 (19%) 3 (10%) SIN3B 19 transcription factor, deacetylase activity, DNA & chromatin binding
SLC22A18_P216_R 17 (55%) 9 (29%) SLC22A18 11 transmembrane transporter
PGR 11
nuclear hormone receptor, neuronal action potential propagation, neurotransmitter secretion, 
sensory perception
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Table 5.8. Most significant differentially hypomethylated gene probes in CNS-PNET. Aberrantly methylated (aberrant): β<0.67, and 
hypomethylated (hypo): β<0.34. 
SLC6A8_P409_F 11 (35%) 3 (10%) SLC6A8 X
amino acid transporter, nicotinic & muscarinic receptor signaling pathways, neuronal action 
potential propagation, neurotransmitter secretion, sensory perception.
SPI1_P48_F 8 (26%) 3 (10%) SPI1 11
transcription factor, interleukin signaling pathway, B cell mediated immunity, macrophage 
activation, cell cycle, mesoderm  & endoderm development, hemopoiesis
SPP1_P647_F 16 (52%) 7 (23%) SPP1 4 extracellular matrix cytokine, cell adhesion, immune system processing
TMPRSS4_P552_F 10 (32%) 8 (26%) TMPRSS4 11 serine protease,  blood coagulation, immune system processing
TRIM29_P135_F 8 (26%) 3 (10%) TRIM29 11 nucleic acid binding protein, nervous system & ectoderm development, cell cycle
WEE1_P924_R 6 (19%) 3 (10%) WEE1 11 mitosis protein kinase
WNT8B_E487_F 6 (19%) 4 (13%) WNT8B 10 signaling molecule, Wnt & cadherin signaling pathway
ZIM3_E203_F 15 (48%) 10 (32%)
ZIM3_P718_R 6 (19%) 1 (3%) ZIM3 19 KRAB box transcription factor, spermatogenesis, nucleic acid metabolic process
327 
 
 
Table 5.9. Most significant differentially fully methylated gene probes in CNS-PNET. Aberrantly methylated (aberrant): β>0.34, and fully 
methylated (fully): β>0.67. 
Aberrant 
No (%)
Fully       
No (%)
CALCA_P171_F 16 (52%) 2 (6%) CALCA 11 peptide hormone, skeletal & mesoderm development, phosphate metabolism
CD81_P272_R 18 (58%) 8 (26%) CD81 11
membrane bound signaling molecule, neuronal action potential propagation, neurotransmitter 
secretion, sensory perception,  B cell mediated immunity
DSC2_E90_F 7 (23%) 7 (23%) DSC2 18 cell junction protein, cell-cell  adhesion, signal transduction
FZD9_E458_F 19 (61%) 17 (55%) FZD9 7 signaling molecule, cadherin & wnt signaling pathway
GRB7_E71_R 7 (23%) 2 (6%) GRB7 17 transmembrane receptor adaptorv protein, signal transduction
HFE_E273_R 14 (45%) 12 (39%) HFE 6 immunoglobulin receptor, B cell mediated immunity, antigen processing & presentation
HTR1B_E232_R 7 (23%) 5 (16%)
HTR1B_P107_F 7 (23%) 4 (13%)
IGFBP1_E48_R 9 (29%) 7 (23%) IGFBP1 7 binding protein, PI3 kinase pathway, cell  matrix adhesion
IRAK3_E130_F 8 (26%) 7 (23%)
IRAK3_P13_F 7 (23%) 5 (16%)
IRAK3_P185_F 13 (42%) 8 (26%)
MAP3K1_E81_F 9 (29%) 6 (19%)
MAP3K1_P7_F 9 (29%) 6 (19%)
MOS_E60_R 9 (29%) 9 (29%) MOS 8 protein kinase, signal transduction, apoptosis regulation, cell  cycle, immune system process
MT1A_E13_R 12 (39%) 10 (32%)
MT1A_P49_R 10 (32%) 8 (26%)
RAB32_E314_R 8 (26%) 6 (19%) RAB32 6 GTPase, signal transduction, neurotransmitter secretion, cell  cycle, endocytosis, exocytosis
RASSF1_E116_F 21 (68%) 19 (61%) RASSF1 3 G-protein modulator, signal transduction, apoptosis
TAL1_E122_F 13 (42%) 6 (19%)
TAL1_P594_F 13 (42%) 7 (23%)
TFAP2C_P765_F 7 (23%) 5 (16%) TFAP2C 20 transcription factor, ectoderm development, nucleic acid metabolism
TNFRSF10C_P7_F 9 (29%) 7 (23%) TNFRSF10C 8
tumour necrosis factor receptor, p53 & apoptosis signaling pathways, B cell mediated immunity, 
macrophage activation, ectoderm & nervous system development
TP73_P945_F 11 (35%) 7 (23%) TP73 1 transcription factor, p53 pathway, apoptosis induction, cell  cycle regulation
Methylation
Probe Gene Chr Function(s)
6
protein kinase, Toll receptor signaling pathway, immune system process, protein metabolismIRAK3 12
transcription factor, DNA binding, nucleic acid metabolism1TAL1
protein kinase, signaling pathways: Toll receptor, Ras, EGF receptor, integrin, FGF & apoptosis MAP3K1 5
MT1A 16 metallothionein protein
G-protein coupled receptor, neuronal action potential propagation, neurotransmitter secretion, 
sensory perceptionHTR1B
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Figure 5.12. Frequency of the most significant aberrantly methylated probes in CNS-
PNET. (a) Probes hypomethylated in normal brain that exhibit aberrant methylation in 
CNS-PNET. Partially methylated (β= 0.34-0.67); fully methylated (β>0.67). (b) Probes 
fully methylated in the normal brain that exhibit aberrant methylation in CNS-PNET. 
Partially methylated (β= 0.34-0.67); hypomethylated (β<0.34). 
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5.3.7 CNS-PNET methylation ontological analysis 
An ontological analysis using the DAVID Functional Classification Tool of the identified 
most significantly differentially methylated genes (section 5.3.6) was performed as 
described in section 5.2.9.2. The list of CNS-PNET aberrantly methylated genes was not 
found to be statistically significantly enriched for any biological pathway or process. 
 
5.3.8 Correlation with CNS-PNET clinical characteristics 
5.3.8.1 Identification of age-specific methylation markers  
The age at diagnosis of patients with a CNS-PNET was known for 30 samples. In 8 cases 
(27%) the samples originated from infants, under the age of 3 years (36 months). In 
22/30 (73%) cases patients were aged 36 months or older at diagnosis. Analysis of the 
76 CNS-PNET specific probes determined in section 5.3.6, as using methods described 
in section 5.2.9.2, identified the probes TAL1_E122_F, MAP3K1_E81_F and 
IGFBP1_E48_R to be statistically significantly associated with age at diagnosis (Figure 
5.13) following false discovery rate correction. For all 3 probes, the methylation profile, 
in common with that observed in the normal brain, was consistently hypomethylated 
in children under the age of 3, but showed variation in older patients. This suggests 
that age-specific methylation events occur in the development of CNS-PNET in infants. 
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Figure 5.13. Methylation probes associated with CNS-PNET age at diagnosis. Methylation scores in individual tumours for three probes 
significantly associated with age at diagnosis (a) TAL1_E122_F, (b) MAP3K1_E81_F and (c) IGFBP1_E48_R. (d) Significant probes heatmap: 
Yellow bar, infant cases; purple bar, children and adults >3 years old.  Hypomethylated (green); partially methylated (black); fully methylated 
(red)
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5.3.8.2 Identification of methylation markers associated with 
metastatic disease  
Metastatic status at diagnosis was known in 29 cases. Metastatic disease (Chang stage 
M1-M4) was identified in 7 (24%) of cases, and 21 (68%) cases classified as non-
metastatic according to the criteria outlined in section 2.1.1 (Chang stage M0 or M0/1). 
The development of metastatic disease was not found to be correlated with aberrant 
methylation in any of the disease specific probes, following analysis, as described in 
section 5.2.9.3. 
 
5.3.9 Survival analysis 
5.3.9.1 Overall CNS-PNET methylation cohort survival analysis 
Survival data was not available for SP40, SP43 and SP45. SP103 and SP113 died within 
7 days from surgery, at day 0 and day 4 post-operatively respectively, and were 
therefore excluded from the survival analysis. The survival analysis therefore 
comprised 26 cases, 9 (35%) of whom are alive and 17 (65%) have died of their disease 
(Figure 5.14). The duration of follow up ranged from 1 – 112 months (median: 24 
months) in the cohort and ranged from 3 – 112 months (median: 41 months) in the 
survivor group.  The overall cohort survival was 72.2% at 1 year (56.7-92%, 95% CI), 
46.2% at 3 years (30-71.5%, 95% CI), and 32.3% at 5 years (16.5-63%, 95% CI). 
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Figure 5.14. Kaplan-Meier plot of survival of patients with CNS-PNET used in the 
methylation array. Graph based on data from 26 cases. Survival (solid line) and 95% 
confidence interval (broken lines) are shown. 
 
5.3.9.2 Identification of methylation markers associated with survival 
Analysis to identify markers associated with survival in CNS-PNET was undertaken 
using the 76 most differentially methylated probes identified in section 5.2.9.4 as 
described in section 5.2.9.1. Shown in Figure 5.15, nine probes (HTR1B_E232_R, 
ITK_P114_F, MMP9_ E88_R, MOS_E60_R, PGR_P456_R, SIN3B_P514_R, 
SLC6A8_P409_F, TRIM29_P135_F and WEE1_P924_R) were found to have a p-value 
<0.05 on univariate analysis, but none of the probes were significant following 
Bonferroni-Hochberg correction for multiple testing. For two probes, (SIN3B_P514_R 
and TRIM29_P135_F) a change in methylation from being hypermethylated in the 
normal brain to becoming hypomethylated in the tumour was associated with a 
survival advantage (p= 0.007 and p= 0.038 respectively). For the other 7 probes, 
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hypermethylation relative to the normal brain was associated with an adverse 
outcome. 
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Figure 5.15. CNS-PNET tumour-specific methylation events associated with survival. 
(a) Kaplan-Meier plots; normally methylated (solid line); aberrantly methylated 
(hatched line). (b) Survival probe features; i) Status, normal brain (black); alive (orange); 
died (purple), ii) Heatmap: Hypomethylated (green); partially methylated (black); fully 
methylated (red). Norm: Normal brain (cohort mean β-value). 
335 
 
5.3.10 Development of a model to discern CNS-PNET from 
normal brain 
A model to discern normal brain from CNS-PNET was constructed using the list of 76 
most differentially methylated probes identified in section 5.3.6. Linear discriminant 
analysis identified two of these probes which, when the β-values for these 2 probes 
were used in conjunction, were able to delineate normal brain from CNS-PNET.  
Control normal brain samples were shown in all cases to exhibit hypomethylation 
(β<0.34) of RASSF1_E116_F and for the HLA_DPB1_E2_R probe to be fully methylated 
(β>0.67).  With this model a change from hypomethylation of RASSF1_E116_F or from 
fully methylated in HLA_DPB1_E2_R to either RASSF1_E116_F becoming fully 
methylated (β>0.67) or HLA_DPB1_E2_R becoming hypomethylated (β<0.34) signified 
that a sample was a CNS-PNET rather than normal brain Figure 5.16. The system 
correctly identifies all control samples (37/37), and 87% (27/31) of CNS-PNETs. In one 
case (SP103) the sample is found to be indeterminate as the β-value for 
HLA_DPB1_E2_R (β=0.612) lies between the cut-off for a CNS-PNET (β<0.34) and that 
for a normal brain sample (β>0.67). For both SP124 and SP125 (2/31, 6%) the classifier 
system incorrectly determines that CNS-PNET samples are normal brain. 
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Figure 5.16. CNS-PNET classifier system. Normal brain can be distinguished from CNS-PNET using the methylation β values of 2 probes: HLA-
DPB1_E2_R and RASSF1_E116_F. (a) Scatter plot showing the statistically significant difference β values between CNS-PNET and control brain, 
which when combined (b) the control normal brain (black) co-cluster separately from the CNS-PNET (green). (c) i) Normal brain (black) and 
CNS-PNET (green) ii) heatmap showing the methylation values (hypomethylated, green; partially methylated, black; fully methylated, red) of 
the samples. iii) Designation using the classifier system: normal brain (black), indeterminate (amber), CNS-PNET (green).  
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5.3.11 Comparison of CNS-PNET with the methylation profiles 
other CNS tumours 
5.3.11.1 CNS-PNET vs pineoblastomas 
The methylation profile of 4 pineoblastomas was compared with that observed in CNS-
PNETs (Figure 5.17). The analysis was repeated with the 1085 differentially methylated 
probes and also with the 1421 probes not located on the x-chromosome, and identical 
results obtained (see Appendix). With the exception of SP113, an atypical CNS-PNET 
with supratentorial and infratentorial components, the pineoblastomas co-cluster 
separate from the CNS-PNETs. 
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Figure 5.17. Unsupervised analysis of the relationship between the CNS-PNET and pineoblastoma methylome. (a) Principal component 
analysis, (b) Hierarchical clustering bootstrapped dendrograms.
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5.3.11.2 CNS-PNET vs medulloblastoma 
The methylation profile of CNS-PNETs was next compared with that of 100 
medulloblastomas. As illustrated in Figure 5.18a, both the infratentorial (MB) and 
supratentorial (CNS-PNET) tumours clustered separately from the normal brain. The 
relationships between the methylation profiles of the MB and CNS-PNET groups were 
further interrogated by including medulloblastoma molecular sub-classification details 
(section 5.2.3.2). This detailed study was performed in triplicate with consistent results 
in each analysis. The triplicate analysis included an unsupervised approach utilising all 
of the 1505 probes on the array (data shown in Figure 5.18 and Figure 5.19), clustering 
using the 1421 probes not located on the X-chromosome, and also using only the 1178 
differentially methylated probes (see section 5.2.9.1) across the study cohort (see 
Appendix 8.2). 
The medulloblastoma and CNS-PNET tumours clustered into 6 groups, with the 
exclusion of 9 medulloblastoma and 10 CNS-PNET outlier samples (Figure 5.19, Group 
A). Two predominant clusters of CNS-PNETs were observed (Figure 5.19, Groups B and 
D). With the exception of NMB161, NMB250 and NMB252, all of the designated group 
1 non-wnt and non-SHH medulloblastoma tumours (59/100) formed a discreet cluster 
separate from both the CNS-PNETs and medulloblastoma Wnt and SHH subgroups 
(Figure 5.19, Group G). NMB161 and NMB250 co-clustered with the Group D CNS-
PNETs, and NMB252 with the SHH cluster (Figure 5.19, Group F). 
Three of the CNS-PNET samples clustered with the medulloblastoma molecular 
subgroups. SP10 clustered within the dysregulated Wnt pathway group (Figure 5.19, 
Group E), and both SP124 and SP125 clustered amongst the medulloblastomas with 
aberrant SHH signalling (Figure 5.19, Group F).  All three of these patients with CNS-
PNETs in medulloblastoma subgroups are alive. 
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Figure 5.18. Principal component analysis (PCA) comparison of the methylomes of 
CNS-PNET and medulloblastoma. (a) PCA plot comparing the CNS-PNET and 
medulloblastoma with the normal brain. (b) PCA plot comparison of CNS-PNET with 
medulloblastoma sub groups. Wnt, Aberrant Wnt/ Wingless pathway signalling; SHH, 
Aberrant sonic hedgehog pathway signalling.
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Figure 5.19. Dendrogram showing relationship between CNS-PNET methylation profiles and subgroups of medulloblastoma tumours. MB, 
medulloblastoma; SHH, sonic hedgehog pathway dysregulation; Wnt, Wnt/ wingless pathway dysregulation. A: Outliers, B: CNS-PNET group 1, 
C: SHH group1, D: CNS-PNET group 2, E: Wnt group, F: SHH group 2, G: MB group 1. 
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5.3.11.3  CNS-PNET vs high-grade gliomas 
The methylation profile of 29 paediatric high-grade gliomas was compared with those 
observed in the normal brain and in CNS-PNET. Unsupervised clustering showed the 
high-grade gliomas to have a different methylation profile to the normal brain, but was 
not found to cluster as a distinct entity separately from the CNS-PNETs (Figure 5.20). 
This overlap occurred in contrast to the predominant separation observed between 
CNS-PNETs and medulloblastomas (see section 5.3.11.2) indicating that CNS-PNET may 
share a greater homology to high-grade gliomas than to medulloblastomas at the 
epigenetic level.  Some subgroups of high grade gliomas were however demonstrated 
including one containing 5 cases (HGG_03_0480, HGG_02_1107, HGG_06_20918, 
HGG_18_71 and HGG_99_14974), and another of 4 (HGG_08_18756, HGG_18_407, 
HGG_18_72 and HGG_01_10325). Consistent results were obtained in two further 
analyses using firstly only the 1134 differentially methylated probes and secondly a 
probe set that excluded the 84 probes located on the X–chromosome. 
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Figure 5.20. Unsupervised analysis of the relationship between the CNS-PNET, 
normal brain and high-grade glioma methylomes. (a) Principal component analysis, (b) 
Hierarchical clustering bootstrapped dendrograms. 
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5.3.11.4 Comparison of CNS-PNET methylation with a panel of primary 
malignant brain tumour and normal brain samples 
The methylation profile of 31 CNS-PNETs was finally compared with that of a panel of 
170 normal brain and malignant primary brain tumour samples (Figure 5.21). In this 
summary analysis, the observations identified from investigation of the methylation 
profiles of CNS-PNET with the normal brain, pineoblastoma, medulloblastoma, and 
high grade gliomas (detailed in sections 5.3.5, 5.3.11.1, 5.3.11.2 and 5.3.11.3 
respectively) are maintained.  
The methylation profile of the normal brain is distinct from that observed in primary 
brain tumours. Medulloblastomas are revealed to exhibit a variant methylation profile 
to that observed in the majority of CNS-PNETs, although as has previously been 
described in isolated cases similar patterns and co-clustering may occur. 
Pineoblastomas are shown to have a similar methylation pattern and co-cluster. A 
similar finding is not observed in assessment of high grade gliomas which do not form 
a discrete group, but can exhibit a similar methylation pattern to CNS-PNETs. 
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Figure 5.21 Comparison of methylation in CNS-PNET and a panel of normal brain and primary malignant brain tumour samples. The 
methylation profile of 31 CNS-PNET samples compared with samples taken from the normal brain (n=37), paediatric high grade gliomas (n=29), 
medulloblastomas (n=100), and pineoblastoma (n=4).
a) b)
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5.4 Discussion  
5.4.1 Epigenetic modification by methylation can be assessed 
using an array based approach in CNS-PNET 
In this study the Illumina Goldengate platform was used for the first time to assess the 
methylation in CNS-PNETs. A high correlation of methylation scores was recorded 
between the Illumina Goldengate method and bisulphite sequencing, with a mean 
difference 0.006, and standard deviation 0.167. This finding is in concordance with the 
previously reported reliability and reproducibility of this method (Martin-Subero, Kreuz 
et al. 2009). 
The cohort included samples derived from both frozen and formalin fixed paraffin 
embedded (FFPE) archival material. In total 3 samples failed the quality control (QC) 
requirements and were accordingly removed from the study. Overall, 95.2% (20/31) of 
the cases where DNA had been derived from frozen material, and 84.6% (11/13) of 
cases where DNA had been extracted from FFPE passed the QC and were included in 
the study. In the case of SP24, DNA was successfully extracted, used in the methylation 
array and passed the QC assessment from a 12 year old FFPE block. These findings 
confirm that epigenetic analyses may successfully be performed in archival material 
including archival FFPE, as has been previously reported (Killian, Bilke et al. 2009). 
Importantly this means that a large scale assessment of epigenetic diversity 
incorporating hundreds of genes may be made using this methylation platform where 
expression or CGH approaches requiring high quality DNA or RNA extracted from 
frozen material is not feasible. In the context of rare tumours such as CNS-PNETs for 
which studies necessitating material derived from frozen material may take over a 
decade to collate, crucially the successful application of this technology to FFPE 
archival material permits further contemporary large studies, with international 
collaboration, utilising libraries of archival FFPE material. 
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5.4.2 Genome-wide methylation changes in CNS-PNET are 
consistent with those reported in other cancers 
Alterations in methylation patterns have been identified in most human cancers 
(Baylin and Herman 2000). It has been shown that genome-wide hypomethylation 
outside of CpG islands occurs during cancer development (Feinberg and Vogelstein 
1983) and occurs across multiple tumour types (Kim, Jen et al. 1994; Cravo, Pinto et al. 
1996; Soares, Pinto et al. 1999). In contrast, aberrant hypermethylation occurs 
particularly at CpG islands (Costello, Fruhwald et al. 2000; Jones and Baylin 2007). It 
has been estimated that on average 400 CpG islands are aberrantly methylated in 
tumours (Costello and Plass 2001). In this current study genome-wide methylation 
patterns in CNS-PNET were shown to be consistent with findings reported in other 
tumour groups. A statistically significant difference (p<0.0001) was observed when 
comparing the number of hypomethylated probes outside of CpG islands in CNS-PNETs 
(median 129, IQR 109-144) compared with the normal brain (median 79, IQR 67.5-
84.5). Consistent with other studies, within CpG islands a statistically significant 
(p=0.002) increase in methylation of probes was observed in CNS-PNET compared with 
the normal brain (median 120, IQR 100-151 in CNS-PNET compared with median 101, 
IQR 96-106 I the normal brain). Methylation of genes within CpG islands may inactivate 
tumour suppressor genes or inactivate DNA repair genes which both may result in 
tumour development (Strathdee and Brown 2002) and therefore the findings in this 
current study in CNS-PNET support the hypothesis that hypermethylation at CpG 
islands is implicated in CNS-PNET tumorigenesis. 
 
5.4.3 CNS-PNETs are a heterogenous group of tumours 
CNS-PNETs are commonly regarded as a heterogenous group of tumours (Eberhart 
2011) for which no accepted classification of subgroups exists. The investigation of the 
methylation profiles of CNS-PNETs afforded the opportunity to ascertain whether 
distinct subgroups do exist in relation to this tumour. As outlined in section 5.1.2, the 
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Goldengate methylation array has been used to identify altered methylation patterns 
in a spectrum of tumours and more detailed examination of the methylation profiles in 
some tumours, including breast, colorectal, AML and testicular, have also revealed 
distinct subgroups (Ang, Loh et al. 2010; Cheung, Lee et al. 2010; Figueroa, Lugthart et 
al. 2010). Investigation of the methylation patterns in CNS-PNET using unsupervised 
clustering methods (principal component analysis and bootstrapping) in this study did 
not however identify distinct subgroups. This study was however limited by the 
availability of tumour material, and therefore distinct subgroups may exist but the 
study failed to identify them as there were insufficient cases. Additional studies 
analysing CNS-PNETs with other brain tumours did however provide critical insights 
into the heterogeneity in this disease (see section 5.4.8). 
 
5.4.4 Age related methylation patterns in CNS-PNET 
Infants, under the age of 3 years, with a CNS-PNET are treated differently to older 
children and adults, but have an inferior prognosis (reviewed in section 1.4.4 and 1.4.5). 
Infant protocols limit the use of radiotherapy to avoid the devastating neurological 
consequences that arise following delivery of cranial irradiation to the developing 
brain (reviewed in section 1.4.5.3). CNS-PNETs are however radio-sensitive tumours 
and therefore it could be hypothesised that the poor outcome seen in young children 
may result from the inability to deliver effective treatment, rather than because of 
biological differences in the disease at different ages. 
In this study however, it has been shown that whilst the methylation profiles of CNS-
PNETs overall do not differ at different ages, isolated age-specific methylation events 
do occur. Using the 76 CNS-PNET specific probes (identified in section 5.3.6), probes 
for three genes were found to be statistically significantly associated with age at 
diagnosis. Hypomethylation of TAL1_E122_F, MAP3K1_E81_F and IGFBP1_E48_R were 
found to occur in infant tumours, whilst in CNS-PNETs arising in older children and 
adults these probes were typically methylated (p=0.027, p=0.027, p=0.043 
respectively). In the normal brain cohort, comprising both infant and adult cases (24% 
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(9/27) < 3 years and 73% (27/37) > 3 years), the probes are universally hypomethylated. 
The hypomethylation of probes TAL1, MAP3K1 and IGFBP1 in infant CNS-PNET cases 
indicates methylation occurring in older patients is a tumour-specific aberration and 
not a normal feature of age in brain tissues.  
The identification of variable patterns of methylation correlated with age of onset 
supports the hypothesis that differences in the clinical outcomes of patients with CNS-
PNETs at different ages reflects fundamental differences at the genetic level. 
Investigation of the role that TAL1, MAP3K1 and IGFB1 have in CNS-PNET 
tumorigeneisis in older children did not form part of the current study, but is work that 
should now be undertaken.   
 
5.4.5 Methylation patterns associated with metastatic disease in 
CNS-PNET 
A number of genes have been identified that inhibit cell growth and tumour invasion 
which may act as metastasis suppressor genes (Reviewed in (Esteller 2005)). 
Methylation of tissue inhibitors of proteases (TIMPs), cadherin genes or laminin genes 
have all previously been identified in a number of cancers including gastric, colorectal, 
breast, lung, prostate bladder, pancreatic and gliomas and have been associated with 
advanced disease (Konduri, Srivenugopal et al. 2003; Sathyanarayana, Padar et al. 
2003; Miotto, Sabbioni et al. 2004; Sato, Parker et al. 2005). 
In this study no aberrant methylation events were found to be significantly associated 
with metastatic disease. An involvement of epigenetic modification by DNA 
methylation in the metastatic potential of this disease, cannot however be excluded. 
The CNS-PNET cohort in this study comprised 31 cases for which a Chang score was 
assigned in 90% (28/31). A significant finding may not have been obtained because the 
study was relatively underpowered. It is also possible that a significant result was not 
identified because the cohort contained archival material. In this study material was 
obtained prior to the introduction of the routine cytological examination of CSF to 
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determine microscopic metastatic disease, and accordingly in 68% of cases an M0/1 
status was assigned. Cases with an M0/1 Chang score were categorized as being non-
metastatic, in accordance with convention when analysing historical samples in this 
disease (Pizer, Weston et al. 2006). Regrettably it is plausible however that in some of 
these cases, had a CSF sample undergone a cytological examination, that evidence of 
metastatic disease would have been identified, the tumour classified as M1 and 
analysed with other known metastatic cases. The non-metastatic group may therefore 
have been contaminated with metastatic cases reducing the likelihood of identifying a 
difference between these 2 groups.  In summary, it is conceivable that a falsely 
negative result (type II error) has been obtained in this study, and that it may be 
possible to determine methylation markers associated with metastatic disease in 
future larger, precisely clinically characterised cohorts. 
 
5.4.6 Identification of genes that may be implicated in CNS-PNET 
survival  
In this study, epigenetic modification by methylation in CNS-PNET was investigated 
across 1505 probes incorporating 807 genes known to be implicated in tumorigenesis. 
This has enabled the most extensive investigation to date, of the effect of methylation 
on survival in this disease. Clinical data were available on 26 CNS-PNET cases to 
perform a survival analysis. The subsequent survival analysis was therefore 
constrained by the cohort size and therefore permitted a relatively underpowered 
study. In addition the cohort contained both archival material as well as samples from 
current cases (range 1-112 months, median 24 months) resulting in early censorship in 
a proportion of cases which further limited the capacity of the study to identify survival 
characteristics.  
Nonetheless, univariate analysis identified 9 genes that may be associated with 
survival. These included TRIM29, HTR1B, MOS, ITK, MMP9, PGR, SIN3B, SLC6AE and 
WEE1.  After correction for multiple testing and calculation of the false discovery rate, 
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none of these probes remained significant at the 5% level. It can therefore only be 
concluded that these genes may be associated with survival in CNS-PNET, but require 
further study in larger series to substantiate any survival effect.  
 
5.4.7 Using methylation as a diagnostic tool 
Alterations in the methylation status for specific genes are currently being evaluated 
for use in diagnosis and screening disease in a range of cancers including breast, lung, 
prostate, gliomas and colorectal oral cancers (Goldenberg, Harden et al. 2004; 
Tokumaru, Harden et al. 2004; Sunami, Shinozaki et al. 2009; Al-Moghrabi, Al-Qasem 
et al. 2011; Hinoue, Weisenberger et al. 2011; Radhakrishnan, Kabekkodu et al. 
2011).To date, the assessment of specific genetic features does not form part of the 
diagnostic protocol for investigating suspected CNS-PNETs. The findings from this study 
suggest that a targeted methylation analysis of 2 genes may be of clinical diagnostic 
value. Specifically, probes for the RASSF1 and HLA-DPB1 genes were found to be 
aberrantly methylated in CNS-PNET.  Hypomethylation of RASSF1_E116_F and 
hypermethylation of HLA_DPB1_E2_R was found to occur in all normal brain samples 
(37/37). In CNS-PNET samples, RASSF1_E116_F became hypemethylated or 
HLA_DPB1_E2_R became hypomethylated in 87% (27/31). In total the determination 
of methylation status of RASSF1_E116_F and HLA_DPB1_E2_R correctly identified 94% 
(64/68) of samples as either normal brain tissue or CNS-PNET. Unfortunately however, 
a second panel of tumours and normal brain samples was not available to perform a 
validation study which is required to confirm that these findings are reproducible in 
different cohorts, work which now needs to be undertaken. 
Aberrant methylation of the RASSF1 and HLA-DPB1 genes is not CNS-PNET specific. As 
has been discussed previously (section 1.5.6 and section 3.4.2) hypermethylation of 
the RASSF1A promoter is a feature observed in many paediatric and adult tumours, 
and in the context of CNS embryonal tumours has been shown to be a frequent event 
in both CNS-PNET and medulloblastoma (section 3.4.1). Increased expression of HLA-
DPB1 has been associated with cervical cancers and pilocytic astrocytomas (Huang, 
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Hara et al. 2005; Liang, Xu et al. 2008), and aberrant methylation observed to be a 
feature of renal tumours (McRonald, Morris et al. 2009). Whilst identification of 
aberrant methylation of RASSF1_E116_F or HLA_DPB1_E2_R may therefore signify 
deviation from the normal tissue and the presence of disease, they cannot be 
employed to determine specifically whether the disease process is a CNS-PNET. 
Should aberrant methylation of RASSF1 and HLA-DPB1, following further validation 
studies, be confirmed to be tumour-specific events in CNS-PNET, then these findings 
will represent the most frequent genetic abnormalities identified to date in this 
disease. The high frequency (87%) in which aberrant methylation of RASSF1 or HLA-
DPB1 occurs in CNS-PNET suggests that the probes on these 2 genes are potentially 
significant novel disease markers which may have clinical applicability and warrants 
further investigation. This study has identified aberrant methylation of RASSF1_E116_F 
or HLA_DPB1_E2_R in tumour tissue but, as will be discussed further in section 5.4.9, 
this should be investigated in blood and CSF samples.  If aberrant methylation was 
identified in circulating DNA either in the blood or CSF in patients with CNS-PNETs, 
then analysing the methylation of these probes may have a considerable clinical utility 
in monitoring treatment response and diagnosing progression or relapse.  
 
5.4.8 Pineoblastomas and CNS-PNETs are distinct entities 
Reviewed in section 1.3.4, following the review of CNS tumours by Hart and Earle in 
1973 and the development of the PNET concept, pineoblastomas and CNS-PNETs 
arising at other supratentorial non-pineal sites were co-classified as suprtatentorial 
PNETs (SPNETs) (Hart and Earle 1973; Becker and Hinton 1983). In the second WHO 
CNS tumour classification system, and maintained in subsequent revisions,  
pineoblastomas were removed from the PNET group and reclassified as pineal 
parenchymal tumours along with other pineal tumours (Kleihues, Burger et al. 1993). 
These tumours have however continued to be both investigated and treated alongside 
CNS-PNETs. 
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In this study the methylation profiles of 31 primary CNS-PNETs was compared with 
that of 4 primary pineoblastomas. The four pineoblastomas, using either PCA or 
hierarchical clustering unsupervised analyses, were shown to co-cluster (Figure 5.17). 
The methylation profiles of these tumours were thus shown to have more in common 
with each other than with CNS-PNETs. The CNS-PNET with a profile that was most 
similar to that observed in pineoblastomas was SP113. SP113 originated from an 11 
year old boy with non-metastatic disease at diagnosis who subsequently died from his 
disease. Unusually, the tumour had both infratentorial and supratentorial components 
occurring in the posterior 3rd ventricle and subthalamic region of the left lateral 
ventricle.  
Despite the pineoblastoma comparator group containing a restricted number of 
tumours, the findings of this study suggest that pineoblastomas are a separate group 
of tumours. In addition, this study has shown that pineoblastomas may be 
distinguished from other supratentorial aggressive brain tumours by investigation of 
their methylome. Finally, this study provides new evidence to support the classification 
change and distinction between CNS-PNETs and pineoblastomas. 
 
5.4.9 CNS-PNET and medulloblastoma exhibit divergent 
methylation profiles 
The methylation profiles of 100 primary medulloblastomas were compared with those 
from 31 primary CNS-PNETs. This study showed a predominantly divergent pattern in 
methylation between the 2 groups of embryonal tumours. As shown in Figure 5.19, 
after removal of the outliers (9/100, group A) in total only 4 medulloblastomas (4/91, 
4.4%) co-located in the CNS-PNET groups, and three CNS-PNETs (3/31, 10%) with 
medulloblastomas. The methylation profiles of these 2 groups of tumours in this study 
have therefore been shown to differ significantly. This finding of divergent methylation 
profiles corroborates similar conclusions made in previous smaller studies supporting 
separate classification and treatments. Differences in epigenetic modifications 
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between medulloblastomas and CNS-PNETs were highlighted in a study investigating a 
microRNA cluster. Amplification of the C19MC microRNA cluster on chromosome 
19q13.41 was identified in 24% (11/45) of CNS-PNETs but not in other paediatric brain 
tumours, including 118 medulloblastomas, 34 high grade gliomas and 111 
ependymomas (p=0.0001) (Li, Lee et al. 2009). Aberrant methylation of the p14ARF 
promoter has been shown to be a feature in CNS-PNETs, but not in medulloblastomas 
(Inda, Munoz et al. 2006). In addition, a number of other studies have previously 
identified aberrant methylation of particular genes (see section 1.5.6) in CNS-PNETs, 
but these have been in small cohorts which have impaired the capacity of such studies 
to make significant comparisons with other tumour groups, and in particular 
medulloblastomas.  
 
5.4.10 Co-clustering with medulloblastomas in isolated cases is 
significant 
Whilst, as described in section 5.4.9, predominantly divergent methylation patterns 
were observed between CNS-PNET and medulloblastomas, in a few isolated cases 
similar profiles were derived.  The identification of tumours which have similar profiles 
may have significant implications for both understanding the biology and improving 
treatments for these tumours. 
SP10 was found to co-cluster with the group of medulloblastomas with aberrant Wnt 
signalling. This sample was taken from a 13 year old male with a 3rd ventricular CNS-
PNET with non-metastatic disease and who is alive 9 years following diagnosis. In 
chapter 3 molecular analysis of SP10 also revealed evidence of aberrant Wnt signalling, 
with the nuclear accumulation of β-catenin. Unfortunately this was an isolated case, 
and therefore it cannot be determined whether aberrant Wnt signalling and clustering 
within the Wnt group confers a significantly different prognosis and a superior 
outcome as has been demonstrated in medulloblastoma (Cho, Tsherniak et al. 2010; 
Northcott, Korshunov et al. 2010). 
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Two cases (SP124 and SP125) clustered with the aberrant SHH signalling group of 
medulloblastomas. Both of these tumours originated in the suprasellar region of 
females aged 14 months and 12 years of age respectively, who are both alive but with 
limited follow up (24 and 3 months respectively). In medulloblastoma this group of 
tumours has been shown to have an outcome that is intermediate between the Wnt 
group and other medulloblastomas (80%, 10 year overall survival) (Northcott, 
Fernandez et al. 2009) but the significance in CNS-PNET has not been established.  
The co-clustering of isolated CNS-PNET cases with SHH and Wnt MB tumours are novel 
findings which require further investigation. This result suggests that in a small 
proportion of cases CNS-PNETs and medulloblastomas may share similar genetic 
features. It is thus conceivable that these cases may continue to benefit from similar 
treatments to those used and being developed to treat medulloblastoma. Furthermore 
this study provides a rationale to extend the ascertainment of Wnt status, determined 
immunohistochemically by screening for the presence of nuclear β-catenin, which is 
now routinely performed in the management of children with medulloblastomas, to 
include CNS-PNETs. When similar methods have been evaluated and validated to 
assess the SHH pathway in medulloblastomas, it would be potentially advantageous 
for these to be applied in addition to CNS-PNETs. 
 
5.4.11 Methylation analysis identifies overlap with high-grade 
gliomas 
High-grade gliomas (HGGs) account for 8-12% of all brain tumours arising in childhood 
(Bondy, Scheurer et al. 2008) and arise throughout the brain but most commonly at 
supratentorial sites. Histologically the most frequently HGGs are either anaplastic 
astrocytomas (AA) (WHO grade 3) or glioblastoma multiforme (GBM) (WHO grade 4) 
(Fangusaro 2009). The survival from these tumours is dismal with overall survival rates 
of 20-40% and 5-15% at 5 years for AAs and GBMs respectively (Tamber and Rutka 
2003), although in a recently report superior outcomes have been described in a 
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subgroup of infants (Sanders, Kocak et al. 2007). Clinically, high grade gliomas and 
CNS-PNETs can be difficult to discern (Burger 2006). The clinical course and 
management of these tumours however differ significantly. The methylation profiles of 
31 CNS-PNETs and 29 paediatric high grade gliomas were therefore assessed to 
investigate the relationship between these two tumour groups and the results given in 
section 5.3.11.3. 
The methylomes of HGGs and CNS-PNETs, as shown in Figure 5.20, were found not be 
mutually exclusive, but exhibited substantial overlap. In contrast to the study with 
medulloblastomas (discussed in section 5.4.9) it is not possible to distinguish CNS-
PNETs from high grade gliomas by analysis of their global methylation patterns using 
the Illumina Goldengate methylation array cancer panel I. To further elucidate and 
validate this phenomenon the methylation profiles of the HGGs and CNS-PNETs were 
also compared with a normal brain panel and with medulloblastomas. When 
investigated alongside the panel of 100 medulloblastoma samples (described in section 
5.2.3.2) in contrast to the relationship observed with CNS-PNETs, the HGGs and 
medulloblastomas form distinct and mutually exclusive clusters (Figure 5.22). 
Comparison with the normal brain cohort (Figure 5.20), which includes samples taken 
from diverse CNS locations including from both the supratentorial and infratentorial 
compartments (further details given in section 5.2.2), showed the normal brain 
samples to form a separate cluster. This in turn suggests that the differential 
methylation patterns observed therefore between the normal brain and CNS-PNETs, 
high-grade gliomas or medulloblastomas, reflect a fundamental difference in 
methylation due to the cancerous process rather than a discrepancy attributable to the 
site of origin. 
The co-clustering between HGGs and CNS-PNETs observed in this study is also 
supported by the hypothesis that brain tumours may arise from neural stem cells. In a 
study by Singh et al, CD133 and nestin (neural stem cell surface markers) were 
identified in gliomas, suggesting that both neuronal and glial neoplastic cells may arise 
from a common neural stem cell (Singh, Clarke et al. 2003) and from this a multi-
potent  brain tumour stem cell (BTSC) may arise (Singh, Clarke et al. 2004). These 
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findings are also consistent with the “cancer stem cell hypothesis”, in which tumours 
are considered to arise from such stem cells capable of self-renewal, differentiaition 
along multiple lines, and possess an ability to migrate throughout the brain 
parenchyma (Wicha, Liu et al. 2006). It has recently also been shown that PNET or glial 
tumours may arise from the same stem cell following different combinations of genetic 
events (Jacques, Swales et al. 2010). In this study recombination of PTEN/p53 was 
shown to give rise to gliomas whilst deletion of Rb/p53 resulted in PNETs. It is 
therefore conceivable that the co-clustering between CNS-PNETs and HGGs may 
reflect a similar origin, which requires further investigation. 
In addition to the histopathological similarities that occur in some cases between HGGs 
and CNS-PNET resulting in the diagnostic challenge illustrated by Burger (Burger 2006), 
there is evidence that this overlap may have clinical significance. Glial differentiation 
has been shown previously to be associated with an adverse outcome in CNS-PNET 
(Janss, Yachnis et al. 1996). In their investigation of 86 PNET tumours (11 CNS-PNETs 
and 75 MBs), GFAP immunohistochemical staining, a feature of glial differentiation, 
was identified in 52 (52/86, 60%) and associated in a Cox model with a 6.7 fold 
increased risk of relapse and an adverse outcome. Furthermore, in a series of 
predominantly case reports tumours with combined features of HGGs and CNS-PNET 
have been described (Wharton, Whittle et al. 2001; Ishizawa, Kan-nuki et al. 2002; 
Kepes 2002; McLendon and Provenzale 2002; Dulai, Bosanko et al. 2004; Kaplan and 
Perry 2007; Kandemir, Bahadir et al. 2009). Recently a review of 53 such cases, 
predominantly arising in adults (range: 12-84 years, median: 54 years) of HGGs with 
CNS-PNET components has been reported, and such tumours were found to be highly 
aggressive and conferring a median survival of only 9 months (Perry, Miller et al. 2009). 
In contrast to HGGs where only 1.1% are reported to be metastatic at diagnosis (Stark, 
Nabavi et al. 2005), but in common with CNS-PNETs, 40% of these tumours were 
metastatic at diagnosis. In this report the authors also commented that in three 
patients who failed to respond to HGG therapy with radiation and temozolamide, a 
response was recorded when their treatment was changed to included platinum-based 
chemotherapy, as is routinely used in CNS-PNET management. This study therefore 
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highlights the potential that the combination of histopathological features and tumour 
behaviour characteristics in this group of tumours can have on clinical management. 
Evidence for an inter-relationship between HGGs and CNS-PNETs has been 
demonstrated in this study, which now requires further investigation. Crucially, the 
relationship between HGG and CNS-PNET tumours may provide novel opportunities for 
the development of an enhanced classification but also in the management of patients 
with these tumours. These concepts will be explored in further detail in chapter 6.  
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Figure 5.22. Unsupervised analysis showing distinct methylation profiles of high 
grade gliomas, and medulloblastoma. (a) Principal component analysis, (b) 
Hierarchical clustering bootstrapped dendrograms. 
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5.4.12 The future role of methylation in CNS-PNET research  
This study has provided the most extensive and detailed investigation into the 
methylome of CNS-PNETs to date. In common with other cancers, alterations in DNA 
methylation appear to be frequent events in CNS-PNET. These investigations have 
afforded a number of critical insights into this disease which warrant further 
investigation and may have clinical utility. 
 As part of this study a list of the most frequently aberrantly methylated genes has 
been generated (section 5.3.6, Table 5.8 and Table 5.9), which has provided evidence 
for a wider range of genes being epigentically modified in this disease than had 
previously been described. Investigating the potential role these candidate genes may 
have in the tumorigenesis of CNS-PNETs was beyond the scope of this study, but could 
form the basis for important further work. 
In this study, two of the most frequently aberrantly methylated genes, RASSF1 and 
HLA-DPB1, were found in combination to be able to discern normal brain tissue from 
CNS-PNET (section 5.3.10 and discussed in section 5.4.7). One of the potential future 
roles for such methylation markers in CNS-PNET would be to detect the presence of 
residual disease or disease progression. Tumour specific methylation markers as well 
as being found in the tumour tissue may also be present in other samples including 
sputum, urine, plasma, stool and saliva (Miyamoto and Ushijima 2005). These may be 
obtained less invasively making them more suitable for follow up screening.  Recently 
however it has also been shown that cell free tumour DNA can be obtained from 
sampling of cerebrospinal fluid in patients with brain tumours (Liu, Cheng et al. 2010). 
In a study of 66 high grade gliomas the methylation profiles of 4 candidate genes 
(MGMT, p16INK4A, TIMP3 and THBS1) were analysed in the tumour, DNA and CSF (Liu, 
Cheng et al. 2010). No aberrant methylation was observed in a panel of 20 normal 
samples. Hypermethylation of CSF DNA was accompanied with hypermethylation in 
the corresponding tumour with 100% specificity, and hypermethylation of MGMT and 
THBS1 in the CSF were found to be independent prognostic markers. In the context of 
CNS-PNET management, the presence of hypomethylation of the HLA-DPB1 marker 
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(HLA_DPB1_E2_R) or methylation of the RASSF1 marker (RASSF1_E116_F) in CSF 
derived DNA could provide useful information in determining response to therapy and 
re-emergence of these markers could be used in predicting recurrence. Studies to 
determine whether tumour DNA is present in the CSF in patients with CNS-PNETs and 
specifically whether these markers are evident would form an important extension of 
this current work. 
Methylation markers may also be used to identify high risk tumours and to monitor 
response to treatment. In breast, bladder and lung cancers for example, DNA 
methylation profiling has been used to predict prognosis (Silva, Dominguez et al. 1999; 
Palmisano, Divine et al. 2000; Hoque, Begum et al. 2006; Belinsky, Schiller et al. 2008; 
Levenson 2010; Wen, Fu et al. 2011; Yamamoto, Nakayama et al. 2011). Furthermore, 
therapeutically DNA methylation patterns have been shown to predict response to 
chemotherapy agents. In the management of high grade gliomas for example, 
methylation of the MGMT promoter is associated with an improved response to 
alkylating agents such as temozolamide (Hegi, Diserens et al. 2004; Stupp, van den 
Bent et al. 2005). The prognostic impact MGMT methylation status has in this disease 
has resulted in a treatment stratification being proposed to reduce the exposure of 
alkylating drugs to those with a hypomethylated MGMT status (Stupp, Hegi et al. 2010). 
In other tumour groups including ovarian, breast, oesophageal and gastric, aberrant 
methylation of different genes have also been shown to predict response to treatment 
(Wei, Brown et al. 2003; Suzuki, Yoshida et al. 2007; Brabender, Arbab et al. 2009; 
Chaudhry, Srinivasan et al. 2009; Hartmann, Spyratos et al. 2009). The current study 
has provided a precedent for using methylation markers to predict survival in CNS-
PNET. Further evaluation of the aberrantly methylated genes identified in this current 
study may therefore yield clinically significant methylation markers which can be used 
in CNS-PNET management. 
In contrast to genetic events, epigenetic modifications are potentially reversible which 
renders aberrant methylation a highly desirable exploitable chemotherapeutic target. 
In two recent reviews the progress in targeting DNA methylation to develop novel 
anticancer therapies is described (Yang, Lay et al. 2010; Ren, Singh et al. 2011). 
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Following experiments which showed that genetic silencing by DNA hypermethylation 
can be reversed using the DNA methyltransferase inhibitor (DNMTi) azacytidine (or 5-
Aza-CR) (Plumb, Strathdee et al. 2000), a series of drugs have now been developed and 
are currently being evaluated  (Yang, Lay et al. 2010; Ren, Singh et al. 2011). 5-Aza-CR 
and the deoxy analogue deoxycytidine (5-Aza-CdR) for example, have been shown to 
be effective in acute myeloid leukaemia and myelodysplastic syndromes (Kornblith, 
Herndon et al. 2002; Bots and Johnstone 2009). Such agents may have a role to play in 
the management of patients with CNS-PNET to impair growth and restore normal 
cellular functions by demethylating genes that have become hypermethyalted in the 
cancer process. However, as has been illustrated in a study in pancreatic cancer where 
the use of Aza-CR resulted in stimulation of the metastatic potential through activation 
of genes promoting tumour invasion, these drugs are not without potentially 
significant side effects (Sato, Maehara et al. 2003). In the context of CNS-PNET, a 
disease of early childhood with two-thirds of such tumours occurring before the age of 
5 (Jakacki, Zeltzer et al. 1995; Louis, Ohgaki et al. 2007), such side effects may also 
arise from alterations to pathways essential for normal development. 
Finally this research, as has been discussed in sections 5.4.8, 5.4.9, 5.4.10 and 5.4.11 
has provided critical insights into the relationship between CNS-PNETs and other highly 
malignant brain tumours. This work has shown that CNS-PNETs are predominantly a 
distinct group of tumours to medulloblastomas, that share a similar to methylome to 
HGGs, but that in isolated cases may be indistinguishable from some of the recently 
identified medulloblastoma subgroups. These findings have applicability not only to 
disease classification, but may also provide rationales for divergent treatment 
regimens within the same tumour group based on their genetic features. Further 
research that seeks to investigate and advance our understanding of these inter-
relationships may therefore also yield evidence for future clinical exploitation.    
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6.1 Background and project summary 
CNS-PNETs are the second most common CNS embryonal tumour, which occur 
predominantly in early childhood and account for 2-3% of all paediatric brain tumours 
(Bruno, Rorke et al. 1981; Gaffney, Sloane et al. 1985; Jakacki, Zeltzer et al. 1995). 
Whilst the overall five year survival rate for children with cancer continues to improve 
and is now 75% (ONS 2010), the prognosis for children with CNS-PNETs remains dismal. 
Despite aggressive multi-modal therapy in children over the age of 3 years, the 3 year 
progression free survival remains only 34-54% (Timmermann, Kortmann et al. 2002; 
Massimino, Gandola et al. 2006; Pizer, Weston et al. 2006), whilst for infants under the 
age of 3 years survival rates are consistently under 20% (Duffner, Horowitz et al. 1993; 
Marec-Berard, Jouvet et al. 2002; Timmermann, Kortmann et al. 2006; Grundy, Wilne 
et al. 2010). New therapies are urgently required to improve the outcome of children 
who develop this catastrophic disease. 
Following the review of CNS tumours by Hart and Earle in 1973 (Hart and Earle 1973), 
and the origination of the term “primitive neuroectodermal tumour” (PNET), CNS-
PNETs have been treated along similar lines to other brain “PNETs” (medulloblastomas) 
in view of their similar histopathological features. Contemporary treatment protocols 
now cure over 70% of children with medulloblastoma, but such improvements have 
not been realised using the same treatments in those with a CNS-PNET (Taylor, Bailey 
et al. 2003; Pizer, Weston et al. 2006; Pizer and Clifford 2008). Clinically therefore, 
these tumours, despite sharing common histopathological features and a classification 
system that suggests a unifying origin, appear to be separate entities requiring distinct 
therapeutic strategies.  The “PNET hypothesis” which has been at the heart of how 
these tumours are investigated and managed for the last three decades, therefore may 
be invalid.   
To date, research into the molecular basis for CNS-PNET development and their 
relationship with medulloblastomas and other brain tumours has been limited. Loss of 
chromosome 17p, which is seen in up to 40% of medulloblastomas (McDonald, 
Daneshvar et al. 1994; Burnett, White et al. 1997), has only rarely been observed in 
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CNS-PNET (Roberts, Chumas et al. 2001; Bayani, Pandita et al. 2005). MYC family gene 
amplification, which occurs in 15-25% of medulloblastomas and is associated with the 
large cell / anaplastic subtype and a poor prognosis (Leonard, Cai et al. 2001; Lamont, 
McManamy et al. 2004; Vita and Henriksson 2006; Pfister, Remke et al. 2009), has only 
been investigated in a few small studies and found to occur in CNS-PNET in 
approximately 5% of cases (Fruhwald, O'Dorisio et al. 2000; Pfister, Remke et al. 2007; 
Behdad and Perry 2010). Conversely, aberrant Wnt signalling is associated with a 
favourable prognosis in medulloblastoma disruption (Ellison, Onilude et al. 2005; 
Gajjar, Chintagumpala et al. 2006; Fattet, Haberler et al. 2009; Ellison, Kocat et al. 2011) 
but the role in CNS-PNET is unclear (Koch, Waha et al. 2001; Rogers, Miller et al. 2009). 
Finally, in 2005 Eberhart et al discovered a significant difference between p53 pathway 
dysregulation in medulloblastomas and CNS-PNETs (Eberhart, Chaudhry et al. 2005). 
Dysregulation of the p53 pathway was suggested in 88% of CNS-PNETs, compared with 
18% of classic medulloblastomas, but only 8 CNS-PNET cases were investigated 
(Eberhart, Chaudhry et al. 2005).  
Epigenetic as well as genetic mechanisms have been shown to be implicated in the 
development of CNS-PNETs. In three small studies epigenetic modification by aberrant 
DNA methylation has revealed  RASSF1A hypermethylation to occur in between 67 – 
83% of cases (Chang, Pang et al. 2005; Muhlisch, Schwering et al. 2006; Inda and 
Castresana 2007). Whilst RASSF1A hypermethylation is the most frequent epigenetic 
event reported in CNS-PNET, previous studies have only investigated a small number of 
candidate genes (see table 1.12), and a detailed study of the DNA methylome in CNS-
PNET disease has, however, never previously been undertaken. 
The aim of this study was to investigate the molecular mechanisms involved in CNS-
PNET development and determine their clinical and histopathological significance by; (i) 
investigating in CNS-PNETs the common genetic features associated with 
medulloblastomas, (ii) considering in CNS-PNETs novel genetic events determined 
through genome-wide studies in other brain tumours and, (iii) examining the DNA 
methylome in CNS-PNETs. 
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A panel of confirmed CNS-PNETs that had undergone a central pathological review 
were investigated in this study for a series of common medulloblastoma defects. 
Multiplex ligation-dependent probe amplification (MLPA) was used to determine the 
copy number of MYCC and MYCN in a cohort of 25 primary CNS-PNETs. An elevated 
copy number of MYCC was not identified in any case, but MYCN amplification was 
identified in 12% (3/25) and confirmed by quantitative real-time PCR and fluorescent 
in situ hybridisation (FISH). Nuclear β-catenin accumulation was assessed 
immunohistochemically to identify cases with aberrant Wnt pathway signalling. Direct 
sequencing of CTNNB1 was also performed to detect the presence of characteristic 
mutations associated with aberrant Wnt signalling. Intense nuclear β-catenin 
accumulation suggesting aberrant Wnt signalling was identified in 2 cases (2/22, 9%) 
which was associated, in one of these cases, with a CTNNB1 mutation providing 
evidence that aberrant Wnt signalling occurs in a small subset of CNS-PNETs. p53 
pathway activation or disruption was determined immunohistochemically and 
observed in 91% (20/22). Additionally, direct sequencing of DNA identified TP53 
mutations in 18% (4/22) and, using MLPA, a copy number gain of MDM2 in a further 
case, but no evidence of homozygous CDKN2A loss was found. Whilst limited by the 
study cohort size and treatment heterogeneity, neither Wnt or p53 pathway disruption 
was found to be correlated with survival, age at diagnosis or the presence of 
metastatic disease. Loss of chromosome 17p was assessed using the homozygous 
mapping of deletions (HOMOD) technique to identify loss of heterozygosity in 25 CNS-
PNETs. In 2 cases a segmental loss was suggested by the presence of an extended 
region of heterozygosity, which was associated with a homozygous mutation of TP53 
(located at 17p13.1) in both cases. The final common feature in medulloblastoma 
investigated was RASSF1A DNA methylation. Direct sequencing of bisulphite converted 
DNA showed that RASSF1A hypermethylation in CNS-PNETs occurred at a similarly high 
frequency (82%, 18/22) to that which has previously been observed in 
medulloblastoma (Lusher, Lindsey et al. 2002; Lindsey, Lusher et al. 2004). 
A genome-wide study by Balss et al (Balss, Meyer et al. 2008) which included 9 CNS-
PNET cases suggested that mutations in IDH1, a novel tumour suppressor gene which 
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occur frequently in glioblastomas whilst do not appear to occur in medulloblastomas, 
may be a feature in CNS-PNET. Direct sequencing in this current study discovered IDH1 
mutations in 8% (2/25) of cases. Mutant cases were found to be associated with 
disease in adults but not CNS-PNETs arising in childhood (p=0.003), suggesting that the 
tumorigenesis of CNS-PNET arising at different ages differ (Hayden, Fruhwald et al. 
2009). 
Hypermethylation of RASSF1A was identified as the most frequent molecular event 
identified in CNS-PNET and therefore the CNS-PNET DNA methylome was investigated 
in detail in chapter 5 using the Illumina Goldengate methylation array platform. A 
series of 76 tumour-specific methylation events were identified including RASSF1 
hypermethylation and HLA-DPB1 hypomethylation which in combination can be used 
to distinguish tumour from normal brain in 94% (64/68) of cases. Age-specific 
methylation patterns were also observed with aberrant methylation of TAL1, MAP3K1 
and IGFBP1 being observed in CNS-PNETs arising in older children and adults (>3 years 
old). Unsupervised hierarchical clustering approaches using the methylation data 
showed CNS-PNETs to be a heterogenous group of tumours, which are predominantly 
distinct from medulloblastomas, but exhibit some overlap with high-grade gliomas. In 
isolated cases however, co-clustering with medulloblastomas occurs associated with 
known molecular subgroups (Wnt pathway and sonic hedgehog pathway activated 
tumours). 
In summary, this project has provided support for the assertion that CNS-PNETs are a 
heterogenous group of tumours that are distinct from medulloblastomas, and has 
shown that they may possess a range of different genetic and epigenetic features that 
may differ in infant, childhood and adult disease. 
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6.2 The challenge of investigating CNS-PNET  
The prognosis for patients diagnosed with a CNS-PNET is poor. New treatments are 
urgently required to resolve this problem but currently there is a paucity of biological 
information available on which to base the development of such therapies. These new 
therapies could potentially include stratified therapies based on molecular 
classification or targeted drugs. Unfortunately, as has been encountered in this study 
and described below, the investigation of CNS-PNETs is challenged by a number of 
factors.  
Investigation of CNS-PNETs is firstly limited by their incidence. CNS-PNETs are rare 
tumours accounting for only 2-3% of all paediatric brain tumours (Bruno, Rorke et al. 
1981; Gaffney, Sloane et al. 1985; Dai, Backstrom et al. 2003) and therefore accruing 
an adequately sized cohort requires sustained national and international collaboration. 
Such an undertaking was realised in this study and the CNS-PNET cohort was 
populated with cases from a 16 year period (1992 – 2008) from multiple centres across 
the UK and overseas (see section 2.1.1). Unfortunately this means that cases included 
have not been treated uniformly, but instead have been managed using a variety 
protocols from within and outside the clinical trial setting. The variation in treatment 
approaches may be a significant confounding factor and therefore results obtained in 
this study subsequently require validation in a clinical trial cohort. 
The second challenging factor in CNS-PNET research results from changes in diagnostic 
practice and the frequent difficulties or uncertainty in confidently diagnosing this 
tumour. CNS-PNETs do not exhibit characteristic pathognomic features that permit the 
assured assignment to this disease category. On the contrary, CNS-PNETs are 
recognised to be a heterogenous group of tumours which may display a plethora of 
features attributable to their divergent differentiation, which may also be observed in 
other tumour groups and therefore creates diagnostic uncertainty (Burger 2006; Louis, 
Ohgaki et al. 2007). In the SIOP PNET3 study, for example, in 12% of cases the central 
pathological review did not confirm the tumour to be a CNS-PNET (Pizer, Weston et al. 
2006). One of the tumour categories that have been misclassified as CNS-PNETs 
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previously are ATRTs (Haberler, Laggner et al. 2006). In accordance with current 
diagnostic practice, in the current study tumours were immunohistochemically 
screened for nuclear INI1 expression and excluded if this was absent, but 
misclassification of ATRTs as CNS-PNETs is possible in historical cases that have not 
undergone a pathological review.  
Changes in disease risk stratification assignment, creates a third challenge. Over the 16 
year period from which the cases in this study were collated the requirements for 
determining metastatic disease status changed. Presently, a CSF sample is taken 2 
weeks after surgery and examined to detect the presence of malignant cells. In the 
absence of radiological evidence of metastasis, the presence of malignant cells in the 
CSF is classified as M1 disease using the modified Chang staging system (Zeltzer, Boyett 
et al. 1999) (see section 1.4.4). However, the cohort in this study contained cases 
collected prior to the routine assessment of CSF, and therefore in 68% (21/31) no 
radiological evidence of metastatic disease only could be reported (M0/1). Whilst 
conventionally in CNS-PNET the M0, M0/1 and M1 cases are analysed together as a 
non-metastatic group (Pizer, Weston et al. 2006), it has been shown in 
medulloblastoma that M1 compared with M0 disease is associated with a poorer 
outcome and should be considered high risk (Sanders, Onar et al. 2008). It is possible 
therefore that the capacity for the study to detect differences between non-metastatic 
and metastatic cases was impaired by contamination of the former group with cases 
that should have been assigned to the latter group if CSF analysis had been undertaken. 
In summary, the future of CNS-PNET research requires that consented material is 
preferably obtained from within large international clinical trials based on a specified 
treatment regimen and includes a central pathological review as part of their entry 
criteria, to advance scientific discovery and improve outcomes.   
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6.3 CNS-PNETs are a heterogenous group of tumours 
CNS-PNET are a group of aggressive tumours that may be poorly differentiated, or 
show divergent differentiation along neuronal, astrocytic and ependymal lines, and are 
accordingly defined as a heterogenous group of tumours based on these 
histopathological features (Louis, Ohgaki et al. 2007). This study has demonstrated that 
the histopathological heterogeneity observed is also reflected in their genetic and 
epigenetic composition.  
In chapters 3 and 4, a series of molecular events were shown to occur in a proportion 
of CNS-PNETs. MYCN gene amplification was found to be present in 12.5% (3/24), TP53 
mutation in 17% (4/24), aberrant Wnt pathway activation in 2/21 (9.5%), and mutation 
of IDH1 was identified in 8% (2/25) of cases. These findings suggest that a range of 
different pathways and molecular events are implicated in the tumorigenesis of 
different CNS-PNET.   
Genome-wide study of the DNA methylome in CNS-PNET (chapter 5) confirmed the 
heterogeneity of this disease.  Whereas in medulloblastoma, DNA methylation 
profiling results in 89% of tumours being assigned to one of 4 defined groups (see 
figure 5.1), unsupervised hierarchical clustering analyses of the DNA methylome in 
CNS-PNET did not reveal comparable discrete disease sub-clusters (see figure 5.7). 
Whilst CNS-PNETs were shown to have a different methylation profile to the normal 
brain, and were predominantly distinct from medulloblastomas comparison with high-
grade gliomas revealed that, even after exclusion of outlier cases, a number of CNS-
PNETs (SP14, SP58 and SP106) showed greater homology with this different tumour 
group than with other CNS-PNETs (Figure 5.20). However, the study cohort included 
only 31 CNS-PNETs and therefore it is feasible that the disease is not as heterogenous 
as this study suggests, and that distinct clusters and sub-groups do occur but that this 
study lacked sufficient power for this to be revealed. Further large-scale studies are 
therefore required to establish precisely the heterogeneity of this disease. 
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6.4 CNS-PNET genetic features vary at different ages 
A significant disparity exists between the outcomes of infants and young children 
under the age of 3 years with CNS-PNET and older children and adults. In infants and 
young children, the 3 year even free survival (EFS) is dismal at 0-19% (Duffner, 
Horowitz et al. 1993; Timmermann, Kortmann et al. 2006; Grundy, Wilne et al. 2010) 
whereas the 3 year EFS in older children is 33-54% (Yang, Nam et al. 1999; Reddy, Janss 
et al. 2000; Timmermann, Kortmann et al. 2002; Paulino, Cha et al. 2004; Fangusaro, 
Finlay et al. 2008) and indeed an EFS of 78 ± 14% has been reported in this group in 
one study (Chintagumpala, Hassall et al. 2009). Whilst, as is discussed in section 1.4.5.3, 
the desirability of delivering effective radiotherapy to infants and young children may 
be a factor in the prognostic disparity, any biological reasons for this difference have 
not yet been fully elucidated.   
It has recently been shown that CNS-PNETs arising in patients of different ages may 
possess different genetic abnormalities. Amplification of 19q13.42 was first shown in 
2009 by Pfister et al, in a 2 year old girl with a CNS-PNET (Pfister, Remke et al. 2009). 
This abnormality has subsequently been found in an additional 48 cases, occurring in 
infants and young children under the age of 6 years (median age 2 years) (Li, Lee et al. 
2009; Korshunov, Remke et al. 2010). In Chapter 3, genetic features frequently 
associated with medulloblastomas were investigated in the CNS-PNET cohort. None of 
these, including RASSF1A hypermethylation, MYCN gene amplification, p53 pathway 
defects, aberrant Wnt signalling, and chromosome 17p loss were found to be 
associated with age. However, whilst this was a comparatively large CNS-PNET study, 
the overall number of tumours investigated and those possessing an abnormality were 
often small, and therefore significant associations with age may exist, but the power of 
this study was insufficient to detect them.  
In chapter 4, a novel study investigating IDH1 mutations in CNS-PNET, found that 
mutations of IDH1 occurred exclusively in adults cases. R132H mutations were 
observed in 2 of the 5 adult cases (26 and 29 years old), and not in any of the 19 
paediatric (<16 years) cases (p=0.04, Fisher’s exact test). When these data were 
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combined with the results of a previously published report including 9 CNS-PNETs 
(Balss, Meyer et al. 2008), this association was confirmed and IDH1 mutations 
identified in 42% (5/12) of adult cases, but not in any paediatric cases (0/22)(p=0.003, 
Fisher’s exact test). This study has therefore provided further evidence to support the 
hypothesis that the molecular mechanisms underlying tumour development differ at 
different ages. It has also shown for the first time, a significant difference in CNS-PNET 
biology between adult and paediatric disease.  
Finally, the study investigating the CNS-PNET DNA methylome provided further 
evidence for age-specific features. Overall, tumours were not found to cluster based 
on age of onset (Figure 5.7), but an analysis of tumour-specific methylation events 
revealed statistically significant age-specific methylation of three genes. TAL1, MAP3K1 
and IGFBP1 were all found to be consistently hypomethylated in infants under the age 
of 3 years, but exhibited variable methylation in older patients (p=0.027, p=0.027, 
p=0.043 respectively).  
Overall, the biology of CNS-PNETs, including both genetic and epigenetic features has 
been shown to vary at different ages. Specifically, disease in infancy (< 3 years), older 
children (3-16 years) and adults (>16 years) have been shown to exhibit different 
biological features. That the biology of infant tumours differs from that in older 
children could explain in part the significant difference in clinical outcome that is 
observed between these two groups, and supports the need for developing distinct 
treatment strategies. The observation in this study that a distinction between adult 
and paediatric disease may also be determined is novel. This requires further 
investigation, but ultimately may suggest that CNS-PNETs in adults are a separate 
group of tumours that would benefit from a distinctive therapeutic strategy. 
 
6.5 Methylation profiling in CNS-PNET 
In this study, the Illumina Goldengate platform was used to assess the CNS-PNET DNA 
methylome in detail for the first time. The tumour cohort included samples derived 
374 
 
from both frozen and formalin fixed paraffin embedded (FFPE) archival material and 
data from both sources was successfully obtained. Large scale assessment of 
epigenetic diversity incorporating hundreds of genes using this platform is therefore 
feasible and, crucially, may provide information where expression or CGH approaches 
requiring high quality DNA or RNA extracted from frozen material are not possible.  
Using this approach a series of genes have been discovered not previously known to be 
implicated in CNS-PNET development (see section 5.3.6), three of which appear to be 
age-specific (TAL1, MAP3K1 and IGFBP1, see section 5.3.8.1). Similarly, this method has 
also identified two genes (RASSF1 and HLA-DPB1, see section 5.3.10) which may have 
clinical utility as markers of disease. These now all require further analysis in follow up 
studies to validate these findings and substantiate any future clinical role. 
Methylation profiling has also afforded an opportunity to examine the relationship 
between CNS-PNETs and other highly malignant brain tumours. CNS-PNETs have been 
shown to exhibit a methylation signature which, with few exceptions, is distinct from 
medulloblastomas, but more closely aligned to the HGG methylome.  Discussed in 
section 6.6, this supports the assertion that the “PNET” concept does not adequately 
reflect the underlying properties of this group of tumours. Moreover, the 
histopathological similarities between HGGs and CNS-PNET, which create significant 
diagnostic challenges for the neuropathologist (Burger 2006), may occur as the these 
two tumour groups are indeed more closely related than is traditionally recognised. 
 
6.6 PNET: A historical concept 
The classification of embryonal brain tumours has always been both complicated and 
controversial which the WHO classification system sought to rectify and produce 
clarity but the difficulties persist. The term PNET, first applied in 1973 by Hart and 
Earle and later modified by others (Becker and Hinton 1983; Rorke 1983) was used to 
co-classify aggressive embryonal tumours based on their similar histopathological 
features, suggesting a common origin, and enabled unified treatment. Unfortunately, 
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the outcomes for patients managed with the same treatment with cerebellar and non-
cerebellar disease, and in particular between what are now classified as 
medulloblastomas and CNS-PNETs (see section 1.3.3), have been shown to differ 
significantly. In the PNET3 study for example, the EFS at 5 years for patients with CNS-
PNET was only 41%, compared with 74% for those with medulloblastomas (Taylor, 
Bailey et al. 2003; Pizer, Weston et al. 2006). This clinical outcome disparity suggests 
that the biological nature of these tumours may be fundamentally different, and that 
the concept of a PNET entity that may simply arise in different parts of the brain, may 
be false.  
In chapter 3, genetic and epigenetic defects frequently observed in medulloblastoma 
were investigated in CNS-PNETs, to determine whether the differences seen in the 
clinical outcome between these tumour groups were also observed in their biology. In 
common with medulloblastomas where RASSF1A promoter hypermethylation has 
been shown to occur in 87% of cases (Lindsey, Lusher et al. 2004), RASSF1A promoter 
hypermethylation was found to be a frequent event CNS-PNET (18/22, 82%). Similarly 
MYC gene amplification which occurs in under 7% of medulloblastomas (Ryan 2009) 
occurred in a subgroup (MYCN:  3/25 (12%), MYCC: 0/25 (0%)). Both RASSF1A 
promoter hypermethylation and MYC gene amplification are however both events 
which occur in a spectrum of cancers (see sections 1.5.6.1 and 1.5.4.1 respectively), 
and therefore their discovery in CNS-PNET disease does not imply that these tumours 
are necessarily related. The results of the study of chromosome 17p loss and p53 
pathway activation in CNS-PNET on the contrary support the assertion that 
medulloblastomas and CNS-PNETs are genetically different tumours. Loss of 
chromosome 17p was observed in only 2 of the 23 CNS-PNET investigated, compared 
with 25% of medulloblastomas (Ellison, Kocat et al. 2011). Conversely, p53 nuclear 
accumulation, which occurs infrequently in medulloblastomas (Eberhart, Chaudhry et 
al. 2005; Tabori, Baskin et al. 2010), occurred significantly more frequently in CNS-
PNET (91%, 20/22, p= 0.0001 Fisher’s exact test).  
The investigation of IDH1 mutations in CNS-PNET provided further evidence to support 
this fundamental difference between CNS-PNETs and medulloblastomas. In total, in 2 
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published studies, 113 medulloblastomas have been investigated for a mutation in 
IDH1 (Balss, Meyer et al. 2008; Yan, Parsons et al. 2009) and no mutant case identified. 
In contrast, by combining the data from the current study and that reported by Balss et 
al (Balss, Meyer et al. 2008), 13.5% (5/37) of CNS-PNETs are found to harbour an IDH1 
mutation, which is statistically significantly more prevalent than in medulloblastoma 
(p=0.0007, Fisher’s exact test).  
Comparison of the DNA methylome using unsupervised clustering analyses in CNS-
PNET with other brain tumours revealed not only that CNS-PNETs were predominantly 
distinct from medulloblastomas, but that they in fact shared greater commonality with 
high-grade gliomas. This finding suggests therefore that the PNET concept is not only 
incorrect but that it is a different relationship, the relationship between CNS-PNET and 
high-grade gliomas, which requires further exploration. 
In summary, this thesis supports, through an extensive investigation and 
characterisation of the genetic and epigenetic features of these tumours, the rejection 
of the PNET hypothesis, and its place merely as a historical concept. The relevance of 
this finding is found however not only in respect to precise nomenclature and 
classification but also in the clinical management of patients with this disease. By 
determining that CNS-PNETs and medulloblastomas are different tumours and vary at 
the genetic and epigenetic levels, further support is provided for the expansion of 
disease specific research and the development of potentially divergent treatment 
strategies to advance and optimise outcome for both tumour groups. 
 
6.7 Towards an improved classification of CNS-PNETS 
Classification plays a vital and fundamental central role in both the study and clinical 
management of cancer. The WHO classification system was indeed originally 
established in 1979 to harmonize the plethora of systems and terms used to generate 
a consensus which would facilitate the study of tumours between different institutions 
internationally (Zulch 1979). The original WHO classification was based on 
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histopathological features, but now findings from additional techniques including 
immunohistochemical and molecular genetic analyses may be used to inform 
classification. Immunohistochemical lack of INI1 nuclear expression, for example, can 
be used to distinguish CNS-PNETs from ATRTs, which have an inferior prognosis and 
are treated differently, and therefore now forms part of the recommended routine 
diagnostic work up of these tumours (Haberler, Laggner et al. 2006). Sub-classification 
based on the results of genetic findings may also be used to improve outcomes by 
developing targeted or risk-adapted therapeutic approaches. In the management of 
childhood acute lymphoblastic leukaemia (ALL) for example, sub-classification based 
on genetic findings is used to identify cases that would benefit from molecular 
targeted therapies and those where a risk-adapted therapeutic approach is taken to 
improve outcome (Schrappe 2008; Harrison 2009; Moorman, Ensor et al. 2010). 
In the current 4th Edition of the WHO classification of brain tumours CNS-PNETs are a 
designated  as a group of embryonal tumours based on their histopathological features 
(Louis, Ohgaki et al. 2007). No subcategory of CNS-PNET to inform risk and treatment 
stratification currently exists, although a separate group of tumours, often classified as 
CNS-PNETs, with distinct pathological and genetic features has recently been proposed 
(see section 1.3.3). This study has identified a number of genetic and epigenetic events 
that suggest that CNS-PNETs sub-classification may be possible and could be used to 
aid in the development and delivery of improved therapeutic strategies.  
Aberrant Wnt signalling, associated with a superior prognosis in medulloblastoma, has 
been shown in this study to occur in a minority (2/22, 9%) of CNS-PNETs. Whether 
aberrant Wnt signalling in CNS-PNET similarly confers a superior outcome which may, 
as has been proposed for medulloblastoma (Pizer and Clifford 2009), direct treatment 
strategy is unknown and requires further study. Unsupervised hierarchical clustering of 
DNA methylomic array data in this study also potentially identified a further sub-group 
of CNS-PNETs with aberrant SHH signalling. SP124 and SP125 (2/31, 6%) were found to 
co-cluster with a group of medulloblastomas with aberrant SHH signalling.  This finding 
however requires further investigation including a detailed study of SHH pathway 
components and association with clinical features in larger cohorts. If validated, 
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molecular sub-classification could be adopted to direct alternative stratified therapies 
for the standard and higher risk tumours. Overall however, confirmatory studies in 
larger and, preferably, clinical trial based cohorts are now needed, to explore the 
utility of the genetic and epigenetic events discussed in determining future 
classification and treatment stratification.    
 
6.8 Development of targeted therapies for CNS-PNET 
Discussed in section 1.4.5.7, for over 50% of those who develop a CNS-PNET, this 
diagnosis is fatal, whilst in survivors the diagnosis is commonly associated with a 
syndrome of chronic morbidity attributable to the detrimental long-term effects of the 
curative treatment. New strategies are therefore urgently required in the management 
of this disease to improve survival whilst minimising treatment toxicities and late 
effects – the current cost of cure (Marder 2010). In this study, a series of biological 
pathways, genetic and epigenetic events have been shown to be involved in the 
development of CNS-PNETs. These findings not only contribute to enhance our 
understanding of the disparate biology in this disease, but may also be exploited 
clinically to aid in the clinical management and improve the prognosis for patients with 
CNS-PNETs. 
Comparison with genetic features associated with medulloblastoma development 
identified a number of findings that may benefit CNS-PNET management in the future. 
Firstly, 91% of CNS-PNETs in this study were shown to exhibit nuclear accumulation of 
p53. Mutant p53 protein is known to confer resistance to vincristine and cisplatin 
(Hamada, Fujiwara et al. 1996; Shelling 1997; Giannakakou, Sackett et al. 2000), and as 
both of these drugs are currently used in the management of this disease, aberrant 
p53 may be a contributing factor in the dismal prognosis. In the future however, 
disruption of the p53 pathway may be exploited positively with the introduction of one 
of the p53 pathway targeted new agents that are currently under development (Lu and 
El-Deiry 2009). Disruption of the canonical Wnt signalling pathway as identified with 
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nuclear accumulation of β-catenin was determined in 2/22 (9%) primary CNS-PNET 
cases. In medulloblastoma such disruption is associated with a favourable prognostic 
phenotype and has directed the development of a stratified therapeutic strategy 
(Ellison, Onilude et al. 2005; Gajjar, Chintagumpala et al. 2006; Fattet, Haberler et al. 
2009; Ellison, Kocat et al. 2011). Small molecule inhibitors such as OSU03012, which 
targets Wnt signalling (Baryawno, Sveinbjornsson et al. 2010), may also therefore 
provide a therapeutic option in CNS-PNET although further investigation of the role of 
Wnt signalling in this subgroup of CNS-PNETs is required. 
Clinical opportunities may also be derived from studies of CNS-PNETs with other 
tumour groups. IDH1 mutations do not appear to occur in medulloblastomas, but 
occur in a third of gliomas (307/917) and associated with an improved survival 
(Parsons, Jones et al. 2008; Bleeker, Lamba et al. 2009; Nobusawa, Watanabe et al. 
2009; Watanabe, Nobusawa et al. 2009; Yan, Parsons et al. 2009). The investigation of 
IDH1 mutations in CNS-PNET in this study (chapter 4) identified IDH1 mutations as a 
potentially novel therapeutic target in adult disease. Agents currently under 
development which inhibit mIDH1 expression or downstream effectors (Semenza 2003; 
Sonoda and Tominaga 2010) may therefore also have a role in CNS-PNET management 
in the treatment of a subgroup with this genetic feature. 
Methylation profiling in CNS-PNET (chapter 5) has yielded a number of findings that 
may have clinical utility. Firstly a number of tumour-specific events were identified 
that, following successful validation, could be used in clinical diagnostic practice. The 
combination of aberrant methylation of RASSF1 and HLA-DPB1 was shown to be able 
to discern normal brain from CNS-PNET in 94% of cases (64/68). In a recent study 
methylation markers were investigated in gliomas and identified in both CSF and 
serum (Liu, Cheng et al. 2010). If in CNS-PNET it is also possible to detect tumour DNA 
in CSF or serum then the presence of aberrantly methylated RASSF1 and HLA-DPB1 
DNA could potentially be used to monitor treatment response or identify cases of 
relapse. In breast cancer, for example, the persistence or resolution of RASSF1A 
methylation in blood sera following treatment with Tamoxifen® indicates treatment 
resistance or a good response respectively (Fiegl, Millinger et al. 2005). Finally, this 
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study also genes that may be associated with survival in CNS-PNET (see section 5.3.9). 
Methylation markers have been shown to predict survival in a range of cancers 
including brain tumours (Silva, Dominguez et al. 1999; Palmisano, Divine et al. 2000; 
Hoque, Begum et al. 2006; Belinsky, Schiller et al. 2008; Levenson 2010; Liu, Cheng et 
al. 2010; Wen, Fu et al. 2011; Yamamoto, Nakayama et al. 2011) and therefore the 
potential for methylation markers to determine prognosis in CNS-PNET needs further 
evaluation.  
Further work is also required to determine the role the tumour-specific genes 
identified in this study may have in CNS-PNET tumorigenesis. Functional studies 
initially using CNS-PNET cell lines including PFSK and CHP707m (see section 2.12) in in-
vitro work could be used to study the effect aberrant methylation has on RNA 
expression and tumour growth. Candidate genes that exhibit in-vitro a demonstrable 
tumourigenic effect may then be studied in CNS-PNET murine models (Tong, Ohgaki et 
al. 2003). As has been discussed previously (see section 5.4.9), this approach has led 
the development of a number of early phase clinical trials in other cancers in which a 
range of agents that affect DNA methylation are being studied, and could provide 
novel therapeutic opportunities in CNS-PNET management.  
 
6.9 Summary 
To date, research investigating CNS-PNET biology has been limited. This study is one of 
the largest undertaken in this disease and has provided a series of critical insights into 
their pathogenesis. In particular, this study has demonstrated that CNS-PNETs are a 
heterogenous group of tumours that differ from medulloblastomas at the genetic level. 
In a minority of cases however, processes involved in the development of 
medulloblastomas are also implicated in CNS-PNET disease including aberrant Wnt 
signalling and MYCN amplification. The future development of targeted therapies for 
medulloblastoma molecular subgroups may therefore have clinical applicability in the 
management of individual cases of CNS-PNET. In contrast, dysregulation of the p53 
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pathways is a common finding in CNS-PNET which may enable advancements in the 
therapeutic targeting of this pathway to play a significant role in this disease. Whilst 
classified separately, a close relationship with high grade gliomas was however also 
observed in a proportion of cases. Research into, and clinical advancements in the 
management of, high grade gliomas may therefore have applicability in a subgroup of 
CNS-PNETs. Finally, this work has identified a number of developmental pathways, 
genetic aberrations and epigenetic events that are associated with CNS-PNET 
development. The associations between the identified findings and clinical features, 
and their functional roles in disease development, warrant further investigation to 
establish their translational capacity in aiding future classification and treatment 
advancements.  
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All buffers were prepared according to (Sambrook and Russell 2001), and were stored 
at room temperature, unless otherwise stated. 
8.1.1 10x TBE: 
Tris base    108g  (Sigma-Aldrich) 
Boric acid    55g  (Sigma-Aldrich) 
EDTA     9.3g  (Sigma-Aldrich) 
Made up to 1000ml with deionised water 
 
8.1.2 1x TE: 
1M Tris-HCl (pH8.0)  10ml  (Sigma-Aldrich) 
0.25M EDTA   400µl (Sigma-Aldrich) 
Make up to 1000ml with deionised water 
 
8.1.3 Phosphate Buffered Saline (PBS): 
NaCl     8g  (VWR) 
KCl     0.2g  (Sigma-Aldrich) 
Na2HPO4    1.44g  (Sigma-Aldrich) 
KH2PO4    0.24g  (Sigma-Aldrich) 
Make up to 800ml with deionised water and adjust pH to 7.4 using hydrochloric acid 
Make up to final volume of 1000ml with deionised water and sterilise by autoclaving 
 
8.1.4 0.01M Citrate Buffer: 
To make 10 litres: 
Citric Acid monohydrate 21g  (VWR) 
Distilled water   10,000ml 
Final solution adjusted to pH6.0 by adding 2M sodium hydrochloride solution 
8.1.5 Tris Buffered Saline (TBS) 0.05M: 
To make 5000ml: 
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Trizma® Base   6.95g  (Sigma-Aldrich) 
Trizma®Hydrochloride  30.3g  (Sigma-Aldrich) 
NaCl     45.0g  (VWR) 
Distilled water   5000ml 
Final solution adjusted with 2M sodium hydrochloride solution to pH7.6 
 
8.1.6 Sodium Hydrochloride 2M: 
Sodium Hydrochloride  32g  (Sigma-Aldrich) 
Distilled water   400ml 
 
8.1.7 Dako High pH9.8 Target Retrieval buffer: 
To make 1000ml: 
High pH Target retrieval 100ml (Dako) 
Distilled Water   900ml 
 
8.1.8 Scott’s Water 
Sodium bicarbonate  7g  (Sigma-Aldrich) 
Magnesium sulphate  40g  (Sigma-Aldrich) 
Thymol crystals   3  (Sigma-Aldrich) 
Water    2000ml 
 
8.1.9 Acid/Alcohol immunohistochemistry solution 
100% Ethanol   1400ml 
Hydrochloric acid  20ml  (Sigma-Aldrich) 
Deionised water   600ml 
 
8.1.10 10x TBS-Tween: 
Sodium Chloride   45g  (Sigma-Aldrich) 
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Tris     30g  (Becton Dickinson) 
Made up to 500ml with deionised water  
Adjust to pH7.5 using hydrochloric acid  (Sigma-Aldrich) 
Tween-20    2.5ml 
Made up to final volume of 5000ml with deionised water 
 
8.1.11 Harris Haematoxylin solution 
Potassium alum   100g  (Sigma-Aldrich) 
Haematoxylin   5g  (Sigma-Aldrich) 
Mercuric oxide   2.5g  (Sigma-Aldrich) 
Acetic acid    40ml  (Sigma-Aldrich) 
100% Ethanol   50ml 
Water    1000ml 
 
The potassium alum is first dissolved in water by gently warming and stirring. 
Haematoxylin is dissolved in 100% ethanol and then added to the potassium alum 
solution which is boiled and removed from the heat before the mecuric acid is added. 
Finally once cooled acetic acid is added and the solution filtered to remove any 
deposits.  
 
 
8.1.12 FISH wash buffer (SSCTM): 
Skimmed milk powder  1g   
Tween-20    250µl (Sigma-Aldrich) 
4xSSC    500ml (Becton Dickinson) 
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8.2  
8.2.1 To generate a table to include a subset of probes 
setwd("T:/Data/Raw Data/Array/subfolder") 
#### Read in two group files. Obviously can subset to define separate groups 
probes<-read.table("filename_a.csv",sep=",",header=TRUE,row.names=1) 
probes2<-as.vector(probes[,1]) 
data<-read.table("filename_b.csv",header=TRUE,row.name=1, as.is =TRUE,sep=",") 
group1<-data[rownames(data) %in% probes2,] 
write.table(group1, file="filename_c.csv", sep=",") 
dev.off() 
 
8.2.2 Principal component analysis script 
# set working directory 
setwd("T:/Data/Raw Data/Array/subfolder") 
# load library for displaying 3D graphs 
library(rgl) 
# Read in data, using arguments header=TRUE - sets first row as column titles, 
# row.names=1 sets row names as first column 
meth<-read.table("filename.csv",sep=",",header=TRUE,row.names=1) 
meth.pca<-prcomp(t(meth)) 
# Label sample types with different colours eg: MB -red, C Pineos-blue, SPNETs-green, 
control, black,  
colour<-c(rep("black",37),rep("green",31),rep("blue",4),rep("red",100)) 
# plot principal component loadings with plot3d 
plot3d(meth.pca$x[,1:3], type="s",size=1.0,col=colour) 
#now plot PCA again, but removing selected samples eg the controls 
meth1<-meth[,-c(1:37)] 
meth1.pca<-prcomp(t(meth1)) 
dim(meth1) 
colour1<-colour[-c(1:37)] 
plot3d(meth1.pca$x[,1:3], type="s",size=1.0,col=colour1) 
 
8.2.3 Bootstrapped hierarchical clustering and dendrograms 
setwd("T:/Data/Raw Data/Array/subfolder") 
library(pvclust) 
library(gplots) 
meth<-read.table("filename.csv",sep=",",header=TRUE,row.names=1) 
# Store output in pdf 
pdf("pdf_filename.pdf",height=11.7,width=16.5) 
# Carry out bootstrapped hierarchical clustering 
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# Make cluster for parallel clustering 
cl<-makeCluster(4) 
clust1<-parPvclust(cl,meth,method.hclust="average",method.dist="cor",nboot=10000) 
# Plot with 'flattened' projection 
plot(clust1, print.pv=TRUE, print.num = FALSE, hang=-
1,cex.pv=0.5,cex=0.7,col.pv=c("red","#0000ff00","#0000ff00")) 
# Plot with height representing where cluster originates 
plot(clust1, print.pv=TRUE, print.num = FALSE, cex=0.7, 
col.pv=c("red","#0000ff00","#0000ff00")) 
# Plot without (red) probability numbers 
plot(clust1, print.pv=TRUE, print.num = FALSE, hang=-
1,cex.pv=0.5,cex=0.7,col.pv=c("#0000ff00","#0000ff00","#0000ff00")) 
plot(clust1, print.pv=TRUE, print.num = 
FALSE,cex.pv=0.5,cex=0.7,col.pv=c("#0000ff00","#0000ff00","#0000ff00")) 
dev.off() 
 
8.2.4 Heatmap of selected probes 
setwd("T:/Data/Raw Data/Array/Array Summer 09") 
# Probe list to be selected 
probes<-read.table("filename_a.csv",sep=",",header=TRUE,row.names=1) 
probes<-as.vector(probes[,1]) 
probes 
# Load data file containing from which only selected probes will be used in heatmap 
methData<-read.table("filename_b.csv",sep=",",header=TRUE,row.names=1) 
methData.edit<-methData[rownames(methData) %in% probes,] 
odd <- function(x) x!=as.integer(x/2)*2 
even <- function(x) x==as.integer(x/2)*2  
# To generate heatmap red/green colour profile using colorpanal function 
colorpanel <- function(n,low='green',mid='black',high='red') 
   { 
     if(even(n)) warning("n is even: colors panel will not be symmetric") 
     # convert to rgb 
     low <- col2rgb(low) 
     mid <- col2rgb(mid) 
     high <- col2rgb(high) 
     # determine length of each component 
     lower <- floor(n/2) 
     upper <- n - lower 
     red  <- c( 
               seq(low[1,1], mid [1,1], length=lower), 
               seq(mid[1,1], high[1,1], length=upper) 
               )/255 
     green <- c( 
                seq(low[3,1], mid [3,1], length=lower), 
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                seq(mid[3,1], high[3,1], length=upper) 
                )/255 
     blue <- c( 
              seq(low[2,1], mid [2,1], length=lower), 
               seq(mid[2,1], high[2,1], length=upper) 
               )/255 
     rgb(red,blue,green) 
   } 
# Generate green-black-red colourscale 
greenred <- function(n) colorpanel(n, 'green', 'black', 'red' ) 
 
#draw heat map 
#second code alters the label font size 
heatmap(as.matrix(methData.edit),col=greenred(255),scale="none",Colv=TRUE,Rowv=
TRUE) 
heatmap(as.matrix(methData.edit),col=greenred(255),scale="none",Colv=TRUE,Rowv=
TRUE,cexCol=0.3) 
 
8.2.5 Comparison of 2 groups of data using Mann-Whitney test 
and correction for multiple tests 
setwd("T:/Data/Raw Data/Array/subfolder") 
library(multtest) 
#### Read in two group files.  
group1<-read.table("filename_a.csv",header=TRUE,row.name=1, as.is=TRUE,sep=",") 
group2<-read.table("filename_b.csv",header=TRUE,row.name=1, as.is =TRUE,sep=",") 
#### Transpose data tables to get samples as rows and probes as columns 
tg1<-t(group1) 
tg2<-t(group2) 
#### Get row numbers 
rowNo<-nrow(group1) 
#### Get probe names from first data set 
probeName<-rownames(group1) 
#### Create matrix to store results 
result<-matrix(nrow=nrow(group1), ncol=4) 
i<-1 
#### Carry out unpaired Mann-Whitney test 
for (i in 1: rowNo) 
  { 
 test<-wilcox.test(as.numeric(tg1[,i]), as.numeric(tg2[,i]), paired = FALSE) 
 result[i,1] <- probeName[i] 
 result[i,2] <- test$p.value 
 result[i,3] <- test$statistic 
 i<-i+1 
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 } 
write.table(result, file="filename.csv", sep=",") 
### Correct for multi-testing (Bonferroni and Benjamini-Hochberg FDR) 
procs<-c("Bonferroni","BH") 
### Get p values from Mann-Whitney 
rawp<-as.numeric(result[,2]) 
 
### Original data has probes with measurements of zero for all groups. This will cause 
NaNs when carrying out test. Need to replace NaN with 1(not sig) so the script does 
not fail. 
rawp[is.nan(rawp)]<-1 
#### Carry out multiple hypothesis testing 
res2<-mt.rawp2adjp(rawp,procs) 
### Sort res2 so that probe alphabetical order is maintained 
res3<-res2$adjp[order(res2$index),] 
### add in abs delta beta 
mean<-matrix(nrow=nrow(group1),ncol=3) 
mean[,1]<-rowMeans(group1) 
mean[,2]<-rowMeans(group2) 
mean[,3]<-abs(mean[,1]-mean[,2]) 
### Now write to final table 
write.table(cbind(probeName,res3,mean), file="age_034_MW_with_fdr.csv", sep=",", 
col.names=c("probeName","rawp","Bonferroni","BH","grp1 beta","grp2 beta","abs 
delta beta")) 
 
8.2.6 Classifier probe selection 
setwd("T:/Data/Raw Data/Array/subfolder") 
library(klaR) 
setwd("T:/Data/Raw Data/Array/subfolder") 
data<-read.csv("filename.csv",header=TRUE,row.names=1) 
probes<-read.table("test1.csv",sep=",",header=TRUE,row.names=1) 
probes2<-as.vector(probes[,1]) 
data<-data[rownames(data) %in% probes2,] 
data<-t(data) 
case<-ifelse(substr(row.names(data),start=1,stop=1)=="c",1,2) 
wpval<-matrix(data=NA,nrow=dim(data)[2],ncol=2) 
wpval[,1]<-apply(data,2, function(x) wilcox.test(x~case,exact=FALSE)$p.value) 
plimit<-0.05 
sum(wpval[,1]<plimit) 
nprobes<-12 
d3<-data[,order(wpval[,1],decreasing=FALSE)[1:nprobes]]   
set.seed(1234) 
pdf("pdf_filename.pdf",height=11.7,width=16.5) 
#1st 
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s3<-stepclass(d3,case,"qda",direction="both",improvement = 0.0005) 
list(s3$model$name) 
l1<-list(s3$model$name) 
pairs(d3[,s3$model$nr],pch=21,bg=c("red", "green3")[unclass(case)]) 
partimat(as.factor(case)~d3[,s3$model$nr],method="qda") 
#Run  last 5 lines of code 10 times, change “l1” in line 3: to “l2” – “l10” in successive 
runs 
dev.off() 
 
8.2.7 Survival analysis 
setwd("T:/Data/Raw Data/Array/subfolder") 
library(survival) 
library(multtest) 
 
## Read in table 
data<-read.table("filename.csv",sep=",",header=T,row.names=1) 
data <- t(data) 
data<-as.data.frame(data) 
###  To plot Kaplan Meier curves 
pval<-c() 
# If 76 probes under investigation 
for(i in 1:76) 
 { 
 KM <- survdiff(Surv(Survival,Status) ~ data[,i+2], data=data) 
 temp <- 1-pchisq(KM$chisq,df=1) 
 pval<-c(pval,temp) 
 } 
names(pval) <- colnames(data)[-c(1:2)] 
names(pval)[pval<0.05] 
data2<-cbind(data[,1:2],data[,colnames(data) %in% names(pval)[pval<0.05]]) 
# Make and store plots for the most significant probes 
pdf("KM_sig_Plots.pdf") 
# For the top 9 significant probes 
for (i in 1:9) 
 { 
 plot(main=colnames(data2)[i+2], lty=1:2, xlab="Months", 
ylab="Proportion",survfit(Surv(Survival,Status) ~ data2[,i+2], data=data2)) 
 legend(bty="n","bottomright",lty=1:2,c("Normally methylated","Aberrantly 
methylated")) 
 KM <- survdiff(Surv(Survival,Status) ~ data2[,i+2], data=data2) 
 temp <- 1-pchisq(KM$chisq,df=1) 
 temp <- round(temp,4) 
 temp <- paste("p =",temp) 
 legend("topright",bty="n",temp) 
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 } 
procs<-"BH" 
pvals_corrected <- mt.rawp2adjp(pval,procs) # none significant 
pval_order <- pval[order(pval)] 
rownames(pvals_corrected$adjp) <- names(pval_order) 
write.table(pvals_corrected$adjp,file="adjusted_logrank_pval.csv",sep=",") 
 
8.2.8 Survival univariate Cox model 
setwd("T:/Data/Raw Data/Array/subfolder") 
library(survival) 
## read in data 
cox <- 
read.table("km_surv_raw_combsignifprobe_apr2011.csv",sep=",",header=T,row.name
s=1) 
cox<-t(cox) 
# Functions 
tableWrite<-function(results, x, columnNames) 
{ 
temp<-paste(x,".csv") 
write.table(results,file=temp,sep=",",col.names=columnNames) 
} 
coxAnalyseUnivariateEFS<-function(methData, filename) 
 { 
 colNumber<-dim(methData)[[2]] 
 i<-1 
 results<-matrix(nrow=(colNumber-2),ncol=3) 
 probeNames<-colnames(methData)[3:colNumber] 
 pvals<-vector() 
 while(i<(colNumber-1)) 
  { 
  try(temp<-coxph(Surv(methData[,2],methData[,1]) 
   ~methData[,i+2]),TRUE) 
  pval<-summary(temp)$coefficients[1,5] 
  pvals[i]<-pval 
 
  results[i,1]<-probeNames[i] 
  i<-i+1 
  } 
 pvals2<-mt.rawp2adjp(pvals,proc="BH") 
 pvals2<-pvals2$adjp[order(pvals2$index),] 
 results[,2:3]<-pvals2 
 tableWrite(results, filename, c("ProbeID","Raw Probe p","BH Probe p")) 
 } 
coxAnalyseUnivariateEFS(cox,"univariateCox") 
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8.2.9 Multivariate analysis 
setwd("T:/Data/Raw Data/Array/subfolder") 
library(multtest) 
library(survival) 
data<-read.table("filename.csv",sep=",",header=T,row.names=1) 
LR_Fn2<- 
function(data,baseVar,covariates){ 
data<-as.data.frame(data) 
 results<-vector(length=length(covariates)) 
names(results) <- colnames(data)[covariates] 
# For 9 most significant probes found on univariate analysis 
i<-1 
while (i <=length(covariates)) 
{ 
 if(length(baseVar)==1){ 
 base <- coxph(Surv(EFS_Time,EFS_Status)~data[,baseVar],data=data) 
lr1<- -2*base$loglik[2] 
 extend<-coxph(Surv(EFS_Time,EFS_Status)~ data[,baseVar] + 
data[,covariates[i]],data=data) 
  lr2<- -2*extend$loglik[2] 
} else if(length(baseVar)==2) { 
base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + 
data[,baseVar[2]],data=data) 
lr1<- -2*base$loglik[2] 
extend<-coxph(Surv(EFS_Time,EFS_Status)~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,covariates[i]],data=data) 
 lr2<- -2*extend$loglik[2] 
} else if(length(baseVar)==3) { 
base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] ,data=data) 
lr1<- -2*base$loglik[2] 
extend<-coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,covariates[i]],data=data) 
 lr2<- -2*extend$loglik[2] 
} else if(length(baseVar)==4) { 
base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] +  data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] ,data=data) 
lr1<- -2*base$loglik[2] 
extend<-coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,covariates[i]],data=data) 
lr2<- -2*extend$loglik[2] 
} else if(length(baseVar)==5) { 
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base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]],data=data) 
 lr1<- -2*base$loglik[2] 
extend<-coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + 
data[,covariates[i]],data=data) 
lr2<- -2*extend$loglik[2] 
} else if(length(baseVar)==6) { 
base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + 
data[,baseVar[6]],data=data) 
 lr1<- -2*base$loglik[2] 
extend<-coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + data[,baseVar[6]] + 
data[,covariates[i]],data=data) 
lr2<- -2*extend$loglik[2] 
 } else if(length(baseVar)==7) { 
  
base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + 
data[,baseVar[6]]+data[,baseVar[7]],data=data) 
 lr1<- -2*base$loglik[2] 
 extend<-coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + data[,baseVar[6]] + 
data[,baseVar[7]] + data[,covariates[i]],data=data) 
lr2<- -2*extend$loglik[2] 
 } else if(length(baseVar)==8) { 
 base <- coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + 
data[,baseVar[6]]+data[,baseVar[7]] + data[,baseVar[8]],data=data) 
 lr1<- -2*base$loglik[2] 
 extend<-coxph(Surv(EFS_Time,EFS_Status) ~ data[,baseVar[1]] + data[,baseVar[2]] + 
data[,baseVar[3]] + data[,baseVar[4]] + data[,baseVar[5]] + data[,baseVar[6]] + 
data[,baseVar[7]] + data[,baseVar[8]] + data[,covariates[i]],data=data) 
 lr2<- -2*extend$loglik[2] 
} 
results[i] <- pchisq(q=lr1-lr2, df=1, lower.tail = FALSE)  
print(paste("i",i,"p val",results[i],covariates[i])) 
 i<-i+1 
 } 
results 
 } 
data<-read.table("filename.csv",sep=",",header=T,row.names=1) 
data <- t(data) 
colnames(data)[1:2] <-c("EFS_Status","EFS_Time") 
colnames(data) 
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rownames(data) 
# Include  most significant probe sequentially in model 
extend_LR<-LR_Fn2(data,baseVar=c(11), covariates=c(5,6,7,8,9,10,12,13,14)) 
extend_LR[order(extend_LR)] 
extend_LR<-LR_Fn2(data,baseVar=c(11,14), covariates=c(5,6,7,8,9,10,12,13)) 
extend_LR[order(extend_LR)] 
extend_LR<-LR_Fn2(data,baseVar=c(11,14,6), covariates=c(5,7,8,9,10,12,13)) 
extend_LR[order(extend_LR)] 
extend_LR<-LR_Fn2(data,baseVar=c(11,14,6,12), covariates=c(5,7,8,9,10,13)) 
extend_LR[order(extend_LR)] 
extend_LR<-LR_Fn2(data,baseVar=c(11,14,6,12,13), covariates=c(5,7,8,9,10)) 
extend_LR[order(extend_LR)] 
data<-as.data.frame(data) 
finalModel <- coxph(Surv(EFS_Time,EFS_Status) ~ SIN3B_P514_R + WEE1_P924_R + 
ITK_P114_F + SLC6A8_P409_F 
+ TRIM29_P135_F,data=data);summary(finalModel) 
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Figure 8.1. Bootstrapped hierarchical clustering dendrogram of the methylation 
profiles of CNS-PNET and normal brain samples. (a) Clustering using variantly 
methylated probes, and (b) clustering excluding the chromosome X probes. Samples: 
SPx, CNS-PNET; Cbx, normal brain.  
a)
b)
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Figure 8.2. Bootstrapped hierarchical clustering dendrogram of the methylation 
profiles of CNS-PNET and pineoblastoma tumours. (a) Clustering using variantly 
methylated probes, and (b) clustering excluding the chromosome X probes. Samples: 
SPx, CNS-PNET; PB, pineoblastoma 
 
a)
b)
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Figure 8.3. Bootstrapped hierarchical clustering dendrogram of the methylation 
profiles of CNS-PNET, medulloblastomas and normal brain samples. (a) Clustering 
using variantly methylated probes, and (b) clustering excluding the chromosome X 
probes. Samples: SP*, CNS-PNET; Cb*, normal brain; RJG*, NMB* or X*, 
medulloblastoma. 
 
a)
b)
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Figure 8.4. Bootstrapped hierarchical clustering dendrogram of the methylation 
profiles of CNS-PNET, high grade gliomas and normal brain samples. (a) Clustering 
using variantly methylated probes, and (b) clustering excluding the chromosome X 
probes. Samples: SPx, CNS-PNET; Cbx, normal brain; HGG*, high grade glioma.  
 
a)
b)
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